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The Iowa Medicaid Drug Utilization Review Commission 
 
Goold Health Systems, an Emdeon company, has developed the following report for the 
Iowa Department of Human Services.  This report provides a summary description of the 
activities of the Iowa Medicaid Drug Utilization Review Commission, along with an 
evaluation of the Iowa Medicaid retrospective drug utilization review program.  Information 
contained in this report covers projects completed and evaluated during the time period of 
July 2014 through June 2015. 
 
Background Information 
 
Established in 1984, the DUR Commission is charged with promoting the appropriate and 
cost-effective use of medications within the Iowa Medicaid member population.  Acting as 
a professional advisory group, the Commission analyzes medication utilization by the 
members of Iowa Medicaid and performs educational initiatives to optimize member 
outcomes.  The Commission performs retroDUR and educational outreach through patient-
focused reviews and problem-focused reviews.  The Commission supports the proDUR 
program through criteria review and acts as a resource to the DHS on other issues 
concerning appropriate medication use.  
 
Patient-Focused Reviews  
 
Patient-focused reviews are completed with the review of 300 member profiles at each 
meeting (six times annually).  The DUR subcontractor generates these profiles through a 
complex screening process.  The first step of the screening process subjects member 
profiles to a therapeutic criteria screen.  If a profile is found to have failed one or more 
therapeutic criteria, the member profiles are then assigned a level of risk based on their 
medication history and potential for adverse events regarding medication.  The profiles 
with the highest level of risk are then selected for the Commission to review.  Six months 
of prescription claims data and medical claims data, if available, are assessed to 
determine this risk factor.   
 
The member profiles selected from this process are manually reviewed by the Commission 
to minimize false positives generated by the computer selection process.  The Commission 
identifies situations where educational intervention might be appropriate.  Through these 
interventions, suggestions regarding medication therapy are communicated to the care 
providers.  Templates are developed for suggestions that are frequently communicated to 
providers.  The reviewer may also author an individualized suggestion if a template 
suggestion is not applicable.  These template suggestions are located in the tab labeled 
Therapeutic Recommendations.  
 
Educational interventions are generally done by letters to prescribers and pharmacists, but 
may also be done by telephone or in person.  The suggestions made by the Commission 
are educational and informative in nature.  Suggestions may be classified as either 
therapeutic or cost saving in nature.  In addition, these suggestions are classified by 
problem identified for reporting purposes.  The classifications are as follows:   
 Not Optimal Drug 
 Not Optimal Dose 
 Not Optimal Duration 
 Unnecessary Drug Use 
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 Therapeutic Duplication 
 High Cost Drug 
 Drug-Drug Interaction 
 Drug-Disease Interaction 
 Adverse Drug Reaction 
 Patient Overuse 
 Patient Underuse 
 Therapeutic Alternative 
 Missing Drug Therapy 
 Not Optimal Dosage Form 
 Potential Generic Use 
 Inappropriate Billing 
 
Suggestions are intended to promote appropriate and cost-effective use of medications.  
When suggestions result in cost savings, these savings are calculated based on 
decreased cost of medications.  However, several of these classes of interventions are 
intended to increase the use of medications.  Examples are member underuse and 
missing drug therapy.  In these cases, the addition of medication therapy will increase 
medication expenditures, but will be beneficial to the member and should result in cost 
savings in medical services and/or improved quality of life.  Cost savings in these 
situations cannot be calculated due to data limitations.  Therefore, these suggestions are 
considered to have a positive impact on the program with no medication cost savings.  
Cost savings on medical services are assumed however not calculated.  
 
Providers are invited to respond to the Commissions’ suggestions and to request 
additional information from the Commission.  Reponses are voluntary and response rates 
are calculated for prescribers and pharmacists.  
 
Once a member's profile is reviewed, it is excluded from the selection process for nine 
months to eliminate repeat selections.  After this waiting period, the current profile for each 
member is generated and reviewed to determine if the Commission's suggestion was 
implemented.  If so, fiscal considerations resulting from that change are also calculated.  
The policy regarding these calculations is included in Appendix B. 
 
 
Problem-Focused Reviews  
 
Problem-focused reviews narrow the emphasis of review to a specific issue that has been 
determined to be an area where a targeted educational effort to providers may be 
valuable.  Topics for review are selected from findings of patient-focused reviews or from 
reviews of medical literature. Criteria are developed to identify the members who may 
benefit from intervention and educational materials are disseminated to their providers.  
Providers are encouraged to voluntarily respond.  The member profile is generated again 
in an appropriate amount of time (typically 6 to 9 months) to determine the impact rate of 
the intervention, along with any fiscal considerations.  The policy regarding these 
calculations is also included in Appendix B.   
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Administrative Review 
 
The Commission will review utilization data and medical literature to make 
recommendations to the Department of Human Services (DHS) regarding policy issues.  
These recommendations are made to promote the appropriate use of medications and 
positive member outcomes.  Recommendations are made at the request of the DHS or at 
the Commission's discretion.  All authority to accept or reject DUR Commission 
recommendations lies with the DHS.  The Commission may make recommendations but 
does not make policy.  Primary areas for recommendations include proDUR, drug prior 
authorization (PA), coverage of medications, and administrative and billing procedures.  
The prospective drug utilization review (proDUR) system is currently administered by 
Goold Health Systems (GHS), an Emdeon company, and was implemented statewide in 
July 1997.  The Commission reviews the criteria utilized by GHS and provides input 
regarding therapeutic validity.  Special attention is given to eliminating false positive 
messaging.   
 
The Commission recommends new or updated guidelines for use in the drug prior 
authorization program.  This process is based on reviews of medical literature in addition 
to comparisons with other public and private sector programs.  Input from providers 
outside the Commission, particularly specialists, is often sought when developing these 
guidelines.  Once developed, the guidelines are sent to the medical and pharmacy 
associations in the state for comments.  After considering these comments, a final 
recommendation is made to the Department.  The Department may or may not accept the 
recommendation or may alter the recommendation.  These guidelines are then subject to 
the administrative rules process prior to any policy implementation. 
 
The Commission also makes recommendations regarding coverage of medication or 
devices.  As most coverage requirements are defined by OBRA ‘90, these 
recommendations generally encourage coverage of optional services.  An example would 
be the coverage of select over-the-counter medications.  If the Department accepts the 
Commission’s recommendation, the proposed coverage change is subject to the 
administrative rules process prior to implementation. 
 
The Commission reviews pharmacy claims with respect to administrative procedures.  
Situations where funding for medication can be obtained from other sources are relayed to 
the Department for their action.  For instance, Medicare will pay for immunosuppressive 
medications for transplant patients and nebulizer solution for dual eligible patients.  The 
Commission also identifies situations where the Department may recover funds from 
inappropriate billing.  
*Savings reported are pre-rebate, total dollars 4 
Overall Results 
 
Activities of the DUR Commission were evaluated for SFY15 for interventions 
performed in the previous or the current fiscal year.  The direct cost savings from 
all activities of the DUR Commission are calculated to be $669,337.04* which 
equates to $2.48* for every $1.00 of combined federal and state dollars spent 
administratively.  This calculation is based on estimates regarding two types of 
reviews:  patient-focused reviews and problem-focused reviews.  These results 
are also found in Appendix C. 
 
 
 
Cost Savings Estimate                                 $669,337.04* 
   
  
 Cost of the Program (state and federal dollars)   $270,000.00 
  
 Net Cost Savings Estimate            $399,337.04* 
 
Savings per Total Dollar Spent (state and federal)             $2.48* 
Savings per State Dollar Spent                             $4.96* 
 
 
Patient-focused reviews resulted in $129,145.36* in direct cost savings, or 
$105.77* per patient evaluated.  This estimate is based on the 1,262 suggestions 
made by the DUR Commission identified from the review of the medication 
therapy of 1,221 patient profiles selected for intervention.  Of these 1,262 
suggestions, 71 suggestions were implemented by the providers, resulting in a 
5.63 percent impact rate. 
 
 
Patient-Focused Profile Review 
 
 Suggestions Made                 1,262 
 Therapy Changed                      71 
 IMPACT RATE                                                    5.63% 
 
 Cost Savings Estimates: 
 
  Dollars Saved per Patient Evaluated        $105.77* 
  Dollars Saved on Medication            $129,145.36* 
 
 
 
 
 
 
 
*Savings reported are pre-rebate, total dollars 5 
Problem-focused reviews resulted in an estimated cost savings of $540,191.68* 
or $192.65 saved per patient evaluated.  This estimate is based on the review of 
profiles with 2,804 patients selected for interventions.  Therapy was changed for 
665 patients, resulting in an impact rate of 23.7 percent. 
 
 
Problem-Focused Profile Review       
 
 Patients Evaluated         2,804 
 Therapy Changed            665 
 IMPACT RATE           23.7% 
 
 Cost Savings Estimates: 
  Dollars Saved on Patient Reviews         $540,191.68* 
  Dollars Saved per Patient Evaluated                $192.65* 
   
Total Dollars Saved on Medication                  $540,191.68* 
 
 
Comparison to Previous Reports 
Cost savings estimates for SFY15 ($669,337.04*) are lower than last year.  This 
decrease is due in part to the type of problem-focused reviews the DUR 
members selected for intervention and the number of members in each 
intervention.  One of the interventions involved the addition of medication.  While 
there is an additional cost upfront, it is assumed cost savings will be realized due 
to improved patient outcomes and decreased spending on medical services.  
Another intervention involved overutilization of seizure medications without a 
seizure diagnosis.  While there was a positive impact, changes in the status of 
medications on the PDL resulted in a higher pre-rebate cost, but post-rebate the 
state realized a cost savings.  
 
The savings from SFY15 patient-focused reviews ($129,145.36*) were lower 
than SFY14 ($166,220.30*).  The number of suggestions made (1,262) vs. 
(1,204) increased as well as the number of suggestions that were accepted (71) 
vs. (63) from SFY14.  The small impact from patient-focused reviews can be 
contributed to the maturation of the Preferred Drug List (PDL) and Point of Sale 
edits (POS) that have been implemented over the years.  It is difficult to 
determine the actual cause for the minimal number of suggestions made.  One 
theory could be, due to the voluntary participation of the prescriber and lack of 
the ability to enforce the recommendations made by the DUR Commission, 
prescribers do not make the recommended change due to lack of time or they do 
not feel it is in the best interest of the patient. 
 
The savings from problem-focused reviews for SFY15 ($540,191.68*) were lower 
than SFY14 ($1,838,278.17*).  This again was due to the type of problem-
focused review selected for intervention, the number of members in each 
intervention, and the fact that in SFY15, two problem-focused reviews did not 
incur a direct cost-savings due to the addition of a medication in one intervention 
and changes to the PDL that increased pre-rebate costs in the other intervention.
*Savings reported are pre-rebate, total dollars 6 
 
Patient-Focused Review 
 
During this evaluation period, 2,802 educational intervention letters were mailed 
to prescribers and pharmacies regarding medication therapy.  Of this total, 1,495 
letters (53.35 percent) were mailed to prescribers, and 1,307 (46.65 percent) 
letters were mailed to pharmacies.  Providers are invited to voluntarily respond to 
DUR Commission letters.  Providers returned 1,059 responses to these letters, 
resulting in an overall response rate by the providers of 37.79 percent.  Of this 
total, 601 (56.75 percent) responses were from prescribers and 428 (43.25 
percent) were from pharmacies.  The response rate differed slightly between 
physicians and pharmacies; 40 percent for physicians and 35 percent for 
pharmacies. 
 
In these 2,802 educational letters, the DUR Commission made 1,262 
suggestions.  Of these suggestions, 1,225 (97.07 percent) were therapeutic in 
nature while 37 (2.93 percent) were cost-saving in nature.  The suggested 
change was implemented in 71 cases, resulting in an overall impact rate of 5.63 
percent.   
 
Of the 1,262 suggestions, four types of suggestions accounted for over 89 
percent of the total.  Those four suggestions were Drug-Drug Interaction (6.18 
percent), Not Optimal Drug (7.61 percent), Therapeutic Duplication (68.86 
percent), and Unnecessary Drug Therapy (6.5 percent).  No other single 
category accounted for more than 3 percent of the total suggestions.  Of the 71 
changes, the most common reasons for the Commission’s inquiry were Drug-
Drug Interaction (7.04 percent), Therapeutic Duplication (60.56 percent), 
Unnecessary Drug Therapy (11.27 percent), and Not Optimal Drug (9.86 
percent).  No other single category accounted for more than 3 percent of the 
changes.  Detailed information is found in Appendix D. 
 
The suggestions that resulted in change the highest percentage of the time were 
Patient Underuse (11.76 percent), Inappropriate Billing (12.5 percent), 
Unnecessary Drug Therapy (9.76 percent), and Potential Generic Use (11.11 
percent). 
 
Implementation of therapeutic suggestions resulted in direct drug cost savings of 
$116,915.46*.  Implementation of the cost-saving suggestions resulted in direct 
drug cost savings of $12,229.90*.  The total amount saved on medication 
utilization was calculated to be $129,145.36* for the 1,221 patients evaluated, or 
$105.77* per patient.  The complete details of the results of patient-focused 
studies reported monthly are also outlined in Appendix D. 
 
Included in Appendix D are Intervention Case Summary examples presented to 
the Commission during the year.  These summaries detail the process of specific 
patient-focused reviews including problem identification, intervention, provider 
response and outcome.  The examples provide an easily understood method to 
demonstrate the value of retrospective patient-focused DUR.  
 
Results by Review Type 
*Savings reported are pre-rebate, total dollars 7 
 
Problem-Focused Reviews 
 
Fourteen problem-focused reviews were evaluated during SFY15.  In conducting 
these studies, 2,804 patient profiles were reviewed and selected for intervention.  
Of these patients, 665 cases showed evidence of a positive outcome, resulting in 
an impact rate of 23.7 percent.  These changes in therapy resulted in annualized 
cost savings of $540,191.68* or $191.68* per patient evaluated.  Results of all 
focus studies are detailed in Appendix E.  The purpose for each problem-focused 
review and a complete description of results are available in Appendix F. 
 
Administrative Review 
 
Prior Authorization 
The DUR Commission annually reviews the prior authorization program for 
clinical appropriateness.  Changes are recommended to the Department.  During 
SFY15, the DUR Commission reviewed all therapeutic categories requiring prior 
authorization as well as therapeutic criteria to support operations of the Preferred 
Drug List.  Recommendations for modifications to existing criteria were made for 
the following categories:  Apixaban (Eliquis), Dabigatran (Pradaxa), Omalizumab 
(Xolair), Palivizumab (Synagis), Chronic Pain Syndromes, Thrombopoietin 
Receptor Agonists, Testosterone Products, Apremilast (Otezla), Hepatitis C 
Agents, CNS Stimulants and Atomoxetine, Dextromethorphan/Quinidine 
(Nuedexta), and Sedative/Hypnotics – Non-Benzodiazepines.  The following is a 
list for which new categories of clinical prior authorization criteria were 
developed:  Oral Immunotherapy, Methotrexate Injection, Apremilast (Otezla), 
Ceritinib (Zykadia), Deferasirox (Exjade), and Vorapaxar (Zontivity).  No 
recommendations were made to remove criteria during this time period.  These 
recommendations can be found in Appendix G.   
 
Prospective Drug Review 
The DUR Commission reviews and recommends prospective drug utilization 
review criteria to be utilized by the Department.  The following prospective DUR 
edits were recommended to the Department by the Commission in SFY15: 
 The DUR reviewed the recommendations they initially made in April 2012 
to implement ProDUR edits on antipsychotics in members less than 18 
years of age.  After discussion, the Commission continues to support the 
implementation of the following ProDUR edits: 
o ProDUR age edit on risperidone for members less than 5 years of 
age and an age edit on all other antipsychotics for members less 
than 6 years of age. 
o Duplicate therapy edit on all antipsychotics. 
 Quantity limit on all short-acting opioids of 120 units per 30 days. 
 Quantity limit on Adderall IR 12.5mg and 20mg of 90 tablets per 30 days. 
 Quantity limit on Concerta 18mg and 27mg of 30 tablets per 30 days. 
 Quantity limit on Focalin IR (all strengths) of 60 tablets per 30 days. 
 Quantity limit on Focalin XR (all strengths) of 30 capsules per 30 days. 
 Quantity limit on Ritalin IR (all strengths) of 90 tablets per 30 days. 
*Savings reported are pre-rebate, total dollars 8 
 Quantity limit on all strengths of alprazolam, clonazepam, and lorazepam 
of 120 units per 30 days. 
 
Information regarding the DUR Commission recommendations for prospective 
DUR can be found in Appendix H. 
 
Other Activities 
 
Three newsletters were written and posted to the website by the DUR 
Commission for the Medicaid provider community during this fiscal year.  A copy 
of these newsletters is provided in Appendix I.  Topics include: 
 Long-Acting Opioid Use in Opioid-Naïve Patients 
 Off-Label Pharmaceutical Marketing:  How to Recognize and Report It 
 How to Dispose f Unused Medications 
 Complex Pharmaceutical Oversight Program (CPOP) 
 Medicaid Modernization 
 
The DUR Commission maintains a web site to improve communication with a 
variety of stakeholders.  The web site is found at www.iadur.org.  The site 
contains information regarding upcoming meeting dates, locations, agendas, 
minutes from the previous meeting, as well as past issues of the provider 
newsletter, the DUR DIGEST.  In addition the web site provides meeting 
agendas and minutes for the Drug Utilization Review Mental Health Advisory 
Group.  A copy of this web site is found in Appendix J. 
 
Laurie Pestel, Pharm.D. was reappointed to serve a third, four-year term 
beginning in August 2015. 
 
Gregory Barclay, M.D. served one, four-year term on the DUR which expired in 
June 2015. 
 
Bimonthly prevalence reports were developed to allow the DUR Commission to 
analyze changes in medication use across the entire Medicaid patient population.  
Copies are found in Appendix K.   
 
Complete meeting minutes for all DUR Commission meetings are available in 
Appendix L. 
 
The Iowa Medicaid Drug Utilization Review Mental Health Advisory Group 
(MHAG) was established in SFY 2008.  Descriptions of the program, as well as 
meeting minutes are found in Appendix M. 
 
Periodically the DUR Commission will make recommendations to the Iowa 
Medicaid Pharmacy & Therapeutics Committee regarding the status of a 
medication on the Preferred Drug List (PDL).  A copy of SFY15 
recommendations can be found in Appendix N. 
Appendix A 
Commission Members 
Iowa Medicaid Drug Utilization Review 
Commission Members 
2014-2015 
 
Larry Ambroson, R.Ph. 
Larry Ambroson currently owns and operates The Medicine Shoppe Pharmacy in 
Newton, Iowa. Mr. Ambroson graduated from the University of Iowa in 1992.  He 
worked for Columbia Regional Hospital in Columbia, MO from 1992 to 1998.  Mr. 
Ambroson returned to Iowa in 1998 and opened The Medicine Shoppe. Mr. 
Ambroson was reappointed for a second term in 2013 which will expire in June 
2017.  
 
Gregory Barclay, M.D. 
Dr. Barclay is the President and Medical Director of Barclay and Associates, P.C. 
in Ames, Iowa.  Dr. Barclay received his medical degree from the University of 
Kentucky College of Medicine and completed his residency training in psychiatric 
medicine at the Naval Regional Medical Center in San Diego, California.  He is 
certified by the American Board of Psychiatry & Neurology, is a Fellow in the 
American Psychiatric Association, is a Governing Board member of the American 
Society of Adolescent Psychiatry, and is a member of the Legislative Affairs 
Committee of the Iowa Psychiatric Society.  Dr. Barclay was appointed to the 
Commission in 2011; his first term expired June 30, 2015 and he did not seek 
reappointment. 
 
Brian Couse, M.D. 
Dr. Couse graduated from the University of Nebraska College of Medicine in 
1998.  He then completed his Primary Care Rural Training Residency Program in 
2001 and is board certified in Family Medicine.  Dr. Couse currently sees patients 
at the Methodist Physicians Clinic in Red Oak, Iowa.  He treats patients of all 
ages and has clinical areas of interest in obstetric care including deliveries and 
C-sections and upper and lower gastrointestinal endoscopy. Dr. Couse was 
appointed to the DUR Commission in 2013; His first term will expire in June 
2017. 
 
Brett Faine, Pharm.D. 
Dr. Faine is a Clinical Pharmacy Specialist in Emergency Medicine at the 
University of Iowa Hospital.  He serves as a preceptor to residents and Pharm.D. 
students in the Emergency Treatment Center.  Dr. Faine received his Pharm.D. 
degree from University of Iowa and completed an ASHP-accredited PGY1 
Pharmacy Residency at the University of Iowa Hospitals and Clinics.  Dr. Faine 
was reappointed for a second term in 2014 which will expire in June 2018. 
 
Mark Graber, M.D., FACEP, MSHCE 
Dr. Graber is a Professor of Emergency Medicine and Family Medicine at the 
University of Iowa Carver College of Medicine.  Dr. Graber graduated from 
Eastern Virginia Medical School and completed his Family Practice Residency at 
the University of Iowa.  In addition to his clinical duties, Dr. Graber serves as an 
advisor to medical students and residents, and has published numerous text 
books, reviews, and papers in publications such as The Annals of 
Pharmacotherapy, Emergency Medicine, and American Family Physician.  Dr. 
Graber also serves as an associate Clinical Editor of the Prescribers Letter.  
Through his travels, Dr. Graber has presented throughout the United States as 
well as Ukraine, Russia, and China.  In 2007, Dr. Graber was honored by 
appearing on the “Best Doctors in America” list.  Dr. Graber was reappointed for 
a second term in 2012 which will expire in June 2016. 
 
Kellen Ludvigson, Pharm.D. 
Dr. Ludvigson graduated with distinction from the University of Iowa College of 
Pharmacy in 2007, and he is kept busy working full-time at three different 
independent pharmacies: both the Holstein and Cherokee branches of Main 
Street Pharmacy, and also the Cherokee Mental Health Institute in Cherokee.  
Additionally, he is employed as a relief pharmacist at the Sioux City Target.  This 
diversity in employment allows him to encounter a variety of prescribers and 
patients in the Medicaid program, and has resulted in a great deal of experience 
with the Iowa Medicaid PDL.  Dr. Ludvigson was appointed to the DUR 
Commission in 2012; his first term will expire in June 2016. 
 
Susan Parker, Pharm.D. 
Dr. Parker is the Pharmacy Director for the Department of Human Services at the 
Iowa Medicaid Enterprise and serves as liaison to the Commission. She 
graduated with a Doctor of Pharmacy degree from Mercer Southern School of 
Pharmacy in Atlanta, Georgia. She is also a graduate of Gannon University in 
Erie, Pennsylvania with a Bachelor of Science degree Physician Assistant. Dr. 
Parker brings to the Commission a variety of experience in health care as an 
Iowa Medicaid drug prior authorization pharmacist, community pharmacist, and 
physician assistant. She is a member of the American Medicaid Pharmacy 
Administrators Association and the Western Medicaid Pharmacy Administrators 
Association. 
 
Laurie Pestel, Pharm,D 
Dr. Pestel is the pharmacy manager at Hy-Vee in Red Oak, Iowa.  She 
graduated with her Doctor of Pharmacy degree from Creighton University in 
2000.  She served on the Board of Professional Affairs as a member of the Iowa 
Pharmacy Association in 2006.  Laurie has experience with both long-term care 
and retail pharmacy.  Dr. Pestel was reappointed for a third term in 2015 which 
will expire in June 2019. 
 
Jason Wilbur, M.D. 
Dr. Wilbur graduated from the Saint Louis University School of Medicine in 1999.  
He then completed his Family Medicine Residency at the University of Iowa, 
where he was Chief Resident 2001-2002, followed by a Geriatric Medicine 
Fellowship 2002-2003.  He is currently Associate Professor of Clinical Family 
Medicine for the Roy J. & Lucille A. Carver College of Medicine at the University 
of Iowa.  Prior to that, he was Medical Director of the Family Medicine Clinic in 
Iowa City from 2006 to 2011.  The University of Iowa Hospitals and Clinics 
awarded him the Above and Beyond Reward in 2006 and again in 2007, along 
with the Teacher of the Year Award, presented by the University of Iowa Family 
Medicine residents, in 2008.  Dr. Wilbur was appointed to the DUR Commission 
in 2012; his first term will expire in June 2016. 
 
 
Appendix B 
Evaluation Procedure 
   
EVALUATION OF THE IMPACT OF PROSPECTIVE AND 
RETROSPECTIVE DRUG UTILIZATION REVIEW INTERVENTIONS 
 
The goal of Drug Utilization Review (DUR) is to evaluate cost savings and 
provide quality assurance of medication use.  The DUR Commission works in 
conjunction with the pharmacy medical program at the Iowa Medicaid Enterprise 
to contribute to the overall success of the program.  The Drug Utilization 
program:  
 Evaluates three areas of activity including Patient-focused Drug 
Utilization Reviews, Problem-focused Drug Utilization Reviews, and 
Administrative Activities. 
 Examines only direct drug costs.  DUR evaluation does not have the 
ability to quantify its impact on other health services such as 
hospitalizations, ER visits, and physician visits. 
 Reports pre-rebate savings since access to supplemental rebates is 
not within the scope of the DUR program. 
 Often provides recommendations that are qualitative, such as 
improved health outcomes, rather than quantitative in nature. 
 
As a general principle, evaluations are based upon an observed change in the 
targeted prescribing or dispensing pattern, as well as changes seen in therapy of 
the individual patients.  One evaluation approach is to observe and quantify 
changes in prescribing due to a given intervention compared to a control group of 
providers who do not receive the intervention.  The intervention’s impact on 
prescribing may be more readily detectable by this method and could be 
measured by comparing the two groups of patients or prescribers.  However, It is 
very difficult to design a scientifically sound control group given the many 
variables surrounding patient care.   Therefore, in most instances the DUR 
Commission has chosen to forego use of a control group to achieve the greatest 
impact.  Although the evaluation of the intervention may be less scientific, 
intervention on behalf of all the patients is more desirable.  In this instance, 
prescribing trends may not be available for comparison, but savings and benefit 
can still be quantified at the individual patient level. 
 
Patient-focused DUR 
Patient-focused DUR concentrates efforts on specific suggestions made about 
an individual patient.  Each suggestion, or template, attempts to make a change 
in therapy.  These changes are either therapeutic or cost-saving in nature; 
however, these situations are not necessarily mutually exclusive.  A therapeutic 
change -- one that improves the patient’s therapy in some way -- may also 
produce cost savings.  Cost-saving changes are attempted when a patient is not 
receiving a medication in the most economical form.  The intervention does not 
change the medication but points out that the same medication could be given in 
a more cost-effective manner.  Each template and intervention is evaluated to 
determine if the proposed change was implemented and, if so, what economic 
implications can be calculated. 
   
 
The calculation relating to therapeutic and cost saving interventions is tabulated 
by comparing a member’s initial profile with the member’s re-review profile. Each 
member profile is a six-month snapshot of medications covered by the Medicaid 
program.  Pertinent information such as patient name and ID, date of service, 
drug name, strength, and quantity, RX number, day supply, prescriber and 
pharmacy ID, total price submitted, and amount paid appear on each profile.  
There are nine months in between the initial and re-review profiles to 
accommodate for provider review, response, and implementation for therapeutic 
and or cost changes.  For each intervention, the total amount paid on the initial 
profile for any one intervention is noted.  According to the intervention at hand, 
the re-review profile is evaluated for change.  The amount paid on the re-review 
profile for the same intervention is also noted.  A comparison between the 
profiles is calculated by subtracting the total amount paid from the initial profile 
with the total amount paid from the re-review profile.  This calculation is then 
annualized multiplying the number by 2 to get the pre-rebate annualized savings.  
Consider this cost saving example: 
 
Template sent to the provider: 
According to the profile, this patient is receiving Lexapro 10mg tablets.  
Substantial cost savings can be realized by using one-half of a Lexapro 20mg 
tablet which is scored and easily broken.  Would this patient be a good candidate 
for this cost-saving measure? 
 
Information on initial profile sent to provider: 
Lexapro 10 mg #30= $83.04 
Lexapro 10 mg #30= $83.04 
Lexapro 10 mg #30= $83.04 
Lexapro 10 mg #30= $83.04 
Lexapro 10 mg #30= $83.04 
Lexapro 10 mg #30= $83.04 
Total Amount Paid $498.24 
 
Information on re-review profile used internally for evaluation: 
Lexapro 20 mg #15 = $45.92 
Lexapro 20 mg #15 = $45.92 
Lexapro 20 mg #15 = $45.92 
Lexapro 20 mg #15 = $45.92 
Lexapro 20 mg #15 = $45.92 
Lexapro 20 mg #15 = $45.92 
   Total Amount Paid $275.52  
 
Calculation of annualized savings  
$498.24 - $275.52 = $222.72 (savings for 6 months) 
$222.72 x 2 = $445.44 (savings for 12 months) 
Reported total pre-rebate annualized savings is  $445.44 
 
   
 
All savings for patient-focused review are based on annualized savings for one 
year only. Reporting on patient-focused interventions will provide the following 
information:   
 Total number of templates mentioned 
 Number of templates that were therapeutic in nature 
 Number of templates that were cost-saving in nature 
 Total number of changes implemented 
 Number of changes that were therapeutic in nature 
 Number of changes with positive impact without savings 
 Number of changes that were cost-saving in nature 
 Total dollars saved from therapeutic changes 
 Total dollars saved from cost-saving changes 
 Total dollars saved 
 Impact of interventions expressed as a percentage 
 
All templates are described by one of sixteen classifications.  These 
classifications indicate the general type of intervention addressed by the 
template.  Reports will also include a breakdown by classification (therapeutic or 
cost-saving) of the templates used in the patient-focused letters. This data will 
show which templates are cited most often, result in change most often, and 
result in higher cost savings.   
 
Templates that are therapeutic in nature include: 
 Not Optimal Drug 
 Not Optimal Dose 
 Not Optimal Duration of Use 
 Unnecessary Drug Use 
 Therapeutic Duplication 
 High Cost Drug 
 Drug-Drug Interaction 
 Drug-Disease Interaction 
 Adverse Drug Reaction 
 Patient Overuse 
 Patient Underuse 
 Therapeutic Alternative 
 Missing Drug Therapy 
 
Templates that are cost saving in nature include: 
 Not Optimal Dosage Form 
 Potential Generic Use 
 Inappropriate Billing 
 
   
Problem-focused DUR 
Problem-focused DUR concentrates efforts on a specific problem or trend in 
prescribing.  While patient-focused reviews may address a multitude of 
situations, a problem-focused review addresses only one concern.  The DUR 
Commission uses guidelines, literature and peer-group prescribing to identify 
particular clinical situations that need addressed.  This process ensures that 
each intervention is unique due to the subject matter and may differ in steps of 
evaluation.   
 
Reporting for problem-focused interventions will include the types of intervention 
done and the resulting savings. Savings are always calculated based on one 
year of therapy only and are calculated in the same manner as explained in the 
patient-focused DUR section. 
 
Administrative Review 
The Drug Utilization Review (DUR) program is a component of the Pharmacy 
Medical Division of the Iowa Medicaid Enterprise (IME).  DUR contributes 
expertise and information that leads to implementation in other programmatic 
areas including, but not limited to:  Prospective Drug Utilization Review, Prior 
Authorization, Preferred Drug List, Disease Management, and Supplemental 
Rebates.  Although the DUR program impacts all of the different pharmacy 
programs it is difficult to determine where its impact begins and ends. Therefore, 
the savings associated with DUR contribution in other pharmacy areas cannot be 
determined.  IME pharmacy programs are listed below along with a DUR impact 
statement and example: 
 
 Prospective DUR 
Definition:  A process in which a request for a drug product for a 
particular patient is screened for potential drug therapy problems 
before the product is dispensed.  
Impact:  The DUR Commission reviews scientific literature regarding 
specific medications and makes recommendations to DHS on 
appropriate utilization guidelines or parameters. 
Example:  The DUR Commission recommended that an age edit be 
placed on Provigil®, restricting its use in patients to those 16 years of 
age and older. 
 Prior Authorization 
Definition:  A process for obtaining approval for a drug before the drug 
is provided to a member, as a precondition for provider reimbursement. 
Prior authorization is requested at the prescriber level and is a 
prescriber fax-only system using the forms provided by the Iowa 
Medicaid Enterprise.   
Impact: The DUR Commission develops sound, cost-effective 
medication use guidelines by reviewing peer reviewed medical 
information form various sources.   The Commission seeks outside 
expertise when necessary and considers public comments prior to 
   
recommending step therapy for appropriate drug use. 
Example:  The DUR Commission developed the criteria for the 
Nicotine Replacement Therapy prior authorization. 
Prior Authorization is required for over-the-counter nicotine 
replacement patches and nicotine gum. Requests for authorization 
must include: 
1) Diagnosis of nicotine dependence and referral to the Quitline Iowa 
program for counseling. 
2) Confirmation of enrollment in the Quitline Iowa counseling program 
is required for approval. 
3) Approvals will only be granted for patients eighteen years of age 
and older. 
4) The maximum allowed duration of therapy is twelve weeks within a 
twelve-month period. 
5) A maximum quantity of 14 nicotine replacement patches and/or 110 
pieces of nicotine gum may be dispensed with the initial prescription. 
Subsequent prescription refills will be allowed to be dispensed as a 4 
week supply at one unit per day of nicotine replacement patches 
and/or 330 pieces of nicotine gum. Following the first 28 days of 
therapy, continuation is available only with documentation of ongoing 
participation in the Quitline Iowa program. 
 Preferred Drug List (PDL) 
Definition:  A list comprised of drugs recommended to the Iowa 
Department of Human Services by the Iowa Medicaid Pharmaceutical 
and Therapeutics Committee that have been identified as being 
therapeutically equivalent within a drug class and that provide cost 
benefit to the Medicaid program.   
Impact:  The DUR Commission makes referrals to and considers 
requests from the Pharmacy and Therapeutics (P&T) Committee to 
improve drug therapy.    
Example:  The DUR Commission recommended that the Iowa 
Medicaid Pharmacy and Therapeutics Committee change the status of 
products containing carisoprodol on the PDL from preferred to 
nonpreferred. 
 Disease management  
Definition:  A coordinated process by which Iowa Medicaid identifies 
and treats diseases within defined patient populations. This goal is 
achieved by identifying and delivering the most effective and efficient 
combination of available resources.  
Impact: The Commission reviews disease state guidelines to 
determine appropriate drug use, shares drug utilization information, 
and makes recommendations to improve therapeutic outcomes. 
Example:  DUR exchanged patient specific information with case 
management regarding utilization patterns of Advair®. 
 
 
   
 Supplemental rebates 
Definition:  A rebate given in addition to rebates received under the 
CMS Rebate Agreement, pursuant to Section 1927 of the Social 
Security Act (42 USC 1396r-8).   
Impact:  The existence of a supplemental rebate and how it may 
impact the price of a medication is taken into consideration when the 
DUR Commission makes recommendations. 
Example: The DUR Commission requested that the Iowa Medicaid 
P&T Committee review the different dosage forms of nicotine 
replacement therapy and share information as to which products were 
the most cost effective. 
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ReportPatient-Focused Reviews SFY15
Initial Review Date Oct-13 Dec-13 Feb-14 Apr-14 Jun-14 Aug-14
Evaluation Date Jul-14 Sep-14 Nov-14 Jan-15 Mar-15 May-15 Total
Profiles Reviewed 300 300 300 300 300 300 1,800
Profiles Evaluated 197 198 199 203 210 214 1,221
Letters Sent 443 462 459 466 496 476 2,802 100.00%
Prescribers 236 243 248 245 271 252 1,495 53.35%
Pharmacy 207 219 211 221 225 224 1,307 46.65%
Responses Received 158 163 178 194 186 180 1,059 100.00%
Prescribers 94 86 107 104 107 103 601 56.75%
Pharmacy 64 77 71 90 79 77 458 43.25%
Total Number of Templates Mentioned 203 208 203 209 220 219 1,262 100.00%
Therapeutic 197 201 201 200 215 211 1,225 97.07%
Cost-Saving 6 7 2 9 5 8 37 2.93%
Total Number of Changes Made 11 12 10 11 14 13 71 100.00%
Therapeutic 11 12 10 11 12 12 68 95.77%
Cost-Saving 0 0 0 0 1 1 2 2.82%
Positive Impact Only 0 0 0 0 1 0 1 1.41%
Total Dollars Saved - Therapeutic Changes $12,880.33 $4,614.78 $50,724.89 $37,955.63 $5,212.75 $5,527.08 $116,915.46 90.53%
Total Dollars Saved - Cost Saving Changes $0.00 $0.00 $0.00 $0.00 $3,215.57 $9,014.33 $12,229.90 9.47%
Total Dollars Saved on Medication* $12,880.33 $4,614.78 $50,724.89 $37,955.63 $8,428.32 $14,541.41 $129,145.36 100.00%
Total Dollars Saved Per Profile Evaluated $65.38 $23.31 $254.90 $186.97 $40.13 $67.95 $105.77
*Savings reported are pre-rebate, total dollars
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SFY15
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Evaluation Date
Template Classification Suggestions Changes Suggestions Changes Suggestions Changes Suggestions Changes Suggestions Changes Suggestions Changes Total Suggestions Total Changes
Adverse Drug Reaction 1 0 0 0 0 0 0 0 0 0 0 0 1 0
Drug-Disease Interaction 1 0 0 0 0 0 0 0 0 0 0 0 1 0
Drug-Drug Interaction 19 1 12 2 14 0 10 1 11 0 12 1 78 5
High Cost Drug 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Innapropriate Billing 2 0 4 0 0 0 2 0 4 1 4 1 16 2
Missing Drug Therapy 0 0 0 0 1 0 2 0 1 1 0 0 4 1
Not Optimal Dosage Form 4 0 1 0 1 0 4 0 0 0 3 0 13 0
Not Optimal Dose 9 1 7 0 2 0 7 0 4 1 4 0 33 2
Not Optimal Drug 19 1 14 2 24 1 10 3 13 0 16 0 96 7
Not Optimal Duration 6 0 9 0 2 0 7 0 9 0 3 0 36 0
Patient Overuse 0 0 0 0 1 0 3 0 2 0 1 0 7 0
Patient Underuse 1 0 2 0 1 0 5 1 3 0 5 1 17 2
Potential Generic Use 0 0 2 0 2 0 3 0 1 0 1 1 9 1
Therapeutic Alternative 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Therapeutic Duplication 138 7 138 6 148 9 150 6 143 7 152 8 869 43
Unnecessary Drug Therapy 3 1 19 2 7 0 6 0 29 4 18 1 82 8
Total 203 11 208 12 203 10 209 11 220 14 219 13 1,262 71
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Therapeutic Alternative 0 0.00% 0.00%
0.00%
Potential Generic Use 9 1.41% 11.11% 0.58%
Patient Overuse 7 0.00% 0.00%
2.09%
Not Optimal Duration 36 0.00% 0.00% 0.00%
Not Optimal Drug 96 9.86% 7.29%
33 2.82% 6.06% 0.26%
13 0.00% 0.00% 0.00%
0.07%
Missing Drug Therapy 4 1.41% 0.00% 0.00%
Inappropriate Billing 16 2.82% 12.50%
0.00% 0.00% 0.00%
78 7.04% 6.41% 0.29%
% Dollars Saved
Drug-Disease Interaction 1 0.00% 0.00% 0.00%
Total Suggestions % of Total Changes % of Suggestions 
Changed
Adverse Drug Reaction
Drug-Drug Interaction
High Cost Drug
Not Optimal Dosage Form
Not Optimal Dose
0.00%Patient Underuse 17 2.82% 11.76%
0
Prepared by the Iowa Medicaid Drug Utilization Review Commission
Savings By Template Class
SFY15
Initial Review Date Oct-13 Dec-13 Feb-14 Apr-14 Jun-14 Aug-14
Evaluation Dte Jul-14 Sep-14 Nov-14 Jan-15 Mar-15 May-15
Total
Template Classification
Adverse Drug Reaction $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Drug-Disease Interaction $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Drug-Drug Interaction $68.19 $154.07 $0.00 $71.74 $0.00 $84.76 $378.76
High Cost Drug $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Inappropriate Billing $0.00 $0.00 $0.00 $0.00 $49.81 $39.63 $89.44
Missing Drug Therapy $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Not Optimal Dosage Form $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Not Optimal Dose $107.68 $0.00 $0.00 $0.00 $231.17 $0.00 $338.85
Not Optimal Drug $704.68 $914.19 $471.26 $609.13 $0.00 $0.00 $2,699.26
Not Optimal Duration $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Patient Overuse $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Patient Underuse $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Potential Generic Use $0.00 $0.00 $0.00 $0.00 $0.00 $753.06 $753.06
Therapeutic Alternative $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Therapeutic Duplication $11,856.37 $1,841.16 $50,253.63 $37,274.76 $6,350.93 $13,030.15 $120,607.00
Unnecessary Drug Therapy $143.41 $1,705.36 $0.00 $0.00 $1,796.41 $633.81 $4,278.99
Total $12,880.33 $4,614.78 $50,724.89 $37,955.63 $8,428.32 $14,541.41 $129,145.36
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Study 110 
Intervention Case Summaries 
August 2014 
 
The Commission reviewed the profile of a 53 year-old female using omeprazole 
and famotidine concurrently.  The Commission asked if the patient could be 
adequately controlled on one or the other medications, pointing PPIs should be 
used at the lowest dose and shortest duration due to the increased risk 
osteoporosis-related fractures of the hip, wrist, and spine; increased risk of 
clostridium difficile-associated diarrhea; and increased risk of hypomagnesemia 
with the long-term use of PPIs.  Upon re-review, omperazole and famotidine 
were discontinued and replaced with ranitidine. 
 Annualized pre-rebate savings (state and federal) = $198.25 (taking into 
consideration the cost of ranitidine) 
 
 
The Commission reviewed the profile of a 43 year-old female taking cetirizine 
and loratadine concurrently.  The Commission asked what the clinical situation 
was for the combined use of the antihistamines and if one could be discontinued.  
Upon re-review, loratadine was discontinued. 
Annualized pre-rebate savings (state and federal) = $149.08 
 
 
The Commission reviewed the profile of a 53 year-old male taking two 
anticonvulsants (gabapentin and topiramate) concurrently without a seizure 
diagnosis.  The Commission asked what the clinical situation was that required 
the combined use of these medications and asked if one medication could be 
discontinued and the dose of the other be adjusted if needed.  Upon re-review, 
gabapentin was discontinued and the dose of topiramate remained the same. 
Annualized pre-rebate savings (state and federal) = $165.15  
 
 
The Commission reviewed the profile of a 54 year-old female taking Cymbalta 
and escitalopram concurrently.  The Commission pointed out the increased risk 
of serotonin syndrome and asked if one of the antidepressants could be 
discontinued with a dose adjustment of the other, if needed.  Upon re-review, 
Cymbalta was discontinued and the dose of escitalopram remained the same. 
Annualized pre-rebate savings (state and federal) = $2,678.62 
 
Study 111 
Intervention Case Summaries 
October 2014 
 
The Commission reviewed the profile of a 60 year-old female using haloperidol 
and quetiapine concurrently (both at sub-optimal doses).  The Commission asked 
if the patient is in the process of having the medications cross-tapered and if a 
sequence of monotherapy trials with each of the antipsychotics at a maximally 
tolerated dose had been tried without success.  Upon re-review, haloperidol was 
discontinued and the dose of quetiapine was increased. 
 Annualized pre-rebate savings (state and federal) = $378.32 (taking into 
consideration the increased dose of quetiapine) 
 
 
The Commission reviewed the profile of a 48 year-old female taking Fanapt and 
risperidone concurrently.  The Commission asked if the patient is in the process 
of having the medications cross-tapered and if a sequence of monotherapy trials 
with each of the antipsychotics at a maximally tolerated dose had been tried 
without success.  Upon re-review, risperidone was discontinued and the dose of 
Fanapt remained the same. 
Annualized pre-rebate savings (state and federal) = $185.74 
 
 
The Commission reviewed the profile of a 13 year-old male taking ziprasidone 
and risperidone concurrently.  The Commission asked if the patient is in the 
process of having the medications cross-tapered and if a sequence of 
monotherapy trials with each of the antipsychotics at a maximally tolerated dose 
had been tried without success.  Upon re-review, ziprasidone was discontinued 
and the dose of risperidone remained the same. 
Annualized pre-rebate savings (state and federal) = $1,290.12  
 
 
The Commission reviewed the profile of a 19 year-old male taking amoxicillin 
chewable tablets chronically.  The Commission asked what the clinical situation 
was that required the use of amoxicillin chronically.  Upon re-review, amoxicillin 
was discontinued. 
Annualized pre-rebate savings (state and federal) = $200.13 
 
Study 122 
Intervention Case Summaries 
December 2014 
 
The Commission reviewed the profile of a 10 year-old female using clonidine and 
guanfacine concurrently.  The Commission asked what the clinical situation was 
that required the use of two alpha2-adrenergic agonists to treat the patient and if 
one medication could be discontinued with a dose adjustment of the other, if 
needed.  Upon re-review, clonidine was discontinued. 
Annualized pre-rebate savings (state and federal) = $137.00  
 
 
The Commission reviewed the profile of a 61 year-old male taking lisinopril and 
Diovan concurrently.  The Commission pointed out the increased risk of 
significant adverse effects with combined use and asked if one of the 
medications could be discontinued.  Upon re-review, lisinopril was discontinued. 
Annualized pre-rebate savings (state and federal) = $139.14 
 
 
The Commission reviewed the profile of a 30 year-old female taking Abilify and 
risperidone concurrently.  The Commission asked if the patient is in the process 
of having the medications cross-tapered and if a sequence of monotherapy trials 
with each of the antipsychotics at a maximally tolerated dose had been tried 
without success.  Upon re-review, Abilify was discontinued and the dose of 
risperidone remained the same. 
Annualized pre-rebate savings (state and federal) = $6,547.00  
 
 
The Commission reviewed the profile of a 55 year-old male taking Abilify and 
quetiapine concurrently.  The Commission asked if the patient is in the process of 
having the medications cross-tapered and if a sequence of monotherapy trials 
with each of the antipsychotics at a maximally tolerated dose had been tried 
without success.  Upon re-review, Abilify was discontinued and the dose of 
quetiapine remained the same. 
Annualized pre-rebate savings (state and federal) = $4,673.47 
 
Study 123 
Intervention Case Summaries 
February 2015 
 
The Commission reviewed the profile of a 47 year-old female taking zolpidem 
15mg daily.  The Commission asked what the clinical situation was that required 
the use of a dose exceeding the maximum recommended dose of 10mg daily 
and if the dose could be decreased to 10mg daily.  Upon re-review, the dose was 
decreased to 10mg daily. 
Annualized pre-rebate savings (state and federal) = $152.02  
 
 
The Commission reviewed the profile of a 48 year-old male taking carvedilol and 
Toprol XL concurrently.  The Commission asked what the clinical situation was 
requiring two beta-blockers and asked if one of the medications could be 
discontinued.  Upon re-review, Toprol XL was discontinued and the dose of 
carvedilol remained the same. 
Annualized pre-rebate savings (state and federal) = $561.45 
 
 
The Commission reviewed the profile of a 63 year-old male taking low dose 
clozapine and Invega concurrently.  The Commission asked if the patient is in the 
process of having the medications cross-tapered and if a sequence of 
monotherapy trials with each of the antipsychotics at a maximally tolerated dose 
had been tried without success.  Upon re-review, clozapine was discontinued 
and the dose of Invega remained the same. 
Annualized pre-rebate savings (state and federal) = $456.15  
 
 
The Commission reviewed the profile of a 21 year-old female taking two short-
acting opioids concurrently (hydromorphone and hydrocodone/apap) and a sub-
therapeutic dose of morphine sulfate ER.  The Commission asked if the patient 
would be a candidate to optimize the long-acting opioid with a dose reduction or 
discontinuation of one or both of the short-acting opioids.  Upon re-review, 
hydrocodone/apap and morphine sulfate ER were discontinued and the patient 
was switched to Avinza.  The hydromorphone dose was unchanged. 
Annualized pre-rebate savings (state and federal) = ($1,324.70) 
 
Study 126 
Intervention Case Summaries 
April 2015 
 
The Commission reviewed the profile of a 59 year-old female taking 
methocarbamol and tizanidine concurrently.  The Commission asked if it was 
possible to discontinue one of the muscle relaxants and adjust the dose of the 
other, if needed.  Upon re-review, tizanidine was discontinued while the dose of 
methocarbamol remained unchanged. 
Annualized pre-rebate savings (state and federal) = $374.54  
 
 
The Commission reviewed the profile of a 19 year-old female taking 
hydromorphone and oxycodone IR concurrently.  The Commission asked if it was 
possible to discontinue one or both of the opioids and adjust the dose of the 
remaining short-acting opioid and/or add a long-acting opioid.  Upon re-review, 
hydromorphone and oxycodone IR were discontinued and methadone was 
added. 
Annualized pre-rebate savings (state and federal) = $942.88 
 
 
The Commission reviewed the profile of a 31 year-old female taking temazepam 
and zalpelon concurrently.  The Commission asked what the clinical situation 
was that required the use of these medications and if one could be discontinued.  
Upon re-review, temazepam and zalpelon were discontinued and eszopiclone 
was added. 
Annualized pre-rebate savings (state and federal) = $49.27   
 
 
The Commission reviewed the profile of a 28 year-old female taking gemfibrozil 
and Tricor concurrently.  The Commission asked if the patient could be 
adequately controlled with one of the medications. Upon re-review, gemfibrozil 
was discontinued while the dose of Tricor remained unchanged.   
Annualized pre-rebate savings (state and federal) = $186.16 
 
Study 129 
Intervention Case Summaries 
June 2015 
 
The Commission reviewed the profile of a 49 year-old female in a nursing home 
receiving promethazine tablets every 4 days (7 times per month) over several 
months.  The Commission pointed out the frequent billing and asked if a larger 
amount of medication could be billed less frequently.  Upon re-review, 
promethazine tablets were being billed in a larger quantity twice per month. 
Annualized pre-rebate savings (state and federal) = $755.42  
 
 
The Commission reviewed the profile of a 55 year-old female taking three 
antipsychotics concurrently (thiothixene, quetiapine, and olanzapine).  The 
Commission asked if it was possible to discontinue one or more of the 
antipsychotics.  Upon re-review, quetiapine (low dose) was discontinued while 
the dose of the other antipsychotics remained the same. 
Annualized pre-rebate savings (state and federal) = $170.16 
 
 
The Commission reviewed the profile of a 39 year-old female taking four 
antidepressants concurrently (amitriptyline, escitalopram, trazodone, and 
venlafaxine er).  The Commission pointed out there is no evidenced-based 
literature to support the use of four antidepressants and asked if one or more of 
the antidepressants could be discontinued.  Upon re-review, amitriptyline and 
escitalopram were discontinued while the dose of the other antidepressants 
remained the same.  Note:  2 prescribers were involved. 
Annualized pre-rebate savings (state and federal) = $376.84   
 
 
The Commission reviewed the profile of a 39 year-old female taking Advair and 
Dulera concurrently.  The Commission asked what the clinical situation was that 
required the combined use of these medications and if one could be 
discontinued. Upon re-review, Advair was discontinued.   
Annualized pre-rebate savings (state and federal) = $3,622.98 
 
Appendix E 
Results Problem-Focused 
Evaluation Period Patients Reviewed
Opioid Overutilization 06/01/2013 - 07/31/2013 06/01/2014 - 07/31/2014 38
Opioid Utilization - Potential Drug Seeking Behavior 06/01/2013 - 07/31/2013 06/01/2014 - 07/31/2014 244
Three or More Antiepileptics with a Seizure Diagnosis 07/01/2013 - 09/30/2013 07/01/2014 - 09/30/2014 291
Three or More Antiepileptics without a Seizure Diagnosis 07/01/2013 - 09/30/2013 07/01/2014 - 09/30/2014 25 ª
Memantine Utilization without a Valid Diagnosis 07/01/2013 - 09/30/2013 07/01/2014 - 09/30/2014 51
Duloxetine Dose Greater Than 120mg Per Day 07/01/2013 - 09/30/2013 07/01/2014 - 09/30/2014 2
Sublingual/Translingual Nitroglycerin Utilization 11/01/2013 - 01/31/2014 09/01/2014 - 11/30/2014 16
Chronic Transdermal Scopolamine Utilization 11/01/2013 - 01/31/2014 09/01/2014 - 11/30/2014 34
Naltrexone Utilization in the Pediatric Population 01/01/2014 - 03/31/2014 11/01/2014 - 01/31/2015 12
Adalimumab Use without Methotrexate 01/01/2014 - 03/31/2014 11/01/2014 - 01/31/2015 10 ª
Prasugrel Contraindications 12/01/2013 - 05/31/2014 01/01/2015 - 03/31/2015 6 $1,194.92
Eszopiclone Dosing 04/01/2014 - 06/30/2014 02/01/2015 - 03/31/2015 52 $48,667.64
Short-Acting Opioid Overutilization - Concurrent Therapy 12/01/2013 - 05/31/2014 10/01/2014 - 03/31/2015 33 $1,876.16
Short-Acting Opioid Overutilization - Four or More Doses Per Day 12/01/2013 - 05/31/2014 10/01/2014 - 03/31/2015 1,990 $93,607.04
TOTAL 2,804
*Savings reported are pre-rebate, total dollars
ª Positive imact only
$2,161.96
$0.00 
$1,769.12
$540,191.68
$21,112.16 
Problem Focused Studies SFY15
$0.00
$0.00
$42,567.64
Review Period
$255,021.08
Focus Study Total Cost Savings*
$5,445.06
$66,768.90
Prepared by the Iowa Medicaid Drug Utilization Review Commission
Review Period Evaluation 
Period
Postive 
Impact
Opioid Overutilization 06/01/2013 - 07/31/2013 06/01/2014 - 07/31/2014 38 22 57.9%
Opioid Utilization - Potential Drug Seeking Behavior 06/01/2013 - 07/31/2013 06/01/2014 - 07/31/2014 244 120 49.2%
Three or More Antiepileptics with a Seizure Diagnosis 07/01/2013 - 09/30/2013 07/30/2014 - 09/30/2014 291 53 18.2%
Three or More Antiepileptics without a Seizure Diagnosis 07/01/2013 - 09/30/2013 07/30/2014 - 09/30/2014 25 10 40.0%
Memantine Utilization without a Valid Diagnosis 07/01/2013 - 09/30/2013 07/01/2014 - 09/30/2014 51 19 37.3%
Duloxetine Dose Greater Than 120mg Per Day 07/01/2013 - 09/30/2013 07/01/2014 - 09/30/2014 2 0 0.0%
Sublingual/Translingual Nitroglycerin Utilization 09/01/2014 - 11/30/2014 16 12 75.0%
Chronic Transdermal Scopolamine Utilization 09/01/2014 - 11/30/2014 34 13 38.2%
Naltrexone Utilization in the Pediatric Population 11/01/2014 - 01/31/2015 12 5 41.7%
Adalimumab Use without Methotrexate 11/01/2014 - 01/31/2015 10 2 20.0%
Prasugrel Contraindications 12/01/2013 - 05/31/2014 01/01/2015 - 03/31/2015 6 2 33.3%
Eszopiclone Dosing 04/01/2014 - 06/30/2014 02/01/2015 - 03/31/2015 52 31 59.6%
Short-Acting Opioid Overutilization - Concurrent Therapy 12/01/2013 - 05/31/2014 10/01/2014 - 03/31/2015 33 9 27.3%
Short-Acting Opioid Overutilization - Four or More Doses Per Day 12/01/2013 - 05/31/2014 10/01/2014 - 03/31/2015 1,990 367 18.4%
TOTAL 2,804 665 23.7%
Problem Focused Studies Impact Rate SFY15
Focus Study Patients Reviewed Impact Rate
11/01/2013 - 01/31/2014
11/01/2013 - 01/31/2014
01/01/2014 - 03/31/2014
01/01/2014 - 03/31/2014
Prepared by the Iowa Medicaid Drug Utilization Review Commission
Appendix F 
Descriptions Problem-Focused 
Number of unique members from original 
study 244
Number of unique members that changed 
therapy 120
Number of unique members that did not 
change therapy 74
Number of members who lost Medicaid 
eligibility since 8/1/2013 50
Number of surveys sent to prescribers 528 Number of surveys received from prescribers 245 Percent of surveys from prescribers 46.40%
Number of surveys sent to pharmacies 413 Number of surveys received from pharmacies 136 Percent of surveys from pharmacies 32.93%
Total number of surveys sent 941 Total number of surveys received 381 Percent of surveys received 40.49%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(6/1/2013 - 7/31/2013)* (6/1/2014 - 7/31/2014)**
Total Dollars Federal $41,219.33 $33,885.47 $6,434.30 $38,605.80
Total Dollars State $28,513.93 $24,719.64 $4,693.85 $28,163.10
Total Dollars (State and Federal) $69,733.26 $58,605.11 $11,128.15 $66,768.90
*  Federal FMAP: 0.59110  State: 0.40890
** Federal FMAP: 0.57820  State: 0.42180
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members, without a cancer diagnosis, that had five or more claims for three or more different opioids in a 60-day period.
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Opioid Overutilization
Number of unique members from original 
study 38
Number of unique members that changed 
therapy 22
Number of unique members that did not 
change therapy 2
Number of members who lost Medicaid 
eligibility since 8/1/2013 14
Number of surveys sent to prescribers 200 Number of surveys received from prescribers 69 Percent of surveys from prescribers 34.50%
Number of surveys sent to pharmacies 175 Number of surveys received from pharmacies 61 Percent of surveys from pharmacies 34.86%
Total number of surveys sent 375 Total number of surveys received 130 Percent of surveys received 34.67%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(6/1/2013 - 7/31/2013)* (6/1/2014 - 7/31/2014)**
Total Dollars Federal $2,530.81 $1,950.85 $524.72 $3,148.32
Total Dollars State $1,750.71 $1,423.16 $382.79 $2,296.74
Total Dollars (State and Federal) $4,281.52 $3,374.01 $907.51 $5,445.06
*  Federal FMAP: 0.59110  State: 0.40890
** Federal FMAP: 0.57820  State: 0.42180
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as having claims for opioids from four or more prescribers and three or more pharmacies in a 60-day period.
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Opioid Overutilization
Number of unique members from original 
study 291
Number of unique members that changed 
therapy 53
Number of unique members that did not 
change therapy 218
Number of members who lost Medicaid 
eligibility since 10/1/2013 20
Number of surveys sent to prescribers 442 Number of surveys received from prescribers 215 Percent of surveys from prescribers 48.64%
Number of surveys sent to pharmacies 309 Number of surveys received from pharmacies 97 Percent of surveys from pharmacies 31.39%
Total number of surveys sent 751 Total number of surveys received 312 Percent of surveys received 41.54%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(7/1/2013 - 9/30/2013)* (7/1/2014 - 9/30/2014)**
Total Dollars Federal $472,528.21 $427,418.75 $36,525.39 $146,101.56
Total Dollars State $337,288.77 $318,642.96 $27,229.88 $108,919.52
Total Dollars (State and Federal) $809,816.98 $746,061.71 $63,755.27 $255,021.08
*  Federal FMAP: 0.58350  State: 0.41650
** Federal FMAP: 0.57290  State: 0.42710
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members, with a seizure/epilepsy diagnosis, identified as taking three or more distinct antiepileptic drugs (AEDs) concurrently for 
more than 60 days
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Use of Three or More Antiepileptic Medications
Number of unique members from original 
study 25
Number of unique members that changed 
therapy 10
Number of unique members that did not 
change therapy 13
Number of members who lost Medicaid 
eligibility since 10/1/2013 2
Number of surveys sent to prescribers 43 Number of surveys received from prescribers 19 Percent of surveys from prescribers 44.19%
Number of surveys sent to pharmacies 30 Number of surveys received from pharmacies 10 Percent of surveys from pharmacies 33.33%
Total number of surveys sent 73 Total number of surveys received 29 Percent of surveys received 39.73%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings**** ^
(7/1/2013 - 9/30/2013)* (7/1/2014 - 9/30/2014)**
Total Dollars Federal $8,431.09 $8,826.91 ($548.98) ($2,195.92)
Total Dollars State $6,018.08 $6,580.50 ($409.26) ($1,637.04)
Total Dollars (State and Federal) $14,449.17 $15,407.41 ($958.24) ($3,832.96)
*  Federal FMAP: 0.58350  State: 0.41650
** Federal FMAP: 0.57290  State: 0.42710
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
 ^Negative cost savings due to pre-rebate costs 
Follow-up on the unique members, without a seizure/epilepsy diagnosis, identified as taking three or more distinct antiepileptic drugs (AEDs) concurrently 
for more than 60 days
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Use of Three or More Antiepileptic Medications
Number of unique members from original 
study 51
Number of unique members that changed 
therapy 19
Number of unique members that did not 
change therapy 29
Number of members who lost Medicaid 
eligibility since 10/1/2013 3
Number of surveys sent to prescribers 55 Number of surveys received from prescribers 29 Percent of surveys from prescribers 52.73%
Number of surveys sent to pharmacies 53 Number of surveys received from pharmacies 19 Percent of surveys from pharmacies 35.85%
Total number of surveys sent 108 Total number of surveys received 48 Percent of surveys received 44.44%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(7/1/2013 - 9/30/2013)* (7/1/2014 - 9/30/2014)**
Total Dollars Federal $18,248.63 $11,820.37 $6,096.75 $24,387.00
Total Dollars State $13,025.80 $8,812.15 $4,545.16 $18,180.64
Total Dollars (State and Federal) $31,274.43 $20,632.52 $10,641.91 $42,567.64
*  Federal FMAP: 0.58350  State: 0.41650
** Federal FMAP: 0.57290  State: 0.42710
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as taking memantine without a valid diagnosis for use in their medical claims history
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Namenda (Memantine) Utilization
Number of unique members from original 
study 2
Number of unique members that changed 
therapy 0
Number of unique members that did not 
change therapy 0
Number of members who lost Medicaid 
eligibility since 10/1/2013 2
Number of surveys sent to prescribers 2 Number of surveys received from prescribers 1 Percent of surveys from prescribers 50.00%
Number of surveys sent to pharmacies 2 Number of surveys received from pharmacies 0 Percent of surveys from pharmacies 0.00%
Total number of surveys sent 4 Total number of surveys received 1 Percent of surveys received 25.00%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(7/1/2013 - 9/30/2013)* (7/1/2014 - 9/30/2014)**
Total Dollars Federal $2,382.72 $0.00 $0.00 $0.00
Total Dollars State $1,700.77 $0.00 $0.00 $0.00
Total Dollars (State and Federal) $4,083.49 $0.00 $0.00 $0.00
*  Federal FMAP: 0.58350  State: 0.41650
** Federal FMAP: 0.57290  State: 0.42710
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as taking duloxetine at a dose greater than 120mg per day
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Cymbalta Dose > 120mg/day
Number of unique members from original 
study 16
Number of unique members that changed 
therapy 12
Number of unique members that did not 
change therapy 3
Number of members who lost Medicaid 
eligibility since 2/1/2014 1
Number of surveys sent to prescribers 27 Number of surveys received from prescribers 12 Percent of surveys from prescribers 44.44%
Number of surveys sent to pharmacies 16 Number of surveys received from pharmacies 7 Percent of surveys from pharmacies 43.75%
Total number of surveys sent 43 Total number of surveys received 19 Percent of surveys received 44.19%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(11/1/2013 - 1/31/2014)* (9/1/2014 - 11/30/2014)**
Total Dollars Federal $529.69 $266.68 $253.38 $1,013.52
Total Dollars State $378.09 $198.82 $188.90 $755.60
Total Dollars (State and Federal) $907.78 $465.50 $442.28 $1,769.12
*  Federal FMAP: 0.58350  State: 0.41650
** Federal FMAP: 0.57290  State: 0.42710
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as having claims for sublingual or translingual nitroglycerin for three consecutive months.
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Nitroglycerin Sublingual/Translingual Over Utilization
Number of unique members from original 
study 34
Number of unique members that changed 
therapy 13
Number of unique members that did not 
change therapy 16
Number of members who lost Medicaid 
eligibility since 2/1/2014 5
Number of surveys sent to prescribers 37 Number of surveys received from prescribers 12 Percent of surveys from prescribers 32.43%
Number of surveys sent to pharmacies 34 Number of surveys received from pharmacies 17 Percent of surveys from pharmacies 50.00%
Total number of surveys sent 71 Total number of surveys received 29 Percent of surveys received 40.85%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(11/1/2013 - 1/31/2014)* (9/1/2014 - 11/30/2014)**
Total Dollars Federal $7,799.18 $4,633.71 $3,023.79 $12,095.16
Total Dollars State $5,567.02 $3,454.45 $2,254.25 $9,017.00
Total Dollars (State and Federal) $13,366.20 $8,088.16 $5,278.04 $21,112.16
*  Federal FMAP: 0.58350  State: 0.41650
** Federal FMAP: 0.57290  State: 0.42710
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as using transdermal scopolamine on a chronic basis.
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Chronic Use of Transdermal Scopolamine
Number of unique members from original 
study 12
Number of unique members that changed 
therapy 5
Number of unique members that did not 
change therapy 6
Number of members who lost Medicaid 
eligibility since 4/1/2014 1
Number of surveys sent to prescribers 12 Number of surveys received from prescribers 6 Percent of surveys from prescribers 50.00%
Number of surveys sent to pharmacies 14 Number of surveys received from pharmacies 8 Percent of surveys from pharmacies 57.14%
Total number of surveys sent 26 Total number of surveys received 14 Percent of surveys received 53.85%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(1/1/2014 - 3/31/2014)* (11/1/2014 - 1/31/2015)**
Total Dollars Federal $657.82 $330.49 $300.19 $1,200.76
Total Dollars State $477.72 $264.56 $240.30 $961.20
Total Dollars (State and Federal) $1,135.54 $595.05 $540.49 $2,161.96
*  Federal FMAP: 0.57930  State: 0.42070
** Federal FMAP: 0.55540  State: 0.44460
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as using Naltrexone for potential off-label use in the pediatric population.
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Naltrexone Utilization in the Pediatric Population
Number of unique members from original 
study 10
Number of unique members that added 
MTX therapy 2
Number of unique members that did not 
add MTX therapy 6
Number of members who lost Medicaid 
eligibility since 4/1/2014 2
Number of surveys sent to prescribers 10 Number of surveys received from prescribers 7 Percent of surveys from prescribers 63.64%
Number of surveys sent to pharmacies 10 Number of surveys received from pharmacies 4 Percent of surveys from pharmacies 36.36%
Total number of surveys sent 20 Total number of surveys received 11 Percent of surveys received 55.00%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(1/1/2014 - 3/31/2014)* (11/1/2014 - 1/31/2015)**
Total Dollars Federal $41,446.89 $39,866.67 ($129.74) ($518.96)
Total Dollars State $30,099.62 $31,913.44 ($103.86) ($415.44)
Total Dollars (State and Federal) $71,546.51 $71,780.11 ($233.60) ($934.40)
*  Federal FMAP: 0.57930  State: 0.42070
** Federal FMAP: 0.55540  State: 0.44460
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as using adalimumab without methotrexate (MTX).
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Adalimumab use without Methotrexate
Number of unique members from original 
study 6
Number of unique members that changed 
therapy 2
Number of unique members that did not 
change therapy 4
Number of members who lost Medicaid 
eligibility since 6/1/2014 0
Number of surveys sent to prescribers 7 Number of surveys received from prescribers 3 Percent of surveys from prescribers 42.86%
Number of surveys sent to pharmacies 7 Number of surveys received from pharmacies 3 Percent of surveys from pharmacies 42.86%
Total number of surveys sent 14 Total number of surveys received 6 Percent of surveys received 42.86%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(12/1/2013 - 5/31/2014)* (1/1/2015 - 3/31/2015)**
Total Dollars Federal $4,119.53 $3,783.66 $165.91 $663.64
Total Dollars State $2,991.69 $3,028.83 $132.82 $531.28
Total Dollars (State and Federal) $7,111.22 $6,812.49 $298.73 $1,194.92
*  Federal FMAP: 0.57930  State: 0.42070
** Federal FMAP: 0.55540  State: 0.44460
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as having a contraindication to use of prasugrel.
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Prasugrel Contraindications
Number of unique members from original 
study 52
Number of unique members that changed 
therapy 31
Number of unique members that did not 
change therapy 14
Number of members who lost Medicaid 
eligibility since 7/1/2014 7
Number of surveys sent to prescribers 52 Number of surveys received from prescribers 23 Percent of surveys from prescribers 44.23%
Number of surveys sent to pharmacies 53 Number of surveys received from pharmacies 14 Percent of surveys from pharmacies 26.42%
Total number of surveys sent 105 Total number of surveys received 37 Percent of surveys received 35.24%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Cost Savings*** Annualized Cost Savings****
(4/1/2014 - 6/30/2014)* (2/1/2015 - 3/31/2015)**
Total Dollars Federal $23,412.65 $15,689.23 $6,757.50 $27,030.00
Total Dollars State $17,002.77 $12,559.29 $5,409.41 $21,637.64
Total Dollars (State and Federal) $40,415.42 $28,248.52 $12,166.91 $48,667.64
*  Federal FMAP: 0.57930  State: 0.42070
** Federal FMAP: 0.55540  State: 0.44460
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as taking eszopiclone 3mg daily
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Eszopiclone Dosing
Number of unique members from original 
study 33
Number of unique members that changed 
therapy 9
Number of unique members that did not 
change therapy 21
Number of members who lost Medicaid 
eligibility since 6/1/2014 3
Number of surveys sent to prescribers 59 Number of surveys received from prescribers 17 Percent of surveys from prescribers 28.81%
Number of surveys sent to pharmacies 50 Number of surveys received from pharmacies 21 Percent of surveys from pharmacies 42.00%
Total number of surveys sent 109 Total number of surveys received 38 Percent of surveys received 34.86%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Additional Cost of Cost Savings*** Annualized Cost Savings****
(12/1/2013 - 5/31/2014)* (10/1/2014 - 3/31/2015)** Long-Acting Opioid
Total Dollars Federal $9,937.14 $8,415.43 $590.73 $521.01 $1,042.02
Total Dollars State $7,216.56 $6,736.58 $472.88 $417.07 $834.14
Total Dollars (State and Federal) $17,153.70 $15,152.01 $1,063.61 $938.08 $1,876.16
*  Federal FMAP: 0.57930  State: 0.42070
** Federal FMAP: 0.55540  State: 0.44460
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as taking two or more chemically distinct short-acting opioids concurrently for 90 or more days without using a long-acting opioid. 
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Opioid Overuse – Concurrent Short-Acting Opioids 
Number of unique members from original study 1,990
Number of unique members that changed therapy 367
  1) discontinued therapy 141
  2) decreased doses/day 188
  3) decreased doses/day added long-acting opioid 38
Number of unique members that did not change therapy 1,327
Number of members who lost Medicaid eligibility since 
6/1/2014 296
Number of surveys sent to prescribers 3,433 Number of surveys received from prescribers 1,495 Percent of surveys from prescribers 63.81%
Number of surveys sent to pharmacies 2,919 Number of surveys received from pharmacies 848 Percent of surveys from pharmacies 36.19%
Total number of surveys sent 6,352 Total number of surveys received 2,343 Percent of surveys received 36.89%
Costs (Pre-Rebate) Original Costs Costs After DUR Intervention Additional Cost of Cost Savings*** Annualized Cost Savings****
(12/1/2013 - 5/31/2014)* (10/1/2014 - 3/31/2015)** Long Acting Opioid
Total Dollars Federal $300,822.88 $259,154.52 $3,262.73 $25,994.67 $51,989.35
Total Dollars State $218,463.98 $207,454.27 $2,611.82 $20,808.85 $41,617.69
Total Dollars (State and Federal) $519,286.86 $466,608.79 $5,874.55 $46,803.52 $93,607.04
*  Federal FMAP: 0.57930  State: 0.42070
** Federal FMAP: 0.55540  State: 0.44460
*** Some savings may be due to changes in reimbursement from the original time period to the follow-up time period.
**** Annualized Cost Savings is based on the reported interval.  Some savings may be due to changes in reimbursement from the original time period to the follow-up period.
Follow-up on the unique members identified as taking four or more doses per day of a short-acting opiod for 90 or more days without using a long-acting opiod.
IOWA DUR FOCUS STUDY
Based on Iowa Paid Non-Reversed Claims
Opioid Overuse - Four or More Doses per day of a Short-Acting Opioid
Appendix G 
Prior Auth Recommendations 
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2014-2015 Therapeutic Prior Authorization Criteria Review 
 
During the fiscal year ending 2015, the Commission reviewed the following 
categories of medications covered under the prior authorization program. 
 
The following criteria were reviewed with recommended changes: 
 Apixaban (Eliquis) – Modifications were made to add criteria specific to 
DVT prophylaxis in addition to dosing requirements for afib, prophylaxis 
after hip/knee replacement, and treatment/prevention of DVT/PE. 
   Dabigatran (Pradaxa) – Modifications were made to add criteria specific 
to the treatment and prevention of DVT or PE. 
   Omalizumab (Xolair) – Modifications were made to add criteria specific to 
the treatment of chronic idiopathic urticaria. 
   Palivizumab (Synagis) – Modifications were made based on the updated 
AAP Guidelines released 7/28/14. 
   Chronic Pain Syndromes – Modifications were made to remove opioid 
trials for applicable diagnoses and require gabapentin plus one other 
medication applicable to diagnosis. 
 Thrombopoietin Receptor Agonists - Modifications were made to add 
criteria for severe aplastic anemia and update criteria for use in chronic 
hepatitis C.  
 Testosterone Products – Modifications were made to clarify criteria to 
eliminate requests for age-related hypogonadism. 
 Apremilast (Otezla) – Modifications were made to add criteria for 
moderate to severe plaque psoriasis. 
 Hepatitis C Agents – Modifications were made to allow for tests other 
than a liver biopsy for documentation of liver fibrosis.  Removed criteria for 
Incivek and Victrelis (withdrawn from the market) and aligned criteria with 
AASLD Guidelines for treatment by genotype. 
 CNS Stimulants and Atomoxetine (f/k/a ADD/ADHD/Narcolepsy) – 
Modifications were made to require PMP check and added criteria specific 
to Binge Eating Disorder (BED) for Vyvanse. 
 Dextromethorphan/Quinidine (Nuedexta) – Modifications were made to 
allow for PBA secondary to a neurological condition and documentation of 
a current EKG. 
 Sedative/Hypnotics Non-Benzodiazepines – Modifications were made 
to require trials and therapy failures with a minimum of 3 preferred agents.  
Added criteria specific to suvorexant (Belsomra). 
 
 
 
 
 
 
 
 
2 
 
The following are new classes for which clinical prior authorization criteria 
were developed and recommended: 
 
Oral Immunotherapy – Prior authorization criteria was developed and accepted 
as follows:  
Prior authorization is required for sublingual allergen immunotherapy.  
Payment will be considered under the following conditions: 
1. Medication is prescribed in consultation with an allergist; and 
2. Patient is diagnosed with pollen-induced allergic rhinitis with or 
without conjunctivitis; and 
3. Patient has documented trials and therapy failures with allergen 
avoidance and pharmacotherapy (intranasal corticosteroids and 
antihistamines); and 
4. Patient has a documented intolerance to immunotherapy injections; 
and 
5. The first dose has been administered under the supervision of a 
health care provider to observe for allergic reactions (date of 
administration and response required prior to consideration). 
6. If patient receives other immunotherapy by subcutaneous allergen 
immunotherapy (SCIT), treatment of allergic rhinitis with sublingual 
allergen immunotherapy (SLIT) will not be approved. 
 
Short Ragweed Pollen (Ragwitek®) In addition to the above criteria being 
met: 
 Patient is 18 through 65 years of age; and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE 
antibodies) to short ragweed pollen. 
 If criteria for coverage are met, authorization will be considered at 
least 12 weeks before the expected onset of ragweed pollen 
season and continued throughout the season. 
 
Grass Pollen (Grastek® and Oralair®) In addition to the above criteria 
being met: 
Oralair® 
 Patient is 10 through 65 years of age (Oralair®); and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE 
antibodies) to sweet vernal, orchard/cocksfoot, perennial rye, 
timothy, and Kentucky blue/June grass. 
 If criteria for coverage are met, authorization will be considered at 
least 4 months prior to the expected onset of each grass pollen 
season and continued throughout the grass pollen season; or 
 Grastek® 
 Patient is 5 through 65 year of age (Grastek®); and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE 
antibodies) to timothy grass (or cross reactive grasses such as 
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sweet vernal, orchard/cocksfoot, perennial rye, Kentucky blue/June, 
meadow fescue, and redtop). 
 If criteria for coverage are met, authorization will be considered at 
least 12 weeks before the expected onset of each grass pollen 
season. 
 
Methotrexate Injection – Prior authorization criteria was developed and 
accepted as follows:   
Prior authorization is required for non-preferred methotrexate injection.  
Payment will be considered under the following conditions: 
1. Diagnosis of severe, active rheumatoid arthritis (RA) or polyarticular 
juvenile idiopathic arthritis (pJIA) and ALL of the following: 
a. Prescribed by a rheumatologist; and 
b. Patient has a documented trial and intolerance with oral 
methotrexate; and 
c. Patient has a documented trial and therapy failure or intolerance 
with at least one other non-biologic DMARD 
(hydroxychloroquine, leflunomide, minocycline or sulfasalazine); 
and 
d. Patient’s visual or motor skills are impaired to such that they 
cannot accurately draw up their own preferred generic 
methotrexate injection and there is no caregiver available to 
provide assistance; and 
e. Patient does not reside in a long-term care facility. 
2. Diagnosis of severe, recalcitrant, disabling psoriasis and ALL of the 
following: 
a. Patient is 18 years of age or older; and 
b. Prescribed by a dermatologist; and 
c. Patient has documentation of an inadequate response to all 
other standard therapies (oral methotrexate, topical 
corticosteroids, vitamin D analogues, cyclosporine, systemic 
retinoids, tazarotene, and phototherapy). 
d. Patient’s visual or motor skills are impaired to such that they 
cannot accurately draw up their own preferred generic 
methotrexate injection and there is no caregiver available to 
provide assistance; and 
e. Patient does not reside in a long-term care facility. 
 
The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
 
Tasimelteon (Hetlioz) – Prior authorization criteria was developed and accepted 
as follows:  
Prior authorization is required for tasimelteon (Hetlioz). Requests for doses 
above the manufacturer recommended dose will not be considered.  Payment 
will be considered under the following conditions: 
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1. Patient has a diagnosis of Non-24-Hour Sleep-Wake Disorder (Non-24), as 
confirmed by a sleep specialist; and 
2. Patient is 18 years of age or older; and 
3. Documentation the patient is totally blind with no perception of light is 
provided; and 
4. Patient has a documented trial and therapy failure with at least one 
preferred sedative/hypnotic – non-benzodiazepine agent; and  
5. Patient has a documented trial and therapy failure with ramelteon 
(Rozerem®). 
 
If criteria for coverage are met, initial requests will be given for 3 months.  
Requests for continuation of therapy will be considered when the patient has 
received 3 months of continuous therapy and patient has achieved adequate 
results with tasimelteon (Hetlioz), such as entrainment, significant increases 
in nighttime sleep, and/or significant decreases in daytime sleep. 
 
Apremilast (Otezla) – Prior authorization criteria was developed and accepted 
as follows: 
Prior authorization is required for apremilast (Otezla®).  Payment will be 
considered under the following conditions: 
1. Patient is 18 years of age or older; and 
2. Patient has a diagnosis of active psoriatic arthritis (≥ 3 swollen 
joints and ≥ 3 tender joints); and 
3. Prescribed by a rheumatologist or a dermatologist; and 
4. Patient does not have severe renal impairment (CrCl < 30 mL/min); 
and 
5. Patient has documentation of a trial and inadequate response to 
therapy with the preferred oral DMARD, methotrexate (leflunomide 
or sulfasalazine may be used if methotrexate is contraindicated); 
and 
6. Patient has documentation of trials and therapy failures with two 
preferred biological agents used for psoriatic arthritis. 
  
The required trials may be overridden when documented evidence is 
provided that the use of these agents would be medically contraindicated. 
 
Ceritinib (Zykadia) – Prior authorization criteria was developed and accepted 
as follows:   
Prior authorization is required for ceritinib (Zykadia™). Payment will be 
considered under the following conditions: 
1. Patient has a diagnosis of metastatic non-small cell lung cancer 
(NSCLC)  that is anaplastic lymphoma kinase (ALK)-positive as 
detected by an FDA-approved test (attach copy of results); and 
2. Patient is 18 years of age or older; and 
3. Prescribed by a oncologist; and 
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4. Patient has documentation of treatment with crizotinib and the 
disease has   progressed while on treatment or is intolerant to 
treatment. 
5. Liver function tests (ALT, AST, and total bilirubin) will be monitored 
at least monthly while on ceritinib. 
 
If criteria for coverage are met, initial requests will be given for 3 months.  
Requests for continuation of therapy will be considered with 
documentation patient has not experienced disease progression or 
unacceptable toxicity. 
 
Deferasirox (Exjade) – Prior authorization criteria was developed and accepted 
as follows: 
Prior authorization is required for deferasirox.  Payment will be considered 
under the following conditions: 
1. Patient does not have a serum creatinine greater than 2 times the 
age-appropriate upper limit of normal or creatinine clearance 
<40mL/min; and 
2. Patient does not have a poor performance status; and 
3. Patient does not have a high-risk myelodysplastic syndrome; and  
4. Patient does not have advanced malignancies; and 
5. Patient does not have a platelet count <50 x 109/L. 
 
Transfusional Iron Overload 
Initiation of Therapy 
1. Patient is 2 years of age or older; and 
2. Patient has documentation of iron overload related to anemia 
(attach documentation); and 
3. Patient has documentation of a recent history of frequent blood 
transfusions that have resulted in chronic iron overload; and 
4. Serum ferritin is consistently >1000 mcg/L (attach lab results dated 
within the past month); and 
5. Starting dose does not exceed 20mg/kg/day.  Calculate dose to the 
nearest whole tablet. 
6. Initial requests will be considered for up to 3 months. 
Continuation of Therapy 
1. Serum ferritin has been measured within 30 days of continuation of 
therapy request (attach lab results); and 
2. Ferritin levels are >500mcg/L; and 
3. Dose does not exceed 40mg/kg/day. 
 
Non-Transfusional Iron Overload 
Initiation of Therapy 
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1. Patient is 10 years of age or older; and 
2. Patient has documentation of iron overload related to anemia 
(attach documentation); and 
3. Serum ferritin and liver iron concentration (LIC) has been measured 
within 30 days of initiation (attach lab results); and 
4. Serum ferritin levels are >300mcg/L. 
5. Liver iron concentration (LIC) are >3mg Fe/g dw; and 
6. Dose does not exceed 10mg/kg/day (if LIC is <15mg Fe/g dw), or 
20mg/kg/day (if LIC is >15mg Fe/g dw). 
7. Initial authorization will be considered for up to 6 months. 
Continuation of Therapy 
1. Serum ferritin and LIC have been measured within 30 days of 
continuation of therapy request; and 
2. Serum ferritin levels are >300mcg/L; and 
3. Liver iron concentration (LIC) is >3mg Fe/g dw; and 
4. Dose does not exceed 10mg/kg/day (if LIC is 3 to 7mg Fe/g dw) or 
20mg/kg/day (if LIC is >7mg Fe/g dw). 
 
Vorapaxar (Zontivity) – Prior authorization criteria was developed and accepted 
as follows: 
Prior authorization is required for vorapaxar (Zontivity™).  Payment will be 
considered under the following conditions: 
1. Patient has a history of myocardial infarction (MI) or peripheral 
artery disease (PAD); and 
2. Patient does not have a history of stroke, transient ischemic attack 
(TIA), intracranial bleeding, or active peptic ulcer; and 
3. Patient has documentation of an adequate trial and therapy failure 
with aspirin plus clopidogrel; and 
4. Patient will use vorapaxar concurrently with aspirin and/or 
clopidogrel. 
 
The required trials may be overridden when documented evidence is 
provided that the use of these agents would be medically contraindicated. 
 
 
 
 
 
 
No recommendations were made to remove criteria during the 2015 state 
fiscal year. 
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August 7, 2014 
 
 
Susan L. Parker, R.Ph., Pharm.D.  
Pharmacy Director 
Iowa Medicaid Enterprise  
100 Army Post Road  
Des Moines, Iowa 50315 
 
 
Dear Susan: 
 
The Iowa Medicaid Drug Utilization Review (DUR) Commission met on Wednesday, August 6, 
2014.  At this meeting, the DUR Commission members discussed the proposed prior 
authorization criteria for Omalizumab (Xolair®), Apixaban (Eliquis®), and Dabigatran (Pradaxa®) 
and coverage of Naloxone Auto-injector (Evzio) by Iowa Medicaid.  The following 
recommendations have been made by the DUR Commission: 
 
The DUR Commission reviewed comments received from the medical/pharmacy associations 
in response to a June 11, 2014 letter that was sent to them detailing the proposed criteria for 
Omalizumab (Xolair®), Apixaban (Eliquis®), and Dabigatran (Pradaxa®).   
 
Omalizumab (Xolair®) 
 
Changes are italicized: 
Prior authorization is required for Xolair®.  Payment for Xolair® will be authorized when 
the following criteria are met: 
 
Moderate to Severe Persistent Asthma 
1. Patient has a diagnosis of moderate to severe persistent asthma for at least one 
year; and 
2. Patient is 12 years of age or older; and 
3. Pretreatment IgE level is between 30 IU/mL and 700 IU/mL; and 
4. Patient’s weight is between 30 kg and 150 kg; and 
5. History of positive skin or RAST test to a perennial aeroallergen; and 
6. Prescriber is an allergist, immunologist, or pulmonologist; and 
7. Patient is currently using a high dose inhaled corticosteroid AND long-acting 
beta-agonist, is compliant with therapy and asthma symptoms are not 
adequately controlled after at least three (3) months of therapy. 
8. Patient must have access to an EpiPen to treat allergic reactions that may occur 
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after administration of Xolair®. 
 
If the criteria for coverage are met, the initial authorization will be given for 16 weeks to 
assess the need for continued therapy. Requests for continuation of therapy will not be 
granted for patients who have not shown adequate response to Xolair® therapy and for 
patients who do not continue concurrent use with a high dose corticosteroid and long-
acting beta-agonist. 
 
Chronic Idiopathic Urticaria 
1. Patient has a diagnosis of moderate to severe chronic idiopathic urticaria; and 
2. Patient is 12 years of age or older; and 
3. Patient has documentation of a trial and therapy failure with at least one second-
generation antihistamine, one of which must be cetirizine at a dose up to 20 mg 
per day; and 
4. Patient has documentation of a trial and therapy failure with at least one first-
generation antihistamine; and  
5. Patient has documentation of a trial and therapy failure with at least one potent 
H1 receptor antagonist (hydroxyzine and/or doxepin); and  
6. Patient has documentation of a trial and therapy failure with a preferred 
leukotriene receptor antagonist in combination with a first- or second-generation 
antihistamine. 
 
If criteria for coverage are met, the initial authorization will be given for 12 weeks to 
assess the need for continued therapy.   
 
The required trials may be overridden when documented evidence is provided that use 
of these agents would be medically contraindicated. 
 
Apixaban (Eliquis®) 
 
Changes are italicized:  
Prior authorization is required for apixaban (Eliquis®). Payment will be considered under 
the following conditions:  
1. Patient does not have a mechanical prosthetic heart valve; and  
2. Patient does not have active pathological bleeding; and 
3. Patient has a diagnosis of non-valvular atrial fibrillation; with  
4. Documentation of a previous trial and therapy failure with warfarin (TIA, stroke, 
or inability to maintain a therapeutic INR with a minimum 6 month trial); and  
5. Presence of at least one additional risk factor for stroke, with a CHADS2 score ≥ 
1; OR 
6. For patients requiring deep vein thrombosis (DVT) prophylaxis undergoing hip or 
knee replacement.  Requests will be considered when the patient has 
contraindications to use of the preferred agent(s).  If patient meets criteria for 
coverage, requests will be approved for the following doses: 
 Hip replacement:  2.5 mg twice daily for up to 35 days following hip 
replacement; or 
 Knee replacement:  2.5 mg twice daily for up to 12 days following knee 
replacement. 
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Dabigatran (Pradaxa®) 
 
Changes are italicized: 
Prior authorization is required for dabigatran (Pradaxa®). Payment will be considered for 
patients under the following conditions: 
1. Patient does not have a mechanical prosthetic heart valve; and 
2. Patient does not have active pathological bleeding; and 
3. Patient has documentation of a previous trial and therapy failure with warfarin 
(TIA, stroke, recurrence of DVT/PE, or inability to maintain a therapeutic INR with 
a minimum 6 month trial). 
 
Non-valvular atrial fibrillation (in addition to the above) 
 Patient has the presence of at least one additional risk factor for stroke, with a 
CHADS2 score ≥ 1; and 
 Patient does not have severe renal impairment (CrCl < 15mL/min) or is not on 
dialysis. 
 
Treatment and prevention of DVT or PE (in addition to the above) 
 Patient does not have a CrCl < 30mL/min or is not on dialysis. 
 For patients with current DVT/PE, in addition to warfarin trial, patient must have 
documentation of 5 to 10 days of parenteral anticoagulation prior to initiation of 
dabigatran. 
 
The required trials may be overridden when documented evidence is provided that use 
of these agents would be medically contraindicated.   
 
The DUR Commission discussed coverage of Naloxone Auto-injector (Evzio).  The DUR 
determined the delivery system used for administration of naloxone was a convenience for the 
patient or patient’s caregiver.  Additionally, the DUR determined that the use of intranasal 
naloxone would be the least costly service which would reasonably meet the medical need of 
the patient.  Since the DUR determined Evzio is a convenience item and there are other cost-
effective alternatives to Evzio, the DUR recommends not covering this product. 
 
Thank you in advance for the Department’s consideration of accepting the DUR Commission’s 
recommendations for clinical prior authorization criteria Omalizumab (Xolair®), Apixaban 
(Eliquis®), and Dabigatran (Pradaxa®) and coverage of Naloxone Auto-injector (Evzio). 
 
 
Sincerely,  
 
 
Pamela Smith, R.Ph.  
Drug Utilization Review Project Coordinator 
Iowa Medicaid Enterprise 
 
Cc:  Erin Halverson, R.Ph., IME 
 Megan Smith, R.Ph., Pharm.D., IME 
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October 2, 2014 
 
 
Susan L. Parker, R.Ph., Pharm.D.  
Pharmacy Director 
Iowa Medicaid Enterprise  
100 Army Post Road  
Des Moines, Iowa 50315 
 
 
Dear Susan: 
 
The Iowa Medicaid Drug Utilization Review (DUR) Commission met on Wednesday, October 
1, 2014.  At this meeting, the DUR Commission members discussed the proposed prior 
authorization criteria for Chronic Pain Syndromes, Oral Immunotherapy, Methotrexate 
Injection, Tasimelteon (Hetlioz™), Apremilast (Otezla®), and Palivizumab (Synagis®). The 
Commission also made a recommendation for the Iowa Medicaid Pharmaceutical and 
Therapeutics (P&T) Committee to change the status of niacin products to non-preferred on the 
Preferred Drug List (PDL) and to implement a quantity limit across all short-acting opioids of 
120 units per 30 days. The following recommendations have been made by the DUR 
Commission: 
 
The DUR Commission reviewed comments received from the medical/pharmacy associations 
in response to an August 12, 2014 letter that was sent to them detailing the proposed criteria 
for Chronic Pain Syndromes, Oral Immunotherapy, Methotrexate Injection, Tasimelteon 
(Hetlioz™), Apremilast (Otezla®), and Palivizumab (Synagis®). 
 
Chronic Pain Syndromes 
 
Proposed Prior Authorization Criteria (changes italicized) 
A prior authorization is required for duloxetine (Cymbalta®), pregabalin (Lyrica®), and 
milnacipran (Savella™).  For patients with a chronic pain diagnosis who are currently 
taking opioids, as seen in pharmacy claims, a plan to decrease and/or discontinue the 
opioid(s) must be provided with the initial request.  Initial authorization will be given for 
three (3) months.  There must be a significant decrease in opioid use or discontinuation 
of opioid(s) after the initial three (3) month authorization for further approval 
consideration.  Additional prior authorizations will be considered with documentation of 
a continued decrease in opioid utilization. Payment will be considered under the 
following conditions: 
1. A diagnosis of fibromyalgia (Cymbalta®, Lyrica®, and Savella™)  
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a. A trial and therapy failure at a therapeutic dose with gabapentin plus one 
of the following: tricyclic antidepressant, SSRI, or SNRI, WITH 
b. Documented non-pharmacologic therapies (cognitive behavior therapies, 
exercise, etc.), AND  
c. Documentation of a previous trial and therapy failure at a therapeutic dose 
with Savella™ when Cymbalta® and Lyrica® are requested.  
2. A diagnosis of postherpetic neuralgia (Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of the 
following: tricyclic antidepressant, topical lidocaine, valproate, or carbamazepine. 
3.  A diagnosis of diabetic peripheral neuropathy (Cymbalta® and Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of the 
following: tricyclic antidepressant or topical lidocaine. 
4.  A diagnosis of partial onset seizures, as adjunct therapy (Lyrica®) 
5.  A diagnosis of major depressive disorder or generalized anxiety disorder   
(Cymbalta®) 
6.  A diagnosis of chronic musculoskeletal pain (Cymbalta®) 
A trial and therapy failure at a therapeutic dose with at least two drugs from two 
distinct therapeutic classes from the following: NSAIDs, opioids, tramadol, or 
tricyclic antidepressants.  
 
Requests for concomitant use of these agents for an indicated chronic pain diagnosis 
may only be considered once each agent has been tried at maximum tolerated dose 
separately. Duplicate use of drugs from the same therapeutic category will not be 
considered.  Requests for doses above the manufacturer recommended dose will not 
be considered. 
 
Oral Immunotherapy 
 
Newly Proposed Prior Authorization Criteria 
Prior authorization is required for sublingual allergen immunotherapy.  Payment will be 
considered under the following conditions: 
1. Medication is prescribed in consultation with an allergist; and 
2. Patient is diagnosed with pollen-induced allergic rhinitis with or without 
conjunctivitis; and 
3. Patient has documented trials and therapy failures with allergen avoidance and 
pharmacotherapy (intranasal corticosteroids and antihistamines); and 
4. Patient has a documented intolerance to immunotherapy injections; and 
5. The first dose has been administered under the supervision of a health care 
provider to observe for allergic reactions (date of administration and response 
required prior to consideration). 
6. If patient receives other immunotherapy by subcutaneous allergen 
immunotherapy (SCIT), treatment of allergic rhinitis with sublingual allergen 
immunotherapy (SLIT) will not be approved. 
 
Short Ragweed Pollen (Ragwitek®) In addition to the above criteria being met: 
 Patient is 18 through 65 years of age; and 
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 Patient has a positive skin test or in vitro testing (pollen-specific IgE antibodies) 
to short ragweed pollen. 
 If criteria for coverage are met, authorization will be considered at least 12 weeks 
before the expected onset of ragweed pollen season and continued throughout 
the season. 
 
Grass Pollen (Grastek® and Oralair®) In addition to the above criteria being met: 
Oralair® 
 Patient is 10 through 65 years of age (Oralair®); and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE antibodies) 
to sweet vernal, orchard/cocksfoot, perennial rye, timothy, and Kentucky 
blue/June grass. 
 If criteria for coverage are met, authorization will be considered at least 4 months 
prior to the expected onset of each grass pollen season and continued 
throughout the grass pollen season; or 
 Grastek® 
 Patient is 5 through 65 year of age (Grastek®); and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE antibodies) 
to timothy grass (or cross reactive grasses such as sweet vernal, 
orchard/cocksfoot, perennial rye, Kentucky blue/June, meadow fescue, and 
redtop). 
 If criteria for coverage are met, authorization will be considered at least 12 weeks 
before the expected onset of each grass pollen season. 
 
Methotrexate Injection 
 
Newly Proposed Prior Authorization Criteria 
Prior authorization is required for non-preferred methotrexate injection.  Payment will be 
considered under the following conditions: 
1. Diagnosis of severe, active rheumatoid arthritis (RA) or polyarticular juvenile 
idiopathic arthritis (pJIA) and ALL of the following: 
a. Prescribed by a rheumatologist; and 
b. Patient has a documented trial and intolerance with oral methotrexate; and 
c. Patient has a documented trial and therapy failure or intolerance with at 
least one other non-biologic DMARD (hydroxychloroquine, leflunomide, 
minocycline or sulfasalazine); and 
d. Patient’s visual or motor skills are impaired to such that they cannot 
accurately draw up their own preferred generic methotrexate injection and 
there is no caregiver available to provide assistance; and 
e. Patient does not reside in a long-term care facility. 
2. Diagnosis of severe, recalcitrant, disabling psoriasis and ALL of the following: 
a. Patient is 18 years of age or older; and 
b. Prescribed by a dermatologist; and 
c. Patient has documentation of an inadequate response to all other 
standard therapies (oral methotrexate, topical corticosteroids, vitamin D 
analogues, cyclosporine, systemic retinoids, tazarotene, and 
phototherapy). 
d. Patient’s visual or motor skills are impaired to such that they cannot 
accurately draw up their own preferred generic methotrexate injection and 
there is no caregiver available to provide assistance; and 
e. Patient does not reside in a long-term care facility. 
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The required trials may be overridden when documented evidence is provided that the 
use of these agents would be medically contraindicated. 
 
Tasimelteon (Hetlioz®) 
 
Newly Proposed Prior Authorization Criteria 
Prior authorization is required for tasimelteon (Hetlioz). Requests for doses above the 
manufacturer recommended dose will not be considered.  Payment will be considered 
under the following conditions: 
1. Patient has a diagnosis of Non-24-Hour Sleep-Wake Disorder (Non-24), as 
confirmed by a sleep specialist; and 
2. Patient is 18 years of age or older; and 
3. Documentation the patient is totally blind with no perception of light is provided; 
and 
4. Patient has a documented trial and therapy failure with at least one preferred 
sedative/hypnotic – non-benzodiazepine agent; and  
5. Patient has a documented trial and therapy failure with ramelteon (Rozerem®). 
 
If criteria for coverage are met, initial requests will be given for 3 months.  Requests for 
continuation of therapy will be considered when the patient has received 3 months of 
continuous therapy and patient has achieved adequate results with tasimelteon 
(Hetlioz), such as entrainment, significant increases in nighttime sleep, and/or 
significant decreases in daytime sleep. 
 
Apremilast (Otezla®) 
 
Newly Proposed Prior Authorization Criteria 
Prior authorization is required for apremilast (Otezla®).  Payment will be considered 
under the following conditions: 
1. Patient is 18 years of age or older; and 
2. Patient has a diagnosis of active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 
tender joints); and 
3. Prescribed by a rheumatologist or a dermatologist; and 
4. Patient does not have severe renal impairment (CrCl < 30 mL/min); and 
5. Patient has documentation of a trial and inadequate response to therapy with the 
preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may be used 
if methotrexate is contraindicated); and 
6. Patient has documentation of trials and therapy failures with two preferred 
biological agents used for psoriatic arthritis. 
  
The required trials may be overridden when documented evidence is provided that the 
use of these agents would be medically contraindicated. 
 
Palivizumab (Synagis) 
 
Proposed Prior Authorization Criteria (changes italicized) 
Prior authorization is required for therapy with palivizumab. Prior authorizations will be 
approved for administration during the RSV season for a maximum of five doses per 
patient. No allowances will be made for a sixth dose. Patients, who experience a 
breakthrough RSV hospitalization, should have their monthly prophylaxis discontinued, 
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as there is an extremely low likelihood of a second RSV hospitalization in the same 
season. Payment for palivizumab will be considered for patients who meet one of the 
following criteria: 
Chronic Lung Disease (CLD) of Prematurity 
 Patient is less than 12 months of age at start of therapy and develops CLD 
of prematurity (defined as gestational age less than 32 weeks and 
required greater than 21% oxygen for at least the first 28 days after birth).  
 Requests for patients during their second year of life (12 months to < 24 
months) will be considered for patients meeting the CLD of prematurity 
definition above and continue to require medical support (chronic 
corticosteroid therapy, diuretic therapy, or supplemental oxygen) during 
the 6-month period before the start of the second RSV season.  
Hemodynamically Significant Congenital Heart Disease (CHD) 
 Patient is less than 12 months of age at start of therapy and has 
hemodynamically significant CHD further defined by any of the following: 
o Patient with acyanotic heart disease who is receiving medication to 
control congestive heart failure and will require cardiac surgical 
procedures or 
o Patient with moderate to severe pulmonary hypertension.  
o Requests for patients with cyanotic heart defects will be considered 
with documentation of consultation with a pediatric cardiologist that 
recommends patient receive palivizumab prophylaxis. 
Premature Infants (without CLD of Prematurity or CHD)  
 Patient is less than 12 months of age at start of therapy with a gestational 
age of less than 29 weeks. 
Children with Anatomic Pulmonary Abnormalities or Neuromuscular Disorder  
 Patient is 12 months of age or younger at the start of therapy and has 
either severe neuromuscular disease or congenital anomaly that impairs 
the ability to clear secretions from the upper airway due to an ineffective 
cough.  
Immunocompromised Children  
 Patient is less than 24 months of age at start of therapy and is profoundly 
immunocopromised during the RSV season (e.g., severe combined 
immunodeficiency, advanced acquired immunodeficiency syndrome, 
receiving chemotherapy). 
 
The DUR Commission reviewed clinical information regarding niacin.  Recent studies have 
found niacin, added to a statin, failed to improve outcomes in patients with cardiovascular 
disease.  Based on this information, the Commission made the recommendation that the Iowa 
Medicaid P&T Committee consider changing the status of niacin products to non-preferred on 
the PDL, requiring documentation of an intolerance to, or failure with, a preferred statin at an 
optimized dose. 
 
The DUR Commission also reviewed recommendations they initially made in April 2012 to 
implement ProDUR edits on antipsychotics in members less than 18 years of age.  
Specifically, the recommendation was to 1) implement an age edit on risperidone for members 
less than five (5) years of age and an age edit on all other antipsychotics for members less 
than six (6) years of age; and 2) apply a duplicate therapy edit to all antipsychotics.  After 
discussion, the Commission continues to support implemention the aforementioned ProDUR 
edits.   
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Finally, the Commission reviewed utilization of short-acting opioids and made the 
recommendation to implement a quantity limit of 120 units per 30 days across all short-acting 
opioids.    
 
Thank you in advance for the Department’s consideration of accepting the DUR Commission’s 
recommendations for clinical prior authorization criteria  for Chronic Pain Syndromes, Oral 
Immunotherapy, Methotrexate Injection, Tasimelteon (Hetlioz™), Apremilast (Otezla®), and 
Palivizumab (Synagis®), in addition to the quantity limit on short-acting opioids. 
 
 
Sincerely,  
 
 
Pamela Smith, R.Ph.  
Drug Utilization Review Project Coordinator 
Iowa Medicaid Enterprise 
 
Cc:  Erin Halverson, R.Ph., IME 
 Megan Smith, R.Ph., Pharm.D., IME 
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December 4, 2014 
 
 
Susan L. Parker, R.Ph., Pharm.D.  
Pharmacy Director 
Iowa Medicaid Enterprise  
100 Army Post Road  
Des Moines, Iowa 50315 
 
 
Dear Susan: 
 
The Iowa Medicaid Drug Utilization Review (DUR) Commission met on Wednesday, December 
3, 2014.  At this meeting, the DUR Commission members discussed the proposed prior 
authorization criteria for Ceritinib (Zykadia™). The Commission also received feedback from 
the Mental Health Advisory Group (MHAG) regarding the Prospective Drug Utilization Review 
(proDUR) edits on antipsychotic drugs for members less than 18 years of age. The following 
recommendations have been made by the DUR Commission: 
 
No comments were received from the medical/pharmacy associations in response to an 
October 2, 2014 letter that was sent to them detailing the proposed criterion for Ceritinib 
(Zykadia™). 
 
Ceritinib (Zykadia™) 
 
Newly Proposed Prior Authorization Criteria 
Prior authorization is required for ceritinib (Zykadia™). Payment will be considered 
under the following conditions: 
1. Patient has a diagnosis of metastatic non-small cell lung cancer (NSCLC) that is 
anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test 
(attach copy of results); and 
2. Patient is 18 years of age or older; and 
3. Prescribed by a oncologist; and 
4. Patient has documentation of treatment with crizotinib and the disease has   
progressed while on treatment or is intolerant to treatment. 
5. Liver function tests (ALT, AST, and total bilirubin) will be monitored at least 
monthly while on ceritinib. 
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If criteria for coverage are met, initial requests will be given for 3 months.  Requests for 
continuation of therapy will be considered with documentation patient has not 
experienced disease progression or unacceptable toxicity. 
 
The DUR Commission received feedback from the MHAG regarding the proDUR edits on 
antipsychotic drugs for members less than 18 years of age.  The MHAG met on October 17, 
2014 to review the recommended proDUR edits that were initially made in April 2012.  
Specifically, the Commission recommendation was to 1) implement an age edit on risperidone 
for members less than five (5) years of age and an age edit on all other antipsychotics for 
members less than six (6) years of age; and 2) apply a duplicate therapy edit to all 
antipsychotics.  The MHAG suggested the age edit for haloperidol and chlorpromazine be 
changed to the FDA approved ages of 3 years and 6 months respectively. The MHAG also 
suggested a 30 day grace period be considered, to allow members to taper off one 
antipsychotic while starting another, without requiring prior authorization.  The Commission 
took this information under consideration, and determined the recommended age edits did not 
need to be changed at this time and a 30 day grace period would be beneficial to members 
and providers. 
 
Thank you in advance for the Department’s consideration of accepting the DUR Commission’s 
recommendations for clinical prior authorization criterion  for Ceritinib (Zykadia™). 
 
 
Sincerely,  
 
 
Pamela Smith, R.Ph.  
Drug Utilization Review Project Coordinator 
Iowa Medicaid Enterprise 
 
Cc:  Erin Halverson, R.Ph., IME 
 Megan Smith, R.Ph., Pharm.D., IME 
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February 6, 2015 
 
 
Susan L. Parker, R.Ph., Pharm.D.  
Pharmacy Director 
Iowa Medicaid Enterprise  
100 Army Post Road  
Des Moines, Iowa 50315 
 
 
Dear Susan: 
 
The Iowa Medicaid Drug Utilization Review (DUR) Commission met on Wednesday, February 
4, 2015.  At this meeting, the DUR Commission members discussed the proposed prior 
authorization criteria for Hepatitis C Agents – Oral; Deferasirox (Exjade®); and Vorapaxar 
(Zontivity™). The Commission also discussed proposed quantity limits for stimulant 
medications and select benzodiazepines. The following recommendations have been made by 
the DUR Commission: 
 
No comments were received from the medical/pharmacy associations in response to a 
December 8, 2014 letter that was sent to them detailing the proposed criteria for Hepatitis C 
Agents – Oral; Deferasirox (Exjade®); and Vorapaxar (Zontivity™). 
 
Hepatitis C Agents - Oral 
 
Proposed Prior Authorization Criteria (changes italicized) 
Prior authorization is required for direct-acting oral antiviral agents against the hepatitis 
C virus.   Requests for non-preferred agents may be considered when documented 
evidence is provided that the use of the preferred agents would be medically 
contraindicated.  Payment will be considered under the following conditions: 
1. Patient is 18 years of age or older; and 
2. Patient’s prior treatment history is provided (treatment naïve, prior null responder, 
partial responder, or relapser); and 
3. Documentation of viral load taken within 6 months before beginning therapy; and 
4. Viral load will be submitted by prescriber 12 weeks after completion of therapy; 
and 
5. If patient has a history of failed treatment due to non-compliance, documentation 
that steps have been taken to correct or address the causes of non-compliance 
are provided; and  
6. For patients on a regimen containing ribavirin, the following must be documented 
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on the PA form: 
a) Patient is not a pregnant female or a male with a pregnant female partner; 
and 
b) Women of childbearing potential and their male partners must use two 
forms of effective contraception (non-hormonal contraception for patients 
taking Sovaldi™) during treatment and for at least 6 months after treatment 
has concluded; and 
c) Documentation that routine monthly pregnancy tests are performed during 
this time; and 
7. Patient has abstained from the use of illicit drugs and alcohol for a minimum of 
three (3) months as evidenced by a negative urine confirmation test; and 
8. Prescriber is an infectious disease specialist, gastroenterologist, hepatologist or 
other hepatitis specialist. 
9. Where applicable, requests for peg-interferon alfa free regimens will be 
considered on a case-by-case basis for patients with hepatitis C genotype 1 or 4 
where peg-interferon alfa is contraindicated.  Contraindications include:  
documented life-threatening side effects; decompensated hepatic disease; 
autoimmune hepatitis and other autoimmune disorders; a baseline neutrophil 
count below 1500/µL, a baseline platelet count below 90,000/ µL, or a baseline 
hemoglobin below 10g/dL; or a history of preexisting unstable cardiac disease. 
10. Non-FDA approved or non-compendia indicated combination therapy regimens 
will not be approved. 
11. If patient is recently eligible for Iowa Medicaid, and has been started and 
stabilized on therapy while covered under a different plan, documentation of how 
long the patient has been on medication will be required.  Patient will be eligible 
for the remainder of therapy needed, based on established length of therapy for 
the particular treatment (defined below). 
12. Lost or stolen medication replacement requests will not be authorized. 
13. The 72-hour emergency supply rule does not apply to oral hepatitis C antiviral 
agents. 
 
Victrelis  
 Patient has a documented diagnosis of hepatitis C genotype 1; and  
 Administered in combination with peg-interferon alfa and ribavirin; and 
 Patient does not have HIV co-infection; and 
 Patient does not have decompensated cirrhosis; and  
 Patient has not previously tried or failed therapy with a hepatitis C protease 
inhibitor; and 
 HCV-RNA results are required at treatment week 8, 12, and 24 (including lead in 
period) for boceprevir (Victrelis™).  
 Additional prior authorizations will be considered with documentation of response 
to treatment, measured by HCV-RNA levels.  
 Prior authorizations will be approved for a maximum of 24, 32, or 44 weeks of 
therapy with boceprevir (Victrelis™) based on response. 
 
Olysio 
 Patient has a documented diagnosis of hepatitis C genotype 1; and  
 Administered in combination with peg-interferon alfa and ribavirin; and 
 Patient does not have HIV co-infection; and 
 Patient does not have the NS3 Q80K polymorphism with hepatitis C genotype 
 3 
1a; and 
 The patient is not receiving dialysis or does not have a CrCl < 30 mL/min; and 
 Patient has not previously tried or failed therapy with a hepatitis C protease 
inhibitor; and 
 HCV-RNA results are required at treatment week 4 for simeprevir (Olysio™). 
 Additional prior authorizations will be considered with documentation of response 
to treatment, measured by HCV-RNA levels. 
 A maximum 12 weeks of therapy will be allowed.  
 
Sovaldi 
 The patient is not receiving dialysis or does not have a CrCl < 30 mL/min; and  
 Patient does not have decompensated cirrhosis; and 
 Documentation the patient has advanced liver disease corresponding to a 
Metavir score 3 or greater fibrosis as confirmed by one of the following indicators 
related to staging of liver fibrosis (attach test results/documentation):  
o Liver biopsy confirming a Metavir score ≥ F3; or   
o Transient elastography (FibroScan) score ≥ 9.5kPa; or  
o FibroSURE (FibroTest) score ≥ 0.58; or 
o APRI score > 1.5; or 
o Radiological imaging consistent with cirrhosis (i.e. evidence of portal 
hypertension); and 
o Physical findings or clinical evidence consistent with cirrhosis. 
 Dosing and length of therapy will be based on the following: 
o Genotype 1:  Patient has a documented diagnosis of hepatitis C genotype 
1 (mono-infected or HCV/HIV co-infected) and used in combination with 
peg-interferon alfa and ribavirin.  A maximum 12 weeks therapy will be 
allowed.   
o Genotype 2:  Patient has a documented diagnosis of hepatitis C genotype 
2 (mono-infected or HCV/HIV co-infected) and used in combination with 
ribavirin.  A maximum 12 weeks of therapy will be allowed. 
o Genotype 3:  Patient has a documented diagnosis of hepatitis C genotype 
3 (mono-infected or HCV/HIV co-infected) and used in combination with 
ribavirin. A maximum 24 weeks of therapy will be allowed. 
o Genotype 4:  Patient has a documented diagnosis of hepatitis C genotype 
4 (mono-infected or HCV/HIV co-infected) and used in combination with 
peg-interferon alfa and ribavirin. A maximum 12 weeks of therapy will be 
allowed. 
 Hepatocellular carcinoma:  Patient has a documented diagnosis of hepatitis C 
genotype 1, 2, 3, 4 with a diagnosis of hepatocellular carcinoma meeting Milan 
criteria (awaiting liver transplantation) and in combination with ribavirin for up to 
48 weeks or until liver transplantation, whichever comes first.  Milan criteria are 
defined as: 
o One lesion smaller than  5 cm in diameter for subjects with a single lesion; 
o Up to 3 lesions smaller than 3 cm in diameter in subjects with multiple 
lesions; 
o No extrahepatic manifestations; 
o No vascular invasion. 
 
Harvoni 
 Patient has documentation of hepatitis C genotype 1a or 1b; and 
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 The patient is not receiving dialysis or does not have a CrCl < 30 mL/min; and  
 Patient is not co-infected with hepatitis B or HIV; and 
 Patient does not have decompensated liver disease; and 
 Patient has a contraindication to a preferred peg-interferon alfa plus ribavirin 
based regimen (e.g. sofosbuvir + peg-interferon + ribavirin); and 
 Documentation the patient has advanced liver disease as confirmed by one of 
the following indicators related to staging of liver fibrosis (attach test 
results/documentation):  
o Liver biopsy confirming a Metavir score ≥ F3; or   
o Transient elastography (FibroScan) score ≥ 9.5kPa; or  
o FibroSURE (FibroTest) score ≥ 0.58; or 
o APRI score > 1.5; or 
o Radiological imaging consistent with cirrhosis (i.e. evidence of portal 
hypertension); and 
o Physical findings or clinical evidence consistent with cirrhosis. 
 Dosing and length of therapy will be based on the following: 
o Patient is treatment-naïve without cirrhosis and has a documented pre-
treatment baseline HCV RNA less than 6 million IU/mL.  A maximum 8 
weeks of therapy will be allowed; or 
o Patient is treatment-naïve with or without cirrhosis and has a documented 
pre-treatment baseline HCV RNA greater than 6 million IU/mL.  A 
maximum 12 weeks of therapy will be allowed; or 
o Patient is treatment-experienced without cirrhosis and experienced failure 
with a previous treatment regimen that included either peg-interferon alfa 
+ ribavirin or an HCV protease inhibitor + peg-interferon alfa + ribavirin.  A 
maximum 12 weeks of therapy will be allowed; or 
o Patient is treatment-experienced with cirrhosis and experienced failure 
with a previous treatment regimen that included either peg-interferon alfa 
+ ribavirin or an HCV protease inhibitor + peg-interferon alfa + ribavirin.  A 
maximum 24 weeks of therapy will be allowed. 
Deferasirox (Exjade®) 
 
Newly Proposed Prior Authorization Criteria 
Prior authorization is required for deferasirox.  Payment will be considered under the 
following conditions: 
1. Patient does not have a serum creatinine greater than 2 times the age-
appropriate upper limit of normal or creatinine clearance <40mL/min; and 
2. Patient does not have a poor performance status; and 
3. Patient does not have a high-risk myelodysplastic syndrome; and  
4. Patient does not have advanced malignancies; and 
5. Patient does not have a platelet count <50 x 109/L. 
 
Transfusional Iron Overload 
Initiation of Therapy 
1. Patient is 2 years of age or older; and 
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2. Patient has documentation of iron overload related to anemia (attach 
documentation); and 
3. Patient has documentation of a recent history of frequent blood transfusions that 
has resulted in chronic iron overload; and 
4. Serum ferritin is consistently >1000 mcg/L (attach lab results dated within the 
past month); and 
5. Starting dose does not exceed 20mg/kg/day.  Calculate dose to the nearest 
whole tablet. 
6. Initial requests will be considered for up to 3 months. 
Continuation of Therapy 
1. Serum ferritin has been measured within 30 days of continuation of therapy 
request (attach lab results); and 
2. Ferritin levels are >500mcg/L; and 
3. Dose does not exceed 40mg/kg/day. 
 
Non-Transfusional Iron Overload 
Initiation of Therapy 
1. Patient is 10 years of age or older; and 
2. Patient has documentation of iron overload related to anemia (attach 
documentation); and 
3. Serum ferritin and liver iron concentration (LIC) has been measured within 30 
days of initiation (attach lab results); and 
4. Serum ferritin levels are >300mcg/L. 
5. Liver iron concentration (LIC) are >3mg Fe/g dw; and 
6. Dose does not exceed 10mg/kg/day (if LIC is <15mg Fe/g dw), or 20mg/kg/day (if 
LIC is >15mg Fe/g dw). 
7. Initial authorization will be considered for up to 6 months. 
Continuation of Therapy 
1. Serum ferritin and LIC have been measured within 30 days of continuation of 
therapy request; and 
2. Serum ferritin levels are >300mcg/L; and 
3. Liver iron concentration (LIC) is >3mg Fe/g dw; and 
4. Dose does not exceed 10mg/kg/day (if LIC is 3 to 7mg Fe/g dw) or 20mg/kg/day 
(if LIC is >7mg Fe/g dw). 
 
Vorapaxar (Zontivity™) 
 
Newly Proposed Prior Authorization Criteria 
Prior authorization is required for vorapaxar (Zontivity™).  Payment will be considered 
under the following conditions: 
1. Patient has a history of myocardial infarction (MI) or peripheral artery disease 
(PAD); and 
2. Patient does not have a history of stroke, transient ischemic attack (TIA), 
intracranial bleeding, or active peptic ulcer; and 
3. Patient has documentation of an adequate trial and therapy failure with aspirin 
plus clopidogrel; and 
4. Patient will use vorapaxar concurrently with aspirin and/or clopidogrel. 
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The required trials may be overridden when documented evidence is provided that the 
use of these agents would be medically contraindicated. 
 
Additionally, the DUR Commission discussed implementing quantity limits on select 
benzodiazepines (alprazolam, clonazepam, lorazepam) as well as quantity limits on multiple 
stimulant medications.  The DUR Commission requested data to be brought back to the next 
meeting to determine the impact to prescribers and prior authorization department of 
implementing these quantity limits and to seek input from the medical and pharmacy 
associations regarding the proposed quantity limits. 
 
Thank you in advance for the Department’s consideration of accepting the DUR Commission’s 
recommendations for clinical prior authorization criteria for Hepatitis C Agents – Oral; 
Deferasirox (Exjade®); and Vorapaxar (Zontivity™). 
 
 
Sincerely,  
 
 
Pamela Smith, R.Ph.  
Drug Utilization Review Project Coordinator 
Iowa Medicaid Enterprise 
 
Cc:  Erin Halverson, R.Ph., IME 
 Megan Smith, R.Ph., Pharm.D., IME 
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April 2, 2015 
 
 
Susan L. Parker, R.Ph., Pharm.D.  
Pharmacy Director 
Iowa Medicaid Enterprise  
100 Army Post Road  
Des Moines, Iowa 50315 
 
 
Dear Susan: 
 
The Iowa Medicaid Drug Utilization Review (DUR) Commission met on Wednesday, April 1, 
2015.  At this meeting, the DUR Commission members discussed the proposed prior 
authorization criteria for Apixaban (Eliquis®); Thrombopoietin Receptor Agonists; Testosterone 
Products; and Apremilast (Otezla®). The Commission further discussed proposed quantity limits 
for stimulant medications. The following recommendations have been made by the DUR 
Commission: 
 
The DUR Commission reviewed comments received from the medical/pharmacy associations in 
response to a February 10, 2015 letter that was sent to them detailing the proposed criteria for 
Apixaban (Eliquis®); Thrombopoietin Receptor Agonists; Testosterone Products; and Apremilast 
(Otezla®) in addition to quantity limits on select CNS stimulants and benzodiazepines. 
 
Apixaban (Eliquis) 
 
Proposed Prior Authorization Criteria (changes italicized) 
Prior authorization is required for apixaban (Eliquis®). Payment will be considered under 
the following conditions:  
1. Patient does not have a mechanical prosthetic heart valve; and  
2. Patient does not have active pathological bleeding.  
 
Atrial Fibrillation 
 Patient has a diagnosis of non-valvular atrial fibrillation; with 
 Documentation of a previous trial and therapy failure with warfarin (TIA, stroke, or 
inability to maintain a therapeutic INR with a minimum 6 month trial); and  
 Presence of at least one additional risk factor for stroke, with a CHADS2 score ≥ 1.  
 Requests will be considered for the following dosing: 
o 5mg twice daily; or 
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o 2.5mg twice daily in patients with any two (2) of the following: 
 Age ≥80 years 
 Body weight ≤60 kg 
 Serum creatinine ≥1.5 mg/dL. 
 
Treatment and Prevention of DVT or PE  
 Patient has documentation of a previous trial and therapy failure with warfarin 
(TIA, stroke, or inability to maintain a therapeutic INR with a minimum 6 month 
trial). 
 Requests will be considered for the following dosing: 
o Initial Treatment of DVT or PE:  10mg twice daily for 7 days, followed by 
5mg twice daily up to 12 months of treatment. 
o Prevention of DVT or PE following initial therapy with standard 
anticoagulation therapy for 6 to 12 months of treatment for DVT or PE: 
2.5mg twice daily 
 
Prophylaxis of DVT following hip or knee replacement surgery 
 Requests will be considered when the patient has contraindications to use of the 
preferred agent(s).  
 Requests will be considered for the following dosing: 
o Hip replacement: 2.5mg twice daily for up to 35 days following hip 
replacement; or 
o Knee replacement: 2.5mg twice daily for up to 12 days after knee 
replacement. 
 
The required trials may be overridden when documented evidence is provided that the 
use of these agents would be medically contraindicated. 
 
Thrombopoietin Receptor Agonists 
 
Proposed Prior Authorization Criteria (changes italicized) 
Payment for a preferred thrombopoietin receptor agonist will only be considered for cases 
in which there is a diagnosis of chronic immune thrombocytopenic purpura (ITP) including 
documentation of an insufficient response to a corticosteroid, an immunoglobulin, or the 
patient has undergone a splenectomy. 
 
Payment for eltrombopag (Promacta®) for the treatment of chronic hepatitis C associated 
thrombocytopenia will only be considered to allow for initiation and/or maintenance of 
interferon-based therapy with ribavirin when the patient has a baseline platelet count less 
then 75 x 109/L. Requests will not be considered under the following conditions: 
1. Patients taking direct acting antiviral agents for the treatment of chronic hepatitis C 
infection in addition to interferon based therapy with ribavirin. 
2. Patients taking direct acting antiviral agents used without interferon for treatment 
of chronic hepatitis C infection. 
3. Patients with decompensated liver disease with a Child-Pugh score > 6 (Class B & 
C). 
4. Patients with a history of ascites. 
5. Patients with hepatic encephalopathy. 
 
Payment for eltrombopag (Promacta®) for the treatment of severe aplastic anemia will 
only be considered under the following conditions: 
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1. Patient has documentation of an insufficient response or intolerance to at least 
one prior immunosuppressive therapy; and 
2. Patient has a platelet count less than or equal 30 X 109/L. 
3. If criteria for coverage are met, initial authorization will be given for 16 weeks.  
Documentation of hematologic response after 16 weeks of therapy will be required 
for further consideration. 
 
Payment for a non-preferred thrombopoietin receptor agonist will be considered following 
documentation of a recent trial and therapy failure with a preferred thrombopoietin 
receptor agonist unless such a trial would be medically contraindicated. 
 
Testosterone Products 
 
Proposed Prior Authorization Criteria (changes italicized) 
Prior authorization is required for testosterone products.  Payment will be considered with 
documentation of a specific testicular or hypothalamic/pituitary disease (primary 
hypogonadism or hypogonadotropic hypogonadism) that results in classic hypogonadism. 
Requests for FDA approved indications other than hypogonadism will not be subject to 
prior authorization criteria with adequate documentation of diagnosis. Payment for non-
preferred testosterone products will be authorized only for cases in which there is 
documentation of previous trials and therapy failures with two preferred agents. Requests 
for erectile dysfunction, infertility, and age-related hypogonadism will not be considered.  
Payment will be considered under the following conditions: 
1. Patient is male and 18 years of age or older (or 12 years of age and older for 
testosterone cypionate); and 
2. Patient has two (2) morning pre-treatment testosterone levels below the lower limit 
of the normal testosterone reference range of the individual laboratory used 
(Please attach lab results); and 
3. Patient has primary hypogonadism or hypogonadotropic hypogonadism (further 
defined below): 
 Primary hypogonadism (congenital or acquired) caused by testicular failure 
due to one of the following: 
o Cryptorchidism 
o Bilateral torsion 
o Orchitis 
o Vanishing testes syndrome, 
o Orchiectomy 
o Klinefelter’s syndrome, 
o Chemotherapy 
o Toxic damage from alcohol or heavy metals 
 Hypogonadotropic hypogonadism  
o Idiopathic gonadotropin or luteinizing hormone-releasing (LHRH) 
deficiency 
o Pituitary-hypothalamic injury from tumors, trauma, or radiation 
4. Patient does not have: 
 Breast or prostate cancer 
 Palpable prostate nodule or prostate-specific antigen (PSA) > 4ng/mL 
 Hematocrit > 50% 
 Untreated severe obstructive sleep apnea 
 Severe lower urinary tract symptoms 
 Uncontrolled or poorly controlled heart failure 
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Requests for continuation of therapy will require the following: 
1. An updated testosterone level (Please attach lab result); and 
2. Documentation the patient has not experienced a hematocrit > 54% or an increase 
in PSA > 1.4ng/mL in the past 12 months. 
 
The required trials may be overridden when documented evidence is provided that use of 
these agents would be medically contraindicated. 
 
Apremilast (Otezla) 
 
Proposed Prior Authorization Criteria (changes italicized) 
Prior authorization is required for apremilast (Otezla®). Payment will be considered under 
the following conditions: 
1. Patient is 18 years of age or older; and  
2. Patient has a diagnosis of active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 
tender joints); or  
3. Patient has a diagnosis of moderate to severe plaque psoriasis; and  
4. Prescribed by a rheumatologist or a dermatologist; and  
5. Patient does not have severe renal impairment (CrCl < 30mL/min). 
 
Psoriatic Arthritis 
 Patient has documentation of a trial and inadequate response to therapy with the 
preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may be used if 
methotrexate is contraindicated); and 
 Patient has documentation of trials and therapy failures with two preferred 
biological agents used for psoriatic arthritis.  
 
Plaque Psoriasis 
 Patient has documentation of a trial and inadequate response to phototherapy, 
systemic retinoids, methotrexate, or cyclosporine; and 
 Patient has documentation of trials and therapy failures with two preferred 
biological agents. 
The required trials may be overridden when documented evidence is provided that the 
use of these agents would be medically contraindicated. 
 
Additionally, the DUR Commission discussed proposed quantity limits on the following stimulant 
medications (to be applied to brand and generic): Adderall 12.5mg, Adderall 20mg, Concerta, 
Focalin IR, Focalin XR, Ritalin IR.  The DUR Commission recommended the proposed quantity 
limits be referred to the Mental Health Advisory Group for their input prior to making a formal 
recommendation. 
 
Thank you in advance for the Department’s consideration of accepting the DUR Commission’s 
recommendations for clinical prior authorization criteria for Apixaban (Eliquis®); Thrombopoietin 
Receptor Agonists; Testosterone Products; and Apremilast (Otezla®). 
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Sincerely,  
 
 
Pamela Smith, R.Ph.  
Drug Utilization Review Project Coordinator 
Iowa Medicaid Enterprise 
 
Cc:  Erin Halverson, R.Ph., IME 
 Megan Smith, R.Ph., Pharm.D., IME 
 1 
 
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 
 100 Army Post Road – (515) 974-3131 -866-626-0216 
 
Brett Faine, Pharm.D. 
Larry Ambroson, R.Ph.  
Brian Couse, M.D.  
Mark Graber, M.D., FACEP, MSHCE   
Kellen Ludvigson, Pharm.D. 
Susan Parker, R.Ph., Pharm.D. 
Laurie Pestel, R.Ph., Pharm.D. 
Gregory Barclay, M.D. 
Jason Wilbur, M. D. 
 
Professional Staff:                               Pam Smith, R.Ph.     
        DUR Project Coordinator 
 
 
June 3, 2015 
 
 
Susan L. Parker, R.Ph., Pharm.D.  
Pharmacy Director 
Iowa Medicaid Enterprise  
100 Army Post Road  
Des Moines, Iowa 50315 
 
 
Dear Susan: 
 
The Iowa Medicaid Drug Utilization Review (DUR) Commission met on Wednesday, June 3, 
2015.  At this meeting, the DUR Commission members discussed the proposed prior 
authorization criteria for Hepatitis C Agents; CNS Stimulants and Atomoxetine; 
Dextromethorphan/Quinidine (Nuedexta®); Chronic Pain Syndromes; and Sedative/Hypnotics – 
Non-Benzodiazepines. The Commission also received feedback from the Mental Health 
Advisory Group (MHAG) regarding proposed quantity limits for stimulant medications and the 
ProDUR edits on antipsychotics in children. The following recommendations have been made 
by the DUR Commission: 
 
The DUR Commission reviewed comments received from the medical/pharmacy associations in 
response to an April 7, 2015 letter that was sent to them detailing the proposed criteria for 
Hepatitis C Agents; CNS Stimulants and Atomoxetine; Dextromethorphan/Quinidine 
(Nuedexta®); Chronic Pain Syndromes; and Sedative/Hypnotics – Non-Benzodiazepines. 
 
Hepatitis C Agents 
 
Proposed Prior Authorization Criteria (changes italicized) 
Prior authorization is required for hepatitis C treatments.   Requests for non-preferred 
agents may be considered when documented evidence is provided that the use of the 
preferred agents would be medically contraindicated.  Payment will be considered under 
the following conditions: 
1. Patient is 18 years of age or older and has a diagnosis of chronic hepatitis C; and 
2. Patient has had testing for hepatitis C virus (HCV) genotype; and 
3. Patient has an active HCV infection verified by a detectable viral load within 12 
months of starting treatment; and 
4. Viral load will be submitted by prescriber 12 weeks after the completion of therapy; 
and 
5. Patient has advanced liver disease corresponding to a Metavir score of 3 or 
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greater fibrosis as confirmed by one of the following: 
 Liver biopsy confirming a Metavir score ≥ F3; or   
 Transient elastography (FibroScan) score ≥ 9.5kPa; or  
 FibroSURE (FibroTest) score ≥ 0.58; or 
 APRI score > 1.5; or 
 Radiological imaging consistent with cirrhosis (i.e. evidence of portal 
hypertension); or 
 Physical findings or clinical evidence consistent with cirrhosis; or 
 Patients at highest risk for severe complications: organ transplant, type 2 or 
3 essential mixed cryoglobulinemia with end-organ manifestations (e.g. 
vasculitis), proteinuria, nephrotic syndrome, or membranoproliferative 
glomerulonephritis. 
6. Patient’s prior treatment history is provided (treatment naïve or treatment 
experienced; and 
7. If patient has a history of non-compliance, documentation that steps have been 
taken to correct or address the causes of non-compliance are provided; and  
8. Patient has abstained from the use of illicit drugs and alcohol for a minimum of 
three (3) months as evidenced by a negative urine confirmation test; and 
9. Patient does not have severe renal impairment (creatinine clearance <30ml/min) 
or end stage renal disease requiring hemodialysis; and 
10. HCV treatment is prescribed by a digestive disease, liver disease, or infectious 
disease provider practice; and. 
11. For patients on a regimen containing ribavirin, the following must be documented 
on the PA form: 
a) Patient is not a pregnant female or a male with a pregnant female partner; 
and 
b) Women of childbearing potential and their male partners must use two 
forms of effective contraception during treatment and for at least 6 months 
after treatment has concluded; and 
c) Monthly pregnancy tests will be performed during treatment; and 
12. Prescriber has reviewed the patient’s current medication list and acknowledged 
that there are no significant drug interactions with the HCV medication. 
13. Documentation is provided for patients who are ineligible to receive interferon or 
ribavirin. 
14. Non-FDA approved or non-compendia indicated combination therapy regimens will 
not be approved. 
15. If patient is recently eligible for Iowa Medicaid, and has been started and stabilized 
on therapy while covered under a different plan, documentation of how long the 
patient has been on medication will be required.  Patient will be eligible for the 
remainder of therapy needed, based on established length of therapy for the 
particular treatment (defined below). 
16. Lost or stolen medication replacement requests will not be authorized. 
17. The 72-hour emergency supply rule does not apply to oral hepatitis C antiviral 
agents. 
 
CNS Stimulants and Atomoxetine 
 
Proposed Prior Authorization Criteria (changes italicized) 
Prior authorization (PA) is required for CNS stimulants and Atomoxetine for patients 21 
years of age or older.  Prior to requesting prior authorization for any covered diagnosis, 
the prescriber must review the patient’s use of controlled substances on the Iowa 
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Prescription Monitoring Program website at https://pmp.iowa.gov/IAPMPWebCenter/.   
Payment for CNS stimulants and Atomoxetine will be considered under the following 
conditions: 
1. Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD) 
meeting the DSM-5 criteria and confirmed by a standardized rating scale (such as 
Conners, Vanderbilt, Brown, SNAP-IV). Symptoms must have been present before 
twelve (12) years of age and there must be clear evidence of clinically significant 
impairment in two or more current environments (social, academic, or 
occupational).  Documentation of a recent clinical visit that confirms the patient 
continues to require medication to treat the symptoms of ADD/ADHD will be 
required for renewals or patients newly eligible that are established on medication 
to treat ADD/ADHD. 
2. Narcolepsy with diagnosis confirmed with a recent sleep study (ESS, MSLT, 
PSG). 
3. Excessive sleepiness from obstructive sleep apnea/hypopnea syndrome (OSAHS) 
with documentation of non-pharmacological therapies tried (weight loss, position 
therapy, CPAP at maximum titration, BiPAP at maximum titration or surgery) and 
results from a recent sleep study (ESS, MSLT, PSG) with the diagnosis confirmed 
by a sleep specialist. 
4. Binge Eating Disorder (Vyvanse only)  
 Patient is 18 to 55 years of age; and 
 Patient meets the DSM-5 criteria for Binge Eating Disorder; and  
 Patient has documentation of moderate to severe BED, as defined by the 
number of binge eating episodes per week (number of episodes must be 
reported); and 
 Patient has documentation of non-pharmacologic therapies tried, such as 
cognitive-behavioral therapy or interpersonal therapy, for a recent 3 month 
period, that did not significantly reduce the number of binge eating 
episodes; and  
 Patient has documentation of an adequate trial and therapy failure at a 
therapeutic dose with topiramate and fluvoxamine 
 Prescription is written by a psychiatrist or psychiatric nurse practitioner; and 
 Patient has a BMI of 25 to 45; and 
 Patient does not have personal history of cardiovascular disease; and 
 Patient has no history of substance abuse; and 
 Is not being prescribed for the treatment of obesity or weight loss; and 
 Doses above 70mg per day will not be considered. 
 Initial requests will be approved for 12 weeks. 
 Requests for renewal must include documentation of a change from 
baseline at week 12 in the number of binge days per week. 
 
DSM-5 Criteria 
i. Recurrent episodes of binge eating, including eating an abnormally 
large amount of food in a discrete period of time and has a feeling of 
lack of control over eating; and 
ii. The binge eating episodes are marked by at least three of the 
following: 
1. Eating more rapidly than normal 
2. Eating until feeling uncomfortably full 
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3. Eating large amounts of food when not feeling physically 
hungry 
4. Eating alone because of embarrassment by the amount of 
food consumed 
5. Feeling disgusted with oneself, depressed, or guilty after 
overeating; and 
iii. Episodes occur at least 1 day a week for at least 3 months; and 
iv. No regular use of inappropriate compensatory behaviors (e.g. 
purging, fasting, or excessive exercise) as are seen in bulimia 
nervosa; and  
v. Does not occur solely during the course of bulimia nervosa or 
anorexia nervosa. 
 
Moderate to Severe BED 
Based on the number of binge eating episodes per week:   
Moderate - 4 to 7  
Severe – 8 to 13 
Extreme – 14 or more 
 
Payment for a non-preferred agent will be authorized only for cases in which there is 
documentation of a previous trial and therapy failure with a preferred agent. *If a non-
preferred long-acting medication is requested, a trial with the preferred immediate release 
and extended release product of the same chemical entity (methylphenidate class) or 
chemically related agent (amphetamine class) is required. 
 
The required trials may be overridden when documented evidence is provided that the 
use of these agents would be medically contraindicated. 
 
Dextromethorphan/Quinidine (Nuedexta) 
 
Proposed Prior Authorization Criteria (changes italicized) 
Prior authorization is required for Nuedexta®. Payment will be considered under the 
following conditions: 
1. Patients must have a diagnosis of pseudobulbar affect (PBA) secondary to a 
neurological condition. 
2. A trial and therapy failure at a therapeutic dose with amitriptyline or an SSRI; and 
3. Patient has documentation of a current EKG (within the past 3 months) without QT 
prolongation. 
4. Initial authorizations will be approved for 12 weeks with a baseline Center for 
Neurologic Studies Lability Scale (CNS-LS) questionnaire.  
5. Subsequent prior authorizations will be considered at 6 month intervals with 
documented efficacy as seen in an improvement in the CNS-LS questionnaire. 
 
The required trials may be overridden when documented evidence is provided that use of 
these agents would be medically contraindicated. 
 
Chronic Pain Syndromes 
 
Proposed Prior Authorization Criteria (changes italicized) 
A prior authorization is required for pregabalin (Lyrica®) and milnacipran (Savella™).  
These drugs will be considered for their FDA indication(s) and other conditions as listed 
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in the compendia.  Requests for doses above the manufacturer recommended dose will 
not be considered.  For patients with a chronic pain diagnosis who are currently taking 
opioids, as seen in pharmacy claims, a plan to decrease and/or discontinue the opioid(s) 
must be provided with the initial request.  Initial authorization will be given for three (3) 
months.  There must be a significant decrease in opioid use or discontinuation of 
opioid(s) after the initial three (3) month authorization for further approval consideration.  
Additional prior authorizations will be considered with documentation of a continued 
decrease in opioid utilization.  Payment will be considered under the following conditions: 
1. A diagnosis of fibromyalgia (Lyrica® and Savella™)  
a. A trial and therapy failure at a therapeutic dose with gabapentin plus one of 
the following preferred generic agents: tricyclic antidepressant or  SNRI, 
WITH 
b. Documented non-pharmacologic therapies (cognitive behavior therapies, 
exercise, etc.).  
2. A diagnosis of postherpetic neuralgia (Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of the 
following: tricyclic antidepressant, topical lidocaine, or valproate. 
3.  A diagnosis of diabetic peripheral neuropathy (Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of the 
following: tricyclic antidepressant, duloxetine or topical lidocaine. 
4.  A diagnosis of partial onset seizures, as adjunct therapy (Lyrica®) 
 
Sedative/Hypnotics Non-Benzodiazepines 
 
Proposed Prior Authorization Criteria (changes italicized) 
Preferred agents are available without prior authorization (PA). Requests for doses above 
the manufacturer recommended dose will not be considered.  Prior authorization is 
required for all non-preferred non-benzodiazepine sedative/hypnotics. Payment for non-
preferred non-benzodiazepine sedative/hypnotics will be authorized only for cases in 
which there is documentation of previous trials and therapy failures with, at a minimum, 
three (3) preferred agents. Payment for non-preferred non-benzodiazepine 
sedative/hypnotics will be considered when the following criteria are met: 
1. A diagnosis of insomnia; and 
2. Medications with a side effect of insomnia (i.e. stimulants) are decreased in dose, 
changed to a short acting product, and/or discontinued; and 
3. Enforcement of good sleep hygiene is documented; and 
4. All medical, neurological, and psychiatric disease states causing chronic insomnia 
are being adequately treated with appropriate medication at therapeutic doses. 
5. In addition to the above criteria, requests for suvorexant (Belsomra) will require 
documentation of a trial and therapy failure with at least one non-preferred agent, 
other than suvorexant, prior to consideration of coverage. 
6. Non-preferred alternative delivery systems will only be considered for cases in 
which the use of the alternative delivery system is medically necessary and there 
is a previous trial and therapy failure with a preferred alternative delivery system if 
available. 
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The required trials may be overridden when documented evidence is provided that use of 
these agents would be medically contraindicated. 
 
Additionally, the DUR Commission received feedback from the MHAG regarding the proposed 
quantity limits on select CNS stimulants and proposed prior authorization criteria for CNS 
stimulants and atomoxetine.  The DUR took the recommendation of the MHAG to keep the 
quantity limit for Concerta 54mg (brand and generic) at the current quantity limit of 60 tablets per 
30 days, as literature supports the use of this dose.  The DUR also clarified the requirement for 
prescribers to check the Iowa PMP website, and recommended it should apply to quantity limit 
override requests as well.  Below are the recommended quantity limits on select CNS 
stimulants: 
 
Drug (applies to 
brand and generic) 
Proposed 
Quantity 
Limit 
Current 
Quantity 
Limit 
Adderall IR 12.5mg  90 120 
Adderall IR 20mg  90 120 
Concerta 18mg  30 60 
Concerta 27mg  30 60 
Focalin IR 2.5mg 60 None 
Focalin IR 5mg 60 None 
Focalin IR 10mg 60 None 
Focalin XR 5mg 30 60 
Focalin XR 10mg 30 60 
Focalin XR 15mg 30 90 
Focalin XR 20mg 30 60 
Focalin XR 25mg 30 60 
Focalin XR 30mg 30 60 
Ritalin IR 5mg 90 None 
Ritalin IR 10mg 90 None 
Ritalin IR 20mg 90 None 
 
The DUR Commission also received feedback from the MHAG regarding the ProDUR edits on 
Antipsychotics in children.  While they appreciate the comments from the MHAG, they feel no 
changes to the initial recommendations are needed.  
 
Finally, the DUR Commission made the recommendation in February to implement a quantity 
limit of 120 units per 30 days for all strengths of alprazolam, clonazepam, and lorazepam after 
letters were mailed to prescribers of members identified as exceeding the recommended 
quantity limit.  The data was refreshed to use current claims data and letters were mailed at the 
end of February. 
 
Thank you in advance for the Department’s consideration of accepting the DUR Commission’s 
recommendations for clinical prior authorization criteria for Hepatitis C Agents; CNS Stimulants 
and Atomoxetine; Dextromethorphan/Quinidine (Nuedexta®); Chronic Pain Syndromes; and 
Sedative/Hypnotics – Non-Benzodiazepines and quantity limits for CNS stimulants and 
benzodiazepines 
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Sincerely,  
 
 
Pamela Smith, R.Ph.  
Drug Utilization Review Project Coordinator 
Iowa Medicaid Enterprise 
 
Cc:  Erin Halverson, R.Ph., IME 
 Megan Smith, R.Ph., Pharm.D., IME 
 Gina Tiernan, R.Ph., IME 
Appendix H 
Prospective DUR 
Prospective DUR 
SFY15 
 
All recommendations are inclusive of brand and generic agents.  The following 
prospective DUR (ProDUR) edits were recommended to the Department: 
 The DUR reviewed the recommendations they initially made in April 2012 
to implement ProDUR edits on antipsychotics in members less than 18 
years of age.  After discussion, the Commission continues to support the 
implementation of the following ProDUR edits: 
o ProDUR age edit on risperidone for members less than 5 years of 
age and an age edit on all other antipsychotics for members less 
than 6 years of age. 
o Duplicate therapy edit on all antipsychotics. 
 Quantity limit on all short-acting opioids of 120 units per 30 days. 
 Quantity limit on Adderall IR 12.5mg and 20mg of 90 tablets per 30 days. 
 Quantity limit on Concerta 18mg and 27mg of 30 tablets per 30 days. 
 Quantity limit on Focalin IR (all strengths) of 60 tablets per 30 days. 
 Quantity limit on Focalin XR (all strengths) of 30 capsules per 30 days. 
 Quantity limit on Ritalin IR (all strengths) of 90 tablets per 30 days. 
 Quantity limit on all strengths of alprazolam, clonazepam, and lorazepam 
of 120 units per 30 days. 
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Long-Acting Opioid Use in Opioid-Naïve Patients 
Long-acting opioids can be useful medications when trying to control a 
patient’s pain allowing for better pain control due to their longer duration 
of action.  Use of long-acting opioids in patients who are opioid naïve 
can be a cause for concern since it is a leading cause of death from 
respiratory depression in these patients.  It is estimated, in 2010, that 
respiratory depression is the cause of death in about 16,000 opioid-
related mortalities in the United States. While the use of any long-acting 
opioid in these patients can lead to death, fentanyl transdermal patch is 
the medication most likely to cause death from respiratory depression.   
 
Several case reports have been published regarding use of fentanyl 
patch in opioid naïve patients.  Use of fentanyl transdermal patch in 
opioid naïve patients often times results in death.  Patients being 
treated for post-operative pain are those that seem to be the most 
susceptible.  Death does not always occur when fentanyl transdermal 
patches are used improperly.  Unfortunately, these deaths could have 
been avoided if proper prescribing practices were followed.  Respiratory 
depression and risk of death seen in opioid naïve patients is increased 
when the patient has preexisting respiratory compromise, such as 
COPD and sleep apnea.   
 
The FDA has issued multiple warnings and has taken several actions 
since 2005 to combat the use of long-acting opioids in opioid naïve 
patients.  These actions include adding these medications to its risk 
evaluation and mitigation strategies (REMS) program in April 2011.  A 
black box warning has been issued to be included on the packaging of 
all long-acting opioids about the risk of respiratory depression and 
death that can result from the misuse of these medications.  Long-
acting opioids are intended to be used in opioid tolerant patients.  To be 
considered opioid tolerant, the patient must have been taking an opioid 
dose of 60mg morphine equivalents or more per day for a minimum of 
one week. 
 
In September 2013, the FDA announced that they would require long-
acting opioids to state that the use of these medications are indicated 
for severe pain management that is inadequately controlled with other 
treatment options and requires long-term, daily, around-the-clock opioid 
therapy.  Very low doses of some long-acting opioids may be used 
successfully in opioid naïve patients without major adverse effects, but 
fentanyl transdermal patches and extended-release hydromorphone are 
contraindicated in these patients and should never be used due to the 
higher risk of respiratory depression associated with their use.   
 
Prescribers should keep in mind a few simple guidelines when 
prescribing long-acting opioids for patients to protect themselves and 
adequately control the patients’ pain.   
 It is important to keep the whole picture of the patient in mind, as 
well as the adverse effects associated with these medications to 
avoid any unnecessary risk.   
  
 
 
  
 When a patient is determined to be an appropriate candidate for opioid therapy, initiation of the 
medication should be done at the lowest dose and titrated upward to the lowest effective dose for 
each patient. 
 Duration of use should be considered when reevaluating the patient’s pain to ensure these 
medications are not used longer than necessary. 
 
To obtain more guidance on safe prescribing of long-acting opioids the FDA has issued its Blueprint for 
Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics which can be found at 
http://www.fda.gov/downloads/drugs/drugsafety/informationbydrugclass/ucm277916.pdf 
 
Patient safety should be at the forefront of all prescribing practices, including when prescribing long-acting 
opioids.  These medications can be valuable tools in controlling pain in patients who suffer from chronic 
pain issues. Prescribing and patient safety issues come into play when long-acting opioids are improperly 
used in patients whom the medications were not intended, including the opioid naïve and those with acute 
or post-operative pain.  The main adverse effect of concern with use of these medications is respiratory 
depression that can lead to death.  These outcomes could be avoided by following the warnings and 
guidance put in place by the FDA to maintain patient safety at all times. 
 
Currently, non-preferred long-acting opioids are subject to prior authorization criteria as follows:  
Prior authorization is required for all non-preferred long-acting narcotics. Payment will be 
considered under the following conditions: 
1. There is documentation of previous trials and therapy failures with two (2) chemically distinct 
preferred long-acting narcotics (such as extended-release morphine sulfate, Opana ER and 
methadone) at therapeutic doses, and 
2. A trial and therapy failure with fentanyl patch at maximum tolerated doses, and 
3. A signed chronic opioid therapy management plan between the prescriber and patient must 
be included with the prior authorization, and 
4. The prescriber must review the patient’s use of controlled substances on the Iowa 
Prescription Monitoring Program website at https://pmp.iowa.gov/IAPMPWebCenter/ prior to 
requesting prior authorization. 
5. Requests for long-acting narcotics will only be considered for FDA approved dosing. 
 
The required trials may be overridden when documented evidence is provided that use of these 
agents would be medically 
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FDA Updates   
 
The FDA is requiring a Boxed Warning for lidocaine topical 2% (viscous) solution alerting health care 
providers and caregivers against its use in treating teething pain in infants and children, which may cause 
serious harm, including death. When too much viscous lidocaine is given to infants and young children, or if 
they accidentally swallow too much, seizures, severe brain injury, and cardiac problems may result. 
Reports of serious adverse events (including death) in infants and young children 5 months to 3.5 years of 
age given lidocaine 2% viscous solution for mouth pain (including pain due to teething and stomatitis), or 
with accidental ingestion, have been reviewed by the FDA. 
The American Academy of Pediatrics recommends managing teething pain with a chilled (not frozen) 
teething ring or gently rubbing/massaging with the caregiver’s finger. The FDA recommends against using 
topical OTC medications for teething pain as some products may cause harm. 
Further information can be found at: 
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm402790.
htm?source=govdelivery&utm_medium=email&utm_source=govdelivery 
 
The FDA is warning that certain OTC topical acne products marketed under various brand names may 
cause rare but serious and potentially life-threatening allergic reactions or severe irritation. Consumers 
should seek immediate emergency medical attention if they experience hypersensitivity reactions such as 
throat tightness, difficulty breathing, faintness, or swelling of the eyes, face, lips, or tongue, and should also 
stop using topical acne products if they develop hives or itching. These serious reactions may occur within 
minutes to a day or longer after product use and differ from the local skin irritation (redness, burning, 
dryness, itching, peeling, or slight swelling) that may occur at the application site. It has not been determined 
if the serious hypersensitivity reactions are triggered by the products’ active ingredients (benzoyl peroxide or 
salicylic acid), inactive ingredients, or by a combination of both. The FDA is monitoring and evaluating this 
safety issue. At first use, consumers should apply a small amount of any OTC topical acne product to 1 or 2 
small affected areas for 3 days to make sure they do not develop hypersensitivity symptoms. 
http://www.fda.gov/Drugs/DrugSafety/ucm400923.htm 
New and Updated Drug Prior Authorization Criteria 
Antidepressants (combines existing criteria for vilazodone (Viibryd) and desvenlafaxine (Pristiq) and 
applies to all non-preferred antidepressants subject to clinical criteria): Prior authorization is required for 
non-preferred antidepressants subject to clinical criteria. Requests for doses above the manufacturer 
recommended dose will not be considered. Payment will be considered for patients when the following 
criteria are met:  
1. The patient has a diagnosis of Major Depressive Disorder (MDD) and is 18 years of age or older; and  
2. Documentation of a previous trial and therapy failure at a therapeutic dose with two preferred generic 
SSRIs; and  
3. Documentation of a previous trial and therapy failure at a therapeutic dose with one preferred generic 
SNRI; and  
4. Documentation of a previous trial and therapy failure at a therapeutic dose with one non-SSRI/SNRI 
generic antidepressant.  
5. If the request is for an isomer, prodrug or metabolite of a medication indicated for MDD, one of the 
trials must be with the preferred parent drug of the same chemical entity that resulted in a partial 
response with a documented intolerance.  
The required trials may be overridden when documented evidence is provided that the use of these agents 
would be medically contraindicated. 
 
 
 
 
 
  
 
 DUR Activities 
 
 
Medicaid Statistics for Prescription Claims   
from April 1, 2014 to June 31, 2014* 
 
Number of claims paid:  1,066,054   Average amount paid per claim:  $63.51 
Total dollars paid: $67,703,983       Average amount paid per claim, brand:  $278.87 
Percent generic prescriptions:  83%   Average Amount paid per claim, generic:  $19.51 
Top Drugs by Number of 
Prescriptions 
Top Drugs by Dollars 
Spent  
Top Therapeutic Class by 
Dollars Spent      
Hydrocodone/APAP 5-325mg 
$14.42/RX 
Abilify 20mg  
$1,499,335 
$572.48/RX  
Antipsychotics – Atypicals 
$6.9 million 
 Loratadine 10mg 
$9.24/RX 
Lantus Injection 100/ml 
$1,695,903 
$279.25/RX 
Stimulants – Amphetamines – 
Long Acting 
$4.7 million 
Ventolin HFA 
$53.17/RX 
Methylphenidate ER  36mg 
$1,085,296 
$171.10/RX 
Anticonvulsants 
$4.1 million 
 
Tramadol 50mg 
$10.71/RX 
Abilify 30mg 
$1,062,305 
$581.77/RX 
Stimulants- Methylphenidate- 
Long Acting 
$3.1 million 
Amoxicillin 400mg/5ml 
$11.01/RX 
Cymbalta 60mg 
$1,245,326 
$233.43/RX 
Antidepressants – Selected 
SSRIs 
 
$2.5 million 
 *All dollars reported are pre-rebate 
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Off-Label Pharmaceutical Marketing:  How to Recognize 
and Report It 
The use of pharmaceuticals for unapproved symptoms or conditions, in 
unapproved patient groups, or in unapproved dosages, is referred to as 
“off-label” use. Promotion of such off-label use by pharmaceutical 
manufacturers is among the top four types of drug promotion problems 
identified by the U.S. Food and Drug Administration (FDA). 
 Off-Label Promotion and the False Claims Act  
Unlawful off-label drug promotion has been the subject of significant 
health care fraud enforcement efforts by the United States Department 
of Justice (DOJ) and the State attorneys general using the Federal 
False Claims Act. The theory underlying these efforts is that, by 
promoting off-label uses that are not medically accepted, the 
manufacturers caused pharmacies to claim Medicaid payment for drugs 
used in ways that are not covered by Medicaid. Most, if not all, State 
Medicaid programs exclude coverage for drugs that are used in off-label 
indications that are not medically accepted. DOJ and State enforcement 
efforts have identified a wide range of deceptive practices that 
promoted off-label uses of many prescription drugs. These practices 
have resulted in large monetary settlements with a number of 
pharmaceutical manufacturers.  
How to Recognize Unlawful Off-Label Promotion  
Unlawful off-label promotion by pharmaceutical manufacturers can take 
a number of different forms. These forms include the following:  
 Paying incentives to sales representatives based on sales for off-
label use; 
 Paying kickbacks to physicians to prescribe drugs for off-label 
use; 
 Disseminating misleading posters promoting off-label use; 
 Paying physicians: 
o To serve as authors of articles about off-label uses written 
by manufacturers’ agents; 
o To serve as members of “advisory boards” promoting off-
label use; 
o To travel to resort locations to listen to promotions about 
off-label use; or 
o To give promotional lectures in favor of off-label use to 
fellow practitioners; 
 Providing advice to prescribers on how to code their claims and 
document their medical records to support payment for off-label 
uses not covered by Medicaid; 
 Publicizing studies showing efficacy of off-label uses while 
suppressing studies showing no efficacy; and 
 Making false representations directly to Medicaid to influence 
decisions about payment for drugs used off-label. 
 
How to Report Unlawful Off-Label Promotion  
Because of the potential for patient harm that some off-label drug uses 
can cause, and because of the potential waste of taxpayer funds when 
 Medicaid pays for off-label uses that are not medically accepted, it is important for health care 
professionals, manufacturers, and pharmaceutical representatives to report unlawful off-label promotion in 
Medicaid.  
Individuals that recognize off-label drug promotion should report it to:  
 The FDA at BadAd@fda.gov or 855-RX-BadAd, 877-RX-DDMAC; 
 The State Medicaid agency or Medicaid Fraud Control Unit at the contact numbers found on the list 
at http://www.cms.gov/medicare-medicaid-coordination/fraud-
prevention/fraudabuseforconsumers/report_ fraud_and_suspected_fraud.html on the Centers for 
Medicare & Medicaid website; or  
 The U.S. Department of Health and Human Services, Office of Inspector General, at 
HHSTips@oig. hhs.gov or 1-800-447-8477 (1-800-HHS-TIPS).  
 
Obtained from the CMS website at:  http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-
Prevention/Medicaid-Integrity-Education/Downloads/off-label-marketing-factsheet.pdf.  Accessed 
10/31/2014. 
 
How to Dispose of Unused Medications 
 
The Drug Enforcement Administration (DEA) has announced a new regulation permitting consumers to 
return unused medications to authorized collectors, including pharmacies, beginning in October 2014. The 
decision comes after increasing concern over the rise in abuse rates for prescription drugs. The new 
regulation covers drugs designated as controlled substances which previously could only be disposed of by 
patients themselves or surrendered to law enforcement. Patients and their relatives will now also be allowed 
to mail unused drugs to authorized collectors using packages available at pharmacies and other locations. 
The program will be voluntary, and pharmacies may choose to register with the DEA to take back controlled 
substances or to receive them through the mail. See the news release for more information at 
http://www.justice.gov/dea/divisions/hq/2014/hq090814.shtml. 
FDA Updates   
 
REVLIMID - Approval of updates to the Warnings and Boxed Warning sections of the prescribing information 
to include information on the risk of arterial thromboembolism. The Boxed Warning already included 
information on the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism). The 
updated Boxed Warning also states that there is an increased risk of myocardial infarction and stroke in 
patients with multiple myeloma receiving REVLIMID with dexamethasone. Further, the prescribing 
information now states that anti-thrombotic prophylaxis is recommended; whereas it previously stated that 
the decision to take prophylactic measures should be made carefully after an assessment of an individual 
patient's underlying risk factors. 
 
CHANTIX - Approval of updates to the prescribing information to provide two new warnings, seizures and an 
interaction with alcohol, and additional clinical trial data. Reports of new-onset or recurrence of seizures 
have occurred with CHANTIX, and these events occurred most commonly in the first month of the therapy. 
In addition, there have been post-marketing reports of patients experiencing increased intoxicating effects of 
alcohol while taking CHANTIX, with some patients experiencing unusual and sometimes aggressive 
behavior. Finally, revisions were made to the warning regarding neuropsychiatric symptoms and suicidality 
to include pooled data from clinical trials and data from observational trials. The results of a meta-analysis of 
five randomized, double-blind trials showed no increase in the incidence of suicidal ideation and/or behavior 
in patients treated with CHANTIX compared to those treated with placebo. A further pooled analysis of 18 
double-blind randomized trials found a similar incidence of common psychiatric events in patients treated 
with CHANTIX and placebo. Observational studies generally supported the conclusions of the randomized 
trials (although limitations to the observational studies were noted). 
  
New and Updated Drug Prior Authorization Criteria 
Pharmacy Prior Authorization: The drug prior authorization unit will consider other conditions as listed in 
the compendia on an individual basis after reviewing documentation submitted regarding the medical 
necessity.  
1. Duplicate use of drugs from the same therapeutic category or therapeutic duplication will not be 
considered.  
2. All required trials must be of appropriate dose and duration for the indication and must be 
documented by the prescriber, on the request for prior authorization form, including dates, dose, and 
nature of failure.  
3. The use of pharmaceutical samples (from the prescriber or manufacturer medication assistance 
program) will not be considered when evaluating the medical condition or prior prescription history for 
drugs that require prior authorization. 
 
Omalizumab (Xolair) – Added Chronic Idiopathic Urticaria indication and criteria (only new criteria listed 
below) 
Chronic Idiopathic Urticaria  
1. Patient has a diagnosis of moderate to severe chronic idiopathic urticaria; and  
2. Patient is 12 years of age or older; and  
3. Patient has documentation of a trial and therapy failure with at least one second-generation 
antihistamine, one of which must be cetirizine at a dose of up to 20mg per day; and  
4. Patient has documentation of a trial and therapy failure with at least one first-generation 
antihistamine; and  
5. Patient has documentation of a trial and therapy failure with at least one potent H1 receptor 
antagonist (hydroxyzine and/or doxepin); and  
6. Patient has documentation of a trial and therapy failure with a preferred leukotriene receptor 
antagonist in combination with a first-or second-generation antihistamine.  
 
If criteria for coverage are met, the initial authorization will be given for 12 weeks to assess the 
needed for continued therapy. 
 
 Coverage of Naloxone 
Effective October 1, 2014, injectable naloxone will be a preferred drug on the Preferred Drug List (PDL) 
and may be prescribed as a rescue medication for a potentially life-threatening overdose. In addition, 
coverage of a mucosal atomization device (LMA MAD Nasal) will be available through the pharmacy Point of 
Sale (POS) system.  
 
a) Stocking the Materials:  
 2mg/ml naloxone (NDC 76329-3369-01) is available from pharmacy wholesalers.  
 The LMA MAD Nasal is available from some wholesalers or directly from the manufacturer, Teleflex.  
 
b) Billing:  
 Use NDC 76329-3369-01 to bill for 2mg/ml naloxone.  
 Use NDC 99999-2718-02 to bill for the LMA MAD Nasal Mucosal Atomization Device without syringe. 
Reimbursement is $5.75 per unit and no dispensing fee will be paid for claims for this item.  
 The quantity limit for naloxone rescue prescriptions is two syringes (4mls) and two nasal mucosal 
atomization devices per 30 days.  
 
 
 
 
 
  DUR Activities 
 
 
Medicaid Statistics for Prescription Claims   
from July 1, 2014 to September 30, 2014* 
 
Number of claims paid:  1,063,606   Average amount paid per claim:  $64.26 
Total dollars paid: $68,350,517       Average amount paid per claim, brand:  $282.17 
Percent generic prescriptions:  83%   Average Amount paid per claim, generic:  $19.57 
Top Drugs by Number of 
Prescriptions 
Top Drugs by Dollars 
Spent  
Top Therapeutic Class by 
Dollars Spent      
Hydrocodone/APAP 5-325mg 
$14.16/RX 
Abilify 20mg  
$1,288,237 
$484.66/RX  
Antipsychotics – Atypicals 
$6.9 million 
 
Ventolin HFA 
$54.23/RX 
 
Lantus Injection 100/ml 
$1,275,288 
$192.35/RX 
Stimulants – Amphetamines – 
Long Acting 
$4.5 million 
Loratadine 10mg 
$9.03/RX 
Methylphenidate ER  36mg 
$1,128,249 
$178.29/RX 
Anticonvulsants 
$4.3 million 
 
Cetirizine 10mg 
$10.35/RX 
Abilify 30mg 
$1,011,284 
$498.17/RX 
Stimulants- Methylphenidate- 
Long Acting 
$3.1 million 
Tramadol 50mg 
$10.67/RX 
Ventolin HFA 
$969,476 
$54.23/RX 
Antidepressants – Selected 
SSRIs 
 
$2.5 million 
 *All dollars reported are pre-rebate 
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Complex Pharmaceutical Oversight Program (CPOP) 
The Iowa Medicaid Enterprise (IME) is pleased to announce the 
availability of a new IME patient care initiative; the Complex 
Pharmaceutical Oversight Program (CPOP). This program provides 
oversight of clinically complex and high-cost drugs, and is designed to 
reduce waste, enhance medication adherence and improve clinical 
outcomes.  
 
The CPOP is a patient-focused and pharmacist-driven program, which 
uses techniques that are not feasible for a traditional prior authorization 
(PA) program. Iowa Medicaid members receiving complex and high-
cost drugs will be proactively identified through claims data by the IME. 
Once enrolled in the program, patients will speak directly with an IME 
pharmacist about their current medication regimen. The IME pharmacist 
will assess medication adherence and administration techniques, 
adverse events, indications, dosing, duration of therapy, and monitoring 
parameters. Providers (prescribers and pharmacists) may be contacted 
by a member of the CPOP team to discuss medication-related issues, 
or to request additional patient records. Evidence-based guidelines and 
clinical trials will be used to support program interventions.  
 
Currently, the CPOP program is following members being treated for 
Hepatitis C.  
 
The CPOP supports the provider/patient relationship, augments existing 
care management efforts, and is available free of charge to Iowa 
Medicaid members.  
 
If you have questions, please contact the CPOP at 515-256-4874 (toll-
free 877-776-1567), or by email at cpopinfo@dhs.state.ia.us. 
 
Medicaid Modernization 
Medicaid modernization is the movement to a comprehensive risk-
based approach for the majority of current populations and services in 
the Medicaid population.  The goals of Iowa’s Medicaid Modernization 
are to:  1) improve quality and access, 2) promote accountability for 
outcomes, and 3) create a more predictable and sustainable Medicaid 
budget.  DHS will contract for delivery of high quality healthcare 
services for the Iowa Medicaid, Iowa Health and Wellness Plan, and 
Healthy and Well Kids in Iowa (hawk-i) programs.  Two to four 
managed care organizations (MCOs) will be selected to coordinate 
care on a statewide basis. Members will have the ability to select their 
own managed care entity.  Services are set to begin January 1, 2016. 
For more information visit: 
https://dhs.iowa.gov/ime/about/initiatives/MedicaidModernization 
 
 
 
 
 
 
   New Drug Prior Authorization Criteria 
Tasimelteon (Hetlioz®)  
Prior authorization is required for tasimelteon (Hetlioz®). Requests for doses above the manufacturer 
recommended dose will not be considered. Payment will be considered under the following conditions:  
1. Patient has a diagnosis of Non-24-Hour Sleep-Wake Disorder (Non-24), as confirmed by a sleep 
specialist; and  
2. Patient is 18 years of age or older; and  
3. Documentation the patient is totally blind with no perception of light is provided; and  
4. Patient has a documented trial and therapy failure with at least one preferred sedative/hypnotic-non-
benzodiazepine agent; and  
5. Patient has a documented trial and therapy failure with ramelteon (Rozerem®).  
If criteria for coverage are met, initial requests will be given for 3 months. Requests for continuation therapy 
will be considered when the patient has received 3 months of continuous therapy and patient has achieved 
adequate results with tasimelteon (Hetlioz®), such as entrainment, significant increases in nighttime sleep, 
and/or significant decreases in daytime sleep. 
 
Methotrexate Injection  
Prior authorization is required for non-preferred methotrexate injection. Payment will be considered under 
the following conditions:  
1. Diagnosis of severe, active rheumatoid arthritis (RA) or polyarticular juvenile idiopathic arthritis (PJIA) 
and ALL of the following:  
a. Prescribed by a rheumatologist; and  
b. Patient has a documented trial and intolerance with oral methotrexate; and  
c. Patient has a documented trial and therapy failure or intolerance with at least one other non-
biologic DMARD (hydroxychloroquine, leflunomide, minocycline or sulfasalazine); and  
d. Patient’s visual or motor skills are impaired to such that they cannot accurately draw up their 
own preferred generic methotrexate injection and there is no caregiver available to provide 
assistance; and  
e. Patient does not reside in a long-term care facility.  
2. Diagnosis of severe, recalcitrant disabling psoriasis and ALL of the following:  
a. Patient is 18 years of age or older; and  
b. Prescribed by a dermatologist; and  
c. Patient has documentation of an inadequate response to all other standard therapies (oral 
methotrexate, topical corticosteroids, vitamin D analogues, cyclosporine, systemic retinoids, 
tazarotene, and phototherapy).  
 
Apremilast (Otezla®):  
Prior authorization is required for apremilast (Otezla®). Payment will be considered under the following 
conditions:  
1. Patient is 18 years of age or older; and  
2. Patient has a diagnosis of active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 tender joints); and  
3. Prescribed by a rheumatologist or a dermatologist; and  
4. Patient does not have severe renal impairment (CrCl < 30 mL/min); and  
5. Patient has documentation of a trial and inadequate response to therapy with the preferred oral 
DMARD, methotrexate (leflunomide or sulfasalazine may be used if methotrexate is contraindicated); 
and  
6. Patient has documentation of trials and therapy failures with two preferred biological agents used for 
psoriatic arthritis.  
The required trials may be overridden when documented evidence is provided that the use of these agents 
would be medically contraindicated. 
   FDA Updates   
Possible risks of pain medicine use during pregnancy - The FDA is aware of and understands the 
concerns arising from recent reports questioning the safety of prescription and over-the-counter (OTC) pain 
medicines when used during pregnancy. As a result, the FDA reviewed studies on the potential risks 
associated with the following medications during pregnancy: prescription non-steroidal anti-inflammatory 
drugs (NSAIDs) and the risk of miscarriage in the first half of pregnancy; opioids and the risk of birth defects 
of the brain, spine, or spinal cord in babies born to women who took these products during the first trimester 
of pregnancy; and acetaminophen and the risk of attention deficit hyperactivity disorder (ADHD) in children 
born to women who took this medicine at any time during pregnancy. FDA found all of the reviewed studies 
to have potential limitations in their designs; sometimes the accumulated studies on a topic contained 
conflicting results that prevented reliable conclusions from being drawn. As a result, FDA’s 
recommendations on how pain medicines are used during pregnancy will remain the same at this time. It is 
important to carefully weigh the benefits and risks of using prescription and OTC pain medicines during 
pregnancy. Pregnant women should always consult with their health care professional before taking any 
prescription or OTC medicine. Women taking pain medicines who are considering becoming pregnant 
should also consult with their health care professionals to discuss the risks and benefits of pain medicine 
use. Health care professionals should continue to follow the recommendations in the drug labels when 
prescribing pain medicines to pregnant patients. See the FDA notice with additional information at: 
http://www.fda.gov/Drugs/DrugSafety/ucm429117.htm?source=govdelivery&utm_medium=email&utm_sourc
e=govdelivery 
 
 
 Outgoing Member of the DUR Commission 
 
 
 
Gregory Barclay, M.D. recently completed a four year term of service with the Iowa Drug Utilization Review 
Commission.  The Commission and the Department of Human Services would like to thank Dr. Barclay for 
his four years of service to the Commission and the members of Iowa Medicaid. 
 
 
 
 
 
 
 
 
 
  DUR Activities 
 
 
Medicaid Statistics for Prescription Claims   
from October 1, 2014 to December 31, 2014* 
 
Number of claims paid:  1,620,655   Average amount paid per claim:  $62.71 
Total dollars paid: $101,638,082     Average amount paid per claim, brand:  $290.41 
Percent generic prescriptions:  84%   Average Amount paid per claim, generic:  $19.90 
Top Drugs by Number of 
Prescriptions 
Top Drugs by Dollars 
Spent  
Top Therapeutic Class by 
Dollars Spent      
Hydrocodone/APAP 5-325mg 
$14.80/RX 
 
Lantus Injection 100/ml 
$2,346,452 
$363.68/RX   
Antipsychotics – Atypicals 
$8.7 million 
 
Ventolin HFA 
$54.45/RX 
 
 
Abilify 20mg  
$1,585,764 
$612.74/RX 
Anticonvulsants 
$5.6 million 
 
 
Tramadol 50mg 
$11.52/RX 
 
 
Cymbalta 60mg 
$1,571,985 
$258.25/RX 
Stimulants – Amphetamines – 
Long Acting 
$5.1 million  
Loratadine 10mg 
$8.80/RX 
 
Ventolin HFA 
$1,389,041 
$54.45/RX 
 
Antidepressants – Selected 
SSRIs 
 
$4.6 million 
Azithromycin 250mg  
$14.43/RX 
 
Methylphenidate ER  36mg 
$1,311,587 
$199.82/RX  
Diabetic – Insulin 
 
$4.6 million 
 *All dollars reported are pre-rebate 
Appendix J 
Web Site 

Appendix K 
Prevalence Reports 
May/June 2014 July/August 2014 % CHANGE
TOTAL PAID AMOUNT $51,563,948 $54,971,588 6.6%
UNIQUE USERS 180,122 183,702 2.0%
COST PER USER $286.27 $299.24 4.5%
TOTAL PRESCRIPTIONS 874,032 908,943 4.0%
AVERAGE PRESCRIPTIONS PER USER 4.85 4.95 2.0%
AVERAGE COST PER PRESCRIPTION $59.00 $60.48 2.5%
# GENERIC PRESCRIPTIONS 732,795 760,002 3.7%
% GENERIC 83.8% 83.6% -0.3%
$ GENERIC $13,469,535 $13,905,235 3.2%
AVERAGE GENERIC PRESCRIPTION COST $18.38 $18.30 -0.4%
AVERAGE GENERIC DAYS SUPPLY 23 23 0.0%
# BRAND PRESCRIPTIONS 137,826 145,239 3.7%
% BRAND 15.8% 16.0% -0.3%
$ BRAND $37,896,610 $40,838,291 3.2%
AVERAGE BRAND PRESCRIPTION COST $274.96 $281.18 -0.4%
AVERAGE BRAND DAYS SUPPLY 26 26 0.0%
Bi-Monthly Statistics
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UTILIZATION BY AGE
AGE May/June 2014 July/August 2014
0-6 31,405 30,511
7-12 25,904 26,125
13-18 22,385 23,132
19-64 90,618 94,175
65+ 9,810 9,759
180,122 183,702
UTILIZATION BY GENDER AND AGE
GENDER AGE May/June 2014 July/August 2014
F
0-6 14,818 14,269
7-12 11,054 11,454
13-18 11,668 12,152
19-64 58,387 60,545
65+ 7,024 6,987
102,951 105,407
M
0-6 16,587 16,242
7-12 14,850 14,671
13-18 10,717 10,980
19-64 32,231 33,630
65+ 2,786 2,772
77,171 78,295
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TOP 100 PHARMACIES BY PRESCRIPTION COUNT
July/August 2014
RANK PHARMACY NAME PHARMACY CITY STATE PRESCRIPTION 
COUNT
PAID AMT AVG COST RX PREVIOUS RANK
1 BROADLAWNS MEDICAL CENTER DES MOINES IA 19,308 $372,472.50 $19.29 1
2 WALGREEN #05239 DAVENPORT IA 11,151 $594,581.97 $53.32 2
3 WALGREEN #05721 DES MOINES IA 9,066 $501,626.17 $55.33 5
4 WALGREEN #04405 COUNCIL BLUFFS IA 8,941 $483,743.61 $54.10 4
5 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 8,843 $422,794.64 $47.81 3
6 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,270 $326,317.76 $44.89 6
7 MARTIN HEALTH SERVICES INC DENVER IA 6,759 $199,022.52 $29.45 7
8 WALGREEN #359 DES MOINES IA 6,468 $325,274.53 $50.29 8
9 MERCY FAMILY PHARMACY DUBUQUE IA 6,253 $372,071.02 $59.50 12
10 WALGREEN #05362 DES MOINES IA 6,226 $291,112.80 $46.76 13
11 WALGREEN COMPANY 07455 WATERLOO IA 6,201 $301,230.48 $48.58 10
12 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 6,022 $309,435.52 $51.38 11
13 WALGREEN CO.#3700 COUNCIL BLUFFS IA 5,936 $309,629.22 $52.16 9
14 SIOUXLAND COMM HEALTH CTR 
PHARMA
SIOUX CITY IA 5,872 $108,228.05 $18.43 16
15 WALGREENS #07453 DES MOINES IA 5,850 $306,837.13 $52.45 14
16 WALGREEN #910 SIOUX CITY IA 5,644 $291,698.55 $51.68 15
17 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,155 $209,455.27 $40.63 17
18 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,041 $247,574.11 $49.11 19
19 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 4,915 $290,805.17 $59.17 18
20 WALGREEN COMPANY 05777 DES MOINES IA 4,790 $243,801.22 $50.90 21
21 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 4,789 $212,950.76 $44.47 22
22 WALGREEN #04041 DAVENPORT IA 4,601 $229,106.31 $49.79 24
23 WALGREEN #05852 DES MOINES IA 4,556 $245,024.78 $53.78 20
24 HY-VEE PHARMACY #4 (1060) CEDAR RAPIDS IA 4,544 $235,554.93 $51.84 23
25 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,430 $220,944.00 $49.87 25
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TOP 100 PHARMACIES BY PRESCRIPTION COUNT
July/August 2014
RANK PHARMACY NAME PHARMACY CITY STATE PRESCRIPTION 
COUNT
PAID AMT AVG COST RX PREVIOUS RANK
26 RASHID PHARMACY PLC FORT MADISON IA 4,340 $231,140.06 $53.26 28
27 WALGREEN #11709 DAVENPORT IA 4,301 $236,533.80 $55.00 27
28 DANIEL PHARMACY INC FORT DODGE IA 4,217 $206,787.97 $49.04 26
29 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 4,031 $300,481.40 $74.54 29
30 PHARMACY MATTERS LTC IOWA CITY IA 3,958 $162,869.40 $41.15 30
31 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,876 $210,804.41 $54.39 32
32 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,866 $199,934.62 $51.72 35
33 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 3,851 $192,514.30 $49.99 33
34 MAHASKA DRUG INC OSKALOOSA IA 3,695 $201,506.99 $54.54 38
35 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 3,616 $181,157.44 $50.10 34
36 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,559 $217,949.15 $61.24 39
37 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,545 $206,245.80 $58.18 41
38 MEDICAP PHARMACY INDIANOLA IA 3,536 $174,200.73 $49.26 40
39 WALGREEN #7452 DES MOINES IA 3,465 $176,280.22 $50.87 36
40 WALGREEN #03595 DAVENPORT IA 3,456 $185,251.53 $53.60 37
41 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,438 $151,584.84 $44.09 42
42 WALGREEN #05044 BURLINGTON IA 3,398 $167,241.91 $49.22 45
43 STERLING LTC PHARMACY #31 ANKENY IA 3,346 $208,339.07 $62.27 31
44 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,307 $129,348.56 $39.11 50
45 WALGREENS #05119 CLINTON IA 3,295 $171,823.13 $52.15 44
46 A AVENUE PHARMACY CEDAR RAPIDS IA 3,256 $264,176.59 $81.14 43
47 WAL-MART PHARMACY #10-5115 DAVENPORT IA 3,202 $124,243.53 $38.80 48
48 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,188 $174,331.80 $54.68 51
49 WALGREENS #10855 WATERLOO IA 3,176 $169,184.98 $53.27 46
50 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,158 $175,668.57 $55.63 47
51 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 3,080 $143,049.07 $46.44 49
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TOP 100 PHARMACIES BY PRESCRIPTION COUNT
July/August 2014
RANK PHARMACY NAME PHARMACY CITY STATE PRESCRIPTION 
COUNT
PAID AMT AVG COST RX PREVIOUS RANK
52 WALGREEN #05886 KEOKUK IA 3,045 $148,165.33 $48.66 55
53 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,037 $179,997.63 $59.27 52
54 WALGREENS #11942 DUBUQUE IA 3,029 $167,917.37 $55.44 58
55 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,022 $172,560.51 $57.10 53
56 THOMPSON-DEAN DRUG SIOUX CITY IA 3,011 $217,526.19 $72.24 63
57 HY VEE PHARMACY #1449 NEWTON IA 2,995 $154,273.53 $51.51 54
58 WAL MART PHARMACY 10-1621 CENTERVILLE IA 2,869 $137,763.86 $48.02 56
59 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 2,866 $154,872.29 $54.04 59
60 HARTIG PHARMACY SERVICES DUBUQUE IA 2,847 $154,618.68 $54.31 61
61 WAL-MART PHARMACY 10-2889 CLINTON IA 2,760 $143,181.57 $51.88 60
62 WALGREENS 07968 DES MOINES IA 2,714 $164,686.44 $60.68 62
63 HY-VEE PHARMACY (1075) CLINTON IA 2,707 $157,034.30 $58.01 67
64 WALGREEN #4714 DES MOINES IA 2,701 $127,604.71 $47.24 68
65 WAL MART PHARMACY 10-3590 SIOUX CITY IA 2,693 $128,181.85 $47.60 66
66 RASHID LONG TERM CARE PHARMACY FORT MADISON IA 2,669 $80,995.12 $30.35 173
67 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,628 $134,389.09 $51.14 57
68 HY-VEE DRUGSTORE # 7035 FT DODGE IA 2,613 $126,333.31 $48.35 64
69 HY-VEE PHARMACY #2 (1044) BURLINGTON IA 2,604 $124,237.64 $47.71 65
70 S - S PHARMACY INC COUNCIL BLUFFS IA 2,603 $166,239.06 $63.86 71
71 WAL-MART PHARMACY #10-0985 FAIRFIELD IA 2,601 $109,355.62 $42.04 73
72 HY-VEE PHARMACY (1875) WEBSTER CITY IA 2,591 $118,259.40 $45.64 69
73 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,587 $152,655.81 $59.01 77
74 WAL-MART PHARMACY #10-1393 OSKALOOSA IA 2,553 $118,009.16 $46.22 83
75 HY-VEE PHARMACY (1058) CENTERVILLE IA 2,553 $123,152.90 $48.24 72
76 HY-VEE PHARMACY 1504 OTTUMWA IA 2,543 $151,270.35 $59.48 70
77 HY-VEE PHARMACY #3 (1056) CEDAR RAPIDS IA 2,511 $123,268.07 $49.09 76
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78 WAL-MART PHARMACY #10-1965 COUNCIL BLUFFS IA 2,484 $103,807.93 $41.79 89
79 WALGREEN #09708 DUBUQUE IA 2,464 $115,722.52 $46.97 87
80 LA GRANGE PHARMACY INC VINTON IA 2,443 $139,362.22 $57.05 75
81 WALGREEN #05942 NEWTON IA 2,435 $111,389.04 $45.74 96
82 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,430 $139,346.36 $57.34 90
83 HY-VEE PHARMACY (1353) KNOXVILLE IA 2,399 $111,952.79 $46.67 92
84 HY-VEE PHARMACY 1071 CLARINDA IA 2,396 $129,938.41 $54.23 84
85 WAL-MART PHARMACY #10-0646 ANAMOSA IA 2,395 $102,411.31 $42.76 80
86 HY-VEE PHARMACY (1522) PERRY IA 2,387 $104,010.25 $43.57 74
87 WALGREEN #05077 IOWA CITY IA 2,386 $133,763.46 $56.06 98
88 WALGREENS #03876 MARION IA 2,378 $124,748.68 $52.46 94
89 WAGNER PHARMACY CLINTON IA 2,375 $168,096.61 $70.78 79
90 SCOTT PHARMACY FAYETTE IA 2,358 $113,687.82 $48.21 97
91 HY-VEE PHARMACY (1009) DBA ALBIA IA 2,339 $117,609.24 $50.28 91
92 HY-VEE FOOD STORE WATERLOO IA 2,338 $162,570.23 $69.53 81
93 HY-VEE DRUGSTORE (7056) MASON CITY IA 2,335 $108,173.84 $46.33 103
94 HY-VEE PHARMACY (1065) CHARITON IA 2,306 $138,300.82 $59.97 102
95 WAL-MART PHARMACY 10-0784 MT PLEASANT IA 2,285 $135,667.95 $59.37 85
96 WALGREENS #09476 BURLINGTON IA 2,280 $108,922.95 $47.77 93
97 MAIN HEALTHCARE SERVICES BETTENDORF IA 2,260 $70,722.31 $31.29 99
98 STANGEL PHARMACY ONAWA IA 2,258 $132,256.69 $58.57 100
99 PHARMERICA MIDWEST INC DBA URBANDALE IA 2,246 $88,833.79 $39.55 86
100 HY-VEE DRUGSTORE #7031 DES MOINES IA 2,243 $142,632.58 $63.59 88
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1 NUCARA PHARMACY #27 PLEASANT HILL IA 2,100 $1,063,797.77 $2,659.49 1
2 ARJ INFUSION SERVICES INC LENEXA KS 23 $925,410.35 $185,082.07 2
3 CAREMARK KANSAS SPEC PHARMACY 
LL
LENEXA KS 170 $631,877.84 $6,722.10 6
4 WALGREEN #05239 DAVENPORT IA 11,151 $594,581.97 $191.62 5
5 ACCREDO HEALTH GROUP INC NASHVILLE TN 17 $503,909.06 $62,988.63 4
6 WALGREEN #05721 DES MOINES IA 9,066 $501,626.17 $185.44 7
7 WALGREEN #04405 COUNCIL BLUFFS IA 8,941 $483,743.61 $202.66 8
8 ACCREDO HEALTH GROUP INC MEMPHIS TN 68 $427,754.03 $11,560.92 3
9 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 8,843 $422,794.64 $199.71 9
10 BROADLAWNS MEDICAL CENTER DES MOINES IA 19,308 $372,472.50 $140.13 10
11 MERCY FAMILY PHARMACY DUBUQUE IA 6,253 $372,071.02 $352.01 11
12 COMMUNITY HEALTHCARE SERVICES LOMA LINDA CA 9 $345,686.52 $172,843.26 78
13 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,270 $326,317.76 $200.07 16
14 WALGREEN #359 DES MOINES IA 6,468 $325,274.53 $160.95 12
15 WALGREEN CO.#3700 COUNCIL BLUFFS IA 5,936 $309,629.22 $179.50 13
16 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 6,022 $309,435.52 $169.46 17
17 WALGREENS #07453 DES MOINES IA 5,850 $306,837.13 $193.47 14
18 WALGREEN COMPANY 07455 WATERLOO IA 6,201 $301,230.48 $147.95 19
19 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 4,031 $300,481.40 $512.77 18
20 WALGREEN #910 SIOUX CITY IA 5,644 $291,698.55 $160.72 21
21 WALGREEN #05362 DES MOINES IA 6,226 $291,112.80 $144.26 20
22 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 4,915 $290,805.17 $393.51 15
23 CYSTIC FIBROSIS SERVICES INC CENTENNIAL CO 60 $267,347.27 $13,367.36 31
24 A AVENUE PHARMACY CEDAR RAPIDS IA 3,256 $264,176.59 $693.38 23
25 AMBER PHARMACY OMAHA NE 128 $249,135.43 $9,227.24 57
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26 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,041 $247,574.11 $209.10 22
27 WALGREEN #05852 DES MOINES IA 4,556 $245,024.78 $170.99 26
28 WALGREEN COMPANY 05777 DES MOINES IA 4,790 $243,801.22 $193.19 33
29 WALGREEN #11709 DAVENPORT IA 4,301 $236,533.80 $212.71 32
30 HY-VEE PHARMACY #4 (1060) CEDAR RAPIDS IA 4,544 $235,554.93 $233.92 25
31 RASHID PHARMACY PLC FORT MADISON IA 4,340 $231,140.06 $281.53 24
32 WALGREEN #04041 DAVENPORT IA 4,601 $229,106.31 $161.12 27
33 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,430 $220,944.00 $185.20 29
34 ACCREDO HEALTH GROUP INC WARRENDALE PA 44 $219,561.08 $14,637.41 38
35 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,559 $217,949.15 $222.40 37
36 THOMPSON-DEAN DRUG SIOUX CITY IA 3,011 $217,526.19 $358.36 36
37 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 4,789 $212,950.76 $184.85 35
38 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,876 $210,804.41 $281.82 40
39 DIPLOMAT SPECIALTY PHARMACY FLINT MI 45 $210,544.03 $10,025.91 49
40 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,155 $209,455.27 $205.15 43
41 HY-VEE PHARMACY SOLUTIONS OMAHA NE 102 $208,678.74 $3,420.96 30
42 STERLING LTC PHARMACY #31 ANKENY IA 3,346 $208,339.07 $588.53 28
43 DANIEL PHARMACY INC FORT DODGE IA 4,217 $206,787.97 $258.16 39
44 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,545 $206,245.80 $312.97 46
45 MAHASKA DRUG INC OSKALOOSA IA 3,695 $201,506.99 $242.49 50
46 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,866 $199,934.62 $325.63 47
47 MARTIN HEALTH SERVICES INC DENVER IA 6,759 $199,022.52 $169.38 42
48 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 3,851 $192,514.30 $259.10 48
49 US BIOSERVICE CORPORATION FRISCO TX 33 $188,384.09 $12,558.94 44
50 WALGREENS SPECIALTY PHARMACY 
#12
ANN ARBOR MI 51 $186,773.80 $7,470.95 72
51 WALGREEN #03595 DAVENPORT IA 3,456 $185,251.53 $167.50 41
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52 DOHMEN LIFE SCIENCE SERVICES LLC CHESTERFIELD MO 20 $181,474.69 $20,163.85 55
53 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 3,616 $181,157.44 $234.96 54
54 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,037 $179,997.63 $266.66 60
55 MEDFUSIONRX LLC FRANKLIN TN 55 $176,551.45 $5,695.21 51
56 WALGREEN #7452 DES MOINES IA 3,465 $176,280.22 $150.67 52
57 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,158 $175,668.57 $267.79 53
58 WALGREENS INFUSION SERVICES OMAHA NE 54 $174,685.69 $9,704.76 363
59 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,188 $174,331.80 $234.32 59
60 MEDICAP PHARMACY INDIANOLA IA 3,536 $174,200.73 $386.25 77
61 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,022 $172,560.51 $303.27 58
62 WALGREENS #05119 CLINTON IA 3,295 $171,823.13 $187.99 61
63 WALGREENS #10855 WATERLOO IA 3,176 $169,184.98 $181.72 56
64 WAGNER PHARMACY CLINTON IA 2,375 $168,096.61 $421.29 64
65 WALGREENS #11942 DUBUQUE IA 3,029 $167,917.37 $204.03 68
66 WALGREEN #05044 BURLINGTON IA 3,398 $167,241.91 $157.33 65
67 S - S PHARMACY INC COUNCIL BLUFFS IA 2,603 $166,239.06 $451.74 62
68 WALGREENS 07968 DES MOINES IA 2,714 $164,686.44 $191.27 73
69 PHARMACY MATTERS LTC IOWA CITY IA 3,958 $162,869.40 $464.02 70
70 HY-VEE FOOD STORE WATERLOO IA 2,338 $162,570.23 $310.25 81
71 HY-VEE PHARMACY (1075) CLINTON IA 2,707 $157,034.30 $292.97 88
72 ACARIAHEALTH PHARMACY #11 INC HOUSTON TX 32 $155,555.47 $7,777.77 34
73 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 2,866 $154,872.29 $260.73 67
74 HARTIG PHARMACY SERVICES DUBUQUE IA 2,847 $154,618.68 $570.55 63
75 HY VEE PHARMACY #1449 NEWTON IA 2,995 $154,273.53 $228.22 79
76 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,587 $152,655.81 $276.55 74
77 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,438 $151,584.84 $176.26 66
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78 HY-VEE PHARMACY 1504 OTTUMWA IA 2,543 $151,270.35 $291.47 75
79 EXPRESS SCRIPTS SPECIALTY ST LOUIS MO 21 $151,083.69 $12,590.31 127
80 WALGREEN #05886 KEOKUK IA 3,045 $148,165.33 $207.81 82
81 GREENVILLE PHARMACY INC SIOUX CITY IA 2,047 $146,243.49 $407.36 89
82 HY-VEE PHARMACY #4 (1148) DES MOINES IA 2,082 $145,854.76 $309.67 91
83 WAL-MART PHARMACY 10-2889 CLINTON IA 2,760 $143,181.57 $216.94 103
84 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 3,080 $143,049.07 $222.13 45
85 HY-VEE DRUGSTORE #7031 DES MOINES IA 2,243 $142,632.58 $361.10 80
86 WAL-MART PHARMACY 10-5315 LAKE MARY FL 34 $141,478.31 $8,322.25 90
87 LA GRANGE PHARMACY INC VINTON IA 2,443 $139,362.22 $286.16 92
88 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,430 $139,346.36 $284.38 104
89 HY-VEE PHARMACY (1065) CHARITON IA 2,306 $138,300.82 $246.53 95
90 WAL MART PHARMACY 10-1621 CENTERVILLE IA 2,869 $137,763.86 $248.22 85
91 MEDICAP PHARMACY MARSHALLTOWN IA 2,031 $136,162.37 $244.46 105
92 L & M PHARMACY CARE LE MARS IA 1,345 $135,859.14 $1,257.96 71
93 WAL-MART PHARMACY 10-0784 MT PLEASANT IA 2,285 $135,667.95 $246.22 84
94 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,628 $134,389.09 $201.79 69
95 WALGREEN #05077 IOWA CITY IA 2,386 $133,763.46 $208.68 125
96 HY-VEE PHARMACY #1 (1610) SIOUX CITY IA 2,055 $133,516.83 $219.24 107
97 STANGEL PHARMACY ONAWA IA 2,258 $132,256.69 $321.79 83
98 PROCARE PHARMACY DIRECT LLC MONROEVILLE PA 30 $130,974.73 $8,731.65 112
99 HY-VEE PHARMACY 1071 CLARINDA IA 2,396 $129,938.41 $283.09 97
100 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,307 $129,348.56 $139.53 94
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1 1780766659 CHESTER ROBERT BADGER $197,640.81 3,662 5.92 1
2 1538368170 CHRISTOPHER ROBERT MATSON $74,208.54 2,384 5.52 4
3 1467682351 NICOLE GILG $69,170.65 2,265 5.28 3
4 1063622637 HUSSAIN BANU $63,685.35 2,216 5.49 5
5 1841407160 RAHUL BANSAL MD $201,392.93 2,194 4.62 8
6 1861562555 LARRY  RICHARDS $133,921.48 2,062 5.34 2
7 1215192224 SHALINA SHAIK $43,322.78 1,850 5.01 9
8 1316922545 MABRA G ABERNATHY $68,793.97 1,816 4.87 6
9 1164414520 KAREN FULWOOD $136,126.02 1,777 4.40 7
10 1649248378 KATHLEEN L WILD ARNP $170,695.04 1,775 3.64 15
11 1982605762 JEFFREY D WILHARM $131,956.33 1,771 5.15 12
12 1013115369 BOBBITA NAG $198,265.48 1,741 3.80 14
13 1295830115 ALAN BOLLINGER DO $147,205.43 1,715 6.57 10
14 1083784797 CAROL  AUNAN $144,839.51 1,714 3.48 17
15 1043211303 ALI  SAFDAR $114,750.57 1,680 3.68 16
16 1619153137 JODI BEST ARNP $160,686.60 1,643 4.99 18
17 1972758126 REBECCA BOLLIN $42,240.64 1,641 5.13 13
18 1245318393 JEAN TOBIN PA $113,409.62 1,628 4.53 26
19 1073509436 MICHAEL KARL MAHARRY MD $60,880.10 1,573 5.66 11
20 1467502286 CHARLES TILLEY PA $169,328.02 1,532 4.32 20
21 1023053972 BRYANT MUTCHLER DO $62,462.55 1,526 5.67 21
22 1801998372 WENDY MICHELE HANSEN-PENMAN DO $37,560.73 1,524 5.75 23
23 1932415403 MITZI M REGALARD $70,661.30 1,506 4.05 32
24 1073594768 JERROLD V FLATT DO $53,108.95 1,502 5.60 24
25 1245388743 TIMOTHY WAYNE SWINTON $52,024.80 1,496 5.62 25
26 1073667606 ELIZABETH MCCURDY DO $44,435.29 1,443 4.27 39
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27 1912991340 GHADA HAMDAN-ALLEN MD $127,858.05 1,358 4.18 19
28 1205015906 DAVID F WIDITZ $106,652.92 1,356 5.10 27
29 1477633188 CYD Q. GRAFFT $106,704.49 1,350 3.78 31
30 1962558957 ALBERT N OKINE PA $155,834.84 1,341 6.51 29
31 1730239732 SRIRAMAMURTHY RAVIPATI MD $104,486.71 1,312 3.68 34
32 1528144383 RAMONCITO AMURAO O'CAMPO $54,222.43 1,284 4.35 28
33 1043434525 ROBERT MARVIN KENT MD $60,799.95 1,268 4.56 45
34 1285681528 MARVIN FRANKLIN PIBURN $109,663.65 1,266 5.60 35
35 1255322996 MARK WILLIAM MITTAUER $131,285.33 1,265 5.62 37
36 1841220290 KENT ELDON KUNZE MD $107,667.07 1,252 4.57 33
37 1902809536 KIRAN KHANOLKAR $60,380.13 1,249 4.96 40
38 1225097843 WILLIAM M NISSEN $66,031.56 1,235 4.32 55
39 1164538674 JOSEPH M WANZEK $56,319.69 1,227 5.03 42
40 1033389226 ANTHONY G ZAMUDIO ARNP $153,044.23 1,212 3.73 53
41 1497736326 RANDY R ROBINSON $55,272.08 1,207 5.34 43
42 1467437806 GEORGIA LAUER PAC $65,939.95 1,201 4.73 36
43 1184945321 DEANNE REMER $64,944.17 1,198 6.37 41
44 1982766705 MALHAR GORE $34,981.56 1,192 4.15 22
45 1598750432 CHRISTOPHER GENE OKIISHI MD $75,635.29 1,152 7.84 72
46 1063491645 ALLYSON L WHEATON MD $115,393.68 1,140 4.35 64
47 1598962870 CHRISTY QUILLEN ARNP $31,532.71 1,138 4.76 75
48 1952459463 DAVID LAWRENCE YURDIN PA $505,828.57 1,129 4.34 48
49 1003004391 DAVID BERMAN WALKER MD $87,691.00 1,111 4.08 51
50 1205821337 MANMOHAN SINGH $58,418.45 1,107 4.77 47
51 1861559486 JOSPEH PATRICK BERTROCHE $117,938.03 1,084 4.30 44
52 1073500690 KATHLEEN S ADAMS $131,852.95 1,082 3.68 50
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53 1316269871 REGINA ROBISON ARNP $84,332.28 1,062 4.92 213
54 1205169273 TERESA ANN DOWLING $28,254.74 1,055 4.04 80
55 1871586271 PATRICIA BLACKLEDGE ARNP $45,217.03 1,054 6.27 57
56 1073945499 JENNIFER LEE ZALAZNIK ARNP $45,972.60 1,051 3.37 265
57 1104089390 EJIRO AGBORO-IDAHOSA MD $92,675.45 1,050 5.00 49
58 1215080759 JUANITA M O'BRIEN $39,289.08 1,050 5.25 71
59 1306133095 DEBRA LEE ANDERSON $38,419.84 1,049 3.77 74
60 1033198908 DANIEL J ARNOLD $49,345.53 1,039 4.12 70
61 1710941000 LAURIE WARREN PA $98,024.92 1,036 3.92 46
62 1558348284 STEVEN G PAULSRUD $61,405.99 1,030 4.86 78
63 1033436480 AMBER J EDWARDS $64,993.81 1,024 4.39 58
64 1215146055 REBECCA J WOLFE $79,379.61 1,020 3.64 59
65 1841293354 KEITH GUESS PA $89,869.87 1,018 4.17 97
66 1013960566 PETER JOSEPH SZEIBEL $94,237.91 1,017 4.77 60
67 1538157383 DAVID WENGER-KELLER MD $48,099.35 1,011 5.08 77
68 1508946088 E RICHARD NIGHTINGALE MD $105,639.98 1,009 4.71 52
69 1902115652 SARAH LYNN BEATTIE ARNP $107,096.41 996 3.62 66
70 1144214248 KRISTIE DEE ANN WALZ MD $58,209.86 993 4.71 62
71 1285697722 DOUGLAS  JONES $88,332.56 988 3.80 86
72 1275844649 KATIE M HANSON ARNP $71,481.45 978 3.64 167
73 1871595207 DALE M GRUNEWALD $39,294.95 972 6.80 179
74 1396724167 MICHAEL O'CONNER MD $31,556.93 970 5.00 61
75 1619186475 STEPHEN PALLONE MD $34,486.78 964 5.10 94
76 1326013426 PAUL DENNIS PETERSON DO $40,376.53 962 2.74 95
77 1669570404 CASIE RINEY PA $106,966.94 954 5.02 69
78 1699075929 HIEDI CHRISTINE LANE $70,477.43 953 4.45 76
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79 1346210184 JAMES BROOKS MD $98,068.37 951 4.95 87
80 1588629414 THOMAS EARWOOD MD $65,386.86 947 4.83 115
81 1356520431 KAY A MARTTILA $108,355.20 938 3.03 109
82 1922144088 THOMAS SCOTT HOPKINS DO $83,585.94 934 3.47 67
83 1629042288 MARTIN J FIALKOV MD $78,327.48 930 4.49 73
84 1124399522 JOYCE E PROUCH ARNP $76,219.68 928 4.71 89
85 1598733891 JERRY LEE WILLE MD $31,444.44 920 4.00 93
86 1942252895 KIMBERLY A THOMPSON $31,649.17 919 3.08 118
87 1730143397 MARK JOSEPH DEARDEN DO $27,934.51 914 5.05 1518
88 1720293087 RAJNI BATRA MD $38,340.61 908 3.01 54
89 1437373073 MOHSEN ABOU SEIF $25,321.89 908 3.97 88
90 1437238110 GENEVIEVE  NELSON $58,078.73 906 3.65 85
91 1407953979 CECELIA M NASSIF ARNP $76,634.54 902 4.77 92
92 1134191018 DUSTIN R SMITH $52,191.69 897 4.75 103
93 1013964634 CARL A AAGESEN $37,735.46 892 4.44 68
94 1386638484 THOR SWANSON MD $64,626.57 889 5.29 83
95 1164530358 DAVID M CRAVEN $42,115.40 886 2.54 65
96 1083681944 MARY CHRISTINE SEGRETO $123,914.49 874 3.47 101
97 1104998251 JIMMY MASCARO DO $65,823.96 870 3.90 98
98 1912991183 MOLLY EARLEYWINE PA $24,593.99 869 4.02 81
99 1235281494 MICHAEL STEVEN BARGER PA $21,873.66 856 3.80 102
100 1306812490 MERRILEE RAMSEY ARNP $44,819.46 848 4.46 127
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1 1013126705 JANICE M. R. STABER $1,680,270.59 $26,254.23 64 1
2 1952459463 DAVID LAWRENCE YURDIN PA $505,828.57 $448.03 1,129 2
3 1548247406 VILMARIE RODRIGUEZ-PADUA MD $345,751.69 $21,609.48 16 17
4 1841407160 RAHUL BANSAL MD $201,392.93 $91.79 2,194 5
5 1285748004 BRUCE L HUGHES MD $199,287.63 $1,294.08 154 11
6 1013115369 BOBBITA NAG $198,265.48 $113.88 1,741 6
7 1780766659 CHESTER ROBERT BADGER $197,640.81 $53.97 3,662 7
8 1013905181 DONALD MACFARLANE MD $187,603.19 $15,633.60 12 163
9 1649248378 KATHLEEN L WILD ARNP $170,695.04 $96.17 1,775 18
10 1467502286 CHARLES TILLEY PA $169,328.02 $110.53 1,532 13
11 1609055771 CHARUTA NARAYAN JOSHI $165,823.05 $388.34 427 3
12 1083609358 JENNIFER S COOK $163,408.56 $242.81 673 16
13 1619153137 JODI BEST ARNP $160,686.60 $97.80 1,643 15
14 1376777524 ALLADDIN MOH ELHADI ABOSAIDA $156,822.15 $514.17 305 8
15 1962558957 ALBERT N OKINE PA $155,834.84 $116.21 1,341 12
16 1356337273 LISA J MENZIES $153,710.77 $272.05 565 9
17 1033389226 ANTHONY G ZAMUDIO ARNP $153,044.23 $126.27 1,212 26
18 1083603773 JACK T STAPLETON $151,192.42 $622.19 243 19
19 1295830115 ALAN BOLLINGER DO $147,205.43 $85.83 1,715 10
20 1083784797 CAROL  AUNAN $144,839.51 $84.50 1,714 31
21 1548256191 JUDITH A MILLER $143,719.76 $3,992.22 36 23
22 1194703074 WENDY ANNE WALDMAN $143,635.70 $211.85 678 25
23 1164414520 KAREN FULWOOD $136,126.02 $76.60 1,777 14
24 1972638864 LIUSKA MARIA PESCE $135,624.22 $479.24 283 21
25 1861562555 LARRY  RICHARDS $133,921.48 $64.95 2,062 4
26 1982605762 JEFFREY D WILHARM $131,956.33 $74.51 1,771 43
27 1073500690 KATHLEEN S ADAMS $131,852.95 $121.86 1,082 22
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28 1255322996 MARK WILLIAM MITTAUER $131,285.33 $103.78 1,265 29
29 1912991340 GHADA HAMDAN-ALLEN MD $127,858.05 $94.15 1,358 20
30 1083681944 MARY CHRISTINE SEGRETO $123,914.49 $141.78 874 27
31 1770561946 DONALD HILLEBRAND MD $118,806.34 $1,697.23 70 103
32 1861559486 JOSPEH PATRICK BERTROCHE $117,938.03 $108.80 1,084 28
33 1790708451 MICHAEL M MCCUBBIN $117,292.64 $342.96 342 66
34 1063491645 ALLYSON L WHEATON MD $115,393.68 $101.22 1,140 41
35 1043211303 ALI  SAFDAR $114,750.57 $68.30 1,680 53
36 1245318393 JEAN TOBIN PA $113,409.62 $69.66 1,628 49
37 1285681528 MARVIN FRANKLIN PIBURN $109,663.65 $86.62 1,266 50
38 1356520431 KAY A MARTTILA $108,355.20 $115.52 938 59
39 1841220290 KENT ELDON KUNZE MD $107,667.07 $86.00 1,252 32
40 1902115652 SARAH LYNN BEATTIE ARNP $107,096.41 $107.53 996 39
41 1669570404 CASIE RINEY PA $106,966.94 $112.12 954 40
42 1477633188 CYD Q. GRAFFT $106,704.49 $79.04 1,350 42
43 1205015906 DAVID F WIDITZ $106,652.92 $78.65 1,356 36
44 1508946088 E RICHARD NIGHTINGALE MD $105,639.98 $104.70 1,009 37
45 1730239732 SRIRAMAMURTHY RAVIPATI MD $104,486.71 $79.64 1,312 47
46 1235124942 JULIE KATHRYN OSTERHAUS $100,050.08 $358.60 279 44
47 1205992724 LOUISE W SMITH $98,144.09 $440.11 223 33
48 1346210184 JAMES BROOKS MD $98,068.37 $103.12 951 45
49 1710941000 LAURIE WARREN PA $98,024.92 $94.62 1,036 30
50 1528247368 MISHELLE L PAULLUS $97,805.32 $998.01 98 51
51 1245203223 MARY BETH HUTCHINSON ARNP $97,317.01 $116.69 834 81
52 1013960566 PETER JOSEPH SZEIBEL $94,237.91 $92.66 1,017 55
53 1104089390 EJIRO AGBORO-IDAHOSA MD $92,675.45 $88.26 1,050 58
54 1285626390 KATHLEEN  GRADOVILLE $92,398.27 $299.99 308 61
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55 1578548376 DANIEL ALBERTO VAENA MD $91,467.12 $1,793.47 51 71
56 1215025309 DEBORAH LYNNE GARRELTS $91,243.96 $126.38 722 52
57 1841293354 KEITH GUESS PA $89,869.87 $88.28 1,018 75
58 1285697722 DOUGLAS  JONES $88,332.56 $89.41 988 74
59 1003004391 DAVID BERMAN WALKER MD $87,691.00 $78.93 1,111 62
60 1679669832 ERIN VOYLES HATCHER ARNP $86,224.57 $112.42 767 73
61 1316269871 REGINA ROBISON ARNP $84,332.28 $79.41 1,062 186
62 1922144088 THOMAS SCOTT HOPKINS DO $83,585.94 $89.49 934 54
63 1356564371 CARLA K ABEL ZIEG ARNP $83,510.61 $110.76 754 68
64 1083671309 JOHN LOUIS COLOMBO MD $83,099.01 $1,204.33 69 76
65 1104034552 DEANNA BOOK BOESEN $82,389.86 $109.85 750 60
66 1194817247 MARIA J STEELE ARNP $80,161.80 $616.63 130 24
67 1215146055 REBECCA J WOLFE $79,379.61 $77.82 1,020 64
68 1629042288 MARTIN J FIALKOV MD $78,327.48 $84.22 930 86
69 1326045808 RAY C STURDEVANT MD $78,197.54 $92.43 846 67
70 1366435125 DANIEL EDWARD WESEMANN ARNP $77,443.53 $111.91 692 77
71 1609867688 DAVID B MOORE, M.D. $77,156.58 $322.83 239 72
72 1487908380 LISA ANN BECHTEL ARNP $77,152.99 $95.60 807 70
73 1407953979 CECELIA M NASSIF ARNP $76,634.54 $84.96 902 92
74 1124399522 JOYCE E PROUCH ARNP $76,219.68 $82.13 928 105
75 1447242359 DANIEL M SLEITER ARNP $76,140.32 $475.88 160 57
76 1215125216 REBECCA WALDING $75,818.00 $102.87 737 78
77 1619963949 EVA TSALIKIAN $75,805.88 $476.77 159 38
78 1598750432 CHRISTOPHER GENE OKIISHI MD $75,635.29 $65.66 1,152 112
79 1134171937 KATHRYN LEE FLANDERS ARNP $74,313.79 $816.64 91 146
80 1538368170 CHRISTOPHER ROBERT MATSON $74,208.54 $31.13 2,384 82
81 1790922441 MARIA CONSUELO LOZANO-CELIS $73,990.17 $102.48 722 104
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82 1699767525 EZZATOLLAH SHIVAPOUR, M.D. $73,644.98 $1,841.12 40 69
83 1053361972 MATTHEW LARRY HILL DO $73,074.66 $902.16 81 115
84 1184722910 LAURA VANCLEVE DO $71,868.14 $142.03 506 111
85 1972812097 MICHELLE L SCHNACK $71,821.58 $86.43 831 126
86 1780793976 MATTHEW D EGGERS MD $71,720.82 $100.03 717 90
87 1275844649 KATIE M HANSON ARNP $71,481.45 $73.09 978 202
88 1750376034 DUANGCHAI NARAWONG MD $71,407.39 $118.81 601 46
89 1245436765 RENE M DUREGGER MD $70,842.66 $99.64 711 84
90 1932415403 MITZI M REGALARD $70,661.30 $46.92 1,506 130
91 1891788485 JOYCE VISTA WAYNE MD $70,493.62 $88.56 796 79
92 1699075929 HIEDI CHRISTINE LANE $70,477.43 $73.95 953 83
93 1891705968 ANITA HANDEVIDT ARNP $70,476.23 $87.66 804 80
94 1821084468 MARY WAGNER NIXON $70,267.30 $108.10 650 95
95 1467682351 NICOLE GILG $69,170.65 $30.54 2,265 63
96 1316922545 MABRA G ABERNATHY $68,793.97 $37.88 1,816 93
97 1477765584 SANGEETA SHAH MD $68,784.35 $198.23 347 98
98 1710972591 ELIZABETH L DOWD $67,802.71 $517.58 131 89
99 1255662276 PATEL R REDDY $67,376.40 $94.36 714 117
100 1639423544 PAMELA S BROWN ARNP $66,689.88 $90.86 734 88
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ANTIPSYCHOTICS - ATYPICALS $4,842,778 1 9.4% $5,127,183 1 9.3% 5.9%
STIMULANTS - AMPHETAMINES - LONG ACTING $3,007,418 2 5.8% $3,042,126 2 5.5% 1.2%
ANTICONVULSANTS $2,752,176 3 5.3% $2,947,512 3 5.4% 7.1%
DIABETIC - INSULIN $2,166,218 5 4.2% $2,488,336 4 4.5% 14.9%
ANTIDEPRESSANTS - SELECTED SSRI's $2,210,817 4 4.3% $2,365,779 5 4.3% 7.0%
ANTIHEMOPHILIC AGENTS $1,776,489 7 3.4% $2,261,885 6 4.1% 27.3%
STIMULANTS - METHYLPHENIDATE - LONG ACTING $1,935,113 6 3.8% $2,004,108 7 3.6% 3.6%
ANTIASTHMATIC - ADRENERGIC COMBOS $1,653,807 8 3.2% $1,748,496 8 3.2% 5.7%
STIMULANTS - METHYLPHENIDATE $1,403,825 9 2.7% $1,411,339 9 2.6% 0.5%
ANTIASTHMATIC - BETA - ADRENERGICS $1,093,960 10 2.1% $1,250,838 10 2.3% 14.3%
BIOLOGIC IMMUNOMODULATORS $1,076,768 11 2.1% $1,219,970 11 2.2% 13.3%
MULTIPLE SCLEROSIS AGENTS $1,018,801 12 2.0% $1,164,352 12 2.1% 14.3%
STIMULANTS - OTHER STIMULANTS / LIKE STIMULANTS $994,527 13 1.9% $1,114,065 13 2.0% 12.0%
DIABETIC - INSULIN  PENFILLS $909,373 16 1.8% $1,091,527 14 2.0% 20.0%
STIMULANTS - AMPHETAMINES - SHORT ACTING $963,789 14 1.9% $1,062,985 15 1.9% 10.3%
ANTIRETROVIRALS $957,343 15 1.9% $1,034,220 16 1.9% 8.0%
ANTIASTHMATIC - STEROID INHALANTS $880,576 18 1.7% $903,782 17 1.6% 2.6%
NARCOTICS - MISC. $881,202 17 1.7% $864,424 18 1.6% -1.9%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS $770,967 19 1.5% $824,317 19 1.5% 6.9%
ANTIASTHMATIC - ANTI-CHOLINERGICS $708,570 20 1.4% $732,713 20 1.3% 3.4%
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ANTIDEPRESSANTS - SELECTED SSRI's 79,914 1 83,750 1 4.8%
ANTICONVULSANTS 42,604 2 44,847 2 5.3%
NARCOTICS - MISC. 40,599 3 42,438 3 4.5%
ANTIPSYCHOTICS - ATYPICALS 29,218 4 30,285 4 3.7%
ANALGESICS - MISC. 26,798 5 27,014 5 0.8%
ANTIASTHMATIC - BETA - ADRENERGICS 24,326 7 26,926 6 10.7%
ANTIHISTAMINES - NON-SEDATING 26,432 6 25,718 7 -2.7%
BETA-LACTAMS / CLAVULANATE COMBO'S 24,079 8 22,258 8 -7.6%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS 20,292 9 21,549 9 6.2%
GI - PROTON PUMP INHIBITOR 19,226 10 20,880 10 8.6%
ANXIOLYTICS - BENZODIAZEPINES 19,108 11 20,023 11 4.8%
NSAIDS 17,642 12 18,192 12 3.1%
ACE INHIBITORS 17,221 13 18,027 13 4.7%
ANTIHYPERTENSIVES - CENTRAL 16,907 14 17,492 14 3.5%
DIURETICS 15,832 15 16,496 15 4.2%
STIMULANTS - AMPHETAMINES - LONG ACTING 15,123 16 15,254 16 0.9%
MUSCLE RELAXANTS 13,946 17 14,658 17 5.1%
GLUCOCORTICOIDS - MINERALOCORTICOIDS 13,688 18 14,531 18 6.2%
THYROID HORMONES 13,047 20 13,781 19 5.6%
NARCOTICS - SELECTED 13,185 19 13,628 20 3.4%
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ABILIFY $2,489,201.42 1 $2,540,658.80 1 2.07%
VYVANSE $2,265,268.73 2 $2,280,790.67 2 0.69%
METHYLPHENIDATE HCL ER $1,631,809.26 3 $1,684,966.95 3 3.26%
LANTUS $1,118,522.75 5 $1,300,276.78 4 16.25%
ADVATE $1,223,051.68 4 $1,235,174.73 5 0.99%
CYMBALTA $1,057,487.01 7 $1,160,305.36 6 9.72%
FOCALIN XR $1,070,807.97 6 $1,094,303.88 7 2.19%
ADDERALL $903,250.22 8 $1,007,983.38 8 11.60%
ADVAIR DISKUS $783,267.92 9 $831,356.22 9 6.14%
STRATTERA $676,126.23 10 $772,707.35 10 14.28%
VENTOLIN HFA $655,766.31 11 $763,108.59 11 16.37%
SPIRIVA HANDIHALER $646,039.45 12 $671,280.98 12 3.91%
ADDERALL XR $628,848.99 13 $656,952.65 13 4.47%
DEPAKOTE ER $566,753.38 14 $615,011.50 14 8.51%
LATUDA $515,803.48 15 $581,421.56 15 12.72%
NOVOLOG $461,967.59 17 $529,774.11 16 14.68%
INVEGA SUSTENNA $422,992.87 19 $514,146.34 17 21.55%
HYDROCODONE/ACETAMINOPHEN $464,450.03 16 $473,723.10 18 2.00%
CRESTOR $416,231.96 20 $459,500.02 19 10.40%
ATRIPLA $409,757.28 21 $446,416.42 20 8.95%
SYMBICORT $429,546.38 18 $446,413.20 21 3.93%
HUMALOG $392,084.46 22 $437,283.60 22 11.53%
HUMIRA PEN $337,373.98 24 $415,881.45 23 23.27%
NOVOSEVEN RT $289,376.56 30 $399,121.32 24 37.92%
LOVENOX $341,886.07 23 $375,534.77 25 9.84%
COPAXONE $312,332.49 25 $340,292.26 26 8.95%
DEXILANT $300,320.32 27 $322,967.27 27 7.54%
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PROVENTIL HFA $282,192.66 32 $320,781.60 28 13.67%
LANTUS SOLOSTAR $290,268.46 29 $320,183.74 29 10.31%
TRICOR $295,311.61 28 $317,721.66 30 7.59%
QVAR $287,292.13 31 $305,256.68 31 6.25%
LEVEMIR $220,986.10 43 $303,165.08 32 37.19%
RISPERDAL CONSTA $270,714.74 33 $301,585.64 33 11.40%
GENOTROPIN $300,469.34 26 $295,688.38 34 -1.59%
LYRICA $227,948.26 42 $290,524.87 35 27.45%
NASONEX $267,315.04 34 $272,617.14 36 1.98%
NOVOLOG FLEXPEN $230,332.55 40 $266,203.17 37 15.57%
TRUVADA $248,209.51 37 $262,018.99 38 5.56%
EPIPEN 2-PAK $202,060.08 49 $257,407.67 39 27.39%
TECFIDERA $206,989.04 48 $254,071.36 40 22.75%
INVEGA $216,398.67 46 $241,581.06 41 11.64%
PULMICORT $258,833.92 35 $235,577.01 42 -8.99%
RECOMBINATE $60,069.68 177 $231,972.62 43 286.17%
MONTELUKAST SODIUM $237,453.84 39 $229,213.47 44 -3.47%
ENBREL $141,188.56 71 $224,018.80 45 58.67%
AZITHROMYCIN $209,310.18 47 $223,728.71 46 6.89%
ENBREL SURECLICK $229,433.44 41 $220,031.55 47 -4.10%
FLOVENT HFA $201,630.88 50 $214,706.78 48 6.49%
HUMIRA $162,738.61 62 $207,094.61 49 27.26%
OMEPRAZOLE $216,844.83 45 $206,808.54 50 -4.63%
KALYDECO $179,338.84 54 $204,948.96 51 14.28%
VIMPAT $186,234.23 52 $200,070.10 52 7.43%
LEVOTHYROXINE SODIUM $170,334.28 58 $195,403.88 53 14.72%
EXJADE $147,260.40 67 $195,274.93 54 32.61%
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COMBIVENT RESPIMAT $173,285.47 56 $189,492.42 55 9.35%
SOVALDI $198,220.09 51 $187,241.84 56 -5.54%
HELIXATE FS $46,621.92 210 $186,178.84 57 299.34%
GABAPENTIN $179,687.72 53 $181,995.75 58 1.28%
CEFDINIR $220,054.03 44 $181,349.89 59 -17.59%
EPIPEN-JR 2-PAK $88,981.76 124 $173,625.30 60 95.12%
VESICARE $167,603.35 59 $171,939.27 61 2.59%
GLEEVEC $145,702.91 69 $171,464.30 62 17.68%
OPANA ER (CRUSH RESISTANT $162,043.18 63 $169,906.94 63 4.85%
PROVIGIL $162,971.81 61 $168,405.73 64 3.33%
INDERAL LA $239,636.57 38 $162,566.08 65 -32.16%
XIFAXAN $139,254.84 72 $159,940.10 66 14.85%
AMOXICILLIN $171,257.01 57 $158,503.55 67 -7.45%
PULMOZYME $175,908.24 55 $158,381.79 68 -9.96%
ZIPRASIDONE HCL $165,235.88 60 $157,104.71 69 -4.92%
SEROQUEL XR $149,825.84 65 $157,000.01 70 4.79%
QUETIAPINE FUMARATE $148,936.99 66 $152,766.92 71 2.57%
RISPERIDONE $159,281.31 64 $151,476.78 72 -4.90%
XYREM $106,714.44 97 $151,083.69 73 41.58%
METHYLPHENIDATE HCL $124,851.87 77 $150,647.26 74 20.66%
TOPROL XL $135,280.57 73 $146,085.18 75 7.99%
TRAMADOL HCL $142,455.17 70 $144,467.37 76 1.41%
INTUNIV $129,173.85 75 $144,047.48 77 11.51%
CREON $90,673.34 121 $128,861.14 78 42.12%
LISINOPRIL $123,270.30 80 $128,221.64 79 4.02%
NORDITROPIN FLEXPRO $107,793.22 95 $128,213.17 80 18.94%
BUPROPION HCL XL $125,616.98 76 $127,065.09 81 1.15%
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SERTRALINE HCL $121,902.30 82 $126,228.14 82 3.55%
BANZEL $113,831.94 86 $124,986.91 83 9.80%
SAPHRIS $116,079.90 83 $124,804.96 84 7.52%
NAGLAZYME $124,528.48 78 $124,528.48 85 0.00%
GILENYA $111,063.06 90 $124,003.58 86 11.65%
DULERA $112,361.78 88 $123,891.38 87 10.26%
COMPLERA $107,813.66 94 $122,897.14 88 13.99%
ESCITALOPRAM OXALATE $115,303.26 84 $121,698.79 89 5.55%
TOBI $146,486.67 68 $119,667.08 90 -18.31%
CEPHALEXIN $103,111.37 103 $117,405.13 91 13.86%
RANITIDINE HCL $113,254.56 87 $117,200.72 92 3.48%
ISENTRESS $109,875.65 91 $116,803.08 93 6.30%
JANUVIA $95,246.10 114 $116,668.52 94 22.49%
ANAFRANIL $122,300.96 81 $115,664.05 95 -5.43%
AMOXICILLIN/CLAVULANATE P $131,831.34 74 $115,435.34 96 -12.44%
ALPRAZOLAM $109,642.44 92 $114,344.60 97 4.29%
PROLASTIN-C $97,524.32 110 $113,646.72 98 16.53%
ADVAIR HFA $106,489.58 99 $113,038.18 99 6.15%
FEIBA NF $81,365.96 140 $113,030.00 100 38.92%
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HYDROCO/APAP TAB 5-325MG 19,185 1 20,316 1 5.90%
VENTOLIN HFA AER 12,327 3 14,183 2 15.06%
TRAMADOL HCL TAB 50MG 13,165 2 13,607 3 3.36%
Loratadine Tab 10 MG 11,954 4 11,937 4 -0.14%
Cetirizine HCl Tab 10 MG 8,248 5 8,583 5 4.06%
ESCITALOPRAM TAB 20MG 8,171 6 8,399 6 2.79%
OMEPRAZOLE   CAP 20MG 7,562 8 8,253 7 9.14%
FLUOXETINE   CAP 20MG 7,840 7 8,201 8 4.60%
CYCLOBENZAPR TAB 10MG 7,456 10 7,957 9 6.72%
GABAPENTIN   CAP 300MG 7,512 9 7,902 10 5.19%
RANITIDINE   TAB 150MG 7,163 11 7,183 11 0.28%
CLONIDINE    TAB 0.1MG 6,499 13 6,717 12 3.35%
Aspirin Tab Delayed Release 81 MG 6,392 15 6,688 13 4.63%
OMEPRAZOLE   CAP 40MG 5,978 18 6,480 14 8.40%
ALBUTEROL    NEB 0.083% 6,155 17 6,439 15 4.61%
Acetaminophen Tab 325 MG 6,483 14 6,364 16 -1.84%
FLUTICASONE  SPR 50MCG 6,246 16 6,153 17 -1.49%
AMOXICILLIN  SUS 400/5ML 7,050 12 6,145 18 -12.84%
IBUPROFEN    TAB 800MG 5,727 21 6,081 19 6.18%
SERTRALINE   TAB 100MG 5,797 20 6,066 20 4.64%
GUANFACINE   TAB 1MG 5,827 19 6,028 21 3.45%
MONTELUKAST  TAB 10MG 5,545 23 5,867 22 5.81%
Ferrous Sulfate Tab 325 MG (65 MG 
Elemental Fe)
5,635 22 5,793 23 2.80%
AZITHROMYCIN TAB 250MG 5,274 25 5,651 24 7.15%
TRAZODONE    TAB 50MG 5,229 26 5,611 25 7.31%
TRAZODONE    TAB 100MG 5,310 24 5,504 26 3.65%
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PROVENTIL    AER HFA 4,871 28 5,339 27 9.61%
METFORMIN    TAB 500MG 4,820 29 5,118 28 6.18%
LISINOPRIL   TAB 10MG 4,934 27 5,099 29 3.34%
HYDROCO/APAP TAB 7.5-325 4,802 30 4,964 30 3.37%
HYDROCHLOROT TAB 25MG 4,753 31 4,949 31 4.12%
LISINOPRIL   TAB 20MG 4,611 34 4,842 32 5.01%
Sennosides-Docusate Sodium Tab 8.6-50 
MG
4,632 32 4,736 33 2.25%
Aspirin Chew Tab 81 MG 4,631 33 4,582 34 -1.06%
CLONAZEPAM   TAB 1MG 4,285 35 4,581 35 6.91%
OXYCOD/APAP  TAB 5-325MG 4,241 36 4,576 36 7.90%
SMZ/TMP DS   TAB 800-160 4,049 40 4,546 37 12.27%
CEPHALEXIN   CAP 500MG 4,163 37 4,444 38 6.75%
HYDROCO/APAP TAB 10-325MG 4,153 38 4,313 39 3.85%
MELOXICAM    TAB 15MG 3,995 45 4,258 40 6.58%
METFORMIN    TAB 1000MG 4,043 41 4,240 41 4.87%
CITALOPRAM   TAB 20MG 4,038 42 4,192 42 3.81%
PREDNISONE   TAB 20MG 3,646 57 4,172 43 14.43%
ALPRAZOLAM   TAB 1MG 3,894 48 4,137 44 6.24%
LANTUS       INJ 100/ML 3,883 49 4,098 45 5.54%
METHYLPHENID TAB 36MG ER 3,971 46 4,042 46 1.79%
MONTELUKAST  CHW 5MG 3,830 51 4,019 47 4.93%
AMOXICILLIN  CAP 500MG 4,151 39 3,985 48 -4.00%
NAPROXEN     TAB 500MG 4,018 44 3,927 49 -2.26%
AZITHROMYCIN SUS 200/5ML 3,900 47 3,903 50 0.08%
VENLAFAXINE  CAP 150MG ER 3,651 56 3,890 51 6.55%
POLYETH GLYC POW 3350 NF 3,776 52 3,887 52 2.94%
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CLONAZEPAM   TAB 0.5MG 3,749 53 3,870 53 3.23%
CITALOPRAM   TAB 40MG 3,831 50 3,853 54 0.57%
SERTRALINE   TAB 50MG 3,740 54 3,813 55 1.95%
ALPRAZOLAM   TAB 0.5MG 3,577 58 3,695 56 3.30%
Acetaminophen Tab 500 MG 3,717 55 3,667 57 -1.35%
ZOLPIDEM     TAB 10MG 3,412 62 3,604 58 5.63%
AMLODIPINE   TAB 10MG 3,474 59 3,568 59 2.71%
FOLIC ACID   TAB 1MG 3,455 60 3,561 60 3.07%
CYMBALTA     CAP 60MG 3,272 63 3,538 61 8.13%
PANTOPRAZOLE TAB 40MG 3,057 66 3,292 62 7.69%
HYDROXYZ PAM CAP 25MG 2,936 68 3,182 63 8.38%
METHYLPHENID TAB 54MG ER 3,081 64 3,155 64 2.40%
LORAZEPAM    TAB 1MG 3,059 65 3,150 65 2.97%
AMLODIPINE   TAB 5MG 2,972 67 3,063 66 3.06%
METOPROL TAR TAB 25MG 2,901 70 3,062 67 5.55%
SIMVASTATIN  TAB 20MG 2,907 69 3,055 68 5.09%
Cetirizine HCl Oral Soln 1 MG/ML (5 
MG/5ML)
3,421 61 2,949 69 -13.80%
BUPROPN HCL  TAB 300MG XL 2,683 75 2,912 70 8.54%
RISPERIDONE  TAB 1MG 2,875 71 2,854 71 -0.73%
LORAZEPAM    TAB 0.5MG 2,615 78 2,846 72 8.83%
AMOX/K CLAV  TAB 875MG 2,672 76 2,770 73 3.67%
ATORVASTATIN TAB 40MG 2,410 88 2,751 74 14.15%
SIMVASTATIN  TAB 40MG 2,650 77 2,742 75 3.47%
BUPROPN HCL  TAB 150MG XL 2,501 83 2,711 76 8.40%
FUROSEMIDE   TAB 40MG 2,581 79 2,692 77 4.30%
PREDNISOLONE SOL 15MG/5ML 4,032 43 2,680 78 -33.53%
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VYVANSE      CAP 30MG 2,694 74 2,660 79 -1.26%
LEVOTHYROXIN TAB 50MCG 2,515 82 2,616 80 4.02%
AMOXICILLIN  SUS 250/5ML 2,846 72 2,601 81 -8.61%
VYVANSE      CAP 40MG 2,558 80 2,588 82 1.17%
FLUCONAZOLE  TAB 150MG 2,402 89 2,578 83 7.33%
PREDNISONE   TAB 10MG 2,432 86 2,576 84 5.92%
VENLAFAXINE  CAP 75MG ER 2,458 84 2,564 85 4.31%
TRIAMCINOLON CRE 0.1% 2,359 91 2,550 86 8.10%
MONTELUKAST  CHW 4MG 2,703 73 2,547 87 -5.77%
MUPIROCIN    OIN 2% 2,211 97 2,537 88 14.74%
SPIRIVA      CAP HANDIHLR 2,443 85 2,536 89 3.81%
LISINOPRIL   TAB 40MG 2,396 90 2,506 90 4.59%
ONDANSETRON  TAB 4MG ODT 2,414 87 2,480 91 2.73%
RISPERIDONE  TAB 0.5MG 2,535 81 2,478 92 -2.25%
METRONIDAZOL TAB 500MG 2,254 95 2,395 93 6.26%
LISINOPRIL   TAB 5MG 2,238 96 2,378 94 6.26%
QUETIAPINE   TAB 100MG 2,268 93 2,365 95 4.28%
CEPHALEXIN   SUS 250/5ML 2,050 105 2,360 96 15.12%
ATORVASTATIN TAB 20MG 2,143 99 2,307 97 7.65%
Sennosides Tab 8.6 MG 2,262 94 2,284 98 0.97%
Permethrin Lotion 1% 1,497 147 2,267 99 51.44%
FUROSEMIDE   TAB 20MG 2,066 104 2,244 100 8.62%
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TOTAL PAID AMOUNT $54,583,235 $59,154,437 8.4%
UNIQUE USERS 182,771 198,167 8.4%
COST PER USER $298.64 $298.51 0.0%
TOTAL PRESCRIPTIONS 897,086 981,523 9.4%
AVERAGE PRESCRIPTIONS PER USER 4.91 4.95 0.8%
AVERAGE COST PER PRESCRIPTION $60.85 $60.27 -0.9%
# GENERIC PRESCRIPTIONS 750,269 821,083 9.4%
% GENERIC 83.6% 83.7% 0.0%
$ GENERIC $13,768,187 $16,065,533 16.7%
AVERAGE GENERIC PRESCRIPTION COST $18.35 $19.57 6.6%
AVERAGE GENERIC DAYS SUPPLY 23 23 0.0%
# BRAND PRESCRIPTIONS 143,171 156,831 9.4%
% BRAND 16.0% 16.0% 0.0%
$ BRAND $40,588,550 $42,868,046 16.7%
AVERAGE BRAND PRESCRIPTION COST $283.50 $273.34 6.6%
AVERAGE BRAND DAYS SUPPLY 26 25 0.0%
Bi-Monthly Statistics
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UTILIZATION BY AGE
AGE July/August 2014 September/October 2014
0-6 30,428 37,548
7-12 26,076 28,659
13-18 23,083 25,256
19-64 93,477 97,002
65+ 9,707 9,702
182,771 198,167
UTILIZATION BY GENDER AND AGE
GENDER AGE July/August 2014 September/October 2014
F
0-6 14,240 17,468
7-12 11,431 12,407
13-18 12,128 13,364
19-64 60,145 62,258
65+ 6,952 6,953
104,896 112,450
M
0-6 16,188 20,080
7-12 14,645 16,252
13-18 10,955 11,892
19-64 33,332 34,744
65+ 2,755 2,749
77,875 85,717
Page 2 Of 2911/10/2014 9:00:02 AM RT33018
trusted, reliable, innovative
TOP 100 PHARMACIES BY PRESCRIPTION COUNT
September/October 2014
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COUNT
PAID AMT AVG COST RX PREVIOUS RANK
1 BROADLAWNS MEDICAL CENTER DES MOINES IA 24,831 $571,427.37 $23.01 1
2 WALGREEN #05239 DAVENPORT IA 11,826 $635,210.92 $53.71 2
3 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 10,353 $546,685.80 $52.80 5
4 WALGREEN #04405 COUNCIL BLUFFS IA 9,732 $533,265.31 $54.80 4
5 WALGREEN #05721 DES MOINES IA 9,038 $518,471.90 $57.37 3
6 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,543 $353,117.00 $46.81 6
7 WALGREEN #359 DES MOINES IA 6,924 $354,268.46 $51.17 8
8 WALGREEN #05362 DES MOINES IA 6,819 $327,441.74 $48.02 10
9 WALGREEN COMPANY 07455 WATERLOO IA 6,804 $332,414.19 $48.86 11
10 WALGREEN CO.#3700 COUNCIL BLUFFS IA 6,779 $340,126.12 $50.17 13
11 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 6,562 $331,061.75 $50.45 12
12 MARTIN HEALTH SERVICES INC DENVER IA 6,507 $194,475.20 $29.89 7
13 SIOUXLAND COMM HEALTH CTR 
PHARMA
SIOUX CITY IA 6,459 $114,116.00 $17.67 15
14 MERCY FAMILY PHARMACY DUBUQUE IA 6,425 $377,769.01 $58.80 9
15 WALGREENS #07453 DES MOINES IA 6,043 $332,257.05 $54.98 14
16 WALGREEN #910 SIOUX CITY IA 5,918 $306,638.45 $51.81 16
17 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,382 $268,213.10 $49.84 18
18 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,278 $318,082.57 $60.27 19
19 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,229 $222,524.49 $42.56 17
20 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,101 $248,849.76 $48.78 21
21 WALGREEN COMPANY 05777 DES MOINES IA 5,098 $249,463.60 $48.93 20
22 WALGREEN #05852 DES MOINES IA 5,025 $259,313.95 $51.60 23
23 WALGREEN #04041 DAVENPORT IA 4,914 $238,529.87 $48.54 22
24 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,827 $239,090.36 $49.53 25
25 RASHID PHARMACY PLC FORT MADISON IA 4,744 $259,463.91 $54.69 26
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26 WALGREEN #11709 DAVENPORT IA 4,719 $272,943.60 $57.84 27
27 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 4,633 $250,412.85 $54.05 24
28 DANIEL PHARMACY INC FORT DODGE IA 4,464 $220,046.18 $49.29 28
29 PHARMACY MATTERS LTC IOWA CITY IA 4,234 $176,580.70 $41.71 30
30 MAHASKA DRUG INC OSKALOOSA IA 4,066 $234,407.33 $57.65 34
31 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,066 $200,249.05 $49.25 35
32 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 4,037 $197,446.40 $48.91 33
33 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,955 $210,721.88 $53.28 31
34 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 3,848 $278,324.98 $72.33 29
35 MEDICAP PHARMACY INDIANOLA IA 3,827 $176,928.13 $46.23 38
36 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,790 $206,197.38 $54.41 32
37 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,734 $217,882.24 $58.35 37
38 WALGREEN #03595 DAVENPORT IA 3,732 $213,446.98 $57.19 40
39 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,717 $178,078.97 $47.91 41
40 WALGREEN #7452 DES MOINES IA 3,713 $198,297.27 $53.41 39
41 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,655 $138,066.99 $37.77 43
42 WALGREENS #05119 CLINTON IA 3,622 $176,964.86 $48.86 45
43 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,606 $243,097.44 $67.41 36
44 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,591 $203,773.39 $56.75 48
45 A AVENUE PHARMACY CEDAR RAPIDS IA 3,548 $288,628.39 $81.35 46
46 STERLING LTC PHARMACY #31 ANKENY IA 3,520 $231,335.73 $65.72 44
47 WAL-MART PHARMACY #10-5115 DAVENPORT IA 3,431 $133,214.43 $38.83 47
48 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,427 $181,556.56 $52.98 50
49 WALGREENS #10855 WATERLOO IA 3,382 $173,614.05 $51.33 49
50 WALGREEN #05044 BURLINGTON IA 3,351 $170,660.61 $50.93 42
51 WALGREENS #11942 DUBUQUE IA 3,287 $181,024.85 $55.07 53
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52 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,249 $191,612.88 $58.98 54
53 WAL MART PHARMACY 10-1621 CENTERVILLE IA 3,219 $139,245.70 $43.26 58
54 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 3,212 $142,797.99 $44.46 51
55 THOMPSON-DEAN DRUG SIOUX CITY IA 3,208 $267,539.87 $83.40 56
56 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,206 $180,973.03 $56.45 55
57 HY VEE PHARMACY #1449 NEWTON IA 3,141 $157,421.13 $50.12 57
58 WALGREENS 07968 DES MOINES IA 3,111 $178,216.17 $57.29 62
59 WALGREEN #05886 KEOKUK IA 3,106 $147,854.92 $47.60 52
60 WAL-MART PHARMACY #10-0985 FAIRFIELD IA 3,104 $127,784.03 $41.17 71
61 HY-VEE PHARMACY (1058) CENTERVILLE IA 3,013 $146,786.14 $48.72 75
62 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 3,005 $156,875.00 $52.20 59
63 WAL-MART PHARMACY 10-2889 CLINTON IA 2,989 $135,843.14 $45.45 61
64 WAL MART PHARMACY 10-3590 SIOUX CITY IA 2,976 $145,816.10 $49.00 65
65 HARTIG PHARMACY SERVICES DUBUQUE IA 2,938 $168,927.41 $57.50 60
66 HY-VEE PHARMACY (1875) WEBSTER CITY IA 2,881 $124,985.23 $43.38 70
67 HY-VEE PHARMACY #3 (1056) CEDAR RAPIDS IA 2,873 $139,759.75 $48.65 77
68 WALGREEN #4714 DES MOINES IA 2,839 $136,561.13 $48.10 64
69 HY-VEE PHARMACY #2 (1044) BURLINGTON IA 2,826 $134,193.09 $47.49 69
70 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,819 $152,046.51 $53.94 66
71 S - S PHARMACY INC COUNCIL BLUFFS IA 2,808 $193,100.11 $68.77 68
72 WAL-MART PHARMACY #10-1393 OSKALOOSA IA 2,789 $116,573.22 $41.80 74
73 HY-VEE PHARMACY (1075) CLINTON IA 2,777 $169,184.28 $60.92 63
74 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,773 $156,998.65 $56.62 72
75 HY-VEE DRUGSTORE # 7035 FT DODGE IA 2,737 $129,924.29 $47.47 73
76 HY-VEE PHARMACY (1522) PERRY IA 2,685 $119,596.46 $44.54 89
77 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,680 $143,777.81 $53.65 81
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78 HY-VEE PHARMACY 1504 OTTUMWA IA 2,654 $153,331.46 $57.77 76
79 WALGREEN #09708 DUBUQUE IA 2,626 $148,176.47 $56.43 79
80 HY-VEE PHARMACY (1009) DBA ALBIA IA 2,624 $125,547.55 $47.85 91
81 HY-VEE DRUGSTORE #7031 DES MOINES IA 2,618 $148,093.91 $56.57 100
82 WALGREEN #05361 FORT DODGE IA 2,615 $126,513.43 $48.38 106
83 WAL-MART PHARMACY #10-1965 COUNCIL BLUFFS IA 2,601 $116,857.17 $44.93 78
84 LA GRANGE PHARMACY INC VINTON IA 2,599 $140,598.89 $54.10 80
85 WAL-MART PHARMACY #10-0646 ANAMOSA IA 2,574 $102,854.16 $39.96 85
86 SCOTT PHARMACY FAYETTE IA 2,569 $131,250.95 $51.09 90
87 HY-VEE FOOD STORE WATERLOO IA 2,535 $181,213.88 $71.48 93
88 WALGREEN #05077 IOWA CITY IA 2,526 $139,016.44 $55.03 88
89 WALGREEN #05942 NEWTON IA 2,519 $131,295.47 $52.12 82
90 WAL-MART PHARMACY 10-0784 MT PLEASANT IA 2,506 $140,057.92 $55.89 96
91 HY-VEE DRUGSTORE (7056) MASON CITY IA 2,497 $118,370.27 $47.40 92
92 WAGNER PHARMACY CLINTON IA 2,487 $164,071.52 $65.97 87
93 HY-VEE PHARMACY (1065) CHARITON IA 2,452 $139,389.20 $56.85 94
94 STANGEL PHARMACY ONAWA IA 2,449 $138,608.38 $56.60 97
95 HY-VEE PHARMACY (1353) KNOXVILLE IA 2,445 $124,834.17 $51.06 83
96 WALGREEN COMPANY DBA OTTUMWA IA 2,423 $117,740.05 $48.59 119
97 HY-VEE PHARMACY 1068 CHEROKEE IA 2,393 $131,021.30 $54.75 114
98 WAL-MART PHARMACY #10-1285 OTTUMWA IA 2,392 $107,010.32 $44.74 110
99 HY-VEE PHARMACY #1 (1054) CEDAR RAPIDS IA 2,381 $135,270.40 $56.81 103
100 MEDICAP PHARMACY MARSHALLTOWN IA 2,378 $136,522.93 $57.41 127
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1 NUCARA PHARMACY #27 PLEASANT HILL IA 2,305 $1,130,931.48 $2,673.60 1
2 ARJ INFUSION SERVICES INC LENEXA KS 36 $951,196.88 $158,532.81 2
3 WALGREEN #05239 DAVENPORT IA 11,826 $635,210.92 $193.07 4
4 CAREMARK KANSAS SPEC PHARMACY 
LL
LENEXA KS 162 $573,744.88 $6,594.77 3
5 BROADLAWNS MEDICAL CENTER DES MOINES IA 24,831 $571,427.37 $206.74 26
6 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 10,353 $546,685.80 $237.48 9
7 ACCREDO HEALTH GROUP INC MEMPHIS TN 76 $538,941.36 $13,144.91 8
8 WALGREEN #04405 COUNCIL BLUFFS IA 9,732 $533,265.31 $198.98 7
9 WALGREEN #05721 DES MOINES IA 9,038 $518,471.90 $186.77 6
10 ACCREDO HEALTH GROUP INC NASHVILLE TN 16 $498,454.57 $83,075.76 5
11 MERCY FAMILY PHARMACY DUBUQUE IA 6,425 $377,769.01 $358.41 10
12 WALGREEN #359 DES MOINES IA 6,924 $354,268.46 $168.38 13
13 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,543 $353,117.00 $204.82 12
14 US BIOSERVICE CORPORATION FRISCO TX 42 $352,752.99 $20,750.18 49
15 WALGREEN CO.#3700 COUNCIL BLUFFS IA 6,779 $340,126.12 $179.77 15
16 WALGREEN COMPANY 07455 WATERLOO IA 6,804 $332,414.19 $153.05 17
17 WALGREENS #07453 DES MOINES IA 6,043 $332,257.05 $190.62 16
18 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 6,562 $331,061.75 $170.21 14
19 WALGREEN #05362 DES MOINES IA 6,819 $327,441.74 $148.70 20
20 COMMUNITY HEALTHCARE SERVICES LOMA LINDA CA 4 $324,599.82 $162,299.91 11
21 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,278 $318,082.57 $431.59 21
22 WALGREEN #910 SIOUX CITY IA 5,918 $306,638.45 $156.61 19
23 A AVENUE PHARMACY CEDAR RAPIDS IA 3,548 $288,628.39 $728.86 23
24 MEDFUSIONRX LLC FRANKLIN TN 69 $286,247.95 $7,951.33 55
25 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 3,848 $278,324.98 $485.73 18
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26 AMBER PHARMACY OMAHA NE 127 $276,168.83 $7,890.54 24
27 WALGREEN #11709 DAVENPORT IA 4,719 $272,943.60 $216.97 29
28 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,382 $268,213.10 $216.83 25
29 THOMPSON-DEAN DRUG SIOUX CITY IA 3,208 $267,539.87 $440.03 36
30 RASHID PHARMACY PLC FORT MADISON IA 4,744 $259,463.91 $292.85 31
31 WALGREEN #05852 DES MOINES IA 5,025 $259,313.95 $162.68 27
32 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 4,633 $250,412.85 $233.16 30
33 WALGREEN COMPANY 05777 DES MOINES IA 5,098 $249,463.60 $175.31 28
34 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,101 $248,849.76 $204.31 37
35 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,606 $243,097.44 $242.61 35
36 CYSTIC FIBROSIS SERVICES INC CENTENNIAL CO 78 $239,870.84 $10,903.22 22
37 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,827 $239,090.36 $192.19 33
38 WALGREEN #04041 DAVENPORT IA 4,914 $238,529.87 $154.39 32
39 MAHASKA DRUG INC OSKALOOSA IA 4,066 $234,407.33 $275.13 47
40 STERLING LTC PHARMACY #31 ANKENY IA 3,520 $231,335.73 $635.54 43
41 WALGREENS SPECIALTY PHARMACY 
#12
ANN ARBOR MI 57 $229,505.57 $6,750.16 50
42 HY-VEE PHARMACY SOLUTIONS OMAHA NE 119 $224,257.60 $3,800.98 39
43 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,229 $222,524.49 $217.31 40
44 DANIEL PHARMACY INC FORT DODGE IA 4,464 $220,046.18 $265.76 42
45 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,734 $217,882.24 $326.17 41
46 WALGREEN #03595 DAVENPORT IA 3,732 $213,446.98 $174.53 51
47 DOHMEN LIFE SCIENCE SERVICES LLC CHESTERFIELD MO 22 $212,219.58 $23,579.95 52
48 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,955 $210,721.88 $325.19 46
49 DIPLOMAT SPECIALTY PHARMACY FLINT MI 57 $209,545.98 $8,381.84 44
50 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,790 $206,197.38 $255.51 38
51 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,591 $203,773.39 $241.15 59
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52 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,066 $200,249.05 $230.17 53
53 WALGREEN #7452 DES MOINES IA 3,713 $198,297.27 $164.15 56
54 ACCREDO HEALTH GROUP INC WARRENDALE PA 45 $198,283.75 $14,163.13 34
55 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 4,037 $197,446.40 $260.14 48
56 MARTIN HEALTH SERVICES INC DENVER IA 6,507 $194,475.20 $166.50 45
57 EXPRESS SCRIPTS SPECIALTY ST LOUIS MO 27 $193,168.38 $12,877.89 77
58 S - S PHARMACY INC COUNCIL BLUFFS IA 2,808 $193,100.11 $533.43 67
59 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,249 $191,612.88 $253.46 54
60 ORSINI PHARMACEUTICAL SERVICES I ELK GROVE VILLAGE IL 13 $187,434.69 $62,478.23 106
61 PROCARE PHARMACY DIRECT LLC MONROEVILLE PA 40 $186,119.23 $8,092.14 98
62 ACARIAHEALTH PHARMACY #11 INC HOUSTON TX 38 $186,115.41 $9,305.77 72
63 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,427 $181,556.56 $241.43 57
64 HY-VEE FOOD STORE WATERLOO IA 2,535 $181,213.88 $312.98 69
65 WALGREENS #11942 DUBUQUE IA 3,287 $181,024.85 $202.49 64
66 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,206 $180,973.03 $295.71 60
67 WALGREENS 07968 DES MOINES IA 3,111 $178,216.17 $167.34 68
68 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,717 $178,078.97 $189.24 78
69 WALGREENS #05119 CLINTON IA 3,622 $176,964.86 $180.39 62
70 MEDICAP PHARMACY INDIANOLA IA 3,827 $176,928.13 $375.64 61
71 PHARMACY MATTERS LTC IOWA CITY IA 4,234 $176,580.70 $516.32 70
72 WALGREENS #10855 WATERLOO IA 3,382 $173,614.05 $173.09 63
73 WALGREEN #05044 BURLINGTON IA 3,351 $170,660.61 $167.81 66
74 HY-VEE PHARMACY (1075) CLINTON IA 2,777 $169,184.28 $302.66 71
75 HARTIG PHARMACY SERVICES DUBUQUE IA 2,938 $168,927.41 $630.33 76
76 WAGNER PHARMACY CLINTON IA 2,487 $164,071.52 $379.80 65
77 HY VEE PHARMACY #1449 NEWTON IA 3,141 $157,421.13 $217.43 74
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78 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,773 $156,998.65 $263.42 75
79 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 3,005 $156,875.00 $249.01 73
80 HY-VEE PHARMACY 1504 OTTUMWA IA 2,654 $153,331.46 $276.27 79
81 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,819 $152,046.51 $208.00 94
82 WALGREEN #09708 DUBUQUE IA 2,626 $148,176.47 $158.65 121
83 HY-VEE DRUGSTORE #7031 DES MOINES IA 2,618 $148,093.91 $329.83 84
84 WALGREEN #05886 KEOKUK IA 3,106 $147,854.92 $196.88 80
85 HY-VEE PHARMACY #4 (1148) DES MOINES IA 2,295 $147,471.43 $270.59 81
86 HY-VEE PHARMACY (1058) CENTERVILLE IA 3,013 $146,786.14 $260.26 111
87 MERCY HEALTH SERVICES IOWA CORP MASON CITY IA 2,314 $146,442.63 $291.14 129
88 WAL MART PHARMACY 10-3590 SIOUX CITY IA 2,976 $145,816.10 $178.04 101
89 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,680 $143,777.81 $259.06 87
90 GREENVILLE PHARMACY INC SIOUX CITY IA 2,015 $143,004.52 $423.09 82
91 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 3,212 $142,797.99 $211.55 85
92 L & M PHARMACY CARE LE MARS IA 1,436 $141,971.34 $1,223.89 91
93 LA GRANGE PHARMACY INC VINTON IA 2,599 $140,598.89 $274.07 88
94 WAL-MART PHARMACY 10-0784 MT PLEASANT IA 2,506 $140,057.92 $242.73 92
95 HY-VEE PHARMACY #3 (1056) CEDAR RAPIDS IA 2,873 $139,759.75 $188.61 110
96 HY-VEE PHARMACY (1065) CHARITON IA 2,452 $139,389.20 $245.84 90
97 WAL MART PHARMACY 10-1621 CENTERVILLE IA 3,219 $139,245.70 $215.22 89
98 WALGREEN #05077 IOWA CITY IA 2,526 $139,016.44 $184.37 95
99 STANGEL PHARMACY ONAWA IA 2,449 $138,608.38 $303.97 97
100 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,655 $138,066.99 $137.52 100
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1 1780766659 CHESTER ROBERT BADGER $189,590.15 3,636 5.90 1
2 1538368170 CHRISTOPHER ROBERT MATSON $85,841.80 2,775 6.50 5
3 1467682351 NICOLE GILG $74,190.06 2,539 5.96 6
4 1841407160 RAHUL BANSAL MD $219,584.91 2,400 5.04 2
5 1063622637 HUSSAIN BANU $65,528.20 2,348 6.29 3
6 1982605762 JEFFREY D WILHARM $143,687.27 2,227 5.75 11
7 1215192224 SHALINA SHAIK $52,203.20 2,074 5.89 7
8 1083784797 CAROL  AUNAN $182,124.57 1,980 3.20 13
9 1205015906 DAVID F WIDITZ $151,398.18 1,909 5.91 27
10 1649248378 KATHLEEN L WILD ARNP $180,856.05 1,905 3.57 10
11 1245318393 JEAN TOBIN PA $134,519.32 1,905 4.67 16
12 1073667606 ELIZABETH MCCURDY DO $58,886.85 1,865 5.45 37
13 1316922545 MABRA G ABERNATHY $64,431.44 1,825 5.11 8
14 1972758126 REBECCA BOLLIN $51,909.78 1,824 6.18 29
15 1013115369 BOBBITA NAG $206,467.22 1,817 3.82 12
16 1043211303 ALI  SAFDAR $119,503.92 1,758 3.80 14
17 1619153137 JODI BEST ARNP $173,739.12 1,744 5.21 15
18 1073509436 MICHAEL KARL MAHARRY MD $70,025.90 1,675 5.90 17
19 1801998372 WENDY MICHELE HANSEN-PENMAN DO $38,505.88 1,661 6.64 30
20 1023053972 BRYANT MUTCHLER DO $67,132.69 1,627 5.30 20
21 1467502286 CHARLES TILLEY PA $184,122.06 1,615 4.56 19
22 1386758613 ROY WILLIAM OVERTON III DO $38,489.71 1,585 1.03 1677
23 1073594768 JERROLD V FLATT DO $60,494.62 1,531 5.24 22
24 1245388743 TIMOTHY SWINTON MD $61,367.79 1,522 5.68 23
25 1477633188 CYD Q. GRAFFT $120,682.03 1,485 3.97 25
26 1962558957 ALBERT N OKINE PA $149,009.25 1,476 6.74 26
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27 1043434525 ROBERT MARVIN KENT MD $66,854.02 1,410 4.58 31
28 1861562555 LARRY  RICHARDS $69,108.41 1,410 5.51 4
29 1982766705 MALHAR GORE $37,168.89 1,399 4.93 69
30 1255399812 MICHAEL D HURT MD $38,950.90 1,390 1.06 2639
31 1730239732 SRIRAMAMURTHY RAVIPATI MD $107,504.08 1,369 3.71 28
32 1720293087 RAJNI BATRA MD $60,576.81 1,367 3.70 88
33 1528144383 RAMONCITO AMURAO O'CAMPO $58,686.39 1,366 4.84 47
34 1467437806 GEORGIA LAUER PAC $77,071.10 1,363 5.73 39
35 1841220290 KENT ELDON KUNZE MD $111,792.77 1,342 4.29 34
36 1073945499 JENNIFER LEE ZALAZNIK ARNP $57,441.71 1,336 3.71 57
37 1164538674 JOSEPH M WANZEK $66,200.88 1,319 5.02 36
38 1902809536 KIRAN BHASKAR KHANOLKAR MD $62,865.20 1,281 4.73 33
39 1255322996 MARK WILLIAM MITTAUER $121,934.73 1,277 5.58 32
40 1023377827 LISA KAY CHASE $49,996.28 1,273 4.65 105
41 1225097843 WILLIAM M NISSEN $68,056.09 1,272 4.59 35
42 1295830115 ALAN BOLLINGER DO $140,838.65 1,270 6.26 18
43 1497736326 RANDY R ROBINSON $50,709.34 1,269 5.45 38
44 1598962870 CHRISTY QUILLEN ARNP $36,448.03 1,258 4.99 43
45 1184945321 DEANNE REMER $71,365.10 1,242 6.79 51
46 1275844649 KATIE M HANSON ARNP $95,954.00 1,238 3.94 72
47 1073500690 KATHLEEN S ADAMS $149,030.64 1,227 4.09 48
48 1508289620 GLORIA A MILLER $97,613.50 1,206 5.27 159
49 1144214248 KRISTIE DEE ANN WALZ MD $68,054.26 1,206 4.71 67
50 1205821337 MANMOHAN SINGH $54,831.11 1,206 4.64 70
51 1033198908 DANIEL J ARNOLD $58,076.54 1,205 4.35 59
52 1013960566 PETER JOSEPH SZEIBEL $106,760.70 1,203 4.83 64
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53 1912991340 GHADA HAMDAN-ALLEN MD $109,173.26 1,202 4.32 24
54 1215146055 REBECCA J WOLFE $91,910.96 1,152 3.84 61
55 1205169273 TERESA ANN DOWLING $32,262.30 1,133 4.68 54
56 1508946088 E RICHARD NIGHTINGALE MD $104,799.14 1,123 5.15 65
57 1952459463 DAVID LAWRENCE YURDIN PA $534,611.33 1,122 4.25 44
58 1356520431 KAY A MARTTILA $124,126.29 1,110 3.47 81
59 1841293354 KEITH GUESS PA C $98,931.04 1,105 4.35 63
60 1003004391 DAVID BERMAN WALKER MD $85,061.77 1,097 4.03 46
61 1306133095 DEBRA LEE ANDERSON ARNP $39,137.31 1,097 3.64 55
62 1558348284 STEVEN G PAULSRUD $58,832.69 1,093 4.25 60
63 1134191018 DUSTIN RALPH SMITH MD $68,016.12 1,088 5.04 94
64 1871586271 PATRICIA BLACKLEDGE ARNP $43,988.11 1,087 5.78 52
65 1346210184 JAMES BROOKS MD $108,445.31 1,082 4.79 79
66 1861559486 JOSPEH PATRICK BERTROCHE $125,031.28 1,077 4.24 49
67 1215080759 JUANITA M O'BRIEN $38,802.77 1,060 4.95 53
68 1104089390 EJIRO AGBORO-IDAHOSA MD $94,834.91 1,058 4.72 56
69 1538157383 DAVID WENGER-KELLER MD $46,079.17 1,056 5.23 66
70 1437373073 MOHSEN ABOU SEIF $38,194.05 1,047 4.44 87
71 1902115652 SARAH LYNN BEATTIE ARNP $110,064.58 1,032 3.71 68
72 1922144088 THOMAS SCOTT HOPKINS DO $94,659.06 1,021 3.69 82
73 1588629414 THOMAS EARWOOD MD $79,416.09 1,021 5.08 80
74 1306812490 MERRILEE RAMSEY ARNP $50,635.77 1,020 4.36 98
75 1730143397 MARK JOSEPH DEARDEN DO $30,835.78 1,020 5.15 89
76 1710941000 LAURIE WARREN PA $107,711.60 1,011 4.28 58
77 1326045808 RAY C STURDEVANT MD $93,207.52 1,007 3.23 100
78 1619186475 STEPHEN PALLONE MD $33,744.96 1,000 4.81 76
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79 1063491645 ALLYSON L WHEATON MD $93,042.41 996 3.88 45
80 1629042288 MARTIN J FIALKOV MD $84,764.80 992 4.79 83
81 1912991183 MOLLY EARLEYWINE PA $26,111.83 984 3.89 97
82 1396724167 MICHAEL O'CONNER MD $30,695.54 983 5.07 74
83 1164414520 KAREN JACKSON FULWOOD ARNP $66,136.95 975 3.37 9
84 1902912538 CHRISTIAN W JONES MD $43,620.56 970 3.29 118
85 1386977387 MARYANN KAPACINSKAS $61,981.64 966 4.16 104
86 1871595207 DALE M GRUNEWALD $36,730.56 964 5.91 73
87 1033389226 ANTHONY G ZAMUDIO ARNP $110,761.05 960 3.47 41
88 1942252895 KIMBERLY A THOMPSON $35,441.16 957 2.70 85
89 1780877878 CHRISTOPHER JACOBS ARNP $36,233.10 955 3.72 111
90 1164530358 DAVID M CRAVEN $47,050.85 946 2.70 93
91 1285697722 DOUGLAS  JONES $82,070.47 946 3.91 71
92 1437238110 GENEVIEVE  NELSON $64,938.96 946 3.67 91
93 1124399522 JOYCE E PROUCH ARNP $81,282.65 935 4.70 84
94 1891705968 ANITA HANDEVIDT ARNP $94,637.06 935 3.06 109
95 1407953979 CECELIA M NASSIF ARNP $71,216.84 933 4.81 90
96 1699075929 HIEDI CHRISTINE LANE $73,663.49 932 4.29 77
97 1285681528 MARVIN F PIBURN JR MD $85,365.92 932 5.65 40
98 1699769794 DAVE FALDMO PA $28,950.68 917 5.12 110
99 1164416269 ANN M PICK ARNP $28,919.23 909 4.29 114
100 1609218304 AMANDA O'TOOL ARNP $75,807.24 908 5.37 108
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1 1013126705 JANICE M. R. STABER $1,549,353.71 $20,386.23 76 1
2 1952459463 DAVID LAWRENCE YURDIN PA $534,611.33 $476.48 1,122 2
3 1548247406 VILMARIE RODRIGUEZ-PADUA MD $324,822.67 $36,091.41 9 3
4 1356337273 LISA J MENZIES $225,390.79 $351.08 642 16
5 1841407160 RAHUL BANSAL MD $219,584.91 $91.49 2,400 4
6 1013115369 BOBBITA NAG $206,467.22 $113.63 1,817 6
7 1285748004 BRUCE L HAYES MD $206,420.82 $1,193.18 173 5
8 1780766659 CHESTER ROBERT BADGER $189,590.15 $52.14 3,636 7
9 1467502286 CHARLES TILLEY PA $184,122.06 $114.01 1,615 10
10 1083784797 CAROL  AUNAN $182,124.57 $91.98 1,980 19
11 1649248378 KATHLEEN L WILD ARNP $180,856.05 $94.94 1,905 9
12 1376777524 ALLADDIN MOH ELHADI ABOSAIDA $180,276.78 $533.36 338 14
13 1619153137 JODI BEST ARNP $173,739.12 $99.62 1,744 13
14 1083603773 JACK T STAPLETON $170,929.51 $647.46 264 18
15 1194703074 WENDY ANNE WALDMAN $154,374.78 $219.91 702 21
16 1548256191 JUDITH A MILLER $151,934.03 $4,604.06 33 20
17 1205015906 DAVID F WIDITZ $151,398.18 $79.31 1,909 43
18 1790708451 MICHAEL M MCCUBBIN $151,020.06 $402.72 375 33
19 1073500690 KATHLEEN S ADAMS $149,030.64 $121.46 1,227 27
20 1962558957 ALBERT N OKINE PA $149,009.25 $100.95 1,476 15
21 1497060776 USHA PEREPU MBBS $148,230.85 $2,117.58 70 448
22 1174584072 BRADLEY SCOTT LAIR MD $147,919.53 $1,309.02 113 102
23 1982605762 JEFFREY D WILHARM $143,687.27 $64.52 2,227 26
24 1083609358 JENNIFER S COOK $142,880.48 $228.98 624 12
25 1194817247 MARIA J STEELE ARNP $141,725.12 $998.06 142 65
26 1295830115 ALAN BOLLINGER DO $140,838.65 $110.90 1,270 22
27 1770561946 DONALD HILLEBRAND MD $140,082.25 $1,285.16 109 31
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28 1245318393 JEAN TOBIN PA $134,519.32 $70.61 1,905 36
29 1013905181 DONALD MACFARLANE MD $126,612.41 $12,661.24 10 8
30 1861559486 JOSPEH PATRICK BERTROCHE $125,031.28 $116.09 1,077 32
31 1356520431 KAY A MARTTILA $124,126.29 $111.83 1,110 37
32 1255322996 MARK WILLIAM MITTAUER $121,934.73 $95.49 1,277 28
33 1477633188 CYD Q. GRAFFT $120,682.03 $81.27 1,485 40
34 1043211303 ALI  SAFDAR $119,503.92 $67.98 1,758 35
35 1972638864 LIUSKA MARIA PESCE $111,967.14 $442.56 253 24
36 1841220290 KENT ELDON KUNZE MD $111,792.77 $83.30 1,342 38
37 1033389226 ANTHONY G ZAMUDIO ARNP $110,761.05 $115.38 960 17
38 1902115652 SARAH LYNN BEATTIE ARNP $110,064.58 $106.65 1,032 39
39 1912991340 GHADA HAMDAN-ALLEN MD $109,173.26 $90.83 1,202 29
40 1346210184 JAMES BROOKS MD $108,445.31 $100.23 1,082 49
41 1710941000 LAURIE WARREN PA $107,711.60 $106.54 1,011 48
42 1730239732 SRIRAMAMURTHY RAVIPATI MD $107,504.08 $78.53 1,369 44
43 1013960566 PETER JOSEPH SZEIBEL $106,760.70 $88.75 1,203 52
44 1164569737 PAULA STULTZ $105,650.92 $528.25 200 189
45 1508946088 E RICHARD NIGHTINGALE MD $104,799.14 $93.32 1,123 42
46 1083681944 MARY CHRISTINE SEGRETO $104,630.02 $131.78 794 30
47 1619963949 EVA TSALIKIAN $104,514.75 $710.98 147 75
48 1235124942 JULIE KATHRYN OSTERHAUS $100,050.25 $378.98 264 46
49 1841293354 KEITH GUESS PA C $98,931.04 $89.53 1,105 55
50 1639483407 LEAH ZHORNE MD $98,308.32 $2,808.81 35 4862
51 1508289620 GLORIA A MILLER $97,613.50 $80.94 1,206 115
52 1669570404 CASIE RINEY PA $96,959.31 $107.14 905 41
53 1609055771 CHARUTA NARAYAN JOSHI $96,488.63 $210.67 458 11
54 1275844649 KATIE M HANSON ARNP $95,954.00 $77.51 1,238 86
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55 1104089390 EJIRO AGBORO-IDAHOSA MD $94,834.91 $89.64 1,058 53
56 1922144088 THOMAS SCOTT HOPKINS DO $94,659.06 $92.71 1,021 61
57 1891705968 ANITA HANDEVIDT ARNP $94,637.06 $101.22 935 90
58 1528247368 MISHELLE L PAULLUS $93,983.69 $1,044.26 90 50
59 1215025309 DEBORAH LYNNE GARRELTS $93,296.20 $127.63 731 56
60 1326045808 RAY C STURDEVANT MD $93,207.52 $92.56 1,007 68
61 1063491645 ALLYSON L WHEATON MD $93,042.41 $93.42 996 34
62 1356564371 CARLA K ABEL ZIEG ARNP $92,444.74 $118.06 783 63
63 1215146055 REBECCA J WOLFE $91,910.96 $79.78 1,152 66
64 1821082850 JOHN F STECKER $91,841.76 $119.59 768 130
65 1679669832 ERIN VOYLES HATCHER ARNP $91,571.01 $113.75 805 59
66 1043418809 MICHAEL ANTHONY CILIBERTO MD $86,234.20 $433.34 199 685
67 1083671309 JOHN LOUIS COLOMBO MD $85,862.53 $1,160.30 74 62
68 1538368170 CHRISTOPHER ROBERT MATSON $85,841.80 $30.93 2,775 97
69 1366435125 DANIEL EDWARD WESEMANN ARNP $85,520.34 $111.65 766 72
70 1285681528 MARVIN F PIBURN JR MD $85,365.92 $91.59 932 45
71 1316269871 REGINA ROBISON ARNP $85,357.67 $102.84 830 60
72 1003004391 DAVID BERMAN WALKER MD $85,061.77 $77.54 1,097 58
73 1629042288 MARTIN J FIALKOV MD $84,764.80 $85.45 992 67
74 1104034552 DEANNA BOOK BOESEN $84,335.34 $107.30 786 64
75 1104029008 KATIE MARIE ULRING LARSON ODE MD $82,230.76 $348.44 236 128
76 1285697722 DOUGLAS  JONES $82,070.47 $86.76 946 57
77 1609867688 DAVID B MOORE, M.D. $81,563.17 $345.61 236 79
78 1124399522 JOYCE E PROUCH ARNP $81,282.65 $86.93 935 76
79 1750376034 DUANGCHAI NARAWONG MD $80,851.70 $126.13 641 87
80 1487908380 LISA ANN BECHTEL ARNP $80,327.07 $100.91 796 69
81 1588629414 THOMAS EARWOOD MD $79,416.09 $77.78 1,021 105
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82 1780793976 MATTHEW D EGGERS MD $78,841.01 $110.89 711 85
83 1205992724 LOUISE W SMITH $78,820.71 $324.37 243 47
84 1841443025 LISA K WATKINS $78,597.11 $142.39 552 112
85 1053361972 MATTHEW LARRY HILL DO $78,310.79 $1,044.14 75 82
86 1003869108 BORIANA KAMENOVA MD $78,271.22 $1,630.65 48 442
87 1245436765 RENE M DUREGGER MD $77,380.21 $105.28 735 88
88 1467437806 GEORGIA LAUER PAC $77,071.10 $56.55 1,363 101
89 1043441264 KATHERINE BLOMGREN PA $76,245.26 $1,622.24 47 464
90 1609218304 AMANDA O'TOOL ARNP $75,807.24 $83.49 908 124
91 1285626390 KATHLEEN  GRADOVILLE $75,694.17 $270.34 280 54
92 1134171937 KATHRYN LEE FLANDERS ARNP $75,343.05 $655.16 115 78
93 1215125216 REBECCA WALDING $74,649.76 $103.54 721 74
94 1467682351 NICOLE GILG $74,190.06 $29.22 2,539 107
95 1255662276 PATEL R REDDY $74,187.31 $107.83 688 98
96 1699075929 HIEDI CHRISTINE LANE $73,663.49 $79.04 932 91
97 1184945321 DEANNE REMER $71,365.10 $57.46 1,242 116
98 1407953979 CECELIA M NASSIF ARNP $71,216.84 $76.33 933 71
99 1073509436 MICHAEL KARL MAHARRY MD $70,025.90 $41.81 1,675 119
100 1760470678 JEFFERY L MEIER $70,021.95 $466.81 150 109
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ANTIPSYCHOTICS - ATYPICALS $5,095,517 1 9.3% $5,214,062 1 8.8% 2.3%
STIMULANTS - AMPHETAMINES - LONG ACTING $3,034,590 2 5.6% $3,201,195 2 5.4% 5.5%
ANTICONVULSANTS $2,923,520 3 5.4% $3,165,011 3 5.4% 8.3%
ANTIDEPRESSANTS - SELECTED SSRI's $2,346,827 5 4.3% $2,544,876 4 4.3% 8.4%
DIABETIC - INSULIN $2,473,057 4 4.5% $2,531,237 5 4.3% 2.4%
STIMULANTS - METHYLPHENIDATE - LONG ACTING $2,002,359 7 3.7% $2,276,981 6 3.8% 13.7%
ANTIHEMOPHILIC AGENTS $2,261,885 6 4.1% $2,059,123 7 3.5% -9.0%
ANTIASTHMATIC - ADRENERGIC COMBOS $1,732,149 8 3.2% $1,869,336 8 3.2% 7.9%
STIMULANTS - METHYLPHENIDATE $1,408,589 9 2.6% $1,551,639 9 2.6% 10.2%
ANTIASTHMATIC - BETA - ADRENERGICS $1,240,694 10 2.3% $1,495,947 10 2.5% 20.6%
BIOLOGIC IMMUNOMODULATORS $1,217,789 11 2.2% $1,316,787 11 2.2% 8.1%
MULTIPLE SCLEROSIS AGENTS $1,159,375 12 2.1% $1,230,250 12 2.1% 6.1%
STIMULANTS - OTHER STIMULANTS / LIKE STIMULANTS $1,108,336 13 2.0% $1,197,553 13 2.0% 8.0%
DIABETIC - INSULIN  PENFILLS $1,088,116 14 2.0% $1,144,583 14 1.9% 5.2%
ANTIASTHMATIC - STEROID INHALANTS $896,763 17 1.6% $1,112,646 15 1.9% 24.1%
ANTIRETROVIRALS $1,031,892 16 1.9% $1,109,189 16 1.9% 7.5%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS $815,366 19 1.5% $882,494 17 1.5% 8.2%
STIMULANTS - AMPHETAMINES - SHORT ACTING $1,056,273 15 1.9% $876,500 18 1.5% -17.0%
NARCOTICS - MISC. $854,098 18 1.6% $870,926 19 1.5% 2.0%
ANTIASTHMATIC - ANTI-CHOLINERGICS $727,697 20 1.3% $851,885 20 1.4% 17.1%
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ANTIDEPRESSANTS - SELECTED SSRI's 82,668 1 88,670 1 7.3%
ANTICONVULSANTS 44,208 2 46,880 2 6.0%
NARCOTICS - MISC. 41,849 3 40,825 3 -2.4%
ANTIASTHMATIC - BETA - ADRENERGICS 26,533 6 33,906 4 27.8%
ANTIPSYCHOTICS - ATYPICALS 29,929 4 30,838 5 3.0%
BETA-LACTAMS / CLAVULANATE COMBO'S 22,129 8 30,656 6 38.5%
ANALGESICS - MISC. 26,661 5 28,448 7 6.7%
ANTIHISTAMINES - NON-SEDATING 25,498 7 28,048 8 10.0%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS 21,183 9 22,814 9 7.7%
GI - PROTON PUMP INHIBITOR 20,569 10 22,345 10 8.6%
ANXIOLYTICS - BENZODIAZEPINES 19,866 11 20,200 11 1.7%
MACROLIDES / ERYTHROMYCIN'S / KETOLIDES 12,082 25 19,821 12 64.1%
NSAIDS 17,859 12 19,670 13 10.1%
GLUCOCORTICOIDS - MINERALOCORTICOIDS 14,364 18 19,313 14 34.5%
ACE INHIBITORS 17,665 13 18,876 15 6.9%
ANTIHYPERTENSIVES - CENTRAL 17,373 14 18,196 16 4.7%
DIURETICS 16,160 15 16,823 17 4.1%
STIMULANTS - AMPHETAMINES - LONG ACTING 15,209 16 16,250 18 6.8%
MUSCLE RELAXANTS 14,374 17 15,387 19 7.0%
CEPHALOSPORINS 12,249 24 14,530 20 18.6%
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TOP 100 DRUGS BY PAID AMOUNT
DRUG DESCRIPTION July/August 2014 PREVIOUS 
RANK
September/October 2014 RANK PERCENT CHANGE
ABILIFY $2,523,907.38 1 $2,506,068.44 1 -0.71%
VYVANSE $2,275,714.32 2 $2,461,511.44 2 8.16%
METHYLPHENIDATE HCL ER $1,683,217.66 3 $1,905,726.18 3 13.22%
LANTUS $1,293,225.66 4 $1,304,368.14 4 0.86%
FOCALIN XR $1,091,950.72 7 $1,207,020.65 5 10.54%
CYMBALTA $1,155,380.63 6 $1,186,638.74 6 2.71%
ADVATE $1,235,174.73 5 $1,084,931.63 7 -12.16%
VENTOLIN HFA $757,898.49 11 $908,399.95 8 19.86%
ADVAIR DISKUS $829,054.19 9 $834,865.41 9 0.70%
STRATTERA $767,664.65 10 $820,180.15 10 6.84%
SPIRIVA HANDIHALER $666,265.33 12 $788,628.28 11 18.37%
ADDERALL $1,001,637.81 8 $740,986.35 12 -26.02%
LATUDA $577,819.66 15 $648,671.30 13 12.26%
ADDERALL XR $654,508.75 13 $640,855.62 14 -2.09%
DEPAKOTE ER $609,899.62 14 $638,587.77 15 4.70%
INVEGA SUSTENNA $514,146.34 17 $547,407.30 16 6.47%
NOVOLOG $527,962.51 16 $531,704.56 17 0.71%
SYMBICORT $440,298.28 21 $498,004.24 18 13.11%
CRESTOR $453,116.50 19 $482,099.18 19 6.40%
HYDROCODONE/ACETAMINOPHEN $469,299.67 18 $472,248.88 20 0.63%
ATRIPLA $446,416.42 20 $457,785.72 21 2.55%
HUMALOG $432,094.79 22 $456,741.74 22 5.70%
LOVENOX $371,700.82 25 $448,699.40 23 20.72%
NOVOSEVEN RT $399,121.32 24 $440,995.35 24 10.49%
HUMIRA PEN $415,881.45 23 $437,102.60 25 5.10%
AZITHROMYCIN $222,533.99 46 $390,496.69 26 75.48%
PROVENTIL HFA $317,359.61 29 $361,224.54 27 13.82%
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DRUG DESCRIPTION July/August 2014 PREVIOUS 
RANK
September/October 2014 RANK PERCENT CHANGE
TECFIDERA $254,071.36 40 $353,924.09 28 39.30%
QVAR $303,898.72 31 $348,383.67 29 14.64%
SOVALDI $187,241.84 55 $341,625.99 30 82.45%
PULMICORT $232,982.36 42 $341,575.86 31 46.61%
DEXILANT $322,610.15 27 $338,630.13 32 4.97%
LEVEMIR $302,456.17 32 $334,999.68 33 10.76%
TRICOR $316,871.30 30 $328,085.39 34 3.54%
GENOTROPIN $295,688.38 34 $320,853.36 35 8.51%
NASONEX $270,666.95 36 $319,183.75 36 17.92%
LANTUS SOLOSTAR $319,532.52 28 $314,489.29 37 -1.58%
RISPERDAL CONSTA $301,260.67 33 $303,355.61 38 0.70%
COPAXONE $335,315.20 26 $303,213.06 39 -9.57%
TRUVADA $261,500.48 38 $298,606.35 40 14.19%
LYRICA $287,377.90 35 $289,453.42 41 0.72%
NOVOLOG FLEXPEN $264,973.29 37 $284,665.79 42 7.43%
CEFDINIR $181,076.74 58 $275,706.59 43 52.26%
MONTELUKAST SODIUM $227,975.49 44 $254,604.58 44 11.68%
FLOVENT HFA $213,978.61 48 $251,015.80 45 17.31%
AMOXICILLIN $157,849.66 68 $237,021.74 46 50.16%
ENBREL SURECLICK $220,031.55 47 $236,903.75 47 7.67%
OMEPRAZOLE $203,880.36 51 $236,852.40 48 16.17%
INVEGA $240,501.25 41 $228,174.49 49 -5.13%
HUMIRA $204,913.87 50 $222,691.84 50 8.68%
FEIBA NF $113,030.00 99 $220,101.61 51 94.73%
LEVOTHYROXINE SODIUM $192,926.43 54 $218,901.58 52 13.46%
GLEEVEC $170,564.10 62 $215,206.64 53 26.17%
COMBIVENT RESPIMAT $184,489.25 57 $214,633.86 54 16.34%
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DRUG DESCRIPTION July/August 2014 PREVIOUS 
RANK
September/October 2014 RANK PERCENT CHANGE
PULMOZYME $158,381.79 67 $211,278.07 55 33.40%
VIMPAT $199,418.43 52 $207,660.42 56 4.13%
EPIPEN 2-PAK $257,307.67 39 $204,566.98 57 -20.50%
GABAPENTIN $179,486.89 59 $204,374.45 58 13.87%
PROVIGIL $168,373.63 63 $203,240.18 59 20.71%
OPANA ER (CRUSH RESISTANT $163,357.06 64 $200,414.37 60 22.68%
XYREM $151,083.69 72 $193,168.38 61 27.86%
NAGLAZYME $124,528.48 83 $186,799.16 62 50.01%
ENBREL $224,018.80 45 $180,024.51 63 -19.64%
EXJADE $195,274.93 53 $179,982.45 64 -7.83%
VESICARE $170,901.71 61 $179,837.00 65 5.23%
KALYDECO $204,948.96 49 $179,346.89 66 -12.49%
METHYLPHENIDATE HCL $150,509.93 73 $178,756.98 67 18.77%
AMOXICILLIN/CLAVULANATE P $114,667.42 95 $167,848.37 68 46.38%
HELIXATE FS $186,178.84 56 $165,037.17 69 -11.36%
SEROQUEL XR $156,866.64 69 $163,943.73 70 4.51%
QUETIAPINE FUMARATE $151,293.67 71 $160,174.84 71 5.87%
RISPERIDONE $150,445.57 74 $158,940.52 72 5.65%
H.P. ACTHAR $94,898.24 120 $158,153.46 73 66.66%
XIFAXAN $158,481.94 66 $157,772.57 74 -0.45%
ZIPRASIDONE HCL $155,508.00 70 $157,376.03 75 1.20%
TOPROL XL $144,604.16 75 $153,837.50 76 6.39%
DULERA $123,092.30 85 $152,784.33 77 24.12%
TRAMADOL HCL $142,051.19 77 $148,305.32 78 4.40%
BUPROPION HCL XL $126,175.13 80 $148,185.63 79 17.44%
ALBUTEROL SULFATE $93,600.87 123 $146,755.84 80 56.79%
SERTRALINE HCL $125,039.24 81 $145,971.37 81 16.74%
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DRUG DESCRIPTION July/August 2014 PREVIOUS 
RANK
September/October 2014 RANK PERCENT CHANGE
LISINOPRIL $124,723.85 82 $145,595.65 82 16.73%
BANZEL $122,040.57 88 $144,243.87 83 18.19%
GILENYA $124,003.58 84 $143,113.49 84 15.41%
INTUNIV $143,488.12 76 $141,688.33 85 -1.25%
JANUVIA $114,774.69 94 $140,701.98 86 22.59%
SAPHRIS $122,990.76 86 $140,155.71 87 13.96%
SPRYCEL $93,101.30 124 $139,905.56 88 50.27%
ESCITALOPRAM OXALATE $120,284.02 89 $138,630.27 89 15.25%
CEPHALEXIN $117,046.43 91 $137,589.43 90 17.55%
FLUTICASONE PROPIONATE $105,779.17 107 $135,475.03 91 28.07%
CREON $126,331.47 79 $133,888.07 92 5.98%
NORDITROPIN FLEXPRO $128,213.17 78 $131,195.77 93 2.33%
VENLAFAXINE HCL ER $110,341.36 102 $128,226.45 94 16.21%
COMPLERA $122,897.14 87 $127,240.95 95 3.53%
RANITIDINE HCL $115,590.24 92 $127,195.73 96 10.04%
TRAZODONE HCL $111,044.96 101 $126,798.12 97 14.19%
ATORVASTATIN CALCIUM $105,589.66 108 $126,578.67 98 19.88%
SABRIL $107,412.28 105 $126,258.89 99 17.55%
QUILLIVANT XR $81,641.47 141 $126,040.17 100 54.38%
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HYDROCO/APAP TAB 5-325MG 20,066 1 18,887 1 -5.88%
VENTOLIN HFA AER 14,060 2 16,704 2 18.81%
TRAMADOL HCL TAB 50MG 13,379 3 12,778 3 -4.49%
Loratadine Tab 10 MG 11,817 4 12,546 4 6.17%
ALBUTEROL    NEB 0.083% 6,353 15 9,991 5 57.26%
AZITHROMYCIN TAB 250MG 5,603 24 9,473 6 69.07%
AMOXICILLIN  SUS 400/5ML 6,136 17 9,369 7 52.69%
Cetirizine HCl Tab 10 MG 8,506 5 9,305 8 9.39%
ESCITALOPRAM TAB 20MG 8,274 6 8,960 9 8.29%
FLUOXETINE   CAP 20MG 8,103 8 8,760 10 8.11%
OMEPRAZOLE   CAP 20MG 8,118 7 8,686 11 7.00%
GABAPENTIN   CAP 300MG 7,774 10 8,410 12 8.18%
CYCLOBENZAPR TAB 10MG 7,800 9 8,150 13 4.49%
FLUTICASONE  SPR 50MCG 6,064 18 7,483 14 23.40%
RANITIDINE   TAB 150MG 7,061 11 7,203 15 2.01%
OMEPRAZOLE   CAP 40MG 6,363 14 7,097 16 11.54%
CLONIDINE    TAB 0.1MG 6,692 12 6,982 17 4.33%
Aspirin Tab Delayed Release 81 MG 6,594 13 6,894 18 4.55%
Acetaminophen Tab 325 MG 6,297 16 6,801 19 8.00%
AZITHROMYCIN SUS 200/5ML 3,885 50 6,581 20 69.40%
SERTRALINE   TAB 100MG 5,998 20 6,458 21 7.67%
IBUPROFEN    TAB 800MG 5,977 21 6,401 22 7.09%
MONTELUKAST  TAB 10MG 5,805 22 6,290 23 8.35%
GUANFACINE   TAB 1MG 6,005 19 6,188 24 3.05%
Ferrous Sulfate Tab 325 MG (65 MG 
Elemental Fe)
5,722 23 5,996 25 4.79%
PROVENTIL    AER HFA 5,162 27 5,957 26 15.40%
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TRAZODONE    TAB 50MG 5,529 25 5,895 27 6.62%
TRAZODONE    TAB 100MG 5,438 26 5,840 28 7.39%
PREDNISONE   TAB 20MG 4,125 43 5,511 29 33.60%
LISINOPRIL   TAB 10MG 4,974 29 5,447 30 9.51%
METFORMIN    TAB 500MG 5,043 28 5,228 31 3.67%
HYDROCHLOROT TAB 25MG 4,790 31 5,142 32 7.35%
LISINOPRIL   TAB 20MG 4,749 32 5,047 33 6.28%
Sennosides-Docusate Sodium Tab 8.6-50 
MG
4,707 33 4,890 34 3.89%
AMOXICILLIN  CAP 500MG 3,941 49 4,875 35 23.70%
Aspirin Chew Tab 81 MG 4,525 34 4,785 36 5.75%
CLONAZEPAM   TAB 1MG 4,499 35 4,779 37 6.22%
SMZ/TMP DS   TAB 800-160 4,496 36 4,663 38 3.71%
HYDROCO/APAP TAB 7.5-325 4,932 30 4,640 39 -5.92%
CEPHALEXIN   CAP 500MG 4,415 38 4,627 40 4.80%
OXYCOD/APAP  TAB 5-325MG 4,489 37 4,573 41 1.87%
PREDNISOLONE SOL 15MG/5ML 3,968 48 4,503 42 13.48%
METFORMIN    TAB 1000MG 4,145 41 4,484 43 8.18%
MELOXICAM    TAB 15MG 4,181 40 4,470 44 6.91%
METHYLPHENID TAB 36MG ER 4,034 45 4,388 45 8.78%
CITALOPRAM   TAB 20MG 4,137 42 4,367 46 5.56%
NAPROXEN     TAB 500MG 3,813 53 4,236 47 11.09%
LANTUS       INJ 100/ML 3,982 47 4,194 48 5.32%
MONTELUKAST  CHW 5MG 4,005 46 4,193 49 4.69%
POLYETH GLYC POW 3350 NF 3,842 51 4,193 50 9.14%
ALPRAZOLAM   TAB 1MG 4,121 44 4,156 51 0.85%
HYDROCO/APAP TAB 10-325MG 4,251 39 4,144 52 -2.52%
Page 26 Of 2911/10/2014 9:00:02 AM RT33018
trusted, reliable, innovative
TOP 100 DRUGS BY PRESCRIPTION COUNT
DRUG DESCRIPTION July/August 2014 PREVIOUS 
RANK
September/October 2014 RANK PERCENT CHANGE
VENLAFAXINE  CAP 150MG ER 3,813 52 4,137 53 8.50%
CLONAZEPAM   TAB 0.5MG 3,797 55 4,112 54 8.30%
SERTRALINE   TAB 50MG 3,781 56 4,048 55 7.06%
CITALOPRAM   TAB 40MG 3,799 54 3,916 56 3.08%
Acetaminophen Tab 500 MG 3,633 58 3,864 57 6.36%
AMLODIPINE   TAB 10MG 3,479 62 3,814 58 9.63%
ZOLPIDEM     TAB 10MG 3,566 59 3,787 59 6.20%
ALPRAZOLAM   TAB 0.5MG 3,659 57 3,784 60 3.42%
AMOX/K CLAV  TAB 875MG 2,732 74 3,754 61 37.41%
AMOXICILLIN  SUS 250/5ML 2,591 80 3,690 62 42.42%
CYMBALTA     CAP 60MG 3,491 61 3,649 63 4.53%
Cetirizine HCl Oral Soln 1 MG/ML (5 
MG/5ML)
2,939 70 3,636 64 23.72%
PANTOPRAZOLE TAB 40MG 3,260 63 3,609 65 10.71%
FOLIC ACID   TAB 1MG 3,527 60 3,581 66 1.53%
METHYLPHENID TAB 54MG ER 3,152 64 3,333 67 5.74%
AMLODIPINE   TAB 5MG 3,009 69 3,323 68 10.44%
PREDNISONE   TAB 10MG 2,538 85 3,232 69 27.34%
LORAZEPAM    TAB 1MG 3,123 65 3,212 70 2.85%
HYDROXYZ PAM CAP 25MG 3,094 66 3,193 71 3.20%
METOPROL TAR TAB 25MG 3,013 68 3,181 72 5.58%
SIMVASTATIN  TAB 20MG 3,026 67 3,143 73 3.87%
BUPROPN HCL  TAB 300MG XL 2,886 71 3,087 74 6.96%
ATORVASTATIN TAB 40MG 2,731 75 3,070 75 12.41%
VYVANSE      CAP 30MG 2,652 79 2,920 76 10.11%
RISPERIDONE  TAB 1MG 2,834 72 2,913 77 2.79%
BUPROPN HCL  TAB 150MG XL 2,691 77 2,906 78 7.99%
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SPIRIVA      CAP HANDIHLR 2,483 89 2,899 79 16.75%
ONDANSETRON  TAB 4MG ODT 2,461 91 2,846 80 15.64%
VYVANSE      CAP 40MG 2,580 81 2,797 81 8.41%
SIMVASTATIN  TAB 40MG 2,730 76 2,794 82 2.34%
VENLAFAXINE  CAP 75MG ER 2,515 88 2,778 83 10.46%
LORAZEPAM    TAB 0.5MG 2,824 73 2,777 84 -1.66%
MONTELUKAST  CHW 4MG 2,543 84 2,721 85 7.00%
LEVOTHYROXIN TAB 50MCG 2,576 82 2,698 86 4.74%
FUROSEMIDE   TAB 40MG 2,654 78 2,683 87 1.09%
CEFDINIR     SUS 250/5ML 1,804 122 2,673 88 48.17%
LISINOPRIL   TAB 40MG 2,435 92 2,651 89 8.87%
METRONIDAZOL TAB 500MG 2,355 94 2,590 90 9.98%
QUETIAPINE   TAB 100MG 2,335 95 2,535 91 8.57%
FLUCONAZOLE  TAB 150MG 2,559 83 2,531 92 -1.09%
ATORVASTATIN TAB 20MG 2,290 97 2,525 93 10.26%
MUPIROCIN    OIN 2% 2,521 87 2,478 94 -1.71%
LISINOPRIL   TAB 5MG 2,330 96 2,466 95 5.84%
RISPERIDONE  TAB 0.5MG 2,465 90 2,456 96 -0.37%
Permethrin Lotion 1% 2,248 98 2,422 97 7.74%
TRIAMCINOLON CRE 0.1% 2,536 86 2,362 98 -6.86%
APAP/CODEINE TAB 300-30MG 1,987 107 2,327 99 17.11%
METOPROL TAR TAB 50MG 2,165 102 2,309 100 6.65%
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September/October 2014 November/December 2014 % CHANGE
TOTAL PAID AMOUNT $58,642,098 $61,413,451 4.7%
UNIQUE USERS 195,870 199,594 1.9%
COST PER USER $299.39 $307.69 2.8%
TOTAL PRESCRIPTIONS 969,483 955,505 -1.4%
AVERAGE PRESCRIPTIONS PER USER 4.95 4.79 -3.2%
AVERAGE COST PER PRESCRIPTION $60.49 $64.27 6.3%
# GENERIC PRESCRIPTIONS 810,416 799,280 -1.4%
% GENERIC 83.6% 83.7% 0.1%
$ GENERIC $15,888,856 $16,248,228 2.3%
AVERAGE GENERIC PRESCRIPTION COST $19.61 $20.33 3.7%
AVERAGE GENERIC DAYS SUPPLY 23 23 0.0%
# BRAND PRESCRIPTIONS 155,494 152,620 -1.4%
% BRAND 16.0% 16.0% 0.1%
$ BRAND $42,534,189 $44,942,116 2.3%
AVERAGE BRAND PRESCRIPTION COST $273.54 $294.47 3.7%
AVERAGE BRAND DAYS SUPPLY 25 25 0.0%
Bi-Monthly Statistics
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UTILIZATION BY AGE
AGE September/October 2014 November/December 2014
0-6 37,433 39,862
7-12 28,579 29,365
13-18 25,187 24,451
19-64 96,172 97,584
65+ 8,499 8,332
195,870 199,594
UTILIZATION BY GENDER AND AGE
GENDER AGE September/October 2014 November/December 2014
F
0-6 17,406 18,590
7-12 12,375 12,898
13-18 13,331 13,019
19-64 61,709 62,414
65+ 6,033 5,925
110,854 112,846
M
0-6 20,027 21,272
7-12 16,204 16,467
13-18 11,856 11,432
19-64 34,463 35,170
65+ 2,466 2,407
85,016 86,748
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RANK PHARMACY NAME PHARMACY CITY STATE PRESCRIPTION 
COUNT
PAID AMT AVG COST RX PREVIOUS RANK
1 BROADLAWNS MEDICAL CENTER DES MOINES IA 16,350 $413,507.90 $25.29 1
2 WALGREEN #05239 DAVENPORT IA 12,019 $672,945.34 $55.99 2
3 WALGREEN #04405 COUNCIL BLUFFS IA 9,492 $530,221.99 $55.86 4
4 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 9,391 $636,938.16 $67.82 3
5 WALGREEN #05721 DES MOINES IA 8,964 $524,322.43 $58.49 5
6 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,151 $345,939.83 $48.38 6
7 WALGREEN COMPANY 07455 WATERLOO IA 6,726 $338,251.81 $50.29 9
8 WALGREEN #359 DES MOINES IA 6,722 $374,273.07 $55.68 7
9 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 6,537 $359,521.57 $55.00 11
10 WALGREEN #05362 DES MOINES IA 6,533 $322,001.65 $49.29 8
11 WALGREEN COMPANY #3700 COUNCIL BLUFFS IA 6,364 $339,615.81 $53.37 10
12 MERCY FAMILY PHARMACY DUBUQUE IA 6,038 $372,290.66 $61.66 13
13 SIOUXLAND COMM HEALTH CTR 
PHARMA
SIOUX CITY IA 6,019 $106,548.93 $17.70 12
14 WALGREENS #07453 DES MOINES IA 5,797 $328,089.32 $56.60 14
15 MARTIN HEALTH SERVICES INC DENVER IA 5,667 $179,252.19 $31.63 15
16 WALGREEN #910 SIOUX CITY IA 5,652 $299,383.36 $52.97 16
17 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,449 $329,791.71 $60.52 18
18 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,154 $261,064.18 $50.65 17
19 WALGREEN #04041 DAVENPORT IA 5,128 $264,419.38 $51.56 22
20 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,092 $251,774.14 $49.45 20
21 MARTIN HEALTH SERVICES INC JOHNSTON IA 4,962 $197,179.73 $39.74 25
22 WALGREEN COMPANY 05777 DES MOINES IA 4,957 $267,733.34 $54.01 19
23 WALGREEN #05852 DES MOINES IA 4,941 $260,704.28 $52.76 21
24 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,750 $269,873.69 $56.82 23
25 RASHID PHARMACY PLC FORT MADISON IA 4,596 $258,959.93 $56.34 24
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26 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 4,550 $257,213.79 $56.53 27
27 WALGREEN #11709 DAVENPORT IA 4,513 $236,783.77 $52.47 26
28 DANIEL PHARMACY INC FORT DODGE IA 4,305 $216,027.05 $50.18 28
29 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,108 $215,311.55 $52.41 30
30 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 3,997 $207,507.30 $51.92 31
31 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,937 $221,951.56 $56.38 35
32 MAHASKA DRUG INC OSKALOOSA IA 3,879 $219,659.13 $56.63 32
33 MEDICAP PHARMACY INDIANOLA IA 3,866 $182,628.61 $47.24 40
34 WALGREEN #7452 DES MOINES IA 3,831 $205,989.26 $53.77 38
35 WALGREENS #05119 CLINTON IA 3,765 $205,634.68 $54.62 42
36 PHARMACY MATTERS LTC IOWA CITY IA 3,753 $156,002.85 $41.57 29
37 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 3,736 $266,518.45 $71.34 34
38 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,721 $218,930.05 $58.84 37
39 WALGREEN #03595 DAVENPORT IA 3,688 $209,037.98 $56.68 36
40 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,684 $212,189.12 $57.60 44
41 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,589 $191,375.56 $53.32 47
42 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,565 $205,607.71 $57.67 33
43 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,528 $182,163.28 $51.63 39
44 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,506 $243,908.88 $69.57 43
45 WALGREEN #05044 BURLINGTON IA 3,470 $177,566.23 $51.17 50
46 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,442 $145,591.91 $42.30 41
47 WAL-MART PHARMACY #10-5115 DAVENPORT IA 3,395 $130,373.07 $38.40 48
48 A AVENUE PHARMACY CEDAR RAPIDS IA 3,267 $233,918.29 $71.60 45
49 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,237 $180,202.25 $55.67 56
50 WALGREEN #05886 KEOKUK IA 3,236 $176,734.28 $54.62 60
51 WAL MART PHARMACY 10-1621 CENTERVILLE IA 3,231 $152,058.87 $47.06 53
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52 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,209 $181,766.21 $56.64 52
53 WALGREENS #10855 WATERLOO IA 3,088 $167,570.43 $54.27 49
54 STERLING LTC PHARMACY #31 ANKENY IA 3,075 $229,768.31 $74.72 46
55 WAL-MART PHARMACY 10-2889 CLINTON IA 3,069 $149,365.83 $48.67 63
56 HY VEE PHARMACY #1449 NEWTON IA 3,044 $160,007.41 $52.56 59
57 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 3,028 $150,493.85 $49.70 61
58 WAL MART PHARMACY 10-3590 SIOUX CITY IA 3,007 $158,534.25 $52.72 64
59 WAL-MART PHARMACY #10-0985 FAIRFIELD IA 2,996 $129,148.95 $43.11 58
60 THOMPSON-DEAN DRUG SIOUX CITY IA 2,994 $253,349.99 $84.62 54
61 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 2,946 $146,820.99 $49.84 55
62 HY-VEE PHARMACY (1075) CLINTON IA 2,918 $170,159.30 $58.31 72
63 WALGREENS #11942 DUBUQUE IA 2,871 $166,931.39 $58.14 51
64 HARTIG PHARMACY SERVICES DUBUQUE IA 2,864 $167,473.86 $58.48 74
65 WALGREENS 07968 DES MOINES IA 2,863 $154,290.43 $53.89 57
66 HY-VEE PHARMACY (1058) CENTERVILLE IA 2,841 $142,151.03 $50.04 62
67 WALGREEN #4714 DES MOINES IA 2,822 $142,275.51 $50.42 67
68 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,815 $169,814.11 $60.32 73
69 HY-VEE PHARMACY (1522) PERRY IA 2,815 $138,449.71 $49.18 77
70 HY-VEE PHARMACY #3 (1056) CEDAR RAPIDS IA 2,800 $137,943.21 $49.27 65
71 WAL-MART PHARMACY #10-1393 OSKALOOSA IA 2,786 $130,696.61 $46.91 71
72 HY-VEE PHARMACY (1875) WEBSTER CITY IA 2,744 $122,685.85 $44.71 66
73 WALGREEN #09708 DUBUQUE IA 2,741 $148,638.98 $54.23 78
74 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,688 $148,661.11 $55.31 68
75 S - S PHARMACY INC COUNCIL BLUFFS IA 2,672 $212,802.57 $79.64 69
76 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,656 $157,034.10 $59.12 75
77 HY-VEE DRUGSTORE (7056) MASON CITY IA 2,644 $127,591.09 $48.26 90
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78 WALGREEN #05942 NEWTON IA 2,644 $147,090.24 $55.63 87
79 HY-VEE PHARMACY (1009) DBA ALBIA IA 2,635 $125,480.22 $47.62 80
80 HY-VEE PHARMACY #2 (1044) BURLINGTON IA 2,626 $132,558.42 $50.48 70
81 HY-VEE DRUGSTORE #7031 DES MOINES IA 2,595 $141,376.61 $54.48 79
82 HY-VEE PHARMACY 1504 OTTUMWA IA 2,559 $153,319.35 $59.91 76
83 WALGREEN #05077 IOWA CITY IA 2,546 $133,747.46 $52.53 86
84 WAL-MART PHARMACY #10-0646 ANAMOSA IA 2,525 $104,416.31 $41.35 85
85 WAL-MART PHARMACY #10-3394 ATLANTIC IA 2,518 $131,953.31 $52.40 101
86 HY-VEE PHARMACY (1065) CHARITON IA 2,508 $151,944.27 $60.58 94
87 WAL-MART PHARMACY 10-0784 MT PLEASANT IA 2,498 $147,633.24 $59.10 92
88 LA GRANGE PHARMACY INC VINTON IA 2,467 $134,332.40 $54.45 82
89 WAGNER PHARMACY CLINTON IA 2,450 $152,097.19 $62.08 91
90 HY-VEE FOOD STORE WATERLOO IA 2,438 $180,433.02 $74.01 88
91 HY-VEE DRUGSTORE # 7035 FT DODGE IA 2,423 $124,922.52 $51.56 83
92 HY-VEE PHARMACY (1353) KNOXVILLE IA 2,392 $110,230.52 $46.08 96
93 NUCARA PHARMACY #27 PLEASANT HILL IA 2,391 $1,239,034.10 $518.21 106
94 SCOTT PHARMACY FAYETTE IA 2,389 $120,313.54 $50.36 89
95 WALGREEN #05361 FORT DODGE IA 2,380 $122,837.28 $51.61 81
96 HY-VEE PHARMACY 1071 CLARINDA IA 2,378 $137,503.10 $57.82 103
97 WALGREENS #03876 MARION IA 2,337 $121,977.63 $52.19 102
98 WAL-MART PHARMACY 10-1723 DES MOINES IA 2,319 $86,336.96 $37.23 118
99 MEDICAP PHARMACY MARSHALLTOWN IA 2,316 $136,551.75 $58.96 100
100 WAL-MART PHARMACY #10-1285 OTTUMWA IA 2,309 $115,650.68 $50.09 97
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1 ARJ INFUSION SERVICES INC LENEXA KS 24 $1,319,192.90 $329,798.23 2
2 NUCARA PHARMACY #27 PLEASANT HILL IA 2,391 $1,239,034.10 $2,699.42 1
3 ACCREDO HEALTH GROUP INC MEMPHIS TN 79 $724,341.97 $17,666.88 7
4 WALGREEN #05239 DAVENPORT IA 12,019 $672,945.34 $190.64 3
5 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 9,391 $636,938.16 $294.06 6
6 CAREMARK KANSAS SPEC PHARMACY 
LL
LENEXA KS 159 $581,051.69 $6,678.76 4
7 WALGREEN #04405 COUNCIL BLUFFS IA 9,492 $530,221.99 $204.48 8
8 WALGREEN #05721 DES MOINES IA 8,964 $524,322.43 $185.54 9
9 ACCREDO HEALTH GROUP INC NASHVILLE TN 13 $484,256.54 $80,709.42 10
10 UNITYPOINT AT HOME URBANDALE IA 460 $448,443.85 $4,114.16 386
11 BROADLAWNS MEDICAL CENTER DES MOINES IA 16,350 $413,507.90 $178.31 5
12 WALGREEN #359 DES MOINES IA 6,722 $374,273.07 $176.54 12
13 MERCY FAMILY PHARMACY DUBUQUE IA 6,038 $372,290.66 $359.70 11
14 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 6,537 $359,521.57 $183.52 18
15 AMBER PHARMACY OMAHA NE 138 $351,071.08 $9,751.97 27
16 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,151 $345,939.83 $203.73 14
17 WALGREEN COMPANY #3700 COUNCIL BLUFFS IA 6,364 $339,615.81 $178.75 15
18 WALGREEN COMPANY 07455 WATERLOO IA 6,726 $338,251.81 $150.94 17
19 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,449 $329,791.71 $424.99 21
20 WALGREENS #07453 DES MOINES IA 5,797 $328,089.32 $196.81 16
21 HY-VEE PHARMACY SOLUTIONS OMAHA NE 162 $327,538.87 $3,946.25 41
22 WALGREEN #05362 DES MOINES IA 6,533 $322,001.65 $146.76 19
23 UNIV OF IOWA COMMUNITY HOMECARE IOWA CITY IA 303 $317,347.83 $4,017.06 709
24 WALGREEN #910 SIOUX CITY IA 5,652 $299,383.36 $152.90 22
25 DIPLOMAT SPECIALTY PHARMACY FLINT MI 76 $287,716.53 $9,281.18 47
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26 WALGREENS SPECIALTY PHARMACY 
#12
ANN ARBOR MI 55 $274,252.57 $8,570.39 40
27 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,750 $269,873.69 $217.29 37
28 WALGREEN COMPANY 05777 DES MOINES IA 4,957 $267,733.34 $205.79 32
29 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 3,736 $266,518.45 $487.24 25
30 WALGREEN #04041 DAVENPORT IA 5,128 $264,419.38 $158.24 38
31 PROCARE PHARMACY DIRECT LLC MONROEVILLE PA 55 $262,300.33 $7,286.12 61
32 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,154 $261,064.18 $208.85 29
33 WALGREEN #05852 DES MOINES IA 4,941 $260,704.28 $165.53 31
34 RASHID PHARMACY PLC FORT MADISON IA 4,596 $258,959.93 $280.26 30
35 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 4,550 $257,213.79 $244.04 33
36 THOMPSON-DEAN DRUG SIOUX CITY IA 2,994 $253,349.99 $423.66 28
37 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,092 $251,774.14 $194.87 34
38 MEDFUSIONRX LLC FRANKLIN TN 52 $248,915.20 $7,542.88 24
39 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,506 $243,908.88 $239.83 35
40 DOHMEN LIFE SCIENCE SERVICES LLC CHESTERFIELD MO 22 $236,971.56 $23,697.16 46
41 WALGREEN #11709 DAVENPORT IA 4,513 $236,783.77 $194.40 26
42 A AVENUE PHARMACY CEDAR RAPIDS IA 3,267 $233,918.29 $601.33 23
43 STERLING LTC PHARMACY #31 ANKENY IA 3,075 $229,768.31 $698.38 42
44 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,937 $221,951.56 $265.49 50
45 MAHASKA DRUG INC OSKALOOSA IA 3,879 $219,659.13 $255.42 39
46 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,721 $218,930.05 $322.91 44
47 DANIEL PHARMACY INC FORT DODGE IA 4,305 $216,027.05 $261.85 43
48 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,108 $215,311.55 $233.53 52
49 S - S PHARMACY INC COUNCIL BLUFFS IA 2,672 $212,802.57 $589.48 57
50 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,684 $212,189.12 $248.47 51
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51 WALGREEN #03595 DAVENPORT IA 3,688 $209,037.98 $169.40 45
52 ACARIAHEALTH PHARMACY #11 INC HOUSTON TX 41 $208,430.78 $10,421.54 84
53 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 3,997 $207,507.30 $263.33 55
54 ACCREDO HEALTH GROUP INC WARRENDALE PA 37 $206,262.71 $15,866.36 53
55 WALGREEN #7452 DES MOINES IA 3,831 $205,989.26 $159.07 54
56 WALGREENS #05119 CLINTON IA 3,765 $205,634.68 $212.87 67
57 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,565 $205,607.71 $338.73 48
58 MARTIN HEALTH SERVICES INC JOHNSTON IA 4,962 $197,179.73 $221.05 49
59 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,589 $191,375.56 $257.57 65
60 MEDICAP PHARMACY INDIANOLA IA 3,866 $182,628.61 $394.45 71
61 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,528 $182,163.28 $202.18 68
62 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,209 $181,766.21 $248.31 58
63 HY-VEE FOOD STORE WATERLOO IA 2,438 $180,433.02 $325.69 64
64 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,237 $180,202.25 $296.39 63
65 MARTIN HEALTH SERVICES INC DENVER IA 5,667 $179,252.19 $174.20 59
66 MERCY HOME INFUSION URBANDALE IA 146 $178,075.85 $4,686.21 489
67 WALGREEN #05044 BURLINGTON IA 3,470 $177,566.23 $167.52 72
68 CYSTIC FIBROSIS SERVICES INC CENTENNIAL CO 60 $177,203.60 $8,860.18 36
69 WALGREEN #05886 KEOKUK IA 3,236 $176,734.28 $223.43 81
70 EXPRESS SCRIPTS SPECIALTY ST LOUIS MO 24 $176,039.19 $10,355.25 56
71 WALGREENS INFUSION SERVICES OMAHA NE 42 $175,712.89 $11,714.19 152
72 HY-VEE PHARMACY (1075) CLINTON IA 2,918 $170,159.30 $292.37 73
73 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,815 $169,814.11 $261.25 78
74 WALGREENS #10855 WATERLOO IA 3,088 $167,570.43 $176.20 70
75 HARTIG PHARMACY SERVICES DUBUQUE IA 2,864 $167,473.86 $675.30 75
76 WALGREENS #11942 DUBUQUE IA 2,871 $166,931.39 $197.09 62
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77 L & M PHARMACY CARE LE MARS IA 1,557 $162,320.79 $1,411.49 91
78 COMMUNITY HEALTHCARE SERVICES LOMA LINDA CA 5 $160,186.92 $80,093.46 20
79 HY VEE PHARMACY #1449 NEWTON IA 3,044 $160,007.41 $222.54 76
80 WAL MART PHARMACY 10-3590 SIOUX CITY IA 3,007 $158,534.25 $177.73 88
81 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,656 $157,034.10 $277.94 89
82 PHARMACY MATTERS LTC IOWA CITY IA 3,753 $156,002.85 $500.01 69
83 WALGREENS 07968 DES MOINES IA 2,863 $154,290.43 $152.76 66
84 HY-VEE PHARMACY 1504 OTTUMWA IA 2,559 $153,319.35 $278.76 79
85 WAGNER PHARMACY CLINTON IA 2,450 $152,097.19 $353.71 74
86 WAL MART PHARMACY 10-1621 CENTERVILLE IA 3,231 $152,058.87 $234.30 95
87 HY-VEE PHARMACY (1065) CHARITON IA 2,508 $151,944.27 $258.41 94
88 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 3,028 $150,493.85 $243.12 77
89 WAL-MART PHARMACY 10-2889 CLINTON IA 3,069 $149,365.83 $191.74 103
90 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,688 $148,661.11 $212.68 80
91 WALGREEN #09708 DUBUQUE IA 2,741 $148,638.98 $144.59 83
92 GREENVILLE PHARMACY INC SIOUX CITY IA 2,091 $147,741.29 $395.03 98
93 WAL-MART PHARMACY 10-0784 MT PLEASANT IA 2,498 $147,633.24 $237.73 93
94 WALGREEN #05942 NEWTON IA 2,644 $147,090.24 $214.11 111
95 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 2,946 $146,820.99 $233.05 90
96 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,442 $145,591.91 $153.09 99
97 WALGREEN #4714 DES MOINES IA 2,822 $142,275.51 $166.79 100
98 HY-VEE PHARMACY (1058) CENTERVILLE IA 2,841 $142,151.03 $256.59 85
99 HY-VEE PHARMACY #4 (1148) DES MOINES IA 2,288 $141,831.62 $260.24 86
100 MERCY HEALTH SERVICES IOWA CORP MASON CITY IA 2,247 $141,442.63 $277.34 87
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1 1780766659 CHESTER ROBERT BADGER $177,999.37 3,357 5.40 1
2 1841407160 RAHUL BANSAL MD $219,957.32 2,436 4.86 4
3 1982605762 JEFFREY D WILHARM $149,289.02 2,312 5.82 6
4 1467682351 NICOLE GILG $71,181.55 2,076 5.20 3
5 1538368170 CHRISTOPHER ROBERT MATSON $76,473.41 2,045 5.53 2
6 1083784797 CAROL AUNAN ARNP $163,782.88 2,021 3.46 8
7 1649248378 KATHLEEN L WILD ARNP $181,160.56 1,994 3.82 10
8 1215192224 SHALINA SHAIK $48,686.95 1,987 5.91 7
9 1063622637 HUSSAIN BANU $56,233.58 1,970 5.92 5
10 1013115369 BOBBITA NAG MD $216,685.85 1,896 3.93 15
11 1205015906 DAVID F WIDITZ $149,520.25 1,891 5.36 12
12 1245318393 JEAN TOBIN PA $131,930.01 1,843 4.53 9
13 1043211303 ALI  SAFDAR $121,008.56 1,787 3.81 16
14 1619153137 JODI BEST ARNP $184,118.24 1,738 5.27 17
15 1316922545 MABRA G ABERNATHY $50,991.55 1,613 4.99 14
16 1073667606 ELIZABETH MCCURDY DO $55,689.62 1,612 5.01 11
17 1073509436 MICHAEL KARL MAHARRY MD $73,120.65 1,591 5.76 19
18 1841220290 KENT ELDON KUNZE MD $133,168.17 1,539 4.90 36
19 1245388743 TIMOTHY SWINTON MD $62,934.60 1,490 5.98 24
20 1467502286 CHARLES TILLEY PA $163,849.28 1,488 4.33 20
21 1801998372 WENDY MICHELE HANSEN-PENMAN DO $40,056.90 1,477 6.18 18
22 1023053972 BRYANT MUTCHLER DO $64,282.91 1,440 5.07 21
23 1962558957 ALBERT N OKINE PA $152,275.04 1,440 6.55 26
24 1477633188 CYD Q. GRAFFT $107,970.65 1,389 4.16 25
25 1912991340 GHADA HAMDAN-ALLEN MD $132,461.59 1,382 4.73 50
26 1073594768 JERROLD V FLATT DO $55,595.44 1,352 4.90 23
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27 1023377827 LISA KAY CHASE $57,825.21 1,337 4.99 40
28 1275844649 KATIE M HANSON ARNP $100,947.68 1,329 3.97 46
29 1720293087 RAJNI BATRA MD $63,550.14 1,326 3.51 31
30 1073945499 JENNIFER LEE ZALAZNIK ARNP $63,266.60 1,312 3.70 35
31 1508289620 GLORIA A MILLER $128,541.28 1,297 6.03 53
32 1467437806 GEORGIA LAUER PAC $72,245.19 1,280 5.82 32
33 1003004391 DAVID BERMAN WALKER MD $108,625.00 1,272 3.47 61
34 1598962870 CHRISTY QUILLEN ARNP $40,710.36 1,269 5.10 43
35 1043434525 ROBERT MARVIN KENT MD $59,426.71 1,266 4.34 30
36 1497736326 RANDY R ROBINSON $55,899.60 1,260 5.55 44
37 1952459463 DAVID LAWRENCE YURDIN PA $601,546.71 1,256 4.35 56
38 1144214248 KRISTIE DEE ANN WALZ MD $74,009.04 1,239 4.59 49
39 1255322996 MARK WILLIAM MITTAUER MD $114,371.40 1,231 5.47 41
40 1508946088 E RICHARD NIGHTINGALE MD $98,690.35 1,207 5.59 62
41 1225097843 WILLIAM M NISSEN $66,881.89 1,188 4.29 39
42 1902809536 KIRAN BHASKAR KHANOLKAR MD $60,058.38 1,169 5.00 38
43 1730143397 MARK JOSEPH DEARDEN DO $36,763.52 1,158 5.76 81
44 1346210184 JAMES BROOKS MD $122,580.18 1,158 4.91 64
45 1184945321 DEANNE REMER $73,568.27 1,154 6.17 45
46 1013960566 PETER JOSEPH SZEIBEL $100,054.11 1,145 4.98 52
47 1306133095 DEBRA LEE ANDERSON ARNP $44,147.89 1,133 3.84 59
48 1558348284 STEVEN G PAULSRUD $58,214.75 1,127 4.47 60
49 1205169273 TERESA ANN DOWLING $32,269.62 1,124 5.04 55
50 1073500690 KATHLEEN S ADAMS $139,169.93 1,121 3.63 47
51 1033198908 DANIEL J ARNOLD $52,973.38 1,120 4.00 51
52 1164538674 JOSEPH M WANZEK $54,751.99 1,119 4.80 37
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53 1528144383 RAMONCITO AMURAO O'CAMPO $51,004.29 1,113 4.17 34
54 1861559486 JOSPEH PATRICK BERTROCHE $122,737.78 1,113 4.38 65
55 1134191018 DUSTIN RALPH SMITH MD $68,137.20 1,104 4.68 66
56 1215146055 REBECCA J WOLFE $88,455.01 1,103 4.12 54
57 1598750432 CHRISTOPHER GENE OKIISHI MD $83,216.17 1,103 7.99 104
58 1841293354 KEITH GUESS PA C $96,626.55 1,100 4.31 58
59 1982766705 MALHAR GORE $34,626.10 1,088 4.12 28
60 1922144088 THOMAS S HOPKINS DO $101,665.32 1,083 3.80 73
61 1730239732 SRIRAMAMURTHY RAVIPATI MD $76,844.41 1,070 3.20 33
62 1609218304 AMANDA O'TOOL ARNP $90,305.05 1,064 5.51 102
63 1205821337 MANMOHAN SINGH $52,288.44 1,050 4.27 48
64 1063491645 ALLYSON L WHEATON MD $96,540.39 1,039 4.17 78
65 1871595207 DALE M GRUNEWALD $43,169.45 1,038 6.97 86
66 1588629414 THOMAS EARWOOD MD $64,721.24 1,032 5.32 72
67 1972758126 REBECCA BOLLIN $29,296.03 1,027 4.56 13
68 1669570404 CASIE RINEY PA $108,147.43 1,020 4.15 100
69 1538157383 DAVID WENGER-KELLER MD $43,293.54 1,014 4.88 70
70 1902115652 SARAH LYNN BEATTIE ARNP $111,076.21 1,009 3.57 71
71 1124399522 JOYCE E PROUCH ARNP $82,097.79 998 4.44 94
72 1871586271 PATRICIA BLACKLEDGE ARNP $43,064.76 997 5.48 63
73 1902912538 CHRISTIAN W JONES MD $40,049.10 995 3.44 83
74 1598733891 JERRY LEE WILLE MD $38,719.60 990 4.32 106
75 1356760011 CHARISSA S ELLIOTT ARNP $51,830.55 975 5.30 152
76 1306812490 MERRILEE RAMSEY ARNP $47,733.01 973 4.19 74
77 1437373073 MOHSEN ABOU SEIF $36,304.50 970 4.53 67
78 1780877878 CHRISTOPHER JACOBS ARNP $37,096.89 970 3.44 87
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79 1912991183 MOLLY EARLEYWINE PA $24,558.80 966 3.76 80
80 1164530358 DAVID M CRAVEN $52,557.31 966 2.48 91
81 1215080759 JUANITA M O'BRIEN $39,956.35 962 5.53 69
82 1629042288 MARTIN J FIALKOV MD $76,711.99 952 4.93 79
83 1326045808 RAY C STURDEVANT MD $89,020.71 950 2.97 77
84 1619186475 STEPHEN PALLONE MD $32,461.39 947 4.81 76
85 1306954391 WILLIAM E HOWARD IV $76,013.70 946 2.89 105
86 1710941000 LAURIE WARREN PA $97,117.32 943 3.88 75
87 1104976109 ISAM ELIAS MARAR MD $59,211.58 939 5.13 120
88 1386977387 MARYANN KAPACINSKAS $51,725.22 928 4.24 85
89 1669623583 ANNE MIREILLE METUGE AHONE $46,093.36 924 4.30 173
90 1356520431 KAY A MARTTILA $92,112.67 923 3.28 57
91 1073550836 SONJA LUCILLE GREINER ARNP $47,502.69 923 4.44 159
92 1437238110 GENEVIEVE  NELSON $58,429.40 916 3.65 90
93 1396731287 VICKI L BOLING ARNP $48,854.59 913 4.19 143
94 1295830115 ALAN BOLLINGER DO $97,745.50 911 4.67 42
95 1487908380 LISA ANN BECHTEL ARNP $90,697.02 902 3.79 140
96 1285697722 DOUGLAS  JONES $78,127.49 900 3.57 89
97 1205808664 DAVID M CRIPPIN MD $40,222.38 899 3.15 112
98 1891705968 ANITA HANDEVIDT ARNP $80,780.68 895 3.23 92
99 1407953979 CECELIA M NASSIF ARNP $69,451.68 892 4.57 95
100 1225168511 FREDERICK C. ALDRICH $39,431.45 885 2.15 98
Page 14 Of 291/12/2015 8:08:23 AM RT33018
trusted, reliable, innovative
TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
November/December 2014
RANK DOCTOR NUM PRESCRIBER NAME PAID AMOUNT AVG COST RX PRESCRIPTION COUNT PREVIOUS RANK
1 1013126705 JANICE M. R. STABER $2,047,304.22 $29,247.20 70 1
2 1952459463 DAVID LAWRENCE YURDIN PA $601,546.71 $478.94 1,256 2
3 1841407160 RAHUL BANSAL MD $219,957.32 $90.29 2,436 5
4 1013115369 BOBBITA NAG MD $216,685.85 $114.29 1,896 6
5 1619153137 JODI BEST ARNP $184,118.24 $105.94 1,738 13
6 1609055771 CHARUTA NARAYAN JOSHI $183,599.55 $377.78 486 52
7 1649248378 KATHLEEN L WILD ARNP $181,160.56 $90.85 1,994 11
8 1285748004 BRUCE L HAYES MD $178,981.01 $1,296.96 138 7
9 1780766659 CHESTER ROBERT BADGER $177,999.37 $53.02 3,357 8
10 1548256191 JUDITH A MILLER $165,651.59 $5,176.61 32 15
11 1467502286 CHARLES TILLEY PA $163,849.28 $110.11 1,488 9
12 1083784797 CAROL AUNAN ARNP $163,782.88 $81.04 2,021 10
13 1083603773 JACK T STAPLETON $160,928.86 $648.91 248 14
14 1548247406 VILMARIE RODRIGUEZ-PADUA MD $160,229.22 $20,028.65 8 3
15 1194703074 WENDY ANNE WALDMAN $159,596.04 $249.76 639 21
16 1962558957 ALBERT N OKINE PA $152,275.04 $105.75 1,440 17
17 1083609358 JENNIFER S COOK $150,315.57 $228.10 659 22
18 1205015906 DAVID F WIDITZ $149,520.25 $79.07 1,891 20
19 1043418809 MICHAEL ANTHONY CILIBERTO MD $149,426.77 $739.74 202 65
20 1982605762 JEFFREY D WILHARM $149,289.02 $64.57 2,312 23
21 1356337273 LISA J MENZIES $147,569.42 $250.97 588 4
22 1790708451 MICHAEL M MCCUBBIN $146,435.75 $439.75 333 16
23 1770561946 DONALD HILLEBRAND MD $144,072.24 $1,242.00 116 25
24 1073500690 KATHLEEN S ADAMS $139,169.93 $124.15 1,121 18
25 1376777524 ALLADDIN MOH ELHADI ABOSAIDA $136,422.94 $324.04 421 12
26 1841220290 KENT ELDON KUNZE MD $133,168.17 $86.53 1,539 36
27 1497060776 USHA PEREPU MBBS $133,046.95 $3,326.17 40 19
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RANK DOCTOR NUM PRESCRIBER NAME PAID AMOUNT AVG COST RX PRESCRIPTION COUNT PREVIOUS RANK
28 1912991340 GHADA HAMDAN-ALLEN MD $132,461.59 $95.85 1,382 39
29 1245318393 JEAN TOBIN PA $131,930.01 $71.58 1,843 28
30 1508289620 GLORIA A MILLER $128,541.28 $99.11 1,297 56
31 1194880328 $127,457.74 $18,208.25 7 7140
32 1861559486 JOSPEH PATRICK BERTROCHE $122,737.78 $110.28 1,113 30
33 1346210184 JAMES BROOKS MD $122,580.18 $105.86 1,158 40
34 1649255431 STEPHANIE DEE PA $122,305.83 $1,747.23 70 293
35 1699767525 EZZATOLLAH SHIVAPOUR, M.D. $121,803.43 $1,933.39 63 161
36 1043211303 ALI  SAFDAR $121,008.56 $67.72 1,787 34
37 1972638864 LIUSKA MARIA PESCE $115,442.38 $471.19 245 35
38 1255322996 MARK WILLIAM MITTAUER MD $114,371.40 $92.91 1,231 32
39 1174584072 BRADLEY SCOTT LAIR MD $112,726.62 $880.68 128 27
40 1902115652 SARAH LYNN BEATTIE ARNP $111,076.21 $110.09 1,009 38
41 1003004391 DAVID BERMAN WALKER MD $108,625.00 $85.40 1,272 72
42 1669570404 CASIE RINEY PA $108,147.43 $106.03 1,020 51
43 1477633188 CYD Q. GRAFFT $107,970.65 $77.73 1,389 33
44 1922144088 THOMAS S HOPKINS DO $101,665.32 $93.87 1,083 54
45 1275844649 KATIE M HANSON ARNP $100,947.68 $75.96 1,329 53
46 1013960566 PETER JOSEPH SZEIBEL $100,054.11 $87.38 1,145 42
47 1508946088 E RICHARD NIGHTINGALE MD $98,690.35 $81.76 1,207 47
48 1295830115 ALAN BOLLINGER DO $97,745.50 $107.29 911 26
49 1710941000 LAURIE WARREN PA $97,117.32 $102.99 943 44
50 1841293354 KEITH GUESS PA C $96,626.55 $87.84 1,100 50
51 1063491645 ALLYSON L WHEATON MD $96,540.39 $92.92 1,039 61
52 1245436765 RENE M DUREGGER MD $96,417.55 $132.08 730 93
53 1215025309 DEBORAH LYNNE GARRELTS $95,624.36 $126.32 757 58
54 1356520431 KAY A MARTTILA $92,112.67 $99.80 923 31
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55 1487908380 LISA ANN BECHTEL ARNP $90,697.02 $100.55 902 78
56 1609218304 AMANDA O'TOOL ARNP $90,305.05 $84.87 1,064 90
57 1841285772 KATHRYN CAROLE BREITBACH $90,039.51 $1,343.87 67 10134
58 1285626390 KATHLEEN  GRADOVILLE $89,962.93 $310.22 290 88
59 1326045808 RAY C STURDEVANT MD $89,020.71 $93.71 950 59
60 1215146055 REBECCA J WOLFE $88,455.01 $80.19 1,103 64
61 1215964796 DONNER DEWDNEY MD $87,962.57 $120.99 727 122
62 1134171937 KATHRYN LEE FLANDERS ARNP $87,921.03 $656.13 134 89
63 1104034552 DEANNA BOOK BOESEN $87,703.46 $99.44 882 73
64 1528247368 MISHELLE L PAULLUS $86,831.38 $1,240.45 70 71
65 1619963949 EVA TSALIKIAN $85,750.96 $669.93 128 46
66 1104029008 KATIE MARIE ULRING LARSON ODE MD $85,733.30 $351.37 244 74
67 1356564371 CARLA K ABEL ZIEG ARNP $85,180.05 $119.30 714 60
68 1750376034 DUANGCHAI NARAWONG MD $84,816.93 $143.27 592 79
69 1780793976 MATTHEW D EGGERS MD $84,678.63 $111.27 761 81
70 1215125216 REBECCA WALDING $84,478.20 $114.01 741 91
71 1841443025 LISA K WATKINS $84,332.19 $141.26 597 84
72 1598750432 CHRISTOPHER GENE OKIISHI MD $83,216.17 $75.45 1,103 126
73 1104089390 EJIRO AGBORO-IDAHOSA MD $82,204.39 $97.51 843 57
74 1124399522 JOYCE E PROUCH ARNP $82,097.79 $82.26 998 77
75 1083671309 JOHN LOUIS COLOMBO MD $81,051.02 $988.43 82 66
76 1891705968 ANITA HANDEVIDT ARNP $80,780.68 $90.26 895 55
77 1053361972 MATTHEW LARRY HILL DO $80,286.68 $944.55 85 82
78 1447242359 DANIEL M SLEITER ARNP $79,549.19 $526.82 151 148
79 1366435125 DANIEL EDWARD WESEMANN ARNP $78,960.85 $101.49 778 68
80 1285697722 DOUGLAS  JONES $78,127.49 $86.81 900 75
81 1285681528 MARVIN F PIBURN JR MD $77,787.41 $88.50 879 96
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82 1235124942 JULIE KATHRYN OSTERHAUS $77,564.78 $316.59 245 48
83 1629064324 KATHY RUPPENKAMP $77,487.83 $1,210.75 64 6801
84 1083681944 MARY CHRISTINE SEGRETO DO $77,348.54 $127.85 605 45
85 1164569737 PAULA STULTZ $77,153.00 $408.22 189 43
86 1760470678 JEFFERY L MEIER $76,995.34 $647.02 119 99
87 1730239732 SRIRAMAMURTHY RAVIPATI MD $76,844.41 $71.82 1,070 41
88 1619195534 AMANDEEP KAUR MD $76,774.45 $872.44 88 172
89 1629042288 MARTIN J FIALKOV MD $76,711.99 $80.58 952 70
90 1538368170 CHRISTOPHER ROBERT MATSON $76,473.41 $37.40 2,045 67
91 1306954391 WILLIAM E HOWARD IV $76,013.70 $80.35 946 169
92 1033361563 ERMEI YAO PA $75,775.40 $369.64 205 123
93 1679669832 ERIN VOYLES HATCHER ARNP $74,383.49 $102.03 729 63
94 1144214248 KRISTIE DEE ANN WALZ MD $74,009.04 $59.73 1,239 103
95 1184602013 RODNEY A SHORT MD $73,896.32 $401.61 184 176
96 1184945321 DEANNE REMER $73,568.27 $63.75 1,154 97
97 1578548376 DANIEL ALBERTO VAENA MD $73,538.17 $2,101.09 35 223
98 1073509436 MICHAEL KARL MAHARRY MD $73,120.65 $45.96 1,591 100
99 1639423544 PAMELA S BROWN ARNP $73,103.23 $95.56 765 107
100 1134402373 JULIE A SCHUCK ARNP $72,504.95 $703.93 103 113
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TOP 20 THERAPEUTIC CLASS BY PAID AMOUNT
CATEGORY DESCRIPTION September/October 2014 RANK % BUDGET November/December 2014 RANK % BUDGET % CHANGE
ANTIPSYCHOTICS - ATYPICALS $5,163,479 1 8.8% $5,223,302 1 8.5% 1.2%
STIMULANTS - AMPHETAMINES - LONG ACTING $3,175,240 2 5.4% $3,204,453 2 5.2% 0.9%
ANTICONVULSANTS $3,137,133 3 5.3% $3,158,909 3 5.1% 0.7%
DIABETIC - INSULIN $2,520,968 5 4.3% $2,735,939 4 4.5% 8.5%
ANTIDEPRESSANTS - SELECTED SSRI's $2,528,648 4 4.3% $2,604,442 5 4.2% 3.0%
STIMULANTS - METHYLPHENIDATE - LONG ACTING $2,258,816 6 3.9% $2,404,535 6 3.9% 6.5%
ANTIHEMOPHILIC AGENTS $2,059,123 7 3.5% $2,280,085 7 3.7% 10.7%
ANTIASTHMATIC - ADRENERGIC COMBOS $1,857,471 8 3.2% $1,847,327 8 3.0% -0.5%
STIMULANTS - METHYLPHENIDATE $1,541,460 9 2.6% $1,587,535 9 2.6% 3.0%
BIOLOGIC IMMUNOMODULATORS $1,316,787 11 2.2% $1,366,737 10 2.2% 3.8%
ANTIASTHMATIC - BETA - ADRENERGICS $1,483,245 10 2.5% $1,337,465 11 2.2% -9.8%
DIABETIC - INSULIN  PENFILLS $1,128,742 14 1.9% $1,270,871 12 2.1% 12.6%
MULTIPLE SCLEROSIS AGENTS $1,181,152 13 2.0% $1,268,070 13 2.1% 7.4%
STIMULANTS - OTHER STIMULANTS / LIKE STIMULANTS $1,185,570 12 2.0% $1,255,061 14 2.0% 5.9%
ANTIRETROVIRALS $1,105,116 15 1.9% $1,177,651 15 1.9% 6.6%
ANTIASTHMATIC - STEROID INHALANTS $1,102,984 16 1.9% $1,049,722 16 1.7% -4.8%
RSV PROPHYLAXIS $8,374 211 0.0% $1,016,861 17 1.7% 12,042.9%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS $877,909 17 1.5% $890,003 18 1.4% 1.4%
INFLUENZA AGENTS $108,130 88 0.2% $877,110 19 1.4% 711.2%
ANTIASTHMATIC - ANTI-CHOLINERGICS $848,927 20 1.4% $845,674 20 1.4% -0.4%
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CATEGORY DESCRIPTION September/October 2014 PREV RANK November/December 2014 CURR RANK PERC CHANGE
ANTIDEPRESSANTS - SELECTED SSRI's 87,931 1 88,712 1 0.9%
ANTICONVULSANTS 46,531 2 46,787 2 0.6%
NARCOTICS - MISC. 40,591 3 36,937 3 -9.0%
BETA-LACTAMS / CLAVULANATE COMBO'S 30,471 6 32,439 4 6.5%
ANTIPSYCHOTICS - ATYPICALS 30,518 5 30,796 5 0.9%
ANTIASTHMATIC - BETA - ADRENERGICS 33,612 4 29,936 6 -10.9%
ANALGESICS - MISC. 25,789 8 25,536 7 -1.0%
ANTIHISTAMINES - NON-SEDATING 27,547 7 23,583 8 -14.4%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS 22,664 9 23,036 9 1.6%
GI - PROTON PUMP INHIBITOR 22,174 10 22,894 10 3.2%
MACROLIDES / ERYTHROMYCIN'S / KETOLIDES 19,668 12 20,688 11 5.2%
ANXIOLYTICS - BENZODIAZEPINES 20,060 11 19,764 12 -1.5%
ACE INHIBITORS 18,761 15 18,870 13 0.6%
NSAIDS 19,476 13 18,507 14 -5.0%
ANTIHYPERTENSIVES - CENTRAL 18,063 16 18,450 15 2.1%
DIURETICS 16,708 17 16,789 16 0.5%
GLUCOCORTICOIDS - MINERALOCORTICOIDS 19,169 14 16,508 17 -13.9%
STIMULANTS - AMPHETAMINES - LONG ACTING 16,110 18 16,290 18 1.1%
MUSCLE RELAXANTS 15,272 19 14,880 19 -2.6%
CEPHALOSPORINS 14,405 20 14,659 20 1.8%
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RANK
November/December 2014 RANK PERCENT CHANGE
ABILIFY $2,481,715.97 1 $2,582,834.62 1 4.07%
VYVANSE $2,440,802.71 2 $2,479,625.95 2 1.59%
METHYLPHENIDATE HCL ER $1,890,688.07 3 $2,006,207.60 3 6.11%
ADVATE $1,084,931.63 7 $1,455,851.80 4 34.19%
LANTUS $1,300,442.39 4 $1,407,126.36 5 8.20%
FOCALIN XR $1,197,492.68 5 $1,248,816.61 6 4.29%
CYMBALTA $1,181,112.92 6 $1,201,689.52 7 1.74%
SYNAGIS $8,374.10 606 $1,016,861.46 8 12,042.93%
STRATTERA $813,902.90 10 $892,047.59 9 9.60%
TAMIFLU $12,271.42 516 $842,575.08 10 6,766.16%
ADVAIR DISKUS $831,050.06 9 $825,000.71 11 -0.73%
VENTOLIN HFA $899,373.10 8 $818,269.89 12 -9.02%
SPIRIVA HANDIHALER $785,934.23 11 $784,956.99 13 -0.12%
DEPAKOTE ER $633,738.80 15 $644,606.61 14 1.71%
LATUDA $639,862.99 13 $637,387.33 15 -0.39%
ADDERALL XR $635,677.27 14 $634,055.94 16 -0.26%
NOVOLOG $528,159.29 17 $577,890.08 17 9.42%
INVEGA SUSTENNA $541,863.29 16 $522,803.53 18 -3.52%
NOVOSEVEN RT $440,995.35 24 $507,202.49 19 15.01%
ATRIPLA $453,712.77 22 $502,316.09 20 10.71%
HUMALOG $455,775.53 21 $498,702.23 21 9.42%
SYMBICORT $494,955.73 18 $490,759.36 22 -0.85%
HUMIRA PEN $437,102.60 25 $484,458.02 23 10.83%
CRESTOR $480,396.17 19 $473,308.32 24 -1.48%
LOVENOX $448,699.40 23 $470,373.01 25 4.83%
AZITHROMYCIN $387,616.17 26 $440,783.41 26 13.72%
HYDROCODONE/ACETAMINOPHEN $470,091.74 20 $428,129.74 27 -8.93%
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LEVEMIR $331,467.32 32 $382,063.89 28 15.26%
H.P. ACTHAR $158,153.46 72 $380,862.11 29 140.82%
LANTUS SOLOSTAR $312,016.40 37 $360,506.04 30 15.54%
TECFIDERA $314,418.25 36 $352,586.64 31 12.14%
DEXILANT $337,056.86 31 $349,927.83 32 3.82%
QVAR $345,667.93 28 $337,981.68 33 -2.22%
COPAXONE $302,819.94 39 $333,240.17 34 10.05%
PULMICORT $337,606.13 30 $326,484.29 35 -3.29%
TRICOR $326,261.94 33 $318,177.34 36 -2.48%
CEFDINIR $273,655.02 43 $317,391.18 37 15.98%
PROVENTIL HFA $359,173.91 27 $315,389.79 38 -12.19%
NOVOLOG FLEXPEN $278,858.34 42 $311,221.38 39 11.61%
SOVALDI $341,625.99 29 $311,154.23 40 -8.92%
TRUVADA $298,606.35 40 $310,248.66 41 3.90%
ADDERALL $734,710.76 12 $300,932.14 42 -59.04%
LYRICA $288,919.76 41 $293,908.78 43 1.73%
RISPERDAL CONSTA $303,355.61 38 $287,586.45 44 -5.20%
AMOXICILLIN $235,861.64 47 $274,175.22 45 16.24%
GENOTROPIN $320,853.36 34 $273,194.61 46 -14.85%
NASONEX $316,428.51 35 $265,689.54 47 -16.03%
ENBREL SURECLICK $236,903.75 46 $252,385.35 48 6.53%
INVEGA $228,174.49 49 $250,095.90 49 9.61%
HUMIRA $222,691.84 50 $234,074.52 50 5.11%
OMEPRAZOLE $235,360.62 48 $232,913.24 51 -1.04%
MONTELUKAST SODIUM $252,669.15 44 $223,964.91 52 -11.36%
LEVOTHYROXINE SODIUM $217,243.54 52 $222,487.23 53 2.41%
FLOVENT HFA $249,071.75 45 $220,403.80 54 -11.51%
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AMPHETAMINE/DEXTROAMPHETA $119,530.22 105 $219,710.51 55 83.81%
ENBREL $180,024.51 63 $216,006.03 56 19.99%
VIMPAT $204,671.49 56 $209,414.60 57 2.32%
COMBIVENT RESPIMAT $214,083.64 54 $208,005.01 58 -2.84%
PULMOZYME $211,278.07 55 $205,682.48 59 -2.65%
OPANA ER (CRUSH RESISTANT $196,480.44 60 $202,690.48 60 3.16%
GABAPENTIN $203,081.34 57 $200,947.78 61 -1.05%
NORDITROPIN FLEXPRO $131,195.77 92 $198,546.97 62 51.34%
PROVIGIL $199,747.34 59 $190,168.79 63 -4.80%
SPRYCEL $130,965.65 93 $184,498.22 64 40.88%
METHYLPHENIDATE HCL $177,582.09 67 $184,175.21 65 3.71%
VESICARE $178,981.81 66 $183,096.33 66 2.30%
AMOXICILLIN/CLAVULANATE P $166,607.97 68 $180,291.64 67 8.21%
XYREM $193,168.38 61 $176,039.19 68 -8.87%
BUPROPION HCL XL $147,078.53 79 $169,687.52 69 15.37%
TOPROL XL $152,703.15 76 $165,208.89 70 8.19%
GLEEVEC $215,206.64 53 $162,529.32 71 -24.48%
QUETIAPINE FUMARATE $158,967.56 71 $161,441.79 72 1.56%
RISPERIDONE $156,990.43 73 $158,078.05 73 0.69%
JANUVIA $139,713.70 86 $154,979.30 74 10.93%
CREON $133,888.07 91 $154,143.40 75 15.13%
KALYDECO $179,346.89 65 $153,732.38 76 -14.28%
SERTRALINE HCL $144,512.76 82 $153,072.57 77 5.92%
GILENYA $143,113.49 84 $152,198.22 78 6.35%
SEROQUEL XR $163,943.73 70 $151,780.86 79 -7.42%
DULERA $151,118.26 77 $151,585.29 80 0.31%
LISINOPRIL $144,729.76 81 $150,938.97 81 4.29%
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TRAMADOL HCL $147,429.32 78 $148,168.67 82 0.50%
QUILLIVANT XR $125,263.08 100 $144,621.37 83 15.45%
SAPHRIS $139,013.38 87 $142,979.42 84 2.85%
XIFAXAN $156,503.19 74 $142,607.38 85 -8.88%
ESCITALOPRAM OXALATE $137,492.96 88 $140,112.85 86 1.91%
HARVONI $23,198.22 380 $139,678.09 87 502.11%
BANZEL $144,243.87 83 $139,644.37 88 -3.19%
INTUNIV $140,502.60 85 $139,623.24 89 -0.63%
VENLAFAXINE HCL ER $127,456.31 94 $137,117.26 90 7.58%
STRIBILD $116,186.81 107 $135,936.12 91 17.00%
ATORVASTATIN CALCIUM $125,716.31 99 $134,957.08 92 7.35%
COMPLERA $127,240.95 95 $133,405.28 93 4.84%
METADATE CD $121,398.11 104 $131,689.71 94 8.48%
ZIPRASIDONE HCL $156,276.12 75 $131,528.53 95 -15.84%
KUVAN $84,352.36 144 $130,902.45 96 55.19%
ALBUTEROL SULFATE $145,563.40 80 $130,420.97 97 -10.40%
CEPHALEXIN $136,617.86 89 $128,258.63 98 -6.12%
TRAZODONE HCL $125,853.06 98 $127,340.59 99 1.18%
RANITIDINE HCL $126,353.75 96 $127,317.53 100 0.76%
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HYDROCO/APAP TAB 5-325MG 18,785 1 16,180 1 -13.87%
VENTOLIN HFA AER 16,538 2 14,978 2 -9.43%
TRAMADOL HCL TAB 50MG 12,700 3 11,954 3 -5.87%
Loratadine Tab 10 MG 12,231 4 10,914 4 -10.77%
AMOXICILLIN  SUS 400/5ML 9,335 7 10,585 5 13.39%
AZITHROMYCIN TAB 250MG 9,399 6 9,079 6 -3.40%
ESCITALOPRAM TAB 20MG 8,880 9 9,009 7 1.45%
FLUOXETINE   CAP 20MG 8,666 10 8,757 8 1.05%
ALBUTEROL    NEB 0.083% 9,919 5 8,741 9 -11.88%
OMEPRAZOLE   CAP 20MG 8,620 11 8,728 10 1.25%
GABAPENTIN   CAP 300MG 8,360 12 8,576 11 2.58%
Cetirizine HCl Tab 10 MG 9,168 8 8,122 12 -11.41%
CYCLOBENZAPR TAB 10MG 8,083 13 7,728 13 -4.39%
AZITHROMYCIN SUS 200/5ML 6,530 18 7,610 14 16.54%
OMEPRAZOLE   CAP 40MG 7,055 16 7,347 15 4.14%
CLONIDINE    TAB 0.1MG 6,942 17 7,040 16 1.41%
RANITIDINE   TAB 150MG 7,158 15 6,840 17 -4.44%
FLUTICASONE  SPR 50MCG 7,410 14 6,634 18 -10.47%
SERTRALINE   TAB 100MG 6,383 20 6,546 19 2.55%
GUANFACINE   TAB 1MG 6,131 23 6,434 20 4.94%
Aspirin Tab Delayed Release 81 MG 6,455 19 6,322 21 -2.06%
MONTELUKAST  TAB 10MG 6,235 22 5,951 22 -4.55%
IBUPROFEN    TAB 800MG 6,331 21 5,908 23 -6.68%
Acetaminophen Tab 325 MG 5,977 25 5,890 24 -1.46%
TRAZODONE    TAB 50MG 5,854 27 5,796 25 -0.99%
TRAZODONE    TAB 100MG 5,797 28 5,725 26 -1.24%
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Ferrous Sulfate Tab 325 MG (65 MG 
Elemental Fe)
5,598 29 5,547 27 -0.91%
LISINOPRIL   TAB 10MG 5,419 31 5,389 28 -0.55%
METFORMIN    TAB 500MG 5,198 32 5,178 29 -0.38%
HYDROCHLOROT TAB 25MG 5,112 33 5,125 30 0.25%
PROVENTIL    AER HFA 5,917 26 5,098 31 -13.84%
LISINOPRIL   TAB 20MG 5,018 34 5,064 32 0.92%
AMOXICILLIN  CAP 500MG 4,836 35 4,958 33 2.52%
CLONAZEPAM   TAB 1MG 4,760 36 4,596 34 -3.45%
OXYCOD/APAP  TAB 5-325MG 4,542 40 4,469 35 -1.61%
METHYLPHENID TAB 36MG ER 4,350 44 4,432 36 1.89%
METFORMIN    TAB 1000MG 4,459 41 4,424 37 -0.78%
MELOXICAM    TAB 15MG 4,441 42 4,418 38 -0.52%
Sennosides-Docusate Sodium Tab 8.6-50 
MG
4,371 43 4,372 39 0.02%
PREDNISONE   TAB 20MG 5,468 30 4,311 40 -21.16%
CITALOPRAM   TAB 20MG 4,329 45 4,273 41 -1.29%
POLYETH GLYC POW 3350 NF 4,156 50 4,232 42 1.83%
Aspirin Chew Tab 81 MG 4,174 48 4,166 43 -0.19%
ALPRAZOLAM   TAB 1MG 4,139 51 4,146 44 0.17%
VENLAFAXINE  CAP 150MG ER 4,112 53 4,145 45 0.80%
HYDROCO/APAP TAB 7.5-325 4,614 38 4,124 46 -10.62%
SERTRALINE   TAB 50MG 4,014 55 4,090 47 1.89%
LANTUS       INJ 100/ML 4,176 47 4,041 48 -3.23%
SMZ/TMP DS   TAB 800-160 4,626 37 4,011 49 -13.29%
AMOXICILLIN  SUS 250/5ML 3,677 61 3,991 50 8.54%
CLONAZEPAM   TAB 0.5MG 4,093 54 3,989 51 -2.54%
CEPHALEXIN   CAP 500MG 4,578 39 3,987 52 -12.91%
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AMLODIPINE   TAB 10MG 3,794 57 3,926 53 3.48%
CITALOPRAM   TAB 40MG 3,886 56 3,843 54 -1.11%
PANTOPRAZOLE TAB 40MG 3,574 64 3,833 55 7.25%
ONDANSETRON  TAB 4MG ODT 2,822 80 3,789 56 34.27%
MONTELUKAST  CHW 5MG 4,167 49 3,786 57 -9.14%
NAPROXEN     TAB 500MG 4,200 46 3,740 58 -10.95%
ALPRAZOLAM   TAB 0.5MG 3,749 59 3,738 59 -0.29%
ZOLPIDEM     TAB 10MG 3,756 58 3,710 60 -1.22%
HYDROCO/APAP TAB 10-325MG 4,133 52 3,690 61 -10.72%
PREDNISOLONE SOL 15MG/5ML 6,115 24 3,674 62 -39.92%
AMOX/K CLAV  TAB 875MG 3,723 60 3,635 63 -2.36%
CYMBALTA     CAP 60MG 3,634 62 3,625 64 -0.25%
Acetaminophen Tab 500 MG 3,396 66 3,413 65 0.50%
METHYLPHENID TAB 54MG ER 3,306 67 3,378 66 2.18%
FOLIC ACID   TAB 1MG 3,468 65 3,355 67 -3.26%
AMLODIPINE   TAB 5MG 3,298 68 3,340 68 1.27%
ATORVASTATIN TAB 40MG 3,053 75 3,268 69 7.04%
BUPROPN HCL  TAB 300MG XL 3,064 74 3,236 70 5.61%
SIMVASTATIN  TAB 20MG 3,127 73 3,168 71 1.31%
METOPROL TAR TAB 25MG 3,166 71 3,167 72 0.03%
CEFDINIR     SUS 250/5ML 2,656 88 3,131 73 17.88%
LORAZEPAM    TAB 1MG 3,182 70 3,108 74 -2.33%
HYDROXYZ PAM CAP 25MG 3,165 72 3,096 75 -2.18%
BUPROPN HCL  TAB 150MG XL 2,882 78 3,057 76 6.07%
TAMIFLU      SUS 6MG/ML 47 1212 2,999 77 6,280.85%
VYVANSE      CAP 30MG 2,896 76 2,874 78 -0.76%
VENLAFAXINE  CAP 75MG ER 2,756 83 2,868 79 4.06%
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RISPERIDONE  TAB 1MG 2,880 79 2,843 80 -1.28%
SPIRIVA      CAP HANDIHLR 2,888 77 2,815 81 -2.53%
LORAZEPAM    TAB 0.5MG 2,750 84 2,812 82 2.25%
VYVANSE      CAP 40MG 2,767 81 2,744 83 -0.83%
SIMVASTATIN  TAB 40MG 2,767 82 2,719 84 -1.73%
ATORVASTATIN TAB 20MG 2,498 93 2,714 85 8.65%
LEVOTHYROXIN TAB 50MCG 2,681 86 2,692 86 0.41%
FUROSEMIDE   TAB 40MG 2,667 87 2,687 87 0.75%
LISINOPRIL   TAB 40MG 2,636 89 2,671 88 1.33%
Cetirizine HCl Oral Soln 1 MG/ML (5 
MG/5ML)
3,613 63 2,654 89 -26.54%
PREDNISONE   TAB 10MG 3,205 69 2,653 90 -17.22%
QUETIAPINE   TAB 100MG 2,513 91 2,569 91 2.23%
RISPERIDONE  TAB 0.5MG 2,429 96 2,475 92 1.89%
FLUCONAZOLE  TAB 150MG 2,507 92 2,434 93 -2.91%
LISINOPRIL   TAB 5MG 2,445 95 2,391 94 -2.21%
METRONIDAZOL TAB 500MG 2,566 90 2,381 95 -7.21%
MONTELUKAST  CHW 4MG 2,699 85 2,380 96 -11.82%
VYVANSE      CAP 50MG 2,244 103 2,359 97 5.12%
Ibuprofen Susp 100 MG/5ML 1,964 118 2,353 98 19.81%
CLOPIDOGREL  TAB 75MG 2,282 101 2,341 99 2.59%
APAP/CODEINE TAB 300-30MG 2,312 99 2,328 100 0.69%
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TOTAL PAID AMOUNT $60,821,416 $63,528,498 4.5%
UNIQUE USERS 198,531 204,409 3.0%
COST PER USER $306.36 $310.79 1.4%
TOTAL PRESCRIPTIONS 947,453 968,276 2.2%
AVERAGE PRESCRIPTIONS PER USER 4.77 4.74 -0.7%
AVERAGE COST PER PRESCRIPTION $64.19 $65.61 2.2%
# GENERIC PRESCRIPTIONS 792,657 817,357 3.1%
% GENERIC 83.7% 84.4% 0.9%
$ GENERIC $16,088,524 $17,295,624 7.5%
AVERAGE GENERIC PRESCRIPTION COST $20.30 $21.16 4.3%
AVERAGE GENERIC DAYS SUPPLY 23 23 0.0%
# BRAND PRESCRIPTIONS 151,227 147,552 3.1%
% BRAND 16.0% 15.2% 0.9%
$ BRAND $44,511,655 $46,048,852 7.5%
AVERAGE BRAND PRESCRIPTION COST $294.34 $312.09 4.3%
AVERAGE BRAND DAYS SUPPLY 25 25 0.0%
Bi-Monthly Statistics
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UTILIZATION BY AGE
AGE November/December 2014 January/February 2015
0-6 39,742 37,589
7-12 29,303 30,605
13-18 24,390 25,146
19-64 96,889 101,614
65+ 8,207 9,455
198,531 204,409
UTILIZATION BY GENDER AND AGE
GENDER AGE November/December 2014 January/February 2015
F
0-6 18,532 17,794
7-12 12,867 13,385
13-18 12,988 12,797
19-64 61,949 64,925
65+ 5,830 6,580
112,166 115,481
M
0-6 21,210 19,795
7-12 16,436 17,220
13-18 11,402 12,349
19-64 34,940 36,689
65+ 2,377 2,875
86,365 88,928
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1 BROADLAWNS MEDICAL CENTER DES MOINES IA 18,706 $466,639.55 $24.95 1
2 WALGREEN #05239 DAVENPORT IA 11,635 $648,837.52 $55.77 2
3 WALGREEN #04405 COUNCIL BLUFFS IA 10,041 $586,676.43 $58.43 3
4 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 9,242 $605,929.74 $65.56 4
5 WALGREEN #05721 DES MOINES IA 9,055 $519,291.20 $57.35 5
6 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,054 $340,978.17 $48.34 6
7 WALGREEN #359 DES MOINES IA 6,863 $370,903.05 $54.04 7
8 WALGREEN COMPANY 07455 WATERLOO IA 6,801 $340,192.98 $50.02 8
9 MERCY FAMILY PHARMACY DUBUQUE IA 6,789 $404,658.18 $59.60 13
10 WALGREEN COMPANY #3700 COUNCIL BLUFFS IA 6,560 $341,805.30 $52.10 11
11 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 6,506 $350,926.87 $53.94 10
12 WALGREEN #05362 DES MOINES IA 6,367 $338,682.13 $53.19 9
13 SIOUXLAND COMM HEALTH CTR 
PHARMA
SIOUX CITY IA 6,151 $105,681.01 $17.18 12
14 MARTIN HEALTH SERVICES INC DENVER IA 5,912 $181,380.12 $30.68 16
15 WALGREENS #07453 DES MOINES IA 5,748 $321,506.59 $55.93 14
16 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,362 $296,609.85 $55.32 19
17 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,211 $315,004.66 $60.45 17
18 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,185 $275,598.30 $53.15 20
19 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,062 $255,740.55 $50.52 23
20 WALGREEN #04041 DAVENPORT IA 5,002 $250,286.52 $50.04 18
21 WALGREEN COMPANY 05777 DES MOINES IA 4,997 $287,421.29 $57.52 22
22 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 4,853 $274,405.88 $56.54 26
23 WALGREEN #05852 DES MOINES IA 4,764 $256,894.65 $53.92 21
24 WALGREEN #910 SIOUX CITY IA 4,672 $259,052.63 $55.45 15
25 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,657 $264,450.39 $56.79 24
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26 RASHID PHARMACY PLC FORT MADISON IA 4,508 $261,676.38 $58.05 25
27 WALGREEN #11709 DAVENPORT IA 4,494 $262,561.17 $58.42 27
28 DANIEL PHARMACY INC FORT DODGE IA 4,314 $238,968.31 $55.39 28
29 WALGREEN #05886 KEOKUK IA 4,270 $244,531.57 $57.27 49
30 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,261 $226,414.47 $53.14 29
31 MAHASKA DRUG INC OSKALOOSA IA 4,040 $245,372.35 $60.74 32
32 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 3,975 $277,666.66 $69.85 38
33 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 3,897 $214,787.10 $55.12 30
34 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,832 $217,094.82 $56.65 31
35 PHARMACY MATTERS LTC IOWA CITY IA 3,817 $165,966.82 $43.48 36
36 MEDICAP PHARMACY INDIANOLA IA 3,746 $195,632.17 $52.22 34
37 WALGREEN #03595 DAVENPORT IA 3,740 $210,243.44 $56.21 39
38 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,729 $219,811.07 $58.95 37
39 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,659 $237,633.92 $64.95 41
40 WALGREEN #7452 DES MOINES IA 3,580 $178,816.95 $49.95 33
41 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,550 $255,338.88 $71.93 43
42 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,545 $191,266.49 $53.95 44
43 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,535 $205,915.61 $58.25 42
44 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,526 $206,451.49 $58.55 40
45 WALGREENS #05119 CLINTON IA 3,464 $191,816.18 $55.37 35
46 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,431 $206,986.09 $60.33 52
47 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,413 $150,957.30 $44.23 46
48 WAL-MART PHARMACY #10-0985 FAIRFIELD IA 3,375 $139,428.93 $41.31 60
49 WALGREEN #05044 BURLINGTON IA 3,288 $188,533.27 $57.34 45
50 WALGREENS #10855 WATERLOO IA 3,226 $165,798.65 $51.39 53
51 WAL-MART PHARMACY 10-2889 CLINTON IA 3,206 $148,407.34 $46.29 56
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52 WAL-MART PHARMACY #10-5115 DAVENPORT IA 3,200 $130,377.03 $40.74 47
53 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 3,160 $145,653.04 $46.09 61
54 WAL MART PHARMACY 10-1621 CENTERVILLE IA 3,155 $159,657.24 $50.60 51
55 HY VEE PHARMACY #1449 NEWTON IA 3,153 $160,146.67 $50.79 54
56 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,151 $200,009.07 $63.47 50
57 THOMPSON-DEAN DRUG SIOUX CITY IA 3,130 $271,294.70 $86.68 59
58 A AVENUE PHARMACY CEDAR RAPIDS IA 3,079 $223,352.35 $72.54 48
59 WAL MART PHARMACY 10-3590 SIOUX CITY IA 3,062 $162,286.88 $53.00 58
60 HY-VEE PHARMACY (1058) CENTERVILLE IA 3,049 $153,944.79 $50.49 66
61 RIGHT DOSE PHARMACY ANKENY IA 3,040 $209,592.97 $68.95 425
62 WALGREENS #11942 DUBUQUE IA 3,012 $173,012.36 $57.44 63
63 WALGREENS 07968 DES MOINES IA 3,000 $162,646.71 $54.22 64
64 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 2,981 $150,777.83 $50.58 57
65 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,892 $167,503.09 $57.92 75
66 WAL-MART PHARMACY #10-1393 OSKALOOSA IA 2,891 $132,525.17 $45.84 68
67 HY-VEE PHARMACY (1075) CLINTON IA 2,869 $172,942.62 $60.28 62
68 WAL-MART PHARMACY #10-0646 ANAMOSA IA 2,853 $120,341.87 $42.18 85
69 WAGNER PHARMACY CLINTON IA 2,838 $177,756.59 $62.63 89
70 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,810 $163,066.24 $58.03 67
71 WALGREENS #15647 SIOUX CITY IA 2,783 $145,495.15 $52.28 138
72 HY-VEE PHARMACY #3 (1056) CEDAR RAPIDS IA 2,776 $145,783.73 $52.52 69
73 HY-VEE PHARMACY (1522) PERRY IA 2,768 $148,001.35 $53.47 70
74 WALGREEN #4714 DES MOINES IA 2,756 $154,251.05 $55.97 65
75 WALGREEN #09708 DUBUQUE IA 2,746 $152,253.10 $55.45 71
76 HARTIG PHARMACY SERVICES DUBUQUE IA 2,731 $174,351.38 $63.84 72
77 HY-VEE PHARMACY #2 (1044) BURLINGTON IA 2,718 $142,987.13 $52.61 79
Page 5 Of 293/10/2015 12:06:56 PM RT33018
trusted, reliable, innovative
TOP 100 PHARMACIES BY PRESCRIPTION COUNT
January/February 2015
RANK PHARMACY NAME PHARMACY CITY STATE PRESCRIPTION 
COUNT
PAID AMT AVG COST RX PREVIOUS RANK
78 HY-VEE PHARMACY (1875) WEBSTER CITY IA 2,671 $134,190.14 $50.24 73
79 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,668 $164,641.40 $61.71 76
80 HY-VEE DRUGSTORE (7056) MASON CITY IA 2,667 $127,800.04 $47.92 78
81 HY-VEE DRUGSTORE #7031 DES MOINES IA 2,627 $144,684.73 $55.08 81
82 HY-VEE PHARMACY (1009) DBA ALBIA IA 2,618 $127,068.29 $48.54 80
83 WALGREEN #05942 NEWTON IA 2,608 $152,019.22 $58.29 77
84 S - S PHARMACY INC COUNCIL BLUFFS IA 2,596 $202,259.16 $77.91 74
85 HY-VEE PHARMACY 1504 OTTUMWA IA 2,584 $165,600.03 $64.09 82
86 WALGREEN #05077 IOWA CITY IA 2,577 $153,280.30 $59.48 83
87 WAL-MART PHARMACY #10-3394 ATLANTIC IA 2,555 $135,345.03 $52.97 84
88 HY-VEE PHARMACY 1071 CLARINDA IA 2,549 $154,889.52 $60.76 94
89 LA GRANGE PHARMACY INC VINTON IA 2,547 $146,407.56 $57.48 88
90 SCOTT PHARMACY FAYETTE IA 2,540 $132,279.70 $52.08 95
91 HY-VEE PHARMACY (1065) CHARITON IA 2,490 $140,643.04 $56.48 86
92 STANGEL PHARMACY ONAWA IA 2,475 $152,471.64 $61.60 110
93 WAL-MART PHARMACY 10-0784 MT PLEASANT IA 2,472 $147,209.89 $59.55 87
94 HY-VEE DRUGSTORE # 7035 FT DODGE IA 2,447 $133,272.31 $54.46 91
95 HY-VEE FOOD STORE WATERLOO IA 2,441 $182,434.99 $74.74 90
96 UI HEALTHCARE RIVER LANDING PHAR CORALVILLE IA 2,420 $48,979.67 $20.24 104
97 WALGREENS #03876 MARION IA 2,418 $140,007.02 $57.90 97
98 WALGREEN COMPANY DBA OTTUMWA IA 2,411 $143,319.28 $59.44 102
99 WALGREEN #05361 FORT DODGE IA 2,390 $131,480.39 $55.01 93
100 WAL-MART PHARMACY 10-1723 DES MOINES IA 2,371 $88,975.76 $37.53 98
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1 NUCARA PHARMACY #27 PLEASANT HILL IA 2,200 $1,118,888.44 $2,638.89 2
2 ARJ INFUSION SERVICES INC LENEXA KS 27 $1,106,266.68 $276,566.67 1
3 CAREMARK KANSAS SPEC PHARMACY 
LL
LENEXA KS 141 $656,177.05 $7,372.78 6
4 WALGREEN #05239 DAVENPORT IA 11,635 $648,837.52 $199.27 4
5 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 9,242 $605,929.74 $277.69 5
6 WALGREEN #04405 COUNCIL BLUFFS IA 10,041 $586,676.43 $223.84 7
7 WALGREEN #05721 DES MOINES IA 9,055 $519,291.20 $183.24 8
8 ACCREDO HEALTH GROUP INC MEMPHIS TN 62 $495,052.77 $12,693.66 3
9 HY-VEE PHARMACY SOLUTIONS OMAHA NE 225 $481,582.69 $3,541.05 19
10 UNITYPOINT AT HOME URBANDALE IA 381 $477,766.53 $4,304.20 10
11 AMBER PHARMACY OMAHA NE 133 $467,466.93 $11,986.33 15
12 BROADLAWNS MEDICAL CENTER DES MOINES IA 18,706 $466,639.55 $187.10 11
13 MERCY FAMILY PHARMACY DUBUQUE IA 6,789 $404,658.18 $359.70 13
14 UNIV OF IOWA COMMUNITY HOMECARE IOWA CITY IA 266 $398,364.92 $4,742.44 24
15 ACCREDO HEALTH GROUP INC NASHVILLE TN 10 $372,037.75 $74,407.55 9
16 WALGREEN #359 DES MOINES IA 6,863 $370,903.05 $181.11 12
17 COMMUNITY HEALTHCARE SERVICES LOMA LINDA CA 7 $362,762.58 $181,381.29 76
18 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 6,506 $350,926.87 $170.60 14
19 WALGREEN COMPANY #3700 COUNCIL BLUFFS IA 6,560 $341,805.30 $182.30 17
20 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,054 $340,978.17 $210.87 16
21 WALGREEN COMPANY 07455 WATERLOO IA 6,801 $340,192.98 $151.94 18
22 WALGREEN #05362 DES MOINES IA 6,367 $338,682.13 $163.85 22
23 WALGREENS #07453 DES MOINES IA 5,748 $321,506.59 $195.80 20
24 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,211 $315,004.66 $421.69 21
25 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,362 $296,609.85 $220.04 35
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26 WALGREENS SPECIALTY PHARMACY 
#12
ANN ARBOR MI 60 $290,351.82 $8,295.77 26
27 WALGREEN COMPANY 05777 DES MOINES IA 4,997 $287,421.29 $211.81 29
28 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 3,975 $277,666.66 $480.39 28
29 DIPLOMAT SPECIALTY PHARMACY FLINT MI 64 $275,814.40 $9,193.81 25
30 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,185 $275,598.30 $227.20 38
31 MEDFUSIONRX LLC FRANKLIN TN 51 $274,436.28 $9,147.88 37
32 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 4,853 $274,405.88 $249.23 34
33 US BIOSERVICE CORPORATION FRISCO TX 28 $273,195.45 $21,015.03 111
34 THOMPSON-DEAN DRUG SIOUX CITY IA 3,130 $271,294.70 $419.96 36
35 PROCARE PHARMACY DIRECT LLC MONROEVILLE PA 61 $265,671.08 $8,050.64 31
36 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,657 $264,450.39 $216.94 27
37 WALGREEN #11709 DAVENPORT IA 4,494 $262,561.17 $222.32 41
38 RASHID PHARMACY PLC FORT MADISON IA 4,508 $261,676.38 $291.72 33
39 ACCREDO HEALTH GROUP INC WARRENDALE PA 45 $260,729.41 $15,337.02 54
40 WALGREEN #910 SIOUX CITY IA 4,672 $259,052.63 $154.20 23
41 WALGREEN #05852 DES MOINES IA 4,764 $256,894.65 $170.58 32
42 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,062 $255,740.55 $292.94 77
43 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,550 $255,338.88 $240.89 39
44 WALGREEN #04041 DAVENPORT IA 5,002 $250,286.52 $159.42 30
45 MAHASKA DRUG INC OSKALOOSA IA 4,040 $245,372.35 $258.83 46
46 WALGREEN #05886 KEOKUK IA 4,270 $244,531.57 $256.59 67
47 DANIEL PHARMACY INC FORT DODGE IA 4,314 $238,968.31 $283.14 47
48 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,659 $237,633.92 $316.42 58
49 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,261 $226,414.47 $242.93 49
50 A AVENUE PHARMACY CEDAR RAPIDS IA 3,079 $223,352.35 $606.94 42
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51 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,729 $219,811.07 $319.49 45
52 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,832 $217,094.82 $260.31 44
53 WALGREENS INFUSION SERVICES OMAHA NE 47 $215,887.60 $11,362.51 69
54 ACARIAHEALTH PHARMACY #11 INC HOUSTON TX 43 $215,273.44 $10,251.12 51
55 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 3,897 $214,787.10 $281.50 52
56 WALGREEN #03595 DAVENPORT IA 3,740 $210,243.44 $172.33 53
57 RIGHT DOSE PHARMACY ANKENY IA 3,040 $209,592.97 $598.84 416
58 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,431 $206,986.09 $265.37 60
59 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,526 $206,451.49 $227.62 50
60 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,535 $205,915.61 $319.74 57
61 S - S PHARMACY INC COUNCIL BLUFFS IA 2,596 $202,259.16 $591.40 48
62 DOHMEN LIFE SCIENCE SERVICES LLC CHESTERFIELD MO 20 $201,085.95 $20,108.60 40
63 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,151 $200,009.07 $321.04 64
64 MEDICAP PHARMACY INDIANOLA IA 3,746 $195,632.17 $406.72 62
65 WALGREENS #05119 CLINTON IA 3,464 $191,816.18 $202.77 56
66 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,545 $191,266.49 $207.00 59
67 EXPRESS SCRIPTS SPECIALTY ST LOUIS MO 26 $189,468.86 $14,574.53 68
68 WALGREEN #05044 BURLINGTON IA 3,288 $188,533.27 $183.22 66
69 HY-VEE FOOD STORE WATERLOO IA 2,441 $182,434.99 $319.50 61
70 MARTIN HEALTH SERVICES INC DENVER IA 5,912 $181,380.12 $176.10 65
71 WALGREEN #7452 DES MOINES IA 3,580 $178,816.95 $148.64 55
72 MERCY HOME INFUSION URBANDALE IA 117 $178,199.13 $4,346.32 63
73 WAGNER PHARMACY CLINTON IA 2,838 $177,756.59 $356.94 87
74 HARTIG PHARMACY SERVICES DUBUQUE IA 2,731 $174,351.38 $645.75 79
75 WALGREENS #11942 DUBUQUE IA 3,012 $173,012.36 $198.86 74
76 HY-VEE PHARMACY (1075) CLINTON IA 2,869 $172,942.62 $291.15 72
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77 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,892 $167,503.09 $233.94 96
78 PHARMACY MATTERS LTC IOWA CITY IA 3,817 $165,966.82 $493.95 82
79 WALGREENS #10855 WATERLOO IA 3,226 $165,798.65 $169.88 73
80 HY-VEE PHARMACY 1504 OTTUMWA IA 2,584 $165,600.03 $294.14 84
81 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,668 $164,641.40 $304.89 81
82 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,810 $163,066.24 $263.86 71
83 WALGREENS 07968 DES MOINES IA 3,000 $162,646.71 $163.46 83
84 WAL MART PHARMACY 10-3590 SIOUX CITY IA 3,062 $162,286.88 $187.40 80
85 HY VEE PHARMACY #1449 NEWTON IA 3,153 $160,146.67 $214.96 78
86 WAL MART PHARMACY 10-1621 CENTERVILLE IA 3,155 $159,657.24 $243.75 86
87 HY-VEE PHARMACY 1071 CLARINDA IA 2,549 $154,889.52 $291.69 103
88 WALGREEN #4714 DES MOINES IA 2,756 $154,251.05 $183.63 97
89 HY-VEE PHARMACY (1058) CENTERVILLE IA 3,049 $153,944.79 $258.73 100
90 WALGREEN #05077 IOWA CITY IA 2,577 $153,280.30 $203.02 108
91 STANGEL PHARMACY ONAWA IA 2,475 $152,471.64 $316.99 107
92 WALGREEN #09708 DUBUQUE IA 2,746 $152,253.10 $147.96 90
93 WALGREEN #05942 NEWTON IA 2,608 $152,019.22 $217.79 93
94 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,413 $150,957.30 $159.24 95
95 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 2,981 $150,777.83 $251.72 88
96 GREENVILLE PHARMACY INC SIOUX CITY IA 2,010 $150,040.24 $387.70 92
97 WAL-MART PHARMACY 10-2889 CLINTON IA 3,206 $148,407.34 $183.22 89
98 HY-VEE PHARMACY (1522) PERRY IA 2,768 $148,001.35 $199.73 106
99 WAL-MART PHARMACY 10-0784 MT PLEASANT IA 2,472 $147,209.89 $246.17 91
100 LA GRANGE PHARMACY INC VINTON IA 2,547 $146,407.56 $283.74 109
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1 1780766659 CHESTER ROBERT BADGER $212,275.22 4,146 5.68 1
2 1982605762 JEFFREY D WILHARM $164,925.40 2,420 5.65 3
3 1841407160 RAHUL BANSAL MD $232,782.81 2,332 4.82 2
4 1538368170 CHRISTOPHER ROBERT MATSON $78,737.21 2,209 6.02 5
5 1467682351 NICOLE GILG $72,557.04 2,150 5.50 4
6 1063622637 HUSSAIN BANU $58,744.49 2,080 6.27 9
7 1649248378 KATHLEEN L WILD ARNP $194,058.80 2,053 3.66 7
8 1083784797 CAROL AUNAN ARNP $170,033.37 1,997 3.64 6
9 1013115369 BOBBITA NAG MD $253,308.24 1,980 4.07 10
10 1205015906 DAVID F WIDITZ $171,510.61 1,938 4.58 11
11 1043211303 ALI  SAFDAR $141,144.43 1,887 3.46 13
12 1215192224 SHALINA SHAIK $47,451.25 1,821 6.19 8
13 1073667606 ELIZABETH MCCURDY DO $63,256.59 1,788 5.64 15
14 1619153137 JODI BEST ARNP $184,987.06 1,647 5.08 14
15 1316922545 MABRA G ABERNATHY $46,502.02 1,550 4.60 16
16 1801998372 WENDY MICHELE HANSEN-PENMAN DO $40,784.40 1,530 6.95 21
17 1023053972 BRYANT MUTCHLER DO $66,377.25 1,524 6.00 23
18 1245388743 TIMOTHY SWINTON MD $61,540.18 1,447 6.35 19
19 1043434525 ROBERT MARVIN KENT MD $65,962.25 1,426 4.47 34
20 1073509436 MICHAEL KARL MAHARRY MD $69,037.53 1,410 5.38 17
21 1720293087 RAJNI BATRA MD $70,667.14 1,390 3.65 29
22 1841220290 KENT ELDON KUNZE MD $138,031.61 1,389 4.35 18
23 1023377827 LISA KAY CHASE $64,364.88 1,388 5.10 27
24 1467437806 GEORGIA LAUER PAC $77,654.54 1,384 6.21 32
25 1275844649 KATIE M HANSON $111,906.05 1,374 3.95 28
26 1073594768 JERROLD V FLATT DO $60,864.01 1,352 4.63 26
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27 1477633188 CYD Q. GRAFFT $114,592.40 1,348 3.92 25
28 1255322996 MARK WILLIAM MITTAUER MD $109,239.83 1,312 3.62 39
29 1730239732 SRIRAMAMURTHY RAVIPATI MD $111,660.54 1,308 3.73 61
30 1972758126 REBECCA BOLLIN $36,134.41 1,290 4.87 66
31 1073500690 KATHLEEN S ADAMS $156,523.85 1,254 3.86 49
32 1508946088 RICHARD E NIGHTINGALE $109,116.86 1,254 5.81 40
33 1912991340 GHADA HAMDAN-ALLEN MD $130,226.51 1,250 4.27 24
34 1962558957 ALBERT N OKINE PA $138,151.55 1,234 6.08 22
35 1144214248 KRISTIE DEE ANN WALZ MD $60,570.90 1,232 4.50 38
36 1003004391 DAVID B WALKER MD $109,514.25 1,224 4.19 33
37 1598962870 CHRISTY QUILLEN ARNP $42,851.93 1,221 5.07 35
38 1346210184 JAMES BROOKS MD $134,743.82 1,218 5.18 43
39 1497736326 RANDY R ROBINSON $56,520.10 1,211 5.38 36
40 1508289620 GLORIA A MILLER $109,151.51 1,189 6.61 31
41 1205169273 TERESA ANN DOWLING $34,784.13 1,184 5.26 48
42 1528144383 RAMONCITO AMURAO O'CAMPO $54,005.30 1,169 4.35 54
43 1033198908 DANIEL J ARNOLD $54,988.99 1,167 4.35 50
44 1164538674 JOSEPH M WANZEK $62,946.19 1,165 4.81 51
45 1982766705 MALHAR GORE $36,615.37 1,157 4.54 59
46 1538157383 DAVID WENGER-KELLER MD $51,595.68 1,141 5.59 69
47 1952459463 DAVID LAWRENCE YURDIN PA $543,138.83 1,132 4.26 37
48 1073550836 SONJA LUCILLE GREINER ARNP $52,530.11 1,119 4.76 90
49 1245318393 JEAN TOBIN PA $76,998.34 1,111 2.63 12
50 1902809536 KIRAN BHASKAR KHANOLKAR MD $55,649.39 1,108 4.88 42
51 1841293354 KEITH GUESS PA C $105,894.20 1,098 4.56 58
52 1588629414 THOMAS EARWOOD MD $76,012.33 1,097 4.77 67
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53 1306133095 DEBRA LEE ANDERSON ARNP $55,003.19 1,090 3.76 46
54 1215080759 JUANITA M O'BRIEN $41,430.95 1,090 4.80 81
55 1225097843 WILLIAM M NISSEN $61,012.90 1,079 3.87 41
56 1184945321 DEANNE REMER $72,632.18 1,077 5.95 44
57 1104976109 ISAM ELIAS MARAR MD $74,279.89 1,071 5.30 85
58 1902912538 CHRISTIAN W JONES MD $48,410.50 1,065 3.47 71
59 1013960566 PETER JOSEPH SZEIBEL $100,434.56 1,048 5.09 45
60 1205821337 MANMOHAN SINGH $50,386.15 1,046 4.51 63
61 1306954391 WILLIAM E HOWARD IV $90,388.97 1,043 2.79 87
62 1356760011 CHARISSA S ELLIOTT ARNP $55,055.12 1,040 5.68 77
63 1134425127 MELANIE HOWARD ARPN $89,243.16 1,038 3.49 122
64 1467502286 CHARLES TILLEY PA $120,521.09 1,031 3.88 20
65 1134191018 DUSTIN RALPH SMITH MD $58,956.04 1,028 4.53 57
66 1306812490 MERRILEE RAMSEY ARNP $49,895.90 1,027 4.14 75
67 1558348284 STEVEN G PAULSRUD $50,876.47 1,024 4.38 47
68 1396731287 VICKI L BOLING ARNP $54,459.61 1,022 4.29 94
69 1922144088 THOMAS S HOPKINS DO $103,557.48 1,019 3.68 60
70 1780877878 CHRISTOPHER JACOBS ARNP $37,525.95 1,009 3.60 76
71 1063491645 ALLYSON L WHEATON MD $96,027.60 1,002 3.88 64
72 1215146055 REBECCA J WOLFE $86,166.97 1,001 3.82 56
73 1669570404 CASIE RINEY PA $115,852.06 998 4.19 68
74 1326045808 RAY C STURDEVANT MD $96,431.59 994 3.20 82
75 1871586271 PATRICIA BLACKLEDGE ARNP $45,292.68 994 5.15 70
76 1285697722 DOUGLAS  JONES $90,093.53 989 3.40 97
77 1861559486 JOSPEH PATRICK BERTROCHE $126,323.20 984 3.92 52
78 1619186475 STEPHEN PALLONE MD $38,856.52 969 5.51 83
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79 1356520431 KAY A MARTTILA $95,658.81 964 3.49 91
80 1609218304 AMANDA O'TOOL ARNP $86,770.42 963 4.96 62
81 1801131461 MEREDITH DALLAS OLSON $52,687.25 955 4.53 129
82 1295830115 ALAN BOLLINGER DO $94,207.06 954 5.68 93
83 1780793976 MATTHEW D EGGERS MD $115,249.85 950 4.52 141
84 1124399522 JOYCE E PROUCH ARNP $88,914.68 947 4.51 72
85 1629042288 MARTIN J FIALKOV MD $82,199.20 942 4.81 84
86 1437373073 MOHSEN ABOU SEIF $30,598.82 938 4.32 78
87 1437238110 GENEVIEVE  NELSON $61,001.32 933 3.76 92
88 1669623583 ANNE MIREILLE METUGE AHONE $42,091.69 933 4.83 89
89 1942252895 KIMBERLY A THOMPSON $33,282.90 927 2.53 116
90 1710941000 LAURIE WARREN PA $108,749.82 925 3.46 86
91 1417241621 ASHLEY M MATHES $29,706.40 917 4.23 131
92 1225168511 FREDERICK C. ALDRICH $35,601.94 911 2.21 99
93 1902115652 SARAH LYNN BEATTIE ARNP $109,574.49 909 3.48 73
94 1104974658 UMA PALAKURTHY MD $38,009.39 909 4.25 107
95 1598733891 JERRY LEE WILLE MD $34,110.08 904 3.98 74
96 1598750432 CHRISTOPHER GENE OKIISHI MD $75,404.94 892 5.91 55
97 1891705968 ANITA HANDEVIDT ARNP $93,960.08 891 2.91 96
98 1164416269 ANN M PICK ARNP $30,348.76 882 4.18 126
99 1639423544 PAMELA S BROWN ARNP $88,954.98 880 3.74 138
100 1326013426 PAUL DENNIS PETERSON DO $43,382.19 875 2.92 102
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1 1013126705 JANICE M. R. STABER $1,709,589.58 $34,191.79 50 1
2 1952459463 DAVID LAWRENCE YURDIN PA $543,138.83 $479.80 1,132 2
3 1548247406 VILMARIE RODRIGUEZ-PADUA MD $362,838.46 $32,985.31 11 14
4 1770561946 DONALD HILLEBRAND MD $268,647.63 $1,865.61 144 22
5 1013115369 BOBBITA NAG MD $253,308.24 $127.93 1,980 4
6 1841407160 RAHUL BANSAL MD $232,782.81 $99.82 2,332 3
7 1780766659 CHESTER ROBERT BADGER $212,275.22 $51.20 4,146 9
8 1194817247 MARIA J STEELE ARNP $200,569.58 $1,269.43 158 976
9 1497060776 USHA PEREPU MBBS $196,870.23 $4,801.71 41 63
10 1649248378 KATHLEEN L WILD ARNP $194,058.80 $94.52 2,053 7
11 1285748004 BRUCE L HAYES MD $189,831.31 $1,291.37 147 8
12 1619153137 JODI BEST ARNP $184,987.06 $112.32 1,647 6
13 1205015906 DAVID F WIDITZ $171,510.61 $88.50 1,938 23
14 1083609358 JENNIFER S COOK $171,177.53 $268.72 637 17
15 1083784797 CAROL AUNAN ARNP $170,033.37 $85.14 1,997 11
16 1356337273 LISA J MENZIES $169,966.72 $305.70 556 19
17 1548256191 JUDITH A MILLER $168,662.59 $5,440.73 31 10
18 1982605762 JEFFREY D WILHARM $164,925.40 $68.15 2,420 20
19 1083603773 JACK T STAPLETON $158,501.06 $713.97 222 13
20 1073500690 KATHLEEN S ADAMS $156,523.85 $124.82 1,254 24
21 1194703074 WENDY ANNE WALDMAN $151,244.81 $243.94 620 15
22 1376777524 ALLADDIN MOH ELHADI ABOSAIDA $148,253.82 $387.09 383 25
23 1699767525 EZZATOLLAH SHIVAPOUR $144,443.81 $2,407.40 60 33
24 1841285772 KATHRYN CAROLE BREITBACH $142,954.37 $1,606.23 89 75
25 1043211303 ALI  SAFDAR $141,144.43 $74.80 1,887 35
26 1962558957 ALBERT N OKINE PA $138,151.55 $111.95 1,234 16
27 1841220290 KENT ELDON KUNZE MD $138,031.61 $99.37 1,389 28
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28 1346210184 JAMES BROOKS MD $134,743.82 $110.63 1,218 34
29 1972638864 LIUSKA MARIA PESCE $134,127.04 $428.52 313 36
30 1912991340 GHADA HAMDAN-ALLEN MD $130,226.51 $104.18 1,250 26
31 1861559486 JOSPEH PATRICK BERTROCHE $126,323.20 $128.38 984 32
32 1790708451 MICHAEL M MCCUBBIN $124,483.72 $333.74 373 21
33 1467502286 CHARLES TILLEY PA $120,521.09 $116.90 1,031 12
34 1609055771 CHARUTA NARAYAN JOSHI $119,034.87 $239.03 498 5
35 1669570404 CASIE RINEY PA $115,852.06 $116.08 998 40
36 1780793976 MATTHEW D EGGERS MD $115,249.85 $121.32 950 66
37 1477633188 CYD Q. GRAFFT $114,592.40 $85.01 1,348 42
38 1275844649 KATIE M HANSON $111,906.05 $81.45 1,374 43
39 1730239732 SRIRAMAMURTHY RAVIPATI MD $111,660.54 $85.37 1,308 88
40 1902115652 SARAH LYNN BEATTIE ARNP $109,574.49 $120.54 909 39
41 1003004391 DAVID B WALKER MD $109,514.25 $89.47 1,224 41
42 1255322996 MARK WILLIAM MITTAUER MD $109,239.83 $83.26 1,312 37
43 1508289620 GLORIA A MILLER $109,151.51 $91.80 1,189 29
44 1508946088 RICHARD E NIGHTINGALE $109,116.86 $87.02 1,254 47
45 1710941000 LAURIE WARREN PA $108,749.82 $117.57 925 49
46 1841293354 KEITH GUESS PA C $105,894.20 $96.44 1,098 51
47 1699760314 DIANE L EASTMAN $104,950.82 $1,153.31 91 119
48 1174584072 BRADLEY SCOTT LAIR MD $103,968.79 $805.96 129 38
49 1487908380 LISA ANN BECHTEL ARNP $103,776.45 $120.67 860 54
50 1922144088 THOMAS S HOPKINS DO $103,557.48 $101.63 1,019 44
51 1447242359 DANIEL M SLEITER ARNP $102,451.84 $602.66 170 78
52 1013960566 PETER JOSEPH SZEIBEL $100,434.56 $95.83 1,048 45
53 1649255431 STEPHANIE DEE PA $100,054.55 $1,563.35 64 31
54 1184602013 RODNEY A SHORT MD $99,348.19 $520.15 191 91
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55 1104034552 DEANNA BOOK BOESEN $97,930.98 $113.48 863 61
56 1871725705 PAUL E YOUSSEF DO $97,583.51 $32,527.84 3
57 1326045808 RAY C STURDEVANT MD $96,431.59 $97.01 994 57
58 1063491645 ALLYSON L WHEATON MD $96,027.60 $95.84 1,002 48
59 1356520431 KAY A MARTTILA $95,658.81 $99.23 964 52
60 1295830115 ALAN BOLLINGER DO $94,207.06 $98.75 954 46
61 1891705968 ANITA HANDEVIDT ARNP $93,960.08 $105.45 891 76
62 1033361563 ERMEI YAO PA $93,844.80 $507.27 185 86
63 1740246008 DANIEL LAMPTEY MD $92,766.65 $2,157.36 43 145
64 1215125216 REBECCA WALDING $92,142.41 $115.32 799 65
65 1629064324 KATHY RUPPENKAMP $92,001.21 $1,642.88 56 99
66 1215025309 DEBORAH LYNNE GARRELTS $91,043.42 $113.38 803 50
67 1306954391 WILLIAM E HOWARD IV $90,388.97 $86.66 1,043 87
68 1285697722 DOUGLAS  JONES $90,093.53 $91.10 989 84
69 1134425127 MELANIE HOWARD ARPN $89,243.16 $85.98 1,038 139
70 1639423544 PAMELA S BROWN ARNP $88,954.98 $101.09 880 96
71 1124399522 JOYCE E PROUCH ARNP $88,914.68 $93.89 947 74
72 1750376034 DUANGCHAI NARAWONG MD $88,428.59 $146.65 603 68
73 1619963949 EVA TSALIKIAN $87,786.33 $655.12 134 69
74 1609218304 AMANDA O'TOOL ARNP $86,770.42 $90.10 963 56
75 1356564371 CARLA K ABEL ZIEG ARNP $86,674.61 $125.98 688 67
76 1134402373 JULIE A SCHUCK $86,433.21 $664.87 130 106
77 1679669832 ERIN VOYLES HATCHER ARNP $86,364.82 $109.88 786 92
78 1215146055 REBECCA J WOLFE $86,166.97 $86.08 1,001 60
79 1841443025 LISA K WATKINS $84,933.44 $153.59 553 70
80 1902885445 BHARAT ASHOK MOTWANI MD $82,765.37 $909.51 91 295
81 1144475146 GAEL YONNET MD $82,362.43 $1,211.21 68 290
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82 1629042288 MARTIN J FIALKOV MD $82,199.20 $87.26 942 89
83 1104998251 JIMMY MASCARO DO $81,699.78 $94.12 868 101
84 1134171937 KATHRYN LEE FLANDERS ARNP $81,105.46 $750.98 108 59
85 1699075929 HIEDI CHRISTINE LANE ARNP $80,623.86 $96.10 839 114
86 1104029008 KATIE MARIE ULRING LARSON ODE MD $79,469.27 $333.90 238 64
87 1013905181 DONALD MACFARLANE MD $79,185.90 $5,656.14 14 4147
88 1538368170 CHRISTOPHER ROBERT MATSON $78,737.21 $35.64 2,209 85
89 1366435125 DANIEL EDWARD WESEMANN ARNP $78,698.38 $106.49 739 79
90 1467437806 GEORGIA LAUER PAC $77,654.54 $56.11 1,384 97
91 1245318393 JEAN TOBIN PA $76,998.34 $69.31 1,111 27
92 1053361972 MATTHEW LARRY HILL DO $76,017.93 $915.88 83 77
93 1588629414 THOMAS EARWOOD MD $76,012.33 $69.29 1,097 118
94 1891756128 PHILIP JOSEPH MULLER DO $75,690.31 $102.98 735 186
95 1598750432 CHRISTOPHER GENE OKIISHI MD $75,404.94 $84.53 892 71
96 1891788485 JOYCE VISTA WAYNE MD $75,356.05 $94.91 794 116
97 1821082850 JOHN F STECKER $74,626.39 $109.10 684 104
98 1588838841 LEENU MISHRA MD $74,412.69 $113.09 658 153
99 1104976109 ISAM ELIAS MARAR MD $74,279.89 $69.36 1,071 138
100 1285681528 MARVIN F PIBURN JR MD $74,053.01 $103.57 715 107
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TOP 20 THERAPEUTIC CLASS BY PAID AMOUNT
CATEGORY DESCRIPTION November/December 2014 RANK % BUDGET January/February 2015 RANK % BUDGET % CHANGE
ANTIPSYCHOTICS - ATYPICALS $5,163,394 1 8.5% $5,405,049 1 8.5% 4.7%
STIMULANTS - AMPHETAMINES - LONG ACTING $3,181,937 2 5.2% $3,369,455 2 5.3% 5.9%
ANTICONVULSANTS $3,134,689 3 5.2% $3,290,753 3 5.2% 5.0%
DIABETIC - INSULIN $2,715,454 4 4.5% $2,880,974 4 4.5% 6.1%
STIMULANTS - METHYLPHENIDATE - LONG ACTING $2,354,682 6 3.9% $2,812,385 5 4.4% 19.4%
ANTIDEPRESSANTS - SELECTED SSRI's $2,581,682 5 4.2% $2,331,556 6 3.7% -9.7%
ANTIHEMOPHILIC AGENTS $2,231,942 7 3.7% $2,293,580 7 3.6% 2.8%
ANTIASTHMATIC - ADRENERGIC COMBOS $1,835,113 8 3.0% $1,931,796 8 3.0% 5.3%
STIMULANTS - METHYLPHENIDATE $1,574,694 9 2.6% $1,717,017 9 2.7% 9.0%
BIOLOGIC IMMUNOMODULATORS $1,360,956 10 2.2% $1,523,704 10 2.4% 12.0%
MULTIPLE SCLEROSIS AGENTS $1,234,931 14 2.0% $1,441,729 11 2.3% 16.7%
ANTIASTHMATIC - BETA - ADRENERGICS $1,327,751 11 2.2% $1,388,705 12 2.2% 4.6%
DIABETIC - INSULIN  PENFILLS $1,258,601 12 2.1% $1,374,517 13 2.2% 9.2%
STIMULANTS - OTHER STIMULANTS / LIKE STIMULANTS $1,243,376 13 2.0% $1,329,350 14 2.1% 6.9%
RSV PROPHYLAXIS $987,314 17 1.6% $1,255,546 15 2.0% 27.2%
ANTIASTHMATIC - STEROID INHALANTS $1,037,724 16 1.7% $1,128,466 16 1.8% 8.7%
ANTIRETROVIRALS $1,156,934 15 1.9% $1,052,116 17 1.7% -9.1%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS $885,217 18 1.5% $927,355 18 1.5% 4.8%
ANTIASTHMATIC - ANTI-CHOLINERGICS $843,616 20 1.4% $889,285 19 1.4% 5.4%
INFLUENZA AGENTS $872,967 19 1.4% $851,159 20 1.3% -2.5%
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TOP 20 THERAPEUTIC CLASS BY PRESCRIPTION COUNT
CATEGORY DESCRIPTION November/December 2014 PREV RANK January/February 2015 CURR RANK PERC CHANGE
ANTIDEPRESSANTS - SELECTED SSRI's 87,975 1 88,415 1 0.5%
ANTICONVULSANTS 46,402 2 47,044 2 1.4%
NARCOTICS - MISC. 36,654 3 36,886 3 0.6%
BETA-LACTAMS / CLAVULANATE COMBO'S 32,250 4 36,575 4 13.4%
ANTIASTHMATIC - BETA - ADRENERGICS 29,700 6 30,897 5 4.0%
ANTIPSYCHOTICS - ATYPICALS 30,470 5 29,654 6 -2.7%
ANALGESICS - MISC. 25,163 7 25,481 7 1.3%
GI - PROTON PUMP INHIBITOR 22,701 10 23,935 8 5.4%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS 22,890 9 23,350 9 2.0%
ANTIHISTAMINES - NON-SEDATING 23,434 8 22,729 10 -3.0%
MACROLIDES / ERYTHROMYCIN'S / KETOLIDES 20,533 11 21,465 11 4.5%
ANXIOLYTICS - BENZODIAZEPINES 19,616 12 19,884 12 1.4%
ACE INHIBITORS 18,751 13 19,151 13 2.1%
NSAIDS 18,325 15 18,952 14 3.4%
ANTIHYPERTENSIVES - CENTRAL 18,336 14 18,533 15 1.1%
GLUCOCORTICOIDS - MINERALOCORTICOIDS 16,395 17 17,278 16 5.4%
DIURETICS 16,672 16 16,987 17 1.9%
CEPHALOSPORINS 14,557 20 16,606 18 14.1%
STIMULANTS - AMPHETAMINES - LONG ACTING 16,180 18 16,273 19 0.6%
MUSCLE RELAXANTS 14,785 19 14,939 20 1.0%
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TOP 100 DRUGS BY PAID AMOUNT
DRUG DESCRIPTION November/December 2014 PREVIOUS 
RANK
January/February 2015 RANK PERCENT CHANGE
ABILIFY $2,545,221.06 1 $2,771,075.89 1 8.87%
VYVANSE $2,462,607.35 2 $2,643,020.83 2 7.33%
METHYLPHENIDATE HCL ER $1,958,102.33 3 $2,382,299.96 3 21.66%
LANTUS $1,399,440.66 5 $1,467,202.25 4 4.84%
FOCALIN XR $1,237,797.14 6 $1,372,741.83 5 10.90%
ADVATE $1,455,851.80 4 $1,274,913.58 6 -12.43%
SYNAGIS $987,314.37 8 $1,255,545.75 7 27.17%
STRATTERA $882,150.59 9 $984,326.73 8 11.58%
CYMBALTA $1,189,198.06 7 $869,175.73 9 -26.91%
TAMIFLU $838,946.01 10 $844,107.16 10 0.62%
ADVAIR DISKUS $820,325.28 11 $842,364.19 11 2.69%
SPIRIVA HANDIHALER $782,898.89 13 $825,633.97 12 5.46%
NOVOSEVEN RT $507,202.49 19 $784,932.14 13 54.76%
VENTOLIN HFA $811,195.98 12 $723,709.64 14 -10.78%
LATUDA $632,203.03 15 $658,857.84 15 4.22%
DEPAKOTE ER $638,246.66 14 $658,302.42 16 3.14%
ADDERALL XR $628,735.47 16 $640,727.25 17 1.91%
NOVOLOG $572,726.15 17 $608,061.30 18 6.17%
HUMALOG $493,046.56 21 $550,257.53 19 11.60%
SYMBICORT $487,863.50 22 $540,371.40 20 10.76%
INVEGA SUSTENNA $516,971.99 18 $510,638.90 21 -1.23%
CRESTOR $470,975.02 24 $503,203.48 22 6.84%
HUMIRA PEN $484,458.02 23 $490,658.31 23 1.28%
AZITHROMYCIN $437,503.74 26 $464,472.63 24 6.16%
ATRIPLA $494,145.40 20 $463,949.01 25 -6.11%
COPAXONE $332,848.05 34 $452,362.31 26 35.91%
HYDROCODONE/ACETAMINOPHEN $425,484.70 27 $433,333.80 27 1.84%
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TOP 100 DRUGS BY PAID AMOUNT
DRUG DESCRIPTION November/December 2014 PREVIOUS 
RANK
January/February 2015 RANK PERCENT CHANGE
LEVEMIR $380,873.93 28 $412,848.47 28 8.40%
HARVONI $139,678.09 86 $401,499.98 29 187.45%
DEXILANT $346,192.58 32 $388,680.79 30 12.27%
SOVALDI $311,154.23 39 $380,743.65 31 22.36%
CEFDINIR $315,054.77 37 $370,584.98 32 17.63%
LANTUS SOLOSTAR $355,107.52 30 $370,393.06 33 4.30%
PULMICORT $322,664.65 35 $358,733.28 34 11.18%
QVAR $336,900.50 33 $358,550.54 35 6.43%
NOVOLOG FLEXPEN $308,751.91 40 $347,986.42 36 12.71%
NORDITROPIN FLEXPRO $198,546.97 62 $340,484.63 37 71.49%
TECFIDERA $352,586.64 31 $331,830.72 38 -5.89%
LYRICA $291,483.83 43 $327,581.06 39 12.38%
AMOXICILLIN $272,907.58 46 $316,222.90 40 15.87%
PROVENTIL HFA $313,828.77 38 $300,434.19 41 -4.27%
ENBREL SURECLICK $252,385.35 48 $296,918.10 42 17.64%
NASONEX $263,500.89 47 $292,720.95 43 11.09%
RISPERDAL CONSTA $286,311.83 44 $285,373.16 44 -0.33%
HUMIRA $231,169.54 50 $269,287.26 45 16.49%
TRUVADA $301,304.80 41 $263,680.52 46 -12.49%
INVEGA $249,299.44 49 $252,182.64 47 1.16%
AMPHETAMINE/DEXTROAMPHETA $218,612.86 55 $249,907.86 48 14.32%
ENBREL $213,129.70 56 $245,049.39 49 14.98%
FLOVENT HFA $219,019.71 54 $236,934.51 50 8.18%
OMEPRAZOLE $231,014.10 51 $233,835.01 51 1.22%
VIMPAT $209,414.60 57 $228,506.70 52 9.12%
LEVOTHYROXINE SODIUM $220,769.54 53 $226,421.84 53 2.56%
ADDERALL $299,133.20 42 $214,634.61 54 -28.25%
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TOP 100 DRUGS BY PAID AMOUNT
DRUG DESCRIPTION November/December 2014 PREVIOUS 
RANK
January/February 2015 RANK PERCENT CHANGE
COMBIVENT RESPIMAT $207,403.17 58 $212,826.07 55 2.61%
MONTELUKAST SODIUM $221,885.83 52 $211,863.46 56 -4.52%
PULMOZYME $205,604.48 59 $209,762.86 57 2.02%
GABAPENTIN $199,330.17 61 $204,873.45 58 2.78%
AMOXICILLIN/CLAVULANATE P $178,899.10 67 $204,586.03 59 14.36%
ENOXAPARIN SODIUM $5,118.96 720 $193,827.53 60 3,686.46%
H.P. ACTHAR $380,862.11 29 $193,603.92 61 -49.17%
JANUVIA $154,068.01 75 $193,124.88 62 25.35%
XYREM $176,039.19 68 $189,468.86 63 7.63%
METHYLPHENIDATE HCL $182,947.16 64 $187,624.67 64 2.56%
XIFAXAN $141,784.60 84 $182,382.33 65 28.63%
VESICARE $181,858.48 66 $174,815.79 66 -3.87%
HELIXATE FS $39,816.17 263 $173,954.95 67 336.90%
BUPROPION HCL XL $167,913.11 69 $173,948.22 68 3.59%
TOPROL XL $164,032.94 70 $173,611.03 69 5.84%
OPANA ER (CRUSH RESISTANT $202,690.48 60 $171,525.43 70 -15.38%
DULERA $150,302.49 80 $170,140.19 71 13.20%
QUILLIVANT XR $143,851.18 83 $168,351.81 72 17.03%
PROVIGIL $190,168.79 63 $166,936.27 73 -12.22%
ANAFRANIL $108,775.97 118 $161,754.53 74 48.70%
GILENYA $152,198.22 77 $158,143.17 75 3.91%
QUETIAPINE FUMARATE $160,367.84 72 $157,812.00 76 -1.59%
SEROQUEL XR $151,780.86 79 $155,508.90 77 2.46%
LISINOPRIL $149,904.24 81 $154,150.17 78 2.83%
SERTRALINE HCL $151,966.93 78 $154,117.44 79 1.42%
PROAIR HFA $7,517.54 625 $151,437.74 80 1,914.46%
RISPERIDONE $155,816.33 73 $148,673.50 81 -4.58%
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TOP 100 DRUGS BY PAID AMOUNT
DRUG DESCRIPTION November/December 2014 PREVIOUS 
RANK
January/February 2015 RANK PERCENT CHANGE
ALBUTEROL SULFATE $129,490.50 97 $148,534.84 82 14.71%
METADATE CD $131,063.15 94 $148,089.54 83 12.99%
SPRYCEL $181,884.54 65 $147,542.56 84 -18.88%
GENOTROPIN $273,194.61 45 $145,445.75 85 -46.76%
TRAMADOL HCL $147,431.47 82 $145,248.87 86 -1.48%
GLEEVEC $162,529.32 71 $143,853.51 87 -11.49%
CEPHALEXIN $127,349.24 98 $142,012.08 88 11.51%
SAPHRIS $141,484.87 85 $141,319.15 89 -0.12%
ATORVASTATIN CALCIUM $134,158.20 92 $141,226.45 90 5.27%
NAGLAZYME $110,611.92 117 $140,446.92 91 26.97%
SABRIL $111,560.34 115 $139,294.26 92 24.86%
LEVEMIR FLEXTOUCH $104,031.44 123 $139,287.98 93 33.89%
VENLAFAXINE HCL ER $136,268.72 90 $138,184.19 94 1.41%
INTUNIV $137,835.17 88 $137,297.89 95 -0.39%
ESCITALOPRAM OXALATE $138,911.72 87 $136,219.84 96 -1.94%
EPIPEN 2-PAK $123,280.20 103 $136,093.98 97 10.39%
BANZEL $136,631.63 89 $135,111.89 98 -1.11%
KUVAN $130,902.45 95 $133,901.45 99 2.29%
TRAZODONE HCL $126,317.45 101 $131,691.48 100 4.25%
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DRUG DESCRIPTION November/December 2014 PREVIOUS 
RANK
January/February 2015 RANK PERCENT CHANGE
HYDROCO/APAP TAB 5-325MG 16,050 1 16,289 1 1.49%
VENTOLIN HFA AER 14,843 2 12,780 2 -13.90%
AMOXICILLIN  SUS 400/5ML 10,552 5 12,534 3 18.78%
TRAMADOL HCL TAB 50MG 11,888 3 11,680 4 -1.75%
Loratadine Tab 10 MG 10,850 4 10,675 5 -1.61%
ALBUTEROL    NEB 0.083% 8,681 9 9,921 6 14.28%
AZITHROMYCIN TAB 250MG 9,015 6 9,266 7 2.78%
OMEPRAZOLE   CAP 20MG 8,643 10 8,982 8 3.92%
FLUOXETINE   CAP 20MG 8,694 8 8,954 9 2.99%
ESCITALOPRAM TAB 20MG 8,937 7 8,761 10 -1.97%
GABAPENTIN   CAP 300MG 8,511 11 8,481 11 -0.35%
OMEPRAZOLE   CAP 40MG 7,292 15 7,828 12 7.35%
AZITHROMYCIN SUS 200/5ML 7,548 14 7,768 13 2.91%
Cetirizine HCl Tab 10 MG 8,061 12 7,747 14 -3.90%
CYCLOBENZAPR TAB 10MG 7,683 13 7,720 15 0.48%
FLUTICASONE  SPR 50MCG 6,567 18 7,204 16 9.70%
CLONIDINE    TAB 0.1MG 7,006 16 7,031 17 0.36%
RANITIDINE   TAB 150MG 6,798 17 6,798 18 0.00%
SERTRALINE   TAB 100MG 6,489 19 6,514 19 0.39%
GUANFACINE   TAB 1MG 6,384 20 6,361 20 -0.36%
Aspirin Tab Delayed Release 81 MG 6,250 21 6,356 21 1.70%
TRAZODONE    TAB 50MG 5,744 25 6,155 22 7.16%
IBUPROFEN    TAB 800MG 5,841 23 6,132 23 4.98%
Acetaminophen Tab 325 MG 5,777 24 5,858 24 1.40%
TRAZODONE    TAB 100MG 5,680 26 5,855 25 3.08%
MONTELUKAST  TAB 10MG 5,893 22 5,824 26 -1.17%
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Ferrous Sulfate Tab 325 MG (65 MG 
Elemental Fe)
5,477 28 5,581 27 1.90%
LISINOPRIL   TAB 10MG 5,354 29 5,434 28 1.49%
AMOXICILLIN  CAP 500MG 4,918 34 5,359 29 8.97%
METFORMIN    TAB 500MG 5,133 30 5,204 30 1.38%
LISINOPRIL   TAB 20MG 5,044 33 5,180 31 2.70%
HYDROCHLOROT TAB 25MG 5,079 31 5,178 32 1.95%
POLYETH GLYC POW 3350 NF 4,185 43 4,621 33 10.42%
CLONAZEPAM   TAB 1MG 4,557 35 4,596 34 0.86%
PROVENTIL    AER HFA 5,066 32 4,567 35 -9.85%
METFORMIN    TAB 1000MG 4,396 37 4,501 36 2.39%
PREDNISONE   TAB 20MG 4,274 41 4,497 37 5.22%
MELOXICAM    TAB 15MG 4,394 38 4,494 38 2.28%
METHYLPHENID TAB 36MG ER 4,328 39 4,385 39 1.32%
Sennosides-Docusate Sodium Tab 8.6-50 
MG
4,300 40 4,358 40 1.35%
AMOXICILLIN  SUS 250/5ML 3,977 51 4,319 41 8.60%
CITALOPRAM   TAB 20MG 4,243 42 4,302 42 1.39%
CEPHALEXIN   CAP 500MG 3,956 53 4,270 43 7.94%
OXYCOD/APAP  TAB 5-325MG 4,436 36 4,267 44 -3.81%
SERTRALINE   TAB 50MG 4,057 48 4,203 45 3.60%
HYDROCO/APAP TAB 7.5-325 4,104 46 4,162 46 1.41%
LANTUS       INJ 100/ML 4,004 49 4,133 47 3.22%
ALPRAZOLAM   TAB 1MG 4,117 45 4,114 48 -0.07%
VENLAFAXINE  CAP 150MG ER 4,118 44 4,085 49 -0.80%
AMLODIPINE   TAB 10MG 3,890 54 4,078 50 4.83%
Aspirin Chew Tab 81 MG 4,101 47 4,028 51 -1.78%
PANTOPRAZOLE TAB 40MG 3,806 56 4,025 52 5.75%
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ONDANSETRON  TAB 4MG ODT 3,750 58 4,016 53 7.09%
AMOX/K CLAV  TAB 875MG 3,599 63 3,996 54 11.03%
NAPROXEN     TAB 500MG 3,709 59 3,926 55 5.85%
CLONAZEPAM   TAB 0.5MG 3,970 52 3,924 56 -1.16%
CEFDINIR     SUS 250/5ML 3,104 73 3,897 57 25.55%
PREDNISOLONE SOL 15MG/5ML 5,478 27 3,878 58 -29.21%
CITALOPRAM   TAB 40MG 3,814 55 3,869 59 1.44%
ALPRAZOLAM   TAB 0.5MG 3,697 60 3,779 60 2.22%
ZOLPIDEM     TAB 10MG 3,678 61 3,735 61 1.55%
SMZ/TMP DS   TAB 800-160 3,987 50 3,735 62 -6.32%
MONTELUKAST  CHW 5MG 3,751 57 3,683 63 -1.81%
HYDROCO/APAP TAB 10-325MG 3,655 62 3,667 64 0.33%
AMLODIPINE   TAB 5MG 3,314 67 3,490 65 5.31%
ATORVASTATIN TAB 40MG 3,247 69 3,476 66 7.05%
FOLIC ACID   TAB 1MG 3,321 66 3,446 67 3.76%
Acetaminophen Tab 500 MG 3,364 65 3,411 68 1.40%
METHYLPHENID TAB 54MG ER 3,305 68 3,388 69 2.51%
METOPROL TAR TAB 25MG 3,144 72 3,263 70 3.78%
HYDROXYZ PAM CAP 25MG 3,074 75 3,177 71 3.35%
LORAZEPAM    TAB 1MG 3,089 74 3,149 72 1.94%
SIMVASTATIN  TAB 20MG 3,152 71 3,105 73 -1.49%
BUPROPN HCL  TAB 300MG XL 3,199 70 3,096 74 -3.22%
TAMIFLU      SUS 6MG/ML 2,990 77 2,957 75 -1.10%
SPIRIVA      CAP HANDIHLR 2,803 81 2,937 76 4.78%
BUPROPN HCL  TAB 150MG XL 3,027 76 2,917 77 -3.63%
VYVANSE      CAP 30MG 2,862 78 2,907 78 1.57%
ATORVASTATIN TAB 20MG 2,693 85 2,858 79 6.13%
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LORAZEPAM    TAB 0.5MG 2,791 82 2,854 80 2.26%
RISPERIDONE  TAB 1MG 2,805 80 2,811 81 0.21%
VENLAFAXINE  CAP 75MG ER 2,847 79 2,786 82 -2.14%
LISINOPRIL   TAB 40MG 2,650 88 2,743 83 3.51%
FUROSEMIDE   TAB 40MG 2,673 86 2,725 84 1.95%
LEVOTHYROXIN TAB 50MCG 2,673 87 2,722 85 1.83%
VYVANSE      CAP 40MG 2,721 83 2,695 86 -0.96%
SIMVASTATIN  TAB 40MG 2,707 84 2,658 87 -1.81%
CYMBALTA     CAP 60MG 3,584 64 2,637 88 -26.42%
PROAIR HFA   AER 253 548 2,609 89 931.23%
FLUCONAZOLE  TAB 150MG 2,410 93 2,601 90 7.93%
PREDNISONE   TAB 10MG 2,636 90 2,593 91 -1.63%
Cetirizine HCl Oral Soln 1 MG/ML (5 
MG/5ML)
2,644 89 2,517 92 -4.80%
QUETIAPINE   TAB 100MG 2,549 91 2,498 93 -2.00%
AZITHROMYCIN SUS 100/5ML 2,156 105 2,469 94 14.52%
METRONIDAZOL TAB 500MG 2,354 96 2,441 95 3.70%
APAP/CODEINE TAB 300-30MG 2,302 100 2,404 96 4.43%
LISINOPRIL   TAB 5MG 2,371 94 2,399 97 1.18%
AMOXICILLIN  TAB 875MG 2,006 113 2,396 98 19.44%
CLOPIDOGREL  TAB 75MG 2,331 98 2,343 99 0.51%
DOXYCYC MONO CAP 100MG 2,189 102 2,321 100 6.03%
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January/February 2015 March/April 2015 % CHANGE
TOTAL PAID AMOUNT $61,999,062 $70,236,272 13.3%
UNIQUE USERS 202,807 211,678 4.4%
COST PER USER $305.70 $331.81 8.5%
TOTAL PRESCRIPTIONS 954,672 1,049,882 10.0%
AVERAGE PRESCRIPTIONS PER USER 4.71 4.96 5.4%
AVERAGE COST PER PRESCRIPTION $64.94 $66.90 3.0%
# GENERIC PRESCRIPTIONS 807,283 890,546 10.3%
% GENERIC 84.6% 84.8% 0.3%
$ GENERIC $16,867,982 $19,677,756 16.7%
AVERAGE GENERIC PRESCRIPTION COST $20.89 $22.10 5.8%
AVERAGE GENERIC DAYS SUPPLY 23 23 0.0%
# BRAND PRESCRIPTIONS 144,063 155,670 10.3%
% BRAND 15.1% 14.8% 0.3%
$ BRAND $44,948,150 $50,237,678 16.7%
AVERAGE BRAND PRESCRIPTION COST $312.00 $322.72 5.8%
AVERAGE BRAND DAYS SUPPLY 25 26 0.0%
Bi-Monthly Statistics
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UTILIZATION BY AGE
AGE January/February 2015 March/April 2015
0-6 37,410 38,259
7-12 30,396 31,614
13-18 24,995 26,120
19-64 100,659 106,462
65+ 9,347 9,223
202,807 211,678
UTILIZATION BY GENDER AND AGE
GENDER AGE January/February 2015 March/April 2015
F
0-6 17,711 17,976
7-12 13,310 13,790
13-18 12,723 13,401
19-64 64,304 67,764
65+ 6,506 6,425
114,554 119,356
M
0-6 19,699 20,283
7-12 17,086 17,824
13-18 12,272 12,719
19-64 36,355 38,698
65+ 2,841 2,798
88,253 92,322
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March/April 2015
RANK PHARMACY NAME PHARMACY CITY STATE PRESCRIPTION 
COUNT
PAID AMT AVG COST RX PREVIOUS RANK
1 BROADLAWNS MEDICAL CENTER DES MOINES IA 19,124 $485,581.44 $25.39 1
2 WALGREEN #05239 DAVENPORT IA 12,869 $724,464.20 $56.30 2
3 WALGREEN #04405 COUNCIL BLUFFS IA 10,622 $613,450.68 $57.75 3
4 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 10,031 $745,799.51 $74.35 4
5 WALGREEN #05721 DES MOINES IA 9,528 $553,286.67 $58.07 5
6 WALGREEN #359 DES MOINES IA 7,592 $424,810.01 $55.95 7
7 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,588 $410,290.86 $54.07 6
8 MERCY FAMILY PHARMACY DUBUQUE IA 7,521 $436,551.60 $58.04 9
9 WALGREEN COMPANY #3700 COUNCIL BLUFFS IA 7,302 $375,193.59 $51.38 10
10 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 7,252 $396,485.70 $54.67 11
11 WALGREEN COMPANY 07455 WATERLOO IA 7,179 $353,667.03 $49.26 8
12 WALGREEN #05362 DES MOINES IA 6,922 $375,044.07 $54.18 12
13 SIOUXLAND COMM HEALTH CTR 
PHARMA
SIOUX CITY IA 6,790 $125,193.26 $18.44 13
14 WALGREENS #07453 DES MOINES IA 6,226 $343,440.51 $55.16 15
15 MARTIN HEALTH SERVICES INC DENVER IA 5,973 $184,635.94 $30.91 14
16 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,824 $325,992.62 $55.97 18
17 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,715 $330,482.47 $57.83 16
18 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,619 $336,742.03 $59.93 17
19 WALGREEN #04041 DAVENPORT IA 5,432 $301,198.53 $55.45 21
20 WALGREEN COMPANY 05777 DES MOINES IA 5,330 $311,020.86 $58.35 20
21 WALGREEN #05852 DES MOINES IA 5,279 $285,235.34 $54.03 23
22 HY-VEE PHARMACY #1 (1136) DES MOINES IA 5,235 $287,811.08 $54.98 25
23 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 5,190 $331,828.89 $63.94 22
24 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,088 $187,224.93 $36.80 19
25 WALGREEN #11709 DAVENPORT IA 5,032 $286,433.71 $56.92 27
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26 RASHID PHARMACY PLC FORT MADISON IA 5,016 $295,030.25 $58.82 26
27 PHARMACY MATTERS LTC IOWA CITY IA 4,843 $213,749.05 $44.14 35
28 WALGREEN #05886 KEOKUK IA 4,758 $271,190.85 $57.00 29
29 DANIEL PHARMACY INC FORT DODGE IA 4,642 $261,266.00 $56.28 28
30 WALGREEN #910 SIOUX CITY IA 4,378 $238,757.60 $54.54 24
31 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,338 $243,115.27 $56.04 30
32 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 4,256 $291,077.16 $68.39 32
33 WALGREEN #7452 DES MOINES IA 4,236 $214,516.65 $50.64 40
34 MAHASKA DRUG INC OSKALOOSA IA 4,120 $253,626.03 $61.56 31
35 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 4,119 $236,089.65 $57.32 33
36 HY-VEE PHARMACY #3 (1142) DES MOINES IA 4,096 $255,144.09 $62.29 34
37 HY-VEE PHARMACY #2 (1138) DES MOINES IA 4,087 $263,907.48 $64.57 39
38 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 4,049 $269,148.15 $66.47 37
39 WALGREEN #03595 DAVENPORT IA 4,006 $220,903.24 $55.14 36
40 WALGREENS #15647 SIOUX CITY IA 3,892 $216,922.24 $55.74 71
41 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,851 $236,305.22 $61.36 44
42 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,799 $265,319.11 $69.84 48
43 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,764 $256,489.17 $68.14 42
44 MEDICAP PHARMACY INDIANOLA IA 3,727 $175,535.89 $47.10 38
45 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,707 $193,065.43 $52.08 43
46 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,702 $196,165.26 $52.99 41
47 WALGREENS #10855 WATERLOO IA 3,643 $191,360.43 $52.53 50
48 THOMPSON-DEAN DRUG SIOUX CITY IA 3,643 $308,641.39 $84.72 56
49 WALGREENS #05119 CLINTON IA 3,617 $199,432.11 $55.14 46
50 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,572 $225,195.43 $63.04 55
51 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,559 $152,945.51 $42.97 45
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52 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 3,542 $178,389.38 $50.36 54
53 WAL-MART PHARMACY #10-5115 DAVENPORT IA 3,531 $152,013.40 $43.05 51
54 HY VEE PHARMACY #1449 NEWTON IA 3,490 $199,665.17 $57.21 57
55 WALGREENS #11942 DUBUQUE IA 3,476 $201,748.24 $58.04 61
56 WALGREEN #05044 BURLINGTON IA 3,475 $194,456.79 $55.96 49
57 RIGHT DOSE PHARMACY ANKENY IA 3,462 $241,828.59 $69.85 62
58 WAL-MART PHARMACY 10-2889 CLINTON IA 3,436 $154,560.92 $44.98 52
59 WAL-MART PHARMACY #10-0985 FAIRFIELD IA 3,429 $143,942.03 $41.98 47
60 WALGREENS 07968 DES MOINES IA 3,336 $169,145.62 $50.70 63
61 WAL MART PHARMACY 10-1621 CENTERVILLE IA 3,298 $159,759.87 $48.44 53
62 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 3,284 $184,480.37 $56.18 64
63 A AVENUE PHARMACY CEDAR RAPIDS IA 3,254 $223,533.24 $68.69 58
64 HY-VEE PHARMACY (1058) CENTERVILLE IA 3,253 $184,277.17 $56.65 60
65 HY-VEE PHARMACY (1075) CLINTON IA 3,190 $225,988.12 $70.84 69
66 WAL MART PHARMACY 10-3590 SIOUX CITY IA 3,153 $167,295.79 $53.06 59
67 HY-VEE PHARMACY #3 (1056) CEDAR RAPIDS IA 3,094 $189,994.45 $61.41 75
68 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 3,088 $210,208.49 $68.07 80
69 WAL-MART PHARMACY #10-1393 OSKALOOSA IA 3,055 $142,711.29 $46.71 65
70 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 3,045 $186,232.88 $61.16 67
71 HY-VEE DRUGSTORE #7031 DES MOINES IA 3,042 $175,801.53 $57.79 81
72 WALGREEN #4714 DES MOINES IA 3,017 $173,405.40 $57.48 73
73 HY-VEE PHARMACY #2 (1044) BURLINGTON IA 3,006 $177,708.19 $59.12 76
74 HY-VEE PHARMACY (1875) WEBSTER CITY IA 3,003 $173,884.76 $57.90 77
75 WALGREEN #05077 IOWA CITY IA 2,935 $174,805.30 $59.56 86
76 HY-VEE PHARMACY 1504 OTTUMWA IA 2,925 $185,007.28 $63.25 84
77 WAL-MART PHARMACY #10-0646 ANAMOSA IA 2,925 $121,991.64 $41.71 66
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78 HY-VEE PHARMACY (1522) PERRY IA 2,920 $145,360.55 $49.78 74
79 WAGNER PHARMACY CLINTON IA 2,915 $185,784.15 $63.73 68
80 WALGREEN #09708 DUBUQUE IA 2,898 $172,066.26 $59.37 72
81 WALGREEN #05942 NEWTON IA 2,898 $168,284.82 $58.07 85
82 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,886 $180,852.75 $62.67 70
83 STANGEL PHARMACY ONAWA IA 2,875 $173,551.78 $60.37 93
84 HY-VEE DRUGSTORE (7056) MASON CITY IA 2,854 $147,038.74 $51.52 79
85 HY-VEE PHARMACY (1065) CHARITON IA 2,825 $159,287.87 $56.39 92
86 HARTIG PHARMACY SERVICES DUBUQUE IA 2,726 $167,302.96 $61.37 78
87 HY-VEE PHARMACY (1009) DBA ALBIA IA 2,723 $137,354.89 $50.44 83
88 HY-VEE DRUGSTORE # 7035 FT DODGE IA 2,701 $145,950.71 $54.04 96
89 HY-VEE FOOD STORE WATERLOO IA 2,695 $252,505.53 $93.69 100
90 LA GRANGE PHARMACY INC VINTON IA 2,693 $154,138.32 $57.24 88
91 WALGREEN #05361 FORT DODGE IA 2,666 $140,479.47 $52.69 98
92 WAL-MART PHARMACY #10-3394 ATLANTIC IA 2,661 $127,340.65 $47.85 87
93 HY-VEE PHARMACY #4 (1148) DES MOINES IA 2,639 $157,711.17 $59.76 102
94 WAL-MART PHARMACY 10-0784 MT PLEASANT IA 2,633 $160,698.82 $61.03 91
95 HY VEE PHARMACY (1170) ESTHERVILLE IA 2,625 $149,522.30 $56.96 113
96 SCOTT PHARMACY FAYETTE IA 2,625 $131,439.18 $50.07 89
97 HY-VEE PHARMACY #1 (1610) SIOUX CITY IA 2,602 $168,664.09 $64.82 105
98 ALL CARE HEALTH CENTER COUNCIL BLUFFS IA 2,602 $51,021.12 $19.61 108
99 S - S PHARMACY INC COUNCIL BLUFFS IA 2,599 $204,825.41 $78.81 82
100 WALGREEN #07454 ANKENY IA 2,598 $167,509.05 $64.48 116
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1 NUCARA PHARMACY #27 PLEASANT HILL IA 2,547 $1,352,798.88 $3,012.92 2
2 ARJ INFUSION SERVICES INC LENEXA KS 42 $1,298,946.71 $216,491.12 1
3 MEDFUSIONRX LLC FRANKLIN TN 99 $868,131.14 $19,730.25 28
4 CAREMARK KANSAS SPEC PHARMACY 
LL
LENEXA KS 158 $752,407.80 $8,550.09 3
5 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 10,031 $745,799.51 $318.72 5
6 WALGREEN #05239 DAVENPORT IA 12,869 $724,464.20 $204.71 4
7 WALGREEN #04405 COUNCIL BLUFFS IA 10,622 $613,450.68 $221.30 6
8 HY-VEE PHARMACY SOLUTIONS OMAHA NE 279 $565,896.69 $3,929.84 9
9 WALGREEN #05721 DES MOINES IA 9,528 $553,286.67 $188.00 7
10 ACCREDO HEALTH GROUP INC NASHVILLE TN 12 $508,376.57 $72,625.22 14
11 BROADLAWNS MEDICAL CENTER DES MOINES IA 19,124 $485,581.44 $195.33 12
12 AMBER PHARMACY OMAHA NE 132 $483,961.93 $14,665.51 11
13 MERCY FAMILY PHARMACY DUBUQUE IA 7,521 $436,551.60 $365.32 13
14 WALGREEN #359 DES MOINES IA 7,592 $424,810.01 $192.05 15
15 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,588 $410,290.86 $239.52 24
16 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 7,252 $396,485.70 $185.36 18
17 ACCREDO HEALTH GROUP INC MEMPHIS TN 77 $395,394.38 $10,405.12 8
18 WALGREEN COMPANY #3700 COUNCIL BLUFFS IA 7,302 $375,193.59 $181.60 19
19 WALGREEN #05362 DES MOINES IA 6,922 $375,044.07 $170.24 21
20 WALGREEN COMPANY 07455 WATERLOO IA 7,179 $353,667.03 $152.51 20
21 WALGREENS #07453 DES MOINES IA 6,226 $343,440.51 $198.06 22
22 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,619 $336,742.03 $454.44 23
23 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 5,190 $331,828.89 $286.55 43
24 DIPLOMAT SPECIALTY PHARMACY FLINT MI 79 $331,468.44 $9,470.53 29
25 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,715 $330,482.47 $258.39 31
26 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,824 $325,992.62 $247.53 46
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27 ACCREDO HEALTH GROUP INC WARRENDALE PA 53 $315,868.28 $17,548.24 34
28 WALGREEN COMPANY 05777 DES MOINES IA 5,330 $311,020.86 $218.57 26
29 THOMPSON-DEAN DRUG SIOUX CITY IA 3,643 $308,641.39 $442.81 32
30 UNIV OF IOWA COMMUNITY HOMECARE IOWA CITY IA 271 $305,242.81 $2,631.40 16
31 PROCARE PHARMACY DIRECT LLC MONROEVILLE PA 75 $304,373.21 $7,423.74 33
32 WALGREENS SPECIALTY PHARMACY 
#12
ANN ARBOR MI 64 $303,117.35 $8,915.22 25
33 WALGREEN #04041 DAVENPORT IA 5,432 $301,198.53 $185.70 42
34 RASHID PHARMACY PLC FORT MADISON IA 5,016 $295,030.25 $303.22 36
35 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 4,256 $291,077.16 $485.13 27
36 HY-VEE PHARMACY #1 (1136) DES MOINES IA 5,235 $287,811.08 $220.88 41
37 WALGREEN #11709 DAVENPORT IA 5,032 $286,433.71 $220.00 35
38 WALGREEN #05852 DES MOINES IA 5,279 $285,235.34 $172.24 38
39 DOHMEN LIFE SCIENCE SERVICES LLC CHESTERFIELD MO 22 $278,349.81 $23,195.82 59
40 WALGREEN #05886 KEOKUK IA 4,758 $271,190.85 $269.31 44
41 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 4,049 $269,148.15 $366.69 56
42 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,799 $265,319.11 $324.35 73
43 HY-VEE PHARMACY #2 (1138) DES MOINES IA 4,087 $263,907.48 $316.06 48
44 DANIEL PHARMACY INC FORT DODGE IA 4,642 $261,266.00 $305.22 47
45 UNITYPOINT AT HOME URBANDALE IA 264 $256,584.39 $2,618.21 10
46 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,764 $256,489.17 $242.66 40
47 HY-VEE PHARMACY #3 (1142) DES MOINES IA 4,096 $255,144.09 $302.30 55
48 MAHASKA DRUG INC OSKALOOSA IA 4,120 $253,626.03 $281.81 45
49 HY-VEE FOOD STORE WATERLOO IA 2,695 $252,505.53 $433.86 94
50 WALGREENS INFUSION SERVICES OMAHA NE 47 $246,061.38 $11,184.61 51
51 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,338 $243,115.27 $264.54 49
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52 RIGHT DOSE PHARMACY ANKENY IA 3,462 $241,828.59 $655.36 54
53 WALGREEN #910 SIOUX CITY IA 4,378 $238,757.60 $155.14 37
54 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,851 $236,305.22 $257.13 61
55 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 4,119 $236,089.65 $302.29 58
56 US BIOSERVICE CORPORATION FRISCO TX 19 $227,385.65 $17,491.20 30
57 HY-VEE PHARMACY (1075) CLINTON IA 3,190 $225,988.12 $387.63 96
58 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,572 $225,195.43 $360.31 62
59 A AVENUE PHARMACY CEDAR RAPIDS IA 3,254 $223,533.24 $596.09 50
60 WALGREEN #03595 DAVENPORT IA 4,006 $220,903.24 $175.32 53
61 WALGREENS #15647 SIOUX CITY IA 3,892 $216,922.24 $158.34 97
62 WALGREEN #7452 DES MOINES IA 4,236 $214,516.65 $158.31 70
63 PHARMACY MATTERS LTC IOWA CITY IA 4,843 $213,749.05 $593.75 76
64 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 3,088 $210,208.49 $364.95 91
65 S - S PHARMACY INC COUNCIL BLUFFS IA 2,599 $204,825.41 $576.97 60
66 WALGREENS #11942 DUBUQUE IA 3,476 $201,748.24 $201.95 72
67 HY VEE PHARMACY #1449 NEWTON IA 3,490 $199,665.17 $254.03 99
68 WALGREENS #05119 CLINTON IA 3,617 $199,432.11 $208.61 66
69 ACARIAHEALTH PHARMACY #11 INC HOUSTON TX 38 $196,873.45 $8,559.72 52
70 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,702 $196,165.26 $212.99 64
71 WALGREEN #05044 BURLINGTON IA 3,475 $194,456.79 $180.39 67
72 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,707 $193,065.43 $292.08 57
73 WALGREENS #10855 WATERLOO IA 3,643 $191,360.43 $187.06 75
74 HY-VEE PHARMACY #3 (1056) CEDAR RAPIDS IA 3,094 $189,994.45 $244.52 134
75 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,088 $187,224.93 $203.28 39
76 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 3,045 $186,232.88 $246.34 80
77 WAGNER PHARMACY CLINTON IA 2,915 $185,784.15 $370.09 71
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78 HY-VEE PHARMACY 1504 OTTUMWA IA 2,925 $185,007.28 $343.24 81
79 MARTIN HEALTH SERVICES INC DENVER IA 5,973 $184,635.94 $180.31 68
80 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 3,284 $184,480.37 $295.64 111
81 HY-VEE PHARMACY (1058) CENTERVILLE IA 3,253 $184,277.17 $314.47 98
82 COMMUNITY HEALTHCARE SERVICES LOMA LINDA CA 3 $182,891.43 $91,445.72 17
83 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,886 $180,852.75 $291.23 82
84 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 3,542 $178,389.38 $243.37 108
85 HY-VEE PHARMACY #2 (1044) BURLINGTON IA 3,006 $177,708.19 $322.52 113
86 HY-VEE PHARMACY 1071 CLARINDA IA 2,575 $176,296.71 $337.09 93
87 HY-VEE DRUGSTORE #7031 DES MOINES IA 3,042 $175,801.53 $353.02 105
88 MEDICAP PHARMACY INDIANOLA IA 3,727 $175,535.89 $375.08 63
89 WALGREEN #05077 IOWA CITY IA 2,935 $174,805.30 $199.78 85
90 HY-VEE PHARMACY (1875) WEBSTER CITY IA 3,003 $173,884.76 $262.27 126
91 STANGEL PHARMACY ONAWA IA 2,875 $173,551.78 $335.04 86
92 WALGREEN #4714 DES MOINES IA 3,017 $173,405.40 $194.84 83
93 WALGREEN #09708 DUBUQUE IA 2,898 $172,066.26 $165.77 84
94 FIFIELD PHARMACY DES MOINES IA 1,902 $170,548.15 $472.43 115
95 HY-VEE MAINSTREET PHARMACY #7070 SIOUX CITY IA 2,570 $170,543.66 $278.21 136
96 WALGREENS 07968 DES MOINES IA 3,336 $169,145.62 $154.19 77
97 HY-VEE PHARMACY #1 (1610) SIOUX CITY IA 2,602 $168,664.09 $241.99 112
98 WALGREEN #05942 NEWTON IA 2,898 $168,284.82 $241.44 88
99 WALGREEN #07454 ANKENY IA 2,598 $167,509.05 $237.60 110
100 HARTIG PHARMACY SERVICES DUBUQUE IA 2,726 $167,302.96 $643.47 74
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1 1780766659 CHESTER ROBERT BADGER $237,162.23 4,541 6.01 1
2 1982605762 JEFFREY D WILHARM $196,957.21 2,980 7.04 2
3 1013115369 BOBBITA NAG MD $294,818.25 2,259 4.38 9
4 1043211303 ALI  SAFDAR $197,856.26 2,250 3.93 11
5 1649248378 KATHLEEN L WILD ARNP $232,846.49 2,218 3.89 7
6 1538368170 CHRISTOPHER ROBERT MATSON $82,246.78 2,176 5.90 4
7 1467682351 NICOLE GILG $78,030.74 2,144 5.78 5
8 1205015906 DAVID F WIDITZ $190,045.70 2,140 5.06 10
9 1063622637 HUSSAIN BANU $60,594.42 2,086 6.58 6
10 1841407160 RAHUL BANSAL MD $231,251.28 2,036 4.52 3
11 1083784797 CAROL AUNAN ARNP $157,539.74 1,998 3.80 8
12 1215192224 SHALINA SHAIK $52,827.58 1,990 6.40 12
13 1073667606 ELIZABETH MCCURDY DO $67,291.69 1,828 5.95 13
14 1801998372 WENDY MICHELE HANSEN-PENMAN DO $49,152.01 1,770 7.38 16
15 1316922545 MABRA G ABERNATHY $59,926.36 1,733 5.38 15
16 1841220290 KENT ELDON KUNZE MD $146,658.32 1,700 5.06 25
17 1255322996 MARK WILLIAM MITTAUER MD $112,737.02 1,656 4.56 28
18 1467502286 CHARLES TILLEY PA $184,255.36 1,606 3.84 65
19 1245388743 TIMOTHY SWINTON MD $74,060.51 1,551 6.83 18
20 1023053972 BRYANT MUTCHLER DO $71,394.93 1,542 5.55 17
21 1023377827 LISA KAY CHASE $68,029.81 1,505 5.47 21
22 1275844649 KATIE M HANSON $127,596.55 1,504 4.57 24
23 1912991340 GHADA HAMDAN-ALLEN MD $152,837.81 1,487 4.94 39
24 1972758126 REBECCA BOLLIN $40,269.26 1,471 5.31 29
25 1477633188 CYD Q. GRAFFT $124,951.83 1,457 4.25 27
26 1043434525 ROBERT MARVIN KENT MD $73,319.61 1,444 4.47 19
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27 1598962870 CHRISTY QUILLEN ARNP $47,975.79 1,409 5.28 34
28 1720293087 RAJNI BATRA MD $74,277.23 1,405 3.72 23
29 1205169273 TERESA ANN DOWLING $41,182.63 1,395 5.74 41
30 1144214248 KRISTI WALZ MD $99,437.57 1,382 4.83 32
31 1073500690 KATHLEEN S ADAMS $186,287.06 1,378 4.03 33
32 1073594768 JERROLD V FLATT DO $57,645.28 1,354 4.57 26
33 1497736326 RANDY R ROBINSON $65,844.67 1,309 6.00 35
34 1952459463 DAVID LAWRENCE YURDIN PA $652,069.44 1,303 4.59 48
35 1679669832 ERIN VOYLES HATCHER ARNP $147,707.79 1,298 3.90 138
36 1184722910 LAURA M VAN CLEVE DO $150,000.46 1,290 3.65 229
37 1508946088 RICHARD E NIGHTINGALE $97,147.49 1,287 6.57 31
38 1891705968 ANITA HANDEVIDT ARNP $130,930.58 1,281 3.49 96
39 1003004391 DAVID B WALKER MD $122,563.84 1,278 4.44 37
40 1467437806 GEORGIA LAUER PAC $72,286.81 1,267 5.53 22
41 1164538674 JOSEPH M WANZEK $66,198.61 1,258 4.80 44
42 1588629414 THOMAS EARWOOD $79,682.30 1,257 5.26 51
43 1538157383 DAVID WENGER-KELLER MD $53,673.58 1,241 5.37 46
44 1780877878 CHRISTOPHER JACOBS ARNP $56,091.14 1,237 4.31 68
45 1215146055 REBECCA J WOLFE $102,881.49 1,223 4.22 73
46 1619153137 JODI BEST ARNP $145,601.73 1,212 4.19 14
47 1841293354 KEITH GUESS PA C $129,435.57 1,211 4.81 58
48 1346210184 JAMES BROOKS MD $139,684.75 1,203 5.35 38
49 1982766705 MALHAR GORE $37,179.16 1,200 4.88 45
50 1962558957 ALBERT N OKINE PA $139,886.95 1,197 6.47 36
51 1215080759 JUANITA M O'BRIEN $43,270.52 1,197 5.73 54
52 1508289620 GLORIA A MILLER $108,976.40 1,188 6.99 40
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RANK NPI NUM PRESCRIBER NAME PAID AMOUNT PRESCRIPTION COUNT AVG SCRIPTS 
MEMBER
PREVIOUS RANK
53 1306133095 DEBRA LEE ANDERSON ARNP $55,992.26 1,180 4.31 52
54 1902809536 KIRAN BHASKAR KHANOLKAR MD $65,689.31 1,179 5.22 50
55 1104976109 ISAM ELIAS MARAR MD $81,658.60 1,176 5.16 55
56 1184945321 DEANNE REMER $79,512.58 1,168 6.25 53
57 1730239732 SRIRAMAMURTHY RAVIPATI MD $104,322.92 1,160 3.36 30
58 1417241621 ASHLEY M MATHES $34,260.91 1,160 4.66 91
59 1134425127 MELANIE HOWARD ARPN $95,550.08 1,156 3.74 63
60 1285697722 DOUGLAS  JONES $117,417.78 1,151 3.80 75
61 1295830115 ALAN BOLLINGER DO $99,118.86 1,139 5.99 80
62 1528144383 RAMONCITO AMURAO O'CAMPO $57,405.09 1,135 4.35 43
63 1396731287 VICKI L BOLING ARNP $61,767.07 1,128 4.36 66
64 1922144088 THOMAS S HOPKINS DO $123,247.94 1,126 4.09 69
65 1730143397 MARK JOSEPH DEARDEN DO $30,315.74 1,123 5.50 141
66 1780793976 MATTHEW D EGGERS MD $139,077.20 1,120 4.96 84
67 1225097843 WILLIAM M NISSEN $57,123.70 1,114 4.10 57
68 1699075929 HIEDI CHRISTINE LANE ARNP $112,968.17 1,114 4.14 118
69 1871586271 PATRICIA BLACKLEDGE ARNP $46,792.95 1,106 5.59 70
70 1013960566 PETER JOSEPH SZEIBEL $102,977.28 1,103 5.23 62
71 1306812490 MERRILEE RAMSEY ARNP $60,787.14 1,096 4.18 67
72 1225168511 FREDERICK C. ALDRICH $43,858.86 1,092 2.52 92
73 1205821337 MANMOHAN SINGH $53,962.14 1,091 4.60 59
74 1861559486 JOSPEH PATRICK BERTROCHE $138,619.95 1,089 4.36 77
75 1063491645 ALLYSON L WHEATON MD $110,084.30 1,086 4.23 74
76 1609218304 AMANDA O'TOOL ARNP $103,952.93 1,085 5.19 81
77 1104974658 UMA PALAKURTHY MD $37,325.06 1,079 4.65 93
78 1134191018 DUSTIN RALPH SMITH MD $64,283.51 1,077 4.43 64
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79 1558348284 STEVEN G PAULSRUD DO $60,504.55 1,073 4.83 71
80 1124399522 JOYCE E PROUCH ARNP $100,793.20 1,063 4.97 86
81 1356760011 CHARISSA S ELLIOTT ARNP $47,159.55 1,059 5.52 60
82 1356520431 KAY A MARTTILA $120,264.61 1,058 3.67 82
83 1073509436 MICHAEL KARL MAHARRY MD $53,147.11 1,048 4.64 20
84 1326013426 PAUL DENNIS PETERSON DO $50,899.84 1,047 3.03 98
85 1669623583 ANNE MIREILLE METUGE AHONE $62,199.59 1,042 4.69 85
86 1033198908 DANIEL J ARNOLD $50,531.12 1,038 4.22 42
87 1619186475 STEPHEN PALLONE MD $44,486.37 1,035 5.75 78
88 1902115652 SARAH LYNN BEATTIE ARNP $129,669.81 1,033 3.91 95
89 1417234899 REBECCA BRIANNA JONES PA $44,454.06 1,024 4.90 101
90 1326045808 RAY C STURDEVANT MD $102,313.61 1,023 3.18 76
91 1790046548 LAURIE L CLAIR PA $48,207.92 1,017 4.84 102
92 1629042288 MARTIN J FIALKOV MD $98,890.52 1,017 5.14 89
93 1558770974 MARC BAUMERT PA C $25,163.54 1,014 3.69 152
94 1902912538 CHRISTIAN W JONES MD $42,343.17 1,013 3.64 56
95 1912991183 MOLLY EARLEYWINE PA $25,909.91 1,002 3.78 106
96 1073949236 KATE ANN TRIPP PA $40,079.78 1,000 4.42 165
97 1780979666 LINDSEY ANN CHRISTIANSON $32,835.17 995 5.21 128
98 1710187406 SHAYLA TOOMBS-WITHERS $32,782.00 994 5.62 108
99 1871789982 RANAE MICHELLE ROBERTS $32,851.94 993 5.31 117
100 1801131461 MEREDITH DALLAS OLSON $56,946.81 990 4.44 79
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RANK DOCTOR NUM PRESCRIBER NAME PAID AMOUNT AVG COST RX PRESCRIPTION COUNT PREVIOUS RANK
1 1013126705 JANICE M. R. STABER $2,016,081.98 $27,244.35 74 1
2 1952459463 DAVID LAWRENCE YURDIN PA $652,069.44 $500.44 1,303 2
3 1770561946 DONALD HILLEBRAND MD $628,612.25 $4,055.56 155 4
4 1013115369 BOBBITA NAG MD $294,818.25 $130.51 2,259 5
5 1780766659 CHESTER ROBERT BADGER $237,162.23 $52.23 4,541 7
6 1649248378 KATHLEEN L WILD ARNP $232,846.49 $104.98 2,218 11
7 1841407160 RAHUL BANSAL MD $231,251.28 $113.58 2,036 6
8 1043211303 ALI  SAFDAR $197,856.26 $87.94 2,250 29
9 1982605762 JEFFREY D WILHARM $196,957.21 $66.09 2,980 18
10 1205015906 DAVID F WIDITZ $190,045.70 $88.81 2,140 16
11 1285748004 BRUCE L HUGHES MD $189,541.58 $1,215.01 156 10
12 1073500690 KATHLEEN S ADAMS $186,287.06 $135.19 1,378 20
13 1083609358 JENNIFER S COOK $185,898.50 $260.73 713 13
14 1467502286 CHARLES TILLEY PA $184,255.36 $114.73 1,606 34
15 1548247406 VILMARIE RODRIGUEZ-PADUA MD $182,937.14 $26,133.88 7 3
16 1083603773 JACK T STAPLETON $179,559.44 $726.96 247 19
17 1194817247 MARIA J STEELE ARNP $171,561.52 $1,072.26 160 9
18 1356337273 LISA J MENZIES $168,012.30 $302.72 555 14
19 1548256191 JUDITH A MILLER $167,326.24 $5,228.95 32 15
20 1083784797 CAROL AUNAN ARNP $157,539.74 $78.85 1,998 17
21 1699767525 EZZATOLLAH SHIVAPOUR $157,168.62 $2,455.76 64 23
22 1194703074 WENDY ANNE WALDMAN $155,152.64 $228.17 680 22
23 1912991340 GHADA HAMDAN-ALLEN MD $152,837.81 $102.78 1,487 31
24 1184722910 LAURA M VAN CLEVE DO $150,000.46 $116.28 1,290 114
25 1679669832 ERIN VOYLES HATCHER ARNP $147,707.79 $113.80 1,298 73
26 1841220290 KENT ELDON KUNZE MD $146,658.32 $86.27 1,700 25
27 1619153137 JODI BEST ARNP $145,601.73 $120.13 1,212 12
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28 1972638864 LIUSKA MARIA PESCE $141,172.02 $399.92 353 24
29 1962558957 ALBERT N OKINE PA $139,886.95 $116.86 1,197 26
30 1346210184 JAMES BROOKS MD $139,684.75 $116.11 1,203 28
31 1780793976 MATTHEW D EGGERS MD $139,077.20 $124.18 1,120 36
32 1861559486 JOSPEH PATRICK BERTROCHE $138,619.95 $127.29 1,089 30
33 1891705968 ANITA HANDEVIDT ARNP $130,930.58 $102.21 1,281 63
34 1902115652 SARAH LYNN BEATTIE ARNP $129,669.81 $125.53 1,033 48
35 1841293354 KEITH GUESS PA C $129,435.57 $106.88 1,211 47
36 1841285772 KATHRYN CAROLE BREITBACH $128,013.03 $1,684.38 76 27
37 1275844649 KATIE M HANSON $127,596.55 $84.84 1,504 37
38 1740246008 DANIEL LAMPTEY MD $126,517.48 $3,419.39 37 58
39 1619963949 EVA TSALIKIAN $125,620.61 $770.68 163 66
40 1477633188 CYD Q. GRAFFT $124,951.83 $85.76 1,457 39
41 1922144088 THOMAS S HOPKINS DO $123,247.94 $109.46 1,126 54
42 1003004391 DAVID B WALKER MD $122,563.84 $95.90 1,278 41
43 1487908380 LISA ANN BECHTEL ARNP $121,129.26 $124.36 974 46
44 1356520431 KAY A MARTTILA $120,264.61 $113.67 1,058 62
45 1285697722 DOUGLAS  JONES $117,417.78 $102.01 1,151 69
46 1104034552 DEANNA BOOK BOESEN $117,240.23 $124.20 944 60
47 1376777524 ALLADDIN MOH ELHADI ABOSAIDA $116,408.79 $309.60 376 21
48 1346255809 JEFFREY  DUNKELBERG $116,262.82 $1,592.64 73 1077
49 1568647303 CHERYL ANGELINE CONRAD ARNP $115,856.57 $394.07 294 153
50 1760477483 WARREN P BISHOP, MD $115,269.88 $480.29 240 183
51 1033418843 RANDHIR JESUDOSS MD $115,080.43 $1,826.67 63 530
52 1790708451 MICHAEL M MCCUBBIN $114,563.71 $269.56 425 32
53 1699075929 HIEDI CHRISTINE LANE ARNP $112,968.17 $101.41 1,114 87
54 1255322996 MARK WILLIAM MITTAUER MD $112,737.02 $68.08 1,656 44
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55 1972616316 JEFFREY ALAN BRANNEN DO $111,046.12 $555.23 200 456
56 1821082850 JOHN F STECKER $110,930.50 $123.12 901 100
57 1063491645 ALLYSON L WHEATON MD $110,084.30 $101.37 1,086 67
58 1508289620 GLORIA A MILLER $108,976.40 $91.73 1,188 38
59 1134402373 JULIE A SCHUCK $107,108.17 $723.70 148 71
60 1124342217 JORGE ANTONIO ZAPATIER-VIDAL MD $106,498.19 $2,878.33 37 221
61 1003957903 JORGE LUIS ALVAREZ MD $105,087.95 $767.07 137 94
62 1447242359 DANIEL M SLEITER ARNP $104,860.95 $582.56 180 52
63 1730239732 SRIRAMAMURTHY RAVIPATI MD $104,322.92 $89.93 1,160 43
64 1184602013 RODNEY A SHORT MD $104,240.72 $461.24 226 51
65 1609218304 AMANDA O'TOOL ARNP $103,952.93 $95.81 1,085 78
66 1710941000 LAURIE WARREN PA $103,700.25 $110.67 937 40
67 1316356496 KIMBERLY NICHOLLE WOOD ARNP $103,185.58 $109.31 944 123
68 1750376034 DUANGCHAI NARAWONG MD $103,080.71 $160.31 643 68
69 1013960566 PETER JOSEPH SZEIBEL $102,977.28 $93.36 1,103 53
70 1215146055 REBECCA J WOLFE $102,881.49 $84.12 1,223 77
71 1326045808 RAY C STURDEVANT MD $102,313.61 $100.01 1,023 59
72 1639423544 PAMELA S BROWN ARNP $101,091.96 $114.36 884 70
73 1124399522 JOYCE E PROUCH ARNP $100,793.20 $94.82 1,063 74
74 1215125216 REBECCA WALDING $100,355.43 $118.20 849 72
75 1609055771 CHARUTA NARAYAN JOSHI $99,567.60 $190.38 523 33
76 1144214248 KRISTI WALZ MD $99,437.57 $71.95 1,382 136
77 1295830115 ALAN BOLLINGER DO $99,118.86 $87.02 1,139 56
78 1629042288 MARTIN J FIALKOV MD $98,890.52 $97.24 1,017 83
79 1902885445 BHARAT ASHOK MOTWANI MD $97,787.28 $769.98 127 75
80 1508946088 RICHARD E NIGHTINGALE $97,147.49 $75.48 1,287 42
81 1033361563 ERMEI YAO PA $96,864.14 $452.64 214 57
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82 1356564371 CARLA K ABEL ZIEG ARNP $96,359.23 $142.54 676 81
83 1891756128 PHILIP JOSEPH MULLER DO $96,272.37 $98.64 976 98
84 1285681528 MARVIN F PIBURN JR MD $96,057.05 $122.21 786 119
85 1134425127 MELANIE HOWARD ARPN $95,550.08 $82.66 1,156 65
86 1801890611 DEBORAH A HUBER ARNP $95,305.83 $1,013.89 94 297
87 1215025309 DEBORAH LYNNE GARRELTS $93,290.35 $107.73 866 61
88 1215964796 DONNER DEWDNEY MD $91,498.34 $102.81 890 130
89 1083681944 MARY CHRISTINE SEGRETO DO $91,190.65 $115.14 792 147
90 1134533599 $90,523.80 $118.64 763 210
91 1104029008 KATIE MARIE ULRING LARSON ODE $89,316.87 $369.08 242 84
92 1366435125 DANIEL EDWARD WESEMANN ARNP $86,367.53 $107.56 803 88
93 1891788485 JOYCE VISTA WAYNE MD $86,091.03 $95.13 905 102
94 1760470678 JEFFERY L MEIER $84,752.94 $839.14 101 139
95 1306954391 WILLIAM E HOWARD DO $83,032.18 $88.52 938 64
96 1538368170 CHRISTOPHER ROBERT MATSON $82,246.78 $37.80 2,176 85
97 1861474710 CAROLYN JOHNSON PA $82,132.80 $285.18 288 110
98 1104976109 ISAM ELIAS MARAR MD $81,658.60 $69.44 1,176 93
99 1821084468 MARY WAGNER NIXON $80,975.00 $121.77 665 128
100 1053361972 MATTHEW LARRY HILL DO $80,248.59 $1,003.11 80 91
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CATEGORY DESCRIPTION January/February 2015 RANK % BUDGET March/April 2015 RANK % BUDGET % CHANGE
ANTIPSYCHOTICS - ATYPICALS $5,102,842 1 8.2% $6,170,282 1 8.8% 20.9%
STIMULANTS - AMPHETAMINES - LONG ACTING $3,190,931 3 5.1% $3,755,434 2 5.3% 17.7%
STIMULANTS - METHYLPHENIDATE - LONG ACTING $2,560,283 5 4.1% $3,611,157 3 5.1% 41.0%
ANTICONVULSANTS $3,235,295 2 5.2% $3,583,828 4 5.1% 10.8%
DIABETIC - INSULIN $2,852,962 4 4.6% $3,139,448 5 4.5% 10.0%
ANTIHEMOPHILIC AGENTS $2,293,157 7 3.7% $2,248,322 6 3.2% -2.0%
ANTIASTHMATIC - ADRENERGIC COMBOS $1,875,806 8 3.0% $2,231,591 7 3.2% 19.0%
ANTIDEPRESSANTS - SELECTED SSRI's $2,310,268 6 3.7% $2,208,478 8 3.1% -4.4%
STIMULANTS - METHYLPHENIDATE $1,673,802 9 2.7% $1,858,539 9 2.6% 11.0%
ANTI-INFLAMMATORIES, NON-NSAID $1,530,559 10 2.5% $1,834,239 10 2.6% 19.8%
HEPATITIS C AGENTS $844,112 20 1.4% $1,761,823 11 2.5% 108.7%
DIABETIC - INSULIN  PENFILLS $1,334,313 13 2.2% $1,559,636 12 2.2% 16.9%
ANTIASTHMATIC - BETA - ADRENERGICS $1,372,115 12 2.2% $1,525,575 13 2.2% 11.2%
STIMULANTS - OTHER STIMULANTS / LIKE STIMULANTS $1,295,599 14 2.1% $1,480,729 14 2.1% 14.3%
MULTIPLE SCLEROSIS AGENTS $1,412,630 11 2.3% $1,462,558 15 2.1% 3.5%
ANTIRETROVIRALS $1,035,835 17 1.7% $1,243,790 16 1.8% 20.1%
ANTIASTHMATIC - STEROID INHALANTS $1,105,203 16 1.8% $1,165,357 17 1.7% 5.4%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS $916,356 18 1.5% $1,040,880 18 1.5% 13.6%
NARCOTICS - MISC. $792,501 23 1.3% $966,925 19 1.4% 22.0%
ANTIASTHMATIC - ANTI-CHOLINERGICS $883,117 19 1.4% $951,540 20 1.4% 7.7%
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ANTIDEPRESSANTS - SELECTED SSRI's 87,482 1 96,195 1 10.0%
ANTICONVULSANTS 46,540 2 50,717 2 9.0%
NARCOTICS - MISC. 36,409 3 40,529 3 11.3%
BETA-LACTAMS / CLAVULANATE COMBO'S 36,236 4 37,543 4 3.6%
ANTIPSYCHOTICS - ATYPICALS 28,874 6 32,117 5 11.2%
ANTIASTHMATIC - BETA - ADRENERGICS 30,542 5 32,055 6 5.0%
ANTIHISTAMINES - NON-SEDATING 22,630 10 28,640 7 26.6%
ANALGESICS - MISC. 25,069 7 26,701 8 6.5%
GI - PROTON PUMP INHIBITOR 23,697 8 26,609 9 12.3%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS 23,141 9 25,698 10 11.0%
ANXIOLYTICS - BENZODIAZEPINES 19,720 12 21,284 11 7.9%
ACE INHIBITORS 19,007 13 20,880 12 9.9%
NSAIDS 18,755 14 20,423 13 8.9%
ANTIHYPERTENSIVES - CENTRAL 18,376 15 20,110 14 9.4%
MACROLIDES / ERYTHROMYCIN'S / KETOLIDES 21,152 11 19,598 15 -7.3%
DIURETICS 16,763 17 18,596 16 10.9%
GLUCOCORTICOIDS - MINERALOCORTICOIDS 17,087 16 18,007 17 5.4%
STIMULANTS - AMPHETAMINES - LONG ACTING 15,409 19 17,986 18 16.7%
CEPHALOSPORINS 16,392 18 17,356 19 5.9%
STIMULANTS - METHYLPHENIDATE - LONG ACTING 13,090 23 17,297 20 32.1%
Page 20 Of 295/11/2015 3:10:25 PM RT33018
trusted, reliable, innovative
TOP 100 DRUGS BY PAID AMOUNT
DRUG DESCRIPTION January/February 2015 PREVIOUS 
RANK
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ABILIFY $2,561,234.71 1 $3,216,816.06 1 25.60%
METHYLPHENIDATE HCL ER $2,141,695.76 3 $3,088,678.96 2 44.22%
VYVANSE $2,479,333.76 2 $3,038,675.22 3 22.56%
LANTUS $1,456,441.73 4 $1,586,192.95 4 8.91%
FOCALIN XR $1,334,688.29 5 $1,482,417.31 5 11.07%
ADVATE $1,274,490.67 6 $1,460,609.41 6 14.60%
STRATTERA $964,852.19 8 $1,078,274.45 7 11.76%
HARVONI $401,499.98 29 $1,047,180.59 8 160.82%
ADVAIR DISKUS $806,661.51 12 $977,279.33 9 21.15%
SPIRIVA HANDIHALER $820,012.95 11 $879,221.53 10 7.22%
LATUDA $610,385.95 17 $817,034.90 11 33.86%
VENTOLIN HFA $713,501.43 14 $769,766.92 12 7.89%
SYNAGIS $1,222,238.63 7 $756,335.10 13 -38.12%
DEPAKOTE ER $649,557.79 15 $684,560.96 14 5.39%
NOVOLOG $600,269.80 18 $675,986.62 15 12.61%
SOVALDI $380,743.65 31 $671,285.21 16 76.31%
NOVOSEVEN RT $784,932.14 13 $664,879.41 17 -15.29%
ADDERALL XR $626,648.87 16 $626,186.21 18 -0.07%
SYMBICORT $530,516.34 20 $624,181.89 19 17.66%
HUMIRA PEN $487,793.69 23 $622,447.91 20 27.60%
HUMALOG $543,298.34 19 $591,871.51 21 8.94%
INVEGA SUSTENNA $503,462.01 21 $576,321.13 22 14.47%
CRESTOR $496,630.56 22 $566,819.24 23 14.13%
ATRIPLA $451,450.75 26 $551,144.34 24 22.08%
HYDROCODONE/ACETAMINOPHEN $426,991.55 27 $544,041.03 25 27.41%
CYMBALTA $864,745.82 9 $539,982.59 26 -37.56%
LEVEMIR $402,773.46 28 $503,281.88 27 24.95%
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NORDITROPIN FLEXPRO $336,899.29 37 $451,928.20 28 34.14%
DEXILANT $385,048.84 30 $444,906.64 29 15.55%
COPAXONE $452,362.31 25 $439,201.17 30 -2.91%
AZITHROMYCIN $457,689.51 24 $420,297.22 31 -8.17%
LANTUS SOLOSTAR $365,155.59 33 $401,919.68 32 10.07%
QVAR $353,707.02 34 $388,161.86 33 9.74%
CEFDINIR $365,247.31 32 $382,567.09 34 4.74%
TECFIDERA $326,643.99 38 $375,779.10 35 15.04%
NASONEX $281,753.51 44 $374,155.37 36 32.80%
NOVOLOG FLEXPEN $342,686.65 36 $354,931.11 37 3.57%
LYRICA $322,804.27 39 $352,200.13 38 9.11%
TAMIFLU $833,476.37 10 $348,743.36 39 -58.16%
PULMICORT $352,296.54 35 $337,297.53 40 -4.26%
TRUVADA $262,403.14 46 $325,524.39 41 24.06%
PROVENTIL HFA $297,928.88 41 $322,127.69 42 8.12%
AMOXICILLIN $314,148.20 40 $319,399.95 43 1.67%
ENBREL SURECLICK $296,918.10 42 $313,544.60 44 5.60%
AMPHETAMINE/DEXTROAMPHETA $247,868.44 48 $290,985.84 45 17.40%
RISPERDAL CONSTA $282,064.83 43 $289,183.28 46 2.52%
HUMIRA $263,584.16 45 $281,888.32 47 6.94%
ENBREL $245,049.39 49 $275,930.89 48 12.60%
FLOVENT HFA $231,645.43 51 $265,224.43 49 14.50%
INVEGA $248,619.07 47 $257,904.24 50 3.73%
EPIPEN 2-PAK $132,747.76 95 $256,888.87 51 93.52%
VIMPAT $226,046.67 52 $256,736.32 52 13.58%
ANAFRANIL $156,437.39 74 $256,457.27 53 63.94%
MONTELUKAST SODIUM $208,651.17 56 $253,763.42 54 21.62%
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OMEPRAZOLE $231,683.07 50 $251,718.80 55 8.65%
LEVOTHYROXINE SODIUM $224,116.72 53 $251,087.49 56 12.03%
COMBIVENT RESPIMAT $209,166.47 55 $234,961.41 57 12.33%
JANUVIA $188,278.38 63 $229,016.43 58 21.64%
GABAPENTIN $203,181.68 58 $228,717.43 59 12.57%
PROAIR HFA $149,781.21 80 $223,229.55 60 49.04%
PROVIGIL $155,704.57 76 $221,842.71 61 42.48%
PULMOZYME $209,762.86 54 $221,502.92 62 5.60%
AMOXICILLIN/CLAVULANATE P $201,704.32 59 $216,638.06 63 7.40%
XIFAXAN $162,854.19 72 $216,199.62 64 32.76%
VESICARE $167,981.44 69 $214,946.63 65 27.96%
METHYLPHENIDATE HCL $185,103.51 64 $214,118.60 66 15.68%
QUILLIVANT XR $165,441.44 71 $212,356.88 67 28.36%
ENOXAPARIN SODIUM $188,903.48 62 $205,880.32 68 8.99%
DULERA $166,132.06 70 $197,305.15 69 18.76%
BUPROPION HCL XL $171,731.45 67 $194,707.02 70 13.38%
TOPROL XL $171,794.93 66 $193,905.48 71 12.87%
GLEEVEC $127,507.94 101 $190,180.55 72 49.15%
LEVEMIR FLEXTOUCH $121,529.47 106 $188,108.28 73 54.78%
GILENYA $158,143.17 73 $181,491.93 74 14.76%
SAPHRIS $131,092.74 97 $177,312.93 75 35.26%
METADATE CD $144,397.38 84 $175,937.98 76 21.84%
OPANA ER (CRUSH RESISTANT $170,318.00 68 $174,390.70 77 2.39%
SERTRALINE HCL $152,363.32 79 $172,124.86 78 12.97%
QUETIAPINE FUMARATE $156,188.96 75 $169,530.03 79 8.54%
LISINOPRIL $153,002.39 77 $167,482.98 80 9.46%
STRIBILD $128,017.36 100 $164,001.23 81 28.11%
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XYREM $189,468.86 61 $163,017.15 82 -13.96%
ATORVASTATIN CALCIUM $140,257.02 89 $161,016.83 83 14.80%
FLUTICASONE PROPIONATE $127,436.55 102 $159,576.35 84 25.22%
RISPERIDONE $146,612.26 83 $157,724.82 85 7.58%
BANZEL $131,152.38 96 $156,227.59 86 19.12%
TRAMADOL HCL $144,374.47 85 $155,916.73 87 7.99%
SEROQUEL XR $152,586.21 78 $152,642.89 88 0.04%
ADVAIR HFA $121,513.79 107 $152,464.72 89 25.47%
VENLAFAXINE HCL ER $136,624.67 90 $152,061.02 90 11.30%
CEPHALEXIN $140,323.94 88 $150,071.46 91 6.95%
SABRIL $133,217.38 94 $149,742.36 92 12.40%
CREON $108,538.38 116 $149,507.21 93 37.75%
ESCITALOPRAM OXALATE $134,561.11 92 $148,394.35 94 10.28%
ONFI $119,754.59 111 $144,017.96 95 20.26%
TRAZODONE HCL $130,666.93 98 $143,774.70 96 10.03%
KALYDECO $75,134.32 166 $143,456.16 97 90.93%
INTUNIV $134,775.49 91 $142,415.29 98 5.67%
FENOFIBRATE $128,494.61 99 $140,622.38 99 9.44%
COMPLERA $104,112.90 125 $140,612.13 100 35.06%
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HYDROCO/APAP TAB 5-325MG 16,102 1 18,080 1 12.28%
VENTOLIN HFA AER 12,603 2 13,478 2 6.94%
AMOXICILLIN  SUS 400/5ML 12,467 3 12,904 3 3.51%
TRAMADOL HCL TAB 50MG 11,603 4 12,610 4 8.68%
Loratadine Tab 10 MG 10,624 5 12,523 5 17.87%
OMEPRAZOLE   CAP 20MG 8,896 8 9,810 6 10.27%
Cetirizine HCl Tab 10 MG 7,711 13 9,633 7 24.93%
ESCITALOPRAM TAB 20MG 8,660 10 9,627 8 11.17%
FLUOXETINE   CAP 20MG 8,863 9 9,582 9 8.11%
ALBUTEROL    NEB 0.083% 9,836 6 9,157 10 -6.90%
FLUTICASONE  SPR 50MCG 7,111 16 9,001 11 26.58%
GABAPENTIN   CAP 300MG 8,417 11 8,956 12 6.40%
OMEPRAZOLE   CAP 40MG 7,756 12 8,851 13 14.12%
AZITHROMYCIN TAB 250MG 9,145 7 8,770 14 -4.10%
CYCLOBENZAPR TAB 10MG 7,624 15 8,532 15 11.91%
CLONIDINE    TAB 0.1MG 6,987 17 7,630 16 9.20%
SERTRALINE   TAB 100MG 6,438 19 7,248 17 12.58%
RANITIDINE   TAB 150MG 6,760 18 7,197 18 6.46%
Aspirin Tab Delayed Release 81 MG 6,267 21 6,998 19 11.66%
MONTELUKAST  TAB 10MG 5,759 26 6,858 20 19.08%
GUANFACINE   TAB 1MG 6,303 20 6,811 21 8.06%
IBUPROFEN    TAB 800MG 6,065 23 6,672 22 10.01%
TRAZODONE    TAB 50MG 6,114 22 6,634 23 8.51%
AZITHROMYCIN SUS 200/5ML 7,636 14 6,603 24 -13.53%
TRAZODONE    TAB 100MG 5,803 25 6,278 25 8.19%
Acetaminophen Tab 325 MG 5,737 27 6,163 26 7.43%
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Ferrous Sulfate Tab 325 MG (65 MG 
Elemental Fe)
5,503 28 6,029 27 9.56%
LISINOPRIL   TAB 10MG 5,392 29 5,893 28 9.29%
METFORMIN    TAB 500MG 5,158 31 5,670 29 9.93%
HYDROCHLOROT TAB 25MG 5,112 33 5,641 30 10.35%
LISINOPRIL   TAB 20MG 5,147 32 5,605 31 8.90%
AMOXICILLIN  CAP 500MG 5,311 30 5,574 32 4.95%
METHYLPHENID TAB 36MG ER 3,921 55 5,381 33 37.24%
PREDNISONE   TAB 20MG 4,448 39 5,072 34 14.03%
POLYETH GLYC POW 3350 NF 4,547 35 5,028 35 10.58%
METFORMIN    TAB 1000MG 4,469 37 4,997 36 11.81%
MELOXICAM    TAB 15MG 4,461 38 4,989 37 11.84%
CLONAZEPAM   TAB 1MG 4,563 34 4,920 38 7.82%
OXYCOD/APAP  TAB 5-325MG 4,227 43 4,766 39 12.75%
PROVENTIL    AER HFA 4,519 36 4,711 40 4.25%
SERTRALINE   TAB 50MG 4,153 45 4,630 41 11.49%
CITALOPRAM   TAB 20MG 4,263 42 4,604 42 8.00%
ONDANSETRON  TAB 4MG ODT 3,958 52 4,599 43 16.20%
CEPHALEXIN   CAP 500MG 4,221 44 4,537 44 7.49%
VENLAFAXINE  CAP 150MG ER 4,041 49 4,522 45 11.90%
AMLODIPINE   TAB 10MG 4,037 50 4,480 46 10.97%
PANTOPRAZOLE TAB 40MG 3,986 51 4,469 47 12.12%
Sennosides-Docusate Sodium Tab 8.6-50 
MG
4,308 40 4,455 48 3.41%
MONTELUKAST  CHW 5MG 3,613 63 4,412 49 22.11%
HYDROCO/APAP TAB 7.5-325 4,104 46 4,409 50 7.43%
ALPRAZOLAM   TAB 1MG 4,091 48 4,367 51 6.75%
LANTUS       INJ 100/ML 4,098 47 4,363 52 6.47%
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SMZ/TMP DS   TAB 800-160 3,690 62 4,316 53 16.96%
NAPROXEN     TAB 500MG 3,883 57 4,281 54 10.25%
Aspirin Chew Tab 81 MG 3,951 53 4,229 55 7.04%
CLONAZEPAM   TAB 0.5MG 3,890 56 4,153 56 6.76%
AMOXICILLIN  SUS 250/5ML 4,299 41 4,149 57 -3.49%
AMOX/K CLAV  TAB 875MG 3,944 54 4,115 58 4.34%
METHYLPHENID TAB 54MG ER 3,068 73 4,089 59 33.28%
CITALOPRAM   TAB 40MG 3,824 59 4,067 60 6.35%
ALPRAZOLAM   TAB 0.5MG 3,741 60 4,044 61 8.10%
ZOLPIDEM     TAB 10MG 3,704 61 4,036 62 8.96%
HYDROCO/APAP TAB 10-325MG 3,571 64 3,990 63 11.73%
CEFDINIR     SUS 250/5ML 3,843 58 3,987 64 3.75%
ATORVASTATIN TAB 40MG 3,456 66 3,954 65 14.41%
AMLODIPINE   TAB 5MG 3,464 65 3,791 66 9.44%
Cetirizine HCl Oral Soln 1 MG/ML (5 
MG/5ML)
2,509 92 3,783 67 50.78%
PREDNISOLONE SOL 15MG/5ML 6,002 24 3,758 68 -37.39%
PROAIR HFA   AER 2,576 88 3,704 69 43.79%
FOLIC ACID   TAB 1MG 3,409 67 3,703 70 8.62%
METOPROL TAR TAB 25MG 3,240 69 3,551 71 9.60%
HYDROXYZ PAM CAP 25MG 3,148 70 3,549 72 12.74%
Acetaminophen Tab 500 MG 3,353 68 3,531 73 5.31%
BUPROPN HCL  TAB 300MG XL 3,052 74 3,449 74 13.01%
VYVANSE      CAP 30MG 2,741 82 3,381 75 23.35%
LORAZEPAM    TAB 1MG 3,121 71 3,331 76 6.73%
SIMVASTATIN  TAB 20MG 3,085 72 3,313 77 7.39%
ATORVASTATIN TAB 20MG 2,839 78 3,220 78 13.42%
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BUPROPN HCL  TAB 150MG XL 2,879 77 3,189 79 10.77%
SPIRIVA      CAP HANDIHLR 2,915 76 3,100 80 6.35%
LORAZEPAM    TAB 0.5MG 2,829 79 3,095 81 9.40%
VYVANSE      CAP 40MG 2,525 91 3,012 82 19.29%
VENLAFAXINE  CAP 75MG ER 2,753 81 2,989 83 8.57%
LISINOPRIL   TAB 40MG 2,727 83 2,960 84 8.54%
LEVOTHYROXIN TAB 50MCG 2,695 84 2,945 85 9.28%
FUROSEMIDE   TAB 40MG 2,692 85 2,932 86 8.92%
RISPERIDONE  TAB 1MG 2,779 80 2,918 87 5.00%
FLUCONAZOLE  TAB 150MG 2,565 89 2,902 88 13.14%
SIMVASTATIN  TAB 40MG 2,634 86 2,867 89 8.85%
PREDNISONE   TAB 10MG 2,555 90 2,779 90 8.77%
MONTELUKAST  CHW 4MG 2,216 103 2,779 91 25.41%
METRONIDAZOL TAB 500MG 2,400 95 2,746 92 14.42%
LISINOPRIL   TAB 5MG 2,379 96 2,698 93 13.41%
QUETIAPINE   TAB 100MG 2,471 93 2,650 94 7.24%
METHYLPHENID TAB 27MG ER 2,097 114 2,641 95 25.94%
CLOPIDOGREL  TAB 75MG 2,321 99 2,579 96 11.12%
VYVANSE      CAP 50MG 2,159 109 2,577 97 19.36%
APAP/CODEINE TAB 300-30MG 2,374 97 2,511 98 5.77%
FUROSEMIDE   TAB 20MG 2,172 108 2,485 99 14.41%
RISPERIDONE  TAB 0.5MG 2,281 101 2,448 100 7.32%
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TOTAL PAID AMOUNT $69,642,277 $67,683,048 -2.8%
UNIQUE USERS 210,268 197,276 -6.2%
COST PER USER $331.21 $343.09 3.6%
TOTAL PRESCRIPTIONS 1,040,931 989,259 -5.0%
AVERAGE PRESCRIPTIONS PER USER 4.95 5.01 1.2%
AVERAGE COST PER PRESCRIPTION $66.90 $68.42 2.3%
# GENERIC PRESCRIPTIONS 882,980 842,823 -4.5%
% GENERIC 84.8% 85.2% 0.4%
$ GENERIC $19,512,470 $18,108,169 -7.2%
AVERAGE GENERIC PRESCRIPTION COST $22.10 $21.49 -2.8%
AVERAGE GENERIC DAYS SUPPLY 23 24 4.3%
# BRAND PRESCRIPTIONS 154,326 142,944 -4.5%
% BRAND 14.8% 14.4% 0.4%
$ BRAND $49,810,474 $49,286,333 -7.2%
AVERAGE BRAND PRESCRIPTION COST $322.76 $344.79 -2.8%
AVERAGE BRAND DAYS SUPPLY 26 26 4.3%
Bi-Monthly Statistics
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UTILIZATION BY AGE
AGE March/April 2015 May/June 2015
0-6 38,197 31,392
7-12 31,566 27,340
13-18 26,081 23,331
19-64 105,255 106,204
65+ 9,169 9,009
210,268 197,276
UTILIZATION BY GENDER AND AGE
GENDER AGE March/April 2015 May/June 2015
F
0-6 17,947 14,711
7-12 13,762 11,748
13-18 13,375 12,231
19-64 66,950 67,454
65+ 6,386 6,276
118,420 112,420
M
0-6 20,250 16,681
7-12 17,804 15,592
13-18 12,706 11,100
19-64 38,305 38,750
65+ 2,783 2,733
91,848 84,856
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RANK PHARMACY NAME PHARMACY CITY STATE PRESCRIPTION 
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1 BROADLAWNS MEDICAL CENTER DES MOINES IA 19,172 $481,293.27 $25.10 1
2 WALGREEN #05239 DAVENPORT IA 12,160 $678,980.76 $55.84 2
3 WALGREEN #04405 COUNCIL BLUFFS IA 10,431 $608,530.71 $58.34 3
4 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 9,396 $1,333,571.04 $141.93 4
5 WALGREEN #05721 DES MOINES IA 9,025 $546,015.58 $60.50 5
6 WALGREEN COMPANY #3700 COUNCIL BLUFFS IA 7,285 $394,481.88 $54.15 9
7 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 7,178 $402,489.85 $56.07 10
8 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,023 $333,611.84 $47.50 6
9 WALGREEN #359 DES MOINES IA 6,824 $373,605.28 $54.75 7
10 WALGREEN COMPANY 07455 WATERLOO IA 6,762 $356,782.95 $52.76 11
11 MERCY FAMILY PHARMACY DUBUQUE IA 6,604 $410,677.73 $62.19 8
12 SIOUXLAND COMM HEALTH CTR 
PHARMA
SIOUX CITY IA 6,594 $126,794.17 $19.23 13
13 WALGREEN #05362 DES MOINES IA 6,226 $375,084.18 $60.24 12
14 WALGREENS #07453 DES MOINES IA 5,818 $324,688.32 $55.81 14
15 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,787 $357,278.84 $61.74 18
16 MARTIN HEALTH SERVICES INC DENVER IA 5,599 $179,341.72 $32.03 15
17 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,442 $334,698.80 $61.50 16
18 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,270 $203,528.16 $38.62 25
19 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,154 $300,797.55 $58.36 17
20 WALGREEN COMPANY 05777 DES MOINES IA 5,154 $305,788.29 $59.33 20
21 WALGREEN #04041 DAVENPORT IA 5,067 $293,955.40 $58.01 19
22 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 5,015 $280,140.66 $55.86 23
23 WALGREEN #05852 DES MOINES IA 4,938 $279,916.79 $56.69 21
24 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,744 $255,086.88 $53.77 22
25 RASHID PHARMACY PLC FORT MADISON IA 4,724 $269,335.36 $57.01 26
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26 WALGREEN #11709 DAVENPORT IA 4,700 $264,656.93 $56.31 24
27 WALGREEN #05886 KEOKUK IA 4,448 $262,239.07 $58.96 28
28 DANIEL PHARMACY INC FORT DODGE IA 4,356 $259,998.56 $59.69 29
29 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 4,231 $293,742.95 $69.43 32
30 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,016 $237,183.73 $59.06 31
31 MAHASKA DRUG INC OSKALOOSA IA 4,011 $251,731.16 $62.76 37
32 PHARMACY MATTERS LTC IOWA CITY IA 3,994 $181,044.85 $45.33 27
33 WALGREENS #15647 SIOUX CITY IA 3,982 $231,834.50 $58.22 40
34 WALGREEN #7452 DES MOINES IA 3,959 $204,988.65 $51.78 33
35 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 3,954 $217,118.81 $54.91 34
36 WALGREEN #03595 DAVENPORT IA 3,935 $205,569.70 $52.24 39
37 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,929 $231,876.33 $59.02 35
38 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,890 $251,229.40 $64.58 38
39 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,803 $245,625.36 $64.59 36
40 WALGREEN #910 SIOUX CITY IA 3,712 $193,490.65 $52.13 30
41 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,700 $232,765.46 $62.91 42
42 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,669 $243,043.95 $66.24 43
43 RIGHT DOSE PHARMACY ANKENY IA 3,573 $239,793.05 $67.11 59
44 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,565 $184,202.81 $51.67 45
45 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,523 $227,556.33 $64.59 41
46 THOMPSON-DEAN DRUG SIOUX CITY IA 3,478 $314,077.45 $90.30 47
47 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,451 $183,423.10 $53.15 46
48 WAL-MART PHARMACY #10-5115 DAVENPORT IA 3,423 $151,224.99 $44.18 53
49 WAL-MART PHARMACY #10-0985 FAIRFIELD IA 3,422 $135,376.19 $39.56 58
50 WALGREENS #05119 CLINTON IA 3,416 $195,058.20 $57.10 49
51 WALGREEN #05044 BURLINGTON IA 3,383 $210,841.15 $62.32 56
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52 WALGREENS #10855 WATERLOO IA 3,332 $169,202.49 $50.78 48
53 HY VEE PHARMACY #1449 NEWTON IA 3,303 $171,436.11 $51.90 54
54 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 3,295 $157,648.02 $47.84 52
55 WAL-MART PHARMACY #10-1496 WATERLOO IA 3,286 $146,760.39 $44.66 51
56 WALGREENS #11942 DUBUQUE IA 3,285 $186,379.65 $56.74 55
57 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,281 $182,541.41 $55.64 50
58 WAL-MART PHARMACY 10-2889 CLINTON IA 3,234 $134,625.48 $41.63 57
59 A AVENUE PHARMACY CEDAR RAPIDS IA 3,227 $221,931.57 $68.77 64
60 WAL MART PHARMACY 10-3590 SIOUX CITY IA 3,163 $183,650.83 $58.06 66
61 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 3,078 $161,678.95 $52.53 61
62 HY-VEE PHARMACY #2 (1044) BURLINGTON IA 3,071 $161,648.46 $52.64 72
63 WAL-MART PHARMACY #10-1393 OSKALOOSA IA 3,062 $141,953.95 $46.36 71
64 HY-VEE PHARMACY (1075) CLINTON IA 3,021 $198,965.03 $65.86 65
65 HY-VEE PHARMACY (1875) WEBSTER CITY IA 2,995 $178,626.03 $59.64 74
66 MEDICAP PHARMACY INDIANOLA IA 2,983 $151,120.61 $50.66 44
67 WAL MART PHARMACY 10-1621 CENTERVILLE IA 2,965 $153,483.36 $51.77 62
68 WALGREENS 07968 DES MOINES IA 2,956 $146,032.00 $49.40 60
69 HY-VEE PHARMACY #3 (1056) CEDAR RAPIDS IA 2,944 $161,021.02 $54.69 67
70 HY-VEE PHARMACY 1504 OTTUMWA IA 2,930 $182,273.65 $62.21 76
71 HY-VEE PHARMACY (1058) CENTERVILLE IA 2,919 $162,628.70 $55.71 63
72 HY-VEE DRUGSTORE #7031 DES MOINES IA 2,901 $175,849.37 $60.62 69
73 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,893 $183,744.88 $63.51 68
74 WALGREEN #05077 IOWA CITY IA 2,787 $153,541.61 $55.09 79
75 WAGNER PHARMACY CLINTON IA 2,778 $177,699.74 $63.97 78
76 HY-VEE PHARMACY (1065) CHARITON IA 2,777 $166,648.11 $60.01 85
77 WALGREEN #09708 DUBUQUE IA 2,755 $153,847.17 $55.84 80
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78 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,748 $159,072.33 $57.89 81
79 STANGEL PHARMACY ONAWA IA 2,743 $164,135.35 $59.84 83
80 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,738 $156,422.13 $57.13 70
81 WAL-MART PHARMACY #10-0646 ANAMOSA IA 2,704 $109,744.57 $40.59 75
82 HY-VEE PHARMACY (1522) PERRY IA 2,691 $126,534.12 $47.02 77
83 HY-VEE DRUGSTORE (7056) MASON CITY IA 2,663 $129,482.57 $48.62 84
84 WALGREEN #05942 NEWTON IA 2,652 $135,726.79 $51.18 82
85 WALGREEN #4714 DES MOINES IA 2,638 $162,086.98 $61.44 73
86 HY-VEE DRUGSTORE # 7035 FT DODGE IA 2,595 $143,666.41 $55.36 89
87 S - S PHARMACY INC COUNCIL BLUFFS IA 2,589 $190,072.01 $73.42 97
88 HARTIG PHARMACY SERVICES DUBUQUE IA 2,575 $150,892.00 $58.60 90
89 LA GRANGE PHARMACY INC VINTON IA 2,548 $143,820.38 $56.44 87
90 WAL-MART PHARMACY #10-3394 ATLANTIC IA 2,537 $124,765.03 $49.18 93
91 ALL CARE HEALTH CENTER COUNCIL BLUFFS IA 2,533 $51,481.62 $20.32 99
92 HY-VEE PHARMACY #1 (1054) CEDAR RAPIDS IA 2,519 $148,099.09 $58.79 114
93 HY-VEE FOOD STORE WATERLOO IA 2,482 $213,174.63 $85.89 88
94 WALGREEN #05361 FORT DODGE IA 2,468 $139,427.84 $56.49 91
95 HY-VEE PHARMACY #4 (1148) DES MOINES IA 2,437 $141,027.30 $57.87 92
96 HY-VEE PHARMACY (1009) DBA ALBIA IA 2,427 $130,796.98 $53.89 86
97 HY-VEE PHARMACY #1 (1610) SIOUX CITY IA 2,415 $160,413.21 $66.42 96
98 WAL-MART PHARMACY 10-1723 DES MOINES IA 2,404 $98,651.92 $41.04 109
99 HY-VEE PHARMACY 1481 OSKALOOSA IA 2,400 $146,339.91 $60.97 117
100 WALGREENS #5885 MUSCATINE IA 2,380 $113,343.16 $47.62 108
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1 ARJ INFUSION SERVICES INC LENEXA KS 47 $1,745,932.00 $249,418.86 2
2 UIHC AMBULATORY CARE PHARMACY IOWA CITY IA 9,396 $1,333,571.04 $590.08 5
3 NUCARA PHARMACY #27 PLEASANT HILL IA 2,362 $1,283,051.84 $3,004.81 1
4 MEDFUSIONRX LLC FRANKLIN TN 92 $1,011,595.87 $21,074.91 3
5 CAREMARK KANSAS SPEC PHARMACY 
LL
LENEXA KS 180 $751,119.46 $7,743.50 4
6 WALGREEN #05239 DAVENPORT IA 12,160 $678,980.76 $206.25 6
7 WALGREEN #04405 COUNCIL BLUFFS IA 10,431 $608,530.71 $221.53 7
8 HY-VEE PHARMACY SOLUTIONS OMAHA NE 212 $607,041.39 $5,372.05 8
9 WALGREEN #05721 DES MOINES IA 9,025 $546,015.58 $198.55 9
10 BROADLAWNS MEDICAL CENTER DES MOINES IA 19,172 $481,293.27 $189.34 12
11 DIPLOMAT SPECIALTY PHARMACY FLINT MI 86 $434,909.30 $9,664.65 23
12 US BIOSERVICE CORPORATION FRISCO TX 35 $417,438.14 $24,555.18 56
13 MERCY FAMILY PHARMACY DUBUQUE IA 6,604 $410,677.73 $382.38 13
14 COMMUNITY HEALTHCARE SERVICES LOMA LINDA CA 4 $402,989.40 $201,494.70 79
15 ACCREDO HEALTH GROUP INC MEMPHIS TN 72 $402,911.67 $10,072.79 16
16 WALGREEN COMPANY #05042 CEDAR RAPIDS IA 7,178 $402,489.85 $198.66 17
17 AMBER PHARMACY OMAHA NE 133 $400,454.56 $10,538.28 11
18 WALGREEN COMPANY #3700 COUNCIL BLUFFS IA 7,285 $394,481.88 $202.71 19
19 ACCREDO HEALTH GROUP INC NASHVILLE TN 10 $385,660.42 $64,276.74 10
20 WALGREEN #05362 DES MOINES IA 6,226 $375,084.18 $189.34 18
21 WALGREEN #359 DES MOINES IA 6,824 $373,605.28 $180.22 14
22 ACCREDO HEALTH GROUP INC WARRENDALE PA 69 $372,371.65 $17,731.98 26
23 DRILLING MORNINGSIDE PHARMACY IN SIOUX CITY IA 5,787 $357,278.84 $470.10 22
24 WALGREEN COMPANY 07455 WATERLOO IA 6,762 $356,782.95 $171.53 20
25 DOHMEN LIFE SCIENCE SERVICES LLC CHESTERFIELD MO 21 $338,473.06 $33,847.31 39
26 HY-VEE PHARMACY (1403) MARSHALLTOWN IA 5,442 $334,698.80 $288.28 30
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27 HY-VEE DRUGSTORE #7060 MUSCATINE IA 7,023 $333,611.84 $215.79 15
28 WALGREENS #07453 DES MOINES IA 5,818 $324,688.32 $204.85 21
29 THOMPSON-DEAN DRUG SIOUX CITY IA 3,478 $314,077.45 $478.78 28
30 PROCARE PHARMACY DIRECT LLC MONROEVILLE PA 75 $313,177.33 $7,829.43 34
31 WALGREEN COMPANY 05777 DES MOINES IA 5,154 $305,788.29 $230.78 27
32 HY-VEE DRUGSTORE #7065 OTTUMWA IA 5,154 $300,797.55 $257.97 25
33 WALGREEN #04041 DAVENPORT IA 5,067 $293,955.40 $196.49 32
34 GREENWOOD DRUG ON KIMBALL 
AVENUE
WATERLOO IA 4,231 $293,742.95 $510.86 35
35 WALGREENS SPECIALTY PHARMACY 
#12
ANN ARBOR MI 54 $280,502.18 $8,765.69 31
36 HY VEE PHARMACY 1060 CEDAR RAPIDS IA 5,015 $280,140.66 $252.61 24
37 WALGREEN #05852 DES MOINES IA 4,938 $279,916.79 $187.74 38
38 RASHID PHARMACY PLC FORT MADISON IA 4,724 $269,335.36 $298.27 33
39 WALGREEN #11709 DAVENPORT IA 4,700 $264,656.93 $214.12 37
40 WALGREEN #05886 KEOKUK IA 4,448 $262,239.07 $283.81 40
41 DANIEL PHARMACY INC FORT DODGE IA 4,356 $259,998.56 $314.77 44
42 HY-VEE PHARMACY #1 (1136) DES MOINES IA 4,744 $255,086.88 $200.07 36
43 MAHASKA DRUG INC OSKALOOSA IA 4,011 $251,731.16 $287.36 49
44 HY-VEE PHARMACY #1 (1042) BURLINGTON IA 3,890 $251,229.40 $352.36 41
45 HY-VEE PHARMACY #2 (1138) DES MOINES IA 3,803 $245,625.36 $324.47 43
46 WALGREEN CO.# (03875) CEDAR RAPIDS IA 3,669 $243,043.95 $236.42 46
47 RIGHT DOSE PHARMACY ANKENY IA 3,573 $239,793.05 $664.25 52
48 WAL-MART PHARMACY #10-1509 MAQUOKETA IA 4,016 $237,183.73 $281.69 51
49 DRUGTOWN PHARMACY #1 (7020) CEDAR RAPIDS IA 3,700 $232,765.46 $297.65 42
50 HY-VEE PHARMACY #3 (1142) DES MOINES IA 3,929 $231,876.33 $305.91 47
51 WALGREENS #15647 SIOUX CITY IA 3,982 $231,834.50 $176.57 60
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52 HY-VEE PHARMACY (1074) CHARLES CITY IA 3,523 $227,556.33 $280.93 54
53 A AVENUE PHARMACY CEDAR RAPIDS IA 3,227 $221,931.57 $588.68 58
54 HY-VEE DRUGSTORE #7030 COUNCIL BLUFFS IA 3,954 $217,118.81 $298.65 55
55 HY-VEE FOOD STORE WATERLOO IA 2,482 $213,174.63 $400.70 48
56 CYSTIC FIBROSIS SERVICES INC FRISCO TX 57 $211,637.59 $8,465.50 160
57 ORSINI PHARMACEUTICAL SERVICES I ELK GROVE VILLAGE IL 14 $210,842.62 $105,421.31 132
58 WALGREEN #05044 BURLINGTON IA 3,383 $210,841.15 $211.48 71
59 WALGREEN #03595 DAVENPORT IA 3,935 $205,569.70 $168.92 59
60 EXPRESS SCRIPTS SPECIALTY ST LOUIS MO 28 $205,465.40 $14,676.10 103
61 WALGREEN #7452 DES MOINES IA 3,959 $204,988.65 $165.45 62
62 MARTIN HEALTH SERVICES INC JOHNSTON IA 5,270 $203,528.16 $227.92 81
63 HY-VEE PHARMACY (1075) CLINTON IA 3,021 $198,965.03 $370.51 64
64 WALGREENS #05119 CLINTON IA 3,416 $195,058.20 $217.94 68
65 WALGREEN #910 SIOUX CITY IA 3,712 $193,490.65 $154.55 53
66 S - S PHARMACY INC COUNCIL BLUFFS IA 2,589 $190,072.01 $510.95 65
67 WALGREENS #11942 DUBUQUE IA 3,285 $186,379.65 $210.84 66
68 SOUTH SIDE DRUG INCOPORATED OTTUMWA IA 3,565 $184,202.81 $302.97 72
69 HY-VEE PHARMACY #5 (1109) DAVENPORT IA 2,893 $183,744.88 $340.90 63
70 WAL MART PHARMACY 10-3590 SIOUX CITY IA 3,163 $183,650.83 $226.45 99
71 IOWA CVS PHARMACY LLC DBA WATERLOO IA 3,451 $183,423.10 $212.30 70
72 HY-VEE PHARMACY #1 (1092) COUNCIL BLUFFS IA 3,281 $182,541.41 $310.97 57
73 HY-VEE PHARMACY 1504 OTTUMWA IA 2,930 $182,273.65 $330.21 77
74 PHARMACY MATTERS LTC IOWA CITY IA 3,994 $181,044.85 $463.03 61
75 MARTIN HEALTH SERVICES INC DENVER IA 5,599 $179,341.72 $179.52 78
76 HY-VEE PHARMACY (1875) WEBSTER CITY IA 2,995 $178,626.03 $273.97 90
77 WAGNER PHARMACY CLINTON IA 2,778 $177,699.74 $392.27 75
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78 HY-VEE DRUGSTORE #7031 DES MOINES IA 2,901 $175,849.37 $355.25 86
79 COMMUNITY A WALGREEN PHARMACY MILWAUKEE WI 35 $172,496.52 $9,078.76 140
80 HY VEE PHARMACY #1449 NEWTON IA 3,303 $171,436.11 $230.12 67
81 WALGREENS #10855 WATERLOO IA 3,332 $169,202.49 $182.92 73
82 HY-VEE PHARMACY (1065) CHARITON IA 2,777 $166,648.11 $275.00 108
83 FIFIELD PHARMACY DES MOINES IA 1,805 $166,194.72 $484.53 95
84 STANGEL PHARMACY ONAWA IA 2,743 $164,135.35 $340.53 89
85 HY-VEE PHARMACY (1058) CENTERVILLE IA 2,919 $162,628.70 $291.97 82
86 WALGREEN #4714 DES MOINES IA 2,638 $162,086.98 $205.96 91
87 HY-VEE PHARMACY #1 (1105) DAVENPORT IA 3,078 $161,678.95 $274.50 80
88 HY-VEE PHARMACY #2 (1044) BURLINGTON IA 3,071 $161,648.46 $292.84 85
89 HY-VEE PHARMACY #3 (1056) CEDAR RAPIDS IA 2,944 $161,021.02 $212.71 74
90 HY-VEE PHARMACY #1 (1610) SIOUX CITY IA 2,415 $160,413.21 $259.57 97
91 HY-VEE PHARMACY #5 (1151) DES MOINES IA 2,748 $159,072.33 $261.20 83
92 HY-VEE DRUGSTORE # 1180 FAIRFIELD IA 3,295 $157,648.02 $235.30 84
93 HY-VEE PHARMACY #1 (1281) IOWA CITY IA 2,738 $156,422.13 $225.39 76
94 GREENVILLE PHARMACY INC SIOUX CITY IA 2,018 $156,218.72 $463.56 107
95 ACARIAHEALTH PHARMACY #11 INC HOUSTON TX 30 $155,503.82 $8,184.41 69
96 WALGREEN #07454 ANKENY IA 2,313 $154,389.04 $230.43 98
97 WALGREEN #09708 DUBUQUE IA 2,755 $153,847.17 $157.63 92
98 WALGREEN #05077 IOWA CITY IA 2,787 $153,541.61 $183.44 94
99 WAL MART PHARMACY 10-1621 CENTERVILLE IA 2,965 $153,483.36 $270.22 111
100 HY-VEE PHARMACY 1071 CLARINDA IA 2,349 $151,820.20 $325.10 88
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1 1780766659 CHESTER ROBERT BADGER $201,109.66 3,668 5.78 1
2 1982605762 JEFFREY D WILHARM $171,682.99 2,768 6.47 2
3 1043211303 ALI  SAFDAR $167,485.27 2,166 3.62 4
4 1467682351 NICOLE GILG $72,245.21 2,144 5.70 7
5 1538368170 CHRISTOPHER ROBERT MATSON $83,451.03 2,123 5.88 6
6 1063622637 HUSSAIN BANU $50,534.65 2,101 6.48 9
7 1649248378 KATHLEEN L WILD ARNP $185,317.61 2,009 3.71 5
8 1205015906 DAVID F WIDITZ $165,293.83 1,952 4.84 8
9 1073667606 ELIZABETH MCCURDY DO $70,235.99 1,914 6.23 13
10 1083784797 CAROL AUNAN ARNP $133,425.04 1,896 3.70 11
11 1013115369 BOBBITA NAG MD $234,225.48 1,860 4.03 3
12 1215192224 SHALINA SHAIK $48,447.71 1,850 6.54 12
13 1467502286 CHARLES TILLEY PA $215,343.45 1,828 4.19 18
14 1801998372 WENDY MICHELE HANSEN-PENMAN DO $52,662.00 1,746 6.96 14
15 1255322996 MARK WILLIAM MITTAUER MD $106,756.39 1,644 4.54 17
16 1316922545 MABRA G ABERNATHY $48,462.85 1,608 5.49 15
17 1245388743 TIMOTHY SWINTON MD $77,465.04 1,577 7.27 19
18 1023053972 BRYANT MUTCHLER DO $76,227.94 1,541 5.45 20
19 1972758126 REBECCA BOLLIN $42,089.45 1,514 5.11 24
20 1144214248 KRISTI WALZ MD $109,044.78 1,489 5.66 29
21 1275844649 KATIE M HANSON $107,876.82 1,403 4.34 21
22 1023377827 LISA KAY CHASE $63,730.48 1,389 5.34 22
23 1205169273 TERESA ANN DOWLING $41,112.60 1,384 5.56 30
24 1598962870 CHRISTY QUILLEN $47,165.99 1,351 5.63 28
25 1497736326 RANDY R ROBINSON $63,468.64 1,347 6.27 33
26 1891705968 ANITA HANDEVIDT $136,054.31 1,314 3.84 39
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27 1841220290 KENT ELDON KUNZE MD $117,775.23 1,311 4.27 16
28 1043434525 ROBERT MARVIN KENT MD $62,355.76 1,308 4.62 26
29 1912991340 GHADA HAMDAN-ALLEN MD $128,579.09 1,286 4.37 23
30 1164538674 JOSEPH M WANZEK $63,979.43 1,280 5.29 42
31 1679669832 ERIN VOYLES HATCHER ARNP $129,646.75 1,278 3.90 35
32 1780979666 LINDSEY ANN CHRISTIANSON $47,215.01 1,274 5.38 97
33 1073945499 JENNIFER LEE ZALAZNIK ARNP $51,307.14 1,271 3.59 101
34 1952459463 DAVID LAWRENCE YURDIN PA $603,284.69 1,267 4.64 34
35 1467437806 GEORGIA LAUER PAC $70,280.43 1,260 5.89 41
36 1073500690 KATHLEEN S ADAMS $155,663.59 1,258 3.65 31
37 1902809536 KIRAN BHASKAR KHANOLKAR MD $55,406.52 1,253 5.54 52
38 1073594768 JERROLD VERLIN FLATT DO $57,228.87 1,233 4.82 32
39 1417241621 ASHLEY M MATHES $36,726.05 1,229 4.62 58
40 1528144383 RAMONCITO AMURAO O'CAMPO $56,420.27 1,229 4.64 64
41 1558770974 MARC BAUMERT PA C $31,198.90 1,220 3.79 94
42 1780877878 CHRISTOPHER JACOBS ARNP $62,352.78 1,216 4.27 43
43 1508946088 RICHARD E NIGHTINGALE $88,079.41 1,204 5.57 37
44 1588629414 THOMAS EARWOOD $74,384.71 1,204 5.21 40
45 1477633188 CYD Q. GRAFFT $103,010.17 1,199 3.82 25
46 1346210184 JAMES BROOKS MD $125,579.27 1,192 5.84 48
47 1073949236 KATE ANN TRIPP PA $34,186.69 1,176 4.86 95
48 1134425127 MELANIE HOWARD ARPN $84,866.02 1,174 3.81 59
49 1184722910 LAURA M VAN CLEVE DO $124,568.22 1,166 3.55 36
50 1003004391 DAVID B WALKER MD $107,826.13 1,160 4.22 38
51 1730239732 SRIRAMAMURTHY RAVIPATI MD $105,001.07 1,149 3.57 57
52 1508289620 GLORIA A MILLER $107,040.09 1,144 7.24 53
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53 1285697722 DOUGLAS  JONES $101,093.99 1,138 3.62 60
54 1295830115 ALAN BOLLINGER DO $112,379.06 1,132 6.32 61
55 1245203223 MARY BETH HUTCHINSON ARNP $80,560.59 1,131 5.71 114
56 1962558957 ALBERT N OKINE PA $138,267.48 1,125 6.43 50
57 1730143397 MARK JOSEPH DEARDEN DO $27,312.83 1,117 5.48 76
58 1184945321 DEANNE REMER $72,861.52 1,114 6.09 56
59 1871586271 PATRICIA BLACKLEDGE ARNP $49,907.69 1,101 5.34 69
60 1891756128 PHILIP JOSEPH MULLER DO $106,206.56 1,098 5.57 103
61 1306812490 MERRILEE RAMSEY ARNP $63,184.06 1,095 4.09 74
62 1225097843 WILLIAM M NISSEN $58,568.24 1,095 3.86 66
63 1306133095 DEBRA LEE ANDERSON ARNP $49,711.22 1,093 4.06 55
64 1538157383 DAVID WENGER-KELLER MD $45,438.73 1,091 5.37 44
65 1871789982 RANAE MICHELLE ROBERTS $33,121.94 1,086 5.51 98
66 1215080759 JUANITA M O'BRIEN $41,224.17 1,075 5.48 51
67 1205821337 MANMOHAN SINGH $48,102.86 1,075 4.69 73
68 1396731287 VICKI L BOLING ARNP $59,719.10 1,073 4.65 63
69 1801131461 MEREDITH DALLAS OLSON $62,784.83 1,042 4.65 99
70 1356760011 CHARISSA S ELLIOTT $51,226.65 1,041 5.88 80
71 1790046548 LAURIE L CLAIR PA $45,779.98 1,039 4.48 92
72 1326013426 PAUL DENNIS PETERSON DO $53,511.38 1,035 3.38 85
73 1912991183 MOLLY EARLEYWINE PA $25,555.70 1,032 4.25 96
74 1437209434 J GREGORY THOMAS MD $45,417.22 1,031 3.88 135
75 1841407160 RAHUL BANSAL MD $105,739.30 1,026 3.48 10
76 1104976109 ISAM ELIAS MARAR MD $76,758.97 1,025 6.10 54
77 1013960566 PETER JOSEPH SZEIBEL $104,777.16 1,024 5.07 68
78 1215146055 REBECCA J WOLFE $83,848.85 1,023 3.82 45
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79 1609218304 AMANDA O'TOOL ARNP $87,343.59 1,019 5.23 71
80 1780793976 MATTHEW D EGGERS MD $129,819.98 1,016 5.03 65
81 1558348284 STEVEN G PAULSRUD DO $46,060.75 1,010 4.57 79
82 1669623583 ANNE MIREILLE METUGE AHONE $56,611.78 1,009 4.74 84
83 1861559486 JOSPEH PATRICK BERTROCHE $123,899.18 1,008 4.11 72
84 1841293354 KEITH GUESS PA C $104,079.77 1,008 4.29 46
85 1720293087 RAJNI BATRA MD $57,523.03 1,007 3.48 27
86 1922144088 THOMAS S HOPKINS DO $103,726.90 995 3.47 62
87 1073509436 MICHAEL KARL MAHARRY MD $45,101.31 989 4.52 83
88 1437238110 GENEVIEVE  NELSON $59,667.10 989 3.97 104
89 1699075929 HIEDI CHRISTINE LANE ARNP $90,049.95 984 3.87 67
90 1902912538 CHRISTIAN W JONES MD $45,763.20 978 3.64 93
91 1437373073 MOHSEN ABOU SEIF MD $30,423.63 978 4.51 138
92 1487908380 LISA ANN BECHTEL ARNP $130,405.25 975 3.14 102
93 1326045808 RAY C STURDEVANT MD $101,230.40 975 3.46 90
94 1316356496 KIMBERLY NICHOLLE WOOD ARNP $102,718.33 971 4.06 107
95 1104034552 DEANNA BOOK BOESEN $112,542.72 968 4.12 109
96 1134191018 DUSTIN RALPH SMITH MD $59,005.56 960 4.30 78
97 1356520431 KAY A MARTTILA $94,794.70 960 3.37 81
98 1598750432 CHRISTOPHER G OKIISHI $71,645.60 950 6.93 108
99 1104877281 LORI KRAUSE PA $24,463.46 937 4.36 118
100 1164416269 ANN PICK ARNP $29,765.25 931 4.17 122
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1 1013126705 JANICE M. R. STABER $2,332,275.67 $31,097.01 75 1
2 1952459463 DAVID LAWRENCE YURDIN PA $603,284.69 $476.15 1,267 2
3 1548247406 VILMARIE RODRIGUEZ-PADUA MD $403,100.57 $40,310.06 10 14
4 1770561946 DONALD HILLEBRAND MD $355,978.43 $2,506.89 142 3
5 1194817247 MARIA J STEELE ARNP $322,527.71 $1,908.45 169 17
6 1346255809 JEFFREY  DUNKELBERG $258,181.29 $3,536.73 73 52
7 1013115369 BOBBITA NAG MD $234,225.48 $125.93 1,860 4
8 1356337273 LISA J MENZIES $232,672.76 $496.10 469 18
9 1467502286 CHARLES TILLEY PA $215,343.45 $117.80 1,828 15
10 1780766659 CHESTER ROBERT BADGER $201,109.66 $54.83 3,668 5
11 1548256191 JUDITH A MILLER $194,904.10 $6,960.86 28 19
12 1649255431 STEPHANIE DEE PA $188,236.13 $1,981.43 95 1222
13 1902885445 BHARAT ASHOK MOTWANI MD $186,785.21 $1,297.12 144 79
14 1649248378 KATHLEEN L WILD ARNP $185,317.61 $92.24 2,009 6
15 1497060776 USHA PEREPU MBBS $181,071.29 $5,487.01 33 404
16 1982605762 JEFFREY D WILHARM $171,682.99 $62.02 2,768 9
17 1043211303 ALI  SAFDAR $167,485.27 $77.32 2,166 8
18 1083609358 JENNIFER S COOK $165,620.19 $262.47 631 12
19 1376777524 ALLADDIN MOH ELHADI ABOSAIDA $165,468.96 $413.67 400 47
20 1205015906 DAVID F WIDITZ $165,293.83 $84.68 1,952 11
21 1760477483 WARREN P BISHOP, MD $165,161.49 $922.69 179 50
22 1033418843 RANDHIR JESUDOSS MD $162,659.45 $2,464.54 66 49
23 1285748004 BRUCE L HUGHES MD $162,366.12 $1,143.42 142 10
24 1194703074 WENDY ANNE WALDMAN $157,794.81 $233.42 676 21
25 1073500690 KATHLEEN S ADAMS $155,663.59 $123.74 1,258 13
26 1699767525 EZZATOLLAH SHIVAPOUR $154,709.96 $2,148.75 72 22
27 1083603773 JACK T STAPLETON $151,373.46 $818.23 185 16
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28 1962558957 ALBERT N OKINE PA $138,267.48 $122.90 1,125 29
29 1891705968 ANITA HANDEVIDT $136,054.31 $103.54 1,314 33
30 1619963949 EVA TSALIKIAN $133,986.04 $778.99 172 39
31 1083784797 CAROL AUNAN ARNP $133,425.04 $70.37 1,896 20
32 1487908380 LISA ANN BECHTEL ARNP $130,405.25 $133.75 975 43
33 1780793976 MATTHEW D EGGERS MD $129,819.98 $127.78 1,016 32
34 1679669832 ERIN VOYLES HATCHER ARNP $129,646.75 $101.45 1,278 26
35 1912991340 GHADA HAMDAN-ALLEN MD $128,579.09 $99.98 1,286 23
36 1801890611 DEBORAH A HUBER ARNP $128,373.03 $937.03 137 84
37 1134402373 JULIE A SCHUCK $127,531.04 $728.75 175 59
38 1447242359 DANIEL M SLEITER ARNP $126,008.79 $703.96 179 71
39 1346210184 JAMES BROOKS MD $125,579.27 $105.35 1,192 30
40 1740246008 DANIEL LAMPTEY MD $125,162.65 $7,362.51 17 38
41 1184722910 LAURA M VAN CLEVE DO $124,568.22 $106.83 1,166 24
42 1790708451 MICHAEL M MCCUBBIN $124,167.81 $307.35 404 51
43 1861559486 JOSPEH PATRICK BERTROCHE $123,899.18 $122.92 1,008 31
44 1245624626 BLAKE WILLIAMS $123,762.77 $20,627.13 6
45 1841220290 KENT ELDON KUNZE MD $117,775.23 $89.84 1,311 25
46 1104034552 DEANNA BOOK BOESEN $112,542.72 $116.26 968 46
47 1497737878 MICHAEL D VOIGT $112,464.31 $1,183.83 95 346
48 1295830115 ALAN BOLLINGER DO $112,379.06 $99.27 1,132 78
49 1053520759 ALICIA GERKE $110,389.65 $2,759.74 40 108
50 1144214248 KRISTI WALZ MD $109,044.78 $73.23 1,489 75
51 1275844649 KATIE M HANSON $107,876.82 $76.89 1,403 35
52 1003004391 DAVID B WALKER MD $107,826.13 $92.95 1,160 42
53 1609055771 CHARUTA NARAYAN JOSHI $107,281.67 $203.96 526 74
54 1508289620 GLORIA A MILLER $107,040.09 $93.57 1,144 58
Page 16 Of 297/14/2015 2:53:28 PM RT33018
trusted, reliable, innovative
TOP 100 PRESCRIBING PROVIDERS BY PAID AMOUNT
May/June 2015
RANK DOCTOR NUM PRESCRIBER NAME PAID AMOUNT AVG COST RX PRESCRIPTION COUNT PREVIOUS RANK
55 1255322996 MARK WILLIAM MITTAUER MD $106,756.39 $64.94 1,644 54
56 1891756128 PHILIP JOSEPH MULLER DO $106,206.56 $96.73 1,098 82
57 1841407160 RAHUL BANSAL MD $105,739.30 $103.06 1,026 7
58 1730239732 SRIRAMAMURTHY RAVIPATI MD $105,001.07 $91.38 1,149 64
59 1013960566 PETER JOSEPH SZEIBEL $104,777.16 $102.32 1,024 68
60 1841293354 KEITH GUESS PA C $104,079.77 $103.25 1,008 34
61 1184602013 RODNEY A SHORT MD $103,962.71 $479.09 217 62
62 1972638864 LIUSKA MARIA PESCE $103,882.62 $332.96 312 28
63 1922144088 THOMAS S HOPKINS DO $103,726.90 $104.25 995 41
64 1477633188 CYD Q. GRAFFT $103,010.17 $85.91 1,199 40
65 1316356496 KIMBERLY NICHOLLE WOOD ARNP $102,718.33 $105.79 971 66
66 1902115652 SARAH L BEATTIE ARNP $102,211.14 $117.21 872 36
67 1326045808 RAY C STURDEVANT MD $101,230.40 $103.83 975 69
68 1285697722 DOUGLAS  JONES $101,093.99 $88.83 1,138 45
69 1609867688 DAVID BRIAN MOORE MD $99,166.47 $411.48 241 124
70 1104029008 KATIE MARIE ULRING LARSON ODE $98,531.78 $421.08 234 90
71 1568647303 CHERYL ANGELINE CONRAD ARNP $97,998.32 $296.96 330 48
72 1083681944 MARY CHRISTINE SEGRETO DO $97,059.69 $110.93 875 88
73 1760470678 JEFFERY L MEIER $95,435.66 $900.34 106 99
74 1356520431 KAY A MARTTILA $94,794.70 $98.74 960 44
75 1255393997 LAURA RAMSEY ARNP $92,975.30 $893.99 104 128
76 1033361563 ERMEI YAO PA $92,652.39 $443.31 209 91
77 1215125216 REBECCA WALDING $92,044.16 $112.52 818 76
78 1710941000 LAURIE WARREN PA $91,832.94 $106.29 864 65
79 1215025309 DEBORAH LYNNE GARRELTS $90,840.33 $100.15 907 86
80 1699075929 HIEDI CHRISTINE LANE ARNP $90,049.95 $91.51 984 53
81 1003957903 JORGE LUIS ALVAREZ MD $89,826.48 $646.23 139 61
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May/June 2015
RANK DOCTOR NUM PRESCRIBER NAME PAID AMOUNT AVG COST RX PRESCRIPTION COUNT PREVIOUS RANK
82 1942379557 JANNE L JOHNSON ARNP $89,345.78 $124.26 719 106
83 1174584072 BRADLEY SCOTT LAIR $88,998.49 $574.18 155 214
84 1508946088 RICHARD E NIGHTINGALE $88,079.41 $73.16 1,204 80
85 1134533599 $87,683.14 $109.47 801 89
86 1477765584 SANGEETA SHAH MD $87,560.89 $189.94 461 136
87 1609218304 AMANDA O'TOOL ARNP $87,343.59 $85.72 1,019 63
88 1235124942 JULIE KATHRYN OSTERHAUS $86,135.50 $345.93 249 116
89 1134171937 KATHRYN LEE FLANDERS ARNP $85,929.13 $698.61 123 104
90 1750376034 DUANGCHAI NARAWONG MD $85,864.96 $160.80 534 67
91 1285681528 MARVIN F PIBURN JR MD $85,379.07 $111.90 763 85
92 1134425127 MELANIE HOWARD ARPN $84,866.02 $72.29 1,174 83
93 1629042288 MARTIN J FIALKOV MD $84,185.17 $96.65 871 77
94 1215146055 REBECCA J WOLFE $83,848.85 $81.96 1,023 70
95 1538368170 CHRISTOPHER ROBERT MATSON $83,451.03 $39.31 2,123 95
96 1861474710 CAROLYN JOHNSON PA $83,202.36 $290.92 286 96
97 1063491645 ALLYSON L WHEATON MD $81,314.00 $92.09 883 57
98 1245203223 MARY BETH HUTCHINSON ARNP $80,560.59 $71.23 1,131 207
99 1417110404 CASEY M RICE $79,507.99 $1,347.59 59 3188
100 1053372029 STEFANIE RENEE YEARIAN ARNP $79,489.53 $87.64 907 125
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TOP 20 THERAPEUTIC CLASS BY PAID AMOUNT
CATEGORY DESCRIPTION March/April 2015 RANK % BUDGET May/June 2015 RANK % BUDGET % CHANGE
ANTIPSYCHOTICS - ATYPICALS $6,132,593 1 8.8% $5,647,387 1 8.3% -7.9%
ANTICONVULSANTS $3,556,465 4 5.1% $3,516,045 2 5.2% -1.1%
STIMULANTS - AMPHETAMINES - LONG ACTING $3,743,650 2 5.4% $3,226,436 3 4.8% -13.8%
DIABETIC - INSULIN $3,105,028 5 4.5% $3,114,399 4 4.6% 0.3%
ANTIHEMOPHILIC AGENTS $2,248,322 6 3.2% $2,860,026 5 4.2% 27.2%
STIMULANTS - METHYLPHENIDATE - LONG ACTING $3,596,243 3 5.2% $2,766,312 6 4.1% -23.1%
HEPATITIS C AGENTS $1,761,715 10 2.5% $2,567,268 7 3.8% 45.7%
ANTIASTHMATIC - ADRENERGIC COMBOS $2,213,171 7 3.2% $2,175,182 8 3.2% -1.7%
ANTI-INFLAMMATORIES, NON-NSAID $1,761,199 11 2.5% $2,124,205 9 3.1% 20.6%
ANTIDEPRESSANTS - SELECTED SSRI's $2,189,059 8 3.1% $1,936,271 10 2.9% -11.5%
STIMULANTS - METHYLPHENIDATE $1,852,604 9 2.7% $1,617,109 11 2.4% -12.7%
DIABETIC - INSULIN  PENFILLS $1,544,028 12 2.2% $1,605,261 12 2.4% 4.0%
MULTIPLE SCLEROSIS AGENTS $1,453,521 15 2.1% $1,417,796 13 2.1% -2.5%
STIMULANTS - OTHER STIMULANTS / LIKE STIMULANTS $1,470,746 14 2.1% $1,403,881 14 2.1% -4.5%
ANTIASTHMATIC - BETA - ADRENERGICS $1,514,107 13 2.2% $1,386,465 15 2.0% -8.4%
ANTIRETROVIRALS $1,232,178 16 1.8% $1,204,377 16 1.8% -2.3%
ANTIASTHMATIC - STEROID INHALANTS $1,157,334 17 1.7% $1,071,646 17 1.6% -7.4%
ANTIASTHMATIC - ANTI-CHOLINERGICS $939,787 20 1.3% $1,069,601 18 1.6% 13.8%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS $1,033,941 18 1.5% $1,060,297 19 1.6% 2.5%
NARCOTICS - MISC. $958,650 19 1.4% $1,016,586 20 1.5% 6.0%
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CATEGORY DESCRIPTION March/April 2015 PREV RANK May/June 2015 CURR RANK PERC CHANGE
ANTIDEPRESSANTS - SELECTED SSRI's 95,290 1 94,330 1 -1.0%
ANTICONVULSANTS 50,300 2 49,630 2 -1.3%
NARCOTICS - MISC. 40,124 3 41,351 3 3.1%
ANTIPSYCHOTICS - ATYPICALS 31,897 5 30,207 4 -5.3%
ANTIHISTAMINES - NON-SEDATING 28,477 7 29,339 5 3.0%
ANTIASTHMATIC - BETA - ADRENERGICS 31,809 6 27,432 6 -13.8%
GI - PROTON PUMP INHIBITOR 26,349 9 26,634 7 1.1%
BETA-LACTAMS / CLAVULANATE COMBO'S 37,338 4 25,857 8 -30.7%
CHOLESTEROL - HMG COA + ABSORB INHIBITORS 25,482 10 25,842 9 1.4%
ANALGESICS - MISC. 26,530 8 25,289 10 -4.7%
ACE INHIBITORS 20,688 12 21,131 11 2.1%
ANXIOLYTICS - BENZODIAZEPINES 21,087 11 21,023 12 -0.3%
NSAIDS 20,222 13 19,554 13 -3.3%
DIURETICS 18,440 16 18,684 14 1.3%
ANTIHYPERTENSIVES - CENTRAL 20,020 14 18,597 15 -7.1%
MUSCLE RELAXANTS 16,501 21 16,519 16 0.1%
THYROID HORMONES 15,925 22 16,267 17 2.1%
GLUCOCORTICOIDS - MINERALOCORTICOIDS 17,877 18 15,335 18 -14.2%
STIMULANTS - AMPHETAMINES - LONG ACTING 17,923 17 15,301 19 -14.6%
BETA BLOCKERS - CARDIO SELECTIVE 14,916 23 15,080 20 1.1%
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TOP 100 DRUGS BY PAID AMOUNT
DRUG DESCRIPTION March/April 2015 PREVIOUS 
RANK
May/June 2015 RANK PERCENT CHANGE
ABILIFY $3,199,250.59 1 $2,670,363.86 1 -16.53%
VYVANSE $3,031,178.10 3 $2,594,393.24 2 -14.41%
METHYLPHENIDATE HCL ER $3,075,348.72 2 $2,300,048.95 3 -25.21%
HARVONI $1,047,180.59 8 $1,718,889.61 4 64.14%
LANTUS $1,571,068.50 4 $1,579,010.32 5 0.51%
FOCALIN XR $1,477,551.58 5 $1,314,232.97 6 -11.05%
ADVATE $1,460,609.41 6 $1,300,874.72 7 -10.94%
NOVOSEVEN RT $664,879.41 17 $1,253,376.98 8 88.51%
STRATTERA $1,069,431.02 7 $1,026,710.84 9 -3.99%
SPIRIVA HANDIHALER $868,100.88 10 $996,290.38 10 14.77%
ADVAIR DISKUS $970,588.88 9 $922,283.74 11 -4.98%
HUMALOG $585,706.07 20 $906,297.95 12 54.74%
SOVALDI $671,285.21 15 $834,531.59 13 24.32%
LATUDA $811,266.69 11 $756,139.92 14 -6.80%
HUMIRA PEN $575,715.48 21 $746,584.64 15 29.68%
VENTOLIN HFA $763,593.33 12 $684,848.11 16 -10.31%
DEPAKOTE ER $675,838.70 14 $662,544.82 17 -1.97%
SYMBICORT $619,746.81 19 $633,693.98 18 2.25%
CRESTOR $563,367.27 23 $580,569.90 19 3.05%
HYDROCODONE/ACETAMINOPHEN $539,458.25 25 $577,688.72 20 7.09%
ADDERALL XR $623,102.71 18 $557,113.59 21 -10.59%
INVEGA SUSTENNA $573,789.69 22 $536,846.53 22 -6.44%
ATRIPLA $542,640.58 24 $528,014.66 23 -2.70%
NORDITROPIN FLEXPRO $448,342.86 28 $519,495.58 24 15.87%
LEVEMIR $493,127.93 27 $507,074.79 25 2.83%
DEXILANT $441,819.22 29 $451,260.95 26 2.14%
LANTUS SOLOSTAR $400,908.42 32 $423,497.77 27 5.63%
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DRUG DESCRIPTION March/April 2015 PREVIOUS 
RANK
May/June 2015 RANK PERCENT CHANGE
TECFIDERA $375,779.10 35 $420,883.40 28 12.00%
NOVOLOG FLEXPEN $352,192.23 37 $388,553.57 29 10.32%
COPAXONE $439,201.17 30 $384,525.31 30 -12.45%
QVAR $386,011.82 33 $378,094.66 31 -2.05%
LYRICA $349,262.10 38 $371,044.36 32 6.24%
ENBREL SURECLICK $307,513.69 44 $363,674.09 33 18.26%
NASONEX $370,148.31 36 $351,394.83 34 -5.07%
NOVOLOG $669,207.88 16 $341,924.29 35 -48.91%
TRUVADA $322,415.87 41 $324,597.47 36 0.68%
ENBREL $273,054.56 48 $324,277.77 37 18.76%
PROVENTIL HFA $319,735.93 42 $318,435.04 38 -0.41%
EPIPEN 2-PAK $252,844.33 53 $285,297.91 39 12.84%
AMPHETAMINE/DEXTROAMPHETA $288,939.84 46 $277,475.41 40 -3.97%
INVEGA $254,435.84 52 $277,262.51 41 8.97%
PULMICORT $335,598.10 40 $277,139.01 42 -17.42%
HUMIRA $279,031.91 47 $275,607.60 43 -1.23%
RISPERDAL CONSTA $289,183.28 45 $274,687.19 44 -5.01%
EURAX $112,716.13 126 $272,106.31 45 141.41%
VIMPAT $255,661.18 51 $258,840.49 46 1.24%
OMEPRAZOLE $249,392.79 55 $258,613.48 47 3.70%
JANUVIA $227,546.06 58 $256,991.57 48 12.94%
LEVOTHYROXINE SODIUM $247,784.07 56 $255,444.88 49 3.09%
AZITHROMYCIN $418,312.68 31 $249,190.00 50 -40.43%
MONTELUKAST SODIUM $252,157.78 54 $245,134.54 51 -2.79%
FLOVENT HFA $263,210.94 49 $241,221.54 52 -8.35%
PULMOZYME $221,477.92 62 $239,253.58 53 8.03%
ALPHANATE/VON WILLEBRAND 999 $238,104.45 54 %
Page 22 Of 297/14/2015 2:53:28 PM RT33018
trusted, reliable, innovative
TOP 100 DRUGS BY PAID AMOUNT
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May/June 2015 RANK PERCENT CHANGE
COMBIVENT RESPIMAT $233,924.08 57 $233,499.74 55 -0.18%
CEFDINIR $381,420.95 34 $230,511.60 56 -39.57%
GABAPENTIN $225,722.77 59 $229,201.21 57 1.54%
PROAIR HFA $221,762.87 61 $228,582.05 58 3.07%
GILENYA $181,491.93 74 $220,741.38 59 21.63%
PROVIGIL $221,842.71 60 $214,743.02 60 -3.20%
CYMBALTA $536,139.72 26 $213,378.40 61 -60.20%
XIFAXAN $209,241.43 67 $213,312.34 62 1.95%
QUILLIVANT XR $211,959.27 65 $210,803.59 63 -0.55%
NAGLAZYME $140,446.92 99 $210,670.38 64 50.00%
VESICARE $210,351.60 66 $209,951.39 65 -0.19%
AMOXICILLIN $318,073.25 43 $208,182.55 66 -34.55%
XYREM $163,017.15 82 $205,465.40 67 26.04%
SAPHRIS $174,042.36 76 $204,966.30 68 17.77%
DULOXETINE HCL $123,660.07 117 $201,429.77 69 62.89%
TOPROL XL $192,345.32 70 $199,112.23 70 3.52%
DULERA $194,177.28 68 $197,054.11 71 1.48%
BUPROPION HCL XL $192,845.61 69 $190,806.01 72 -1.06%
METHYLPHENIDATE HCL $212,688.74 64 $181,900.93 73 -14.48%
LEVEMIR FLEXTOUCH $187,243.71 73 $178,202.61 74 -4.83%
BANZEL $156,227.59 86 $174,513.23 75 11.70%
OPANA ER (CRUSH RESISTANT $173,561.85 77 $174,283.90 76 0.42%
GLEEVEC $190,180.55 72 $170,882.75 77 -10.15%
LISINOPRIL $165,945.01 80 $170,573.35 78 2.79%
ATORVASTATIN CALCIUM $159,598.35 83 $169,528.09 79 6.22%
SERTRALINE HCL $170,729.61 78 $168,845.35 80 -1.10%
QUETIAPINE FUMARATE $168,480.91 79 $168,363.12 81 -0.07%
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STRIBILD $164,001.23 81 $168,145.07 82 2.53%
KALYDECO $143,456.16 95 $167,364.02 83 16.67%
ENOXAPARIN SODIUM $192,087.52 71 $167,138.66 84 -12.99%
KUVAN $132,866.95 111 $165,332.14 85 24.43%
PATANOL $132,867.38 110 $158,369.93 86 19.19%
TRAMADOL HCL $154,652.97 87 $153,236.01 87 -0.92%
VENLAFAXINE HCL ER $150,853.88 89 $153,212.38 88 1.56%
SEROQUEL XR $152,642.89 88 $151,503.59 89 -0.75%
RISPERIDONE $156,494.83 85 $147,514.85 90 -5.74%
FLUTICASONE PROPIONATE $158,369.35 84 $146,944.76 91 -7.21%
ONFI $143,329.97 96 $146,507.20 92 2.22%
AMOXICILLIN/CLAVULANATE P $215,123.88 63 $143,213.04 93 -33.43%
CEPHALEXIN $149,499.04 92 $142,546.00 94 -4.65%
COMPLERA $134,340.92 107 $142,102.70 95 5.78%
ESCITALOPRAM OXALATE $146,841.46 94 $141,561.64 96 -3.60%
ADVAIR HFA $149,711.00 91 $139,348.20 97 -6.92%
PATADAY $118,312.97 119 $137,509.58 98 16.23%
TRAZODONE HCL $142,719.17 97 $136,366.33 99 -4.45%
ALPRAZOLAM $134,882.85 105 $136,356.04 100 1.09%
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HYDROCO/APAP TAB 5-325MG 17,880 1 18,308 1 2.39%
Loratadine Tab 10 MG 12,450 5 12,760 2 2.49%
TRAMADOL HCL TAB 50MG 12,500 4 12,456 3 -0.35%
VENTOLIN HFA AER 13,367 2 12,057 4 -9.80%
Cetirizine HCl Tab 10 MG 9,578 7 10,036 5 4.78%
OMEPRAZOLE   CAP 20MG 9,719 6 9,678 6 -0.42%
FLUOXETINE   CAP 20MG 9,504 9 9,584 7 0.84%
ESCITALOPRAM TAB 20MG 9,519 8 9,364 8 -1.63%
OMEPRAZOLE   CAP 40MG 8,764 13 9,060 9 3.38%
GABAPENTIN   CAP 300MG 8,868 12 8,826 10 -0.47%
CYCLOBENZAPR TAB 10MG 8,465 15 8,475 11 0.12%
FLUTICASONE  SPR 50MCG 8,924 11 8,117 12 -9.04%
AMOXICILLIN  SUS 400/5ML 12,891 3 7,778 13 -39.66%
SERTRALINE   TAB 100MG 7,179 17 7,169 14 -0.14%
CLONIDINE    TAB 0.1MG 7,601 16 7,080 15 -6.85%
MONTELUKAST  TAB 10MG 6,791 20 6,922 16 1.93%
Aspirin Tab Delayed Release 81 MG 6,979 19 6,818 17 -2.31%
RANITIDINE   TAB 150MG 7,152 18 6,790 18 -5.06%
IBUPROFEN    TAB 800MG 6,597 22 6,576 19 -0.32%
ALBUTEROL    NEB 0.083% 9,105 10 6,354 20 -30.21%
TRAZODONE    TAB 50MG 6,587 24 6,270 21 -4.81%
GUANFACINE   TAB 1MG 6,790 21 6,112 22 -9.99%
TRAZODONE    TAB 100MG 6,227 25 6,026 23 -3.23%
LISINOPRIL   TAB 10MG 5,848 28 5,946 24 1.68%
Acetaminophen Tab 325 MG 6,114 26 5,862 25 -4.12%
Ferrous Sulfate Tab 325 MG (65 MG 
Elemental Fe)
5,971 27 5,850 26 -2.03%
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AZITHROMYCIN TAB 250MG 8,686 14 5,768 27 -33.59%
LISINOPRIL   TAB 20MG 5,564 32 5,696 28 2.37%
METFORMIN    TAB 500MG 5,619 29 5,680 29 1.09%
HYDROCHLOROT TAB 25MG 5,601 30 5,534 30 -1.20%
MELOXICAM    TAB 15MG 4,933 38 5,339 31 8.23%
OXYCOD/APAP  TAB 5-325MG 4,716 40 5,146 32 9.12%
METFORMIN    TAB 1000MG 4,946 37 5,054 33 2.18%
CLONAZEPAM   TAB 1MG 4,893 39 4,895 34 0.04%
CEPHALEXIN   CAP 500MG 4,492 45 4,781 35 6.43%
PROVENTIL    AER HFA 4,668 41 4,614 36 -1.16%
PREDNISONE   TAB 20MG 5,022 35 4,579 37 -8.82%
AMLODIPINE   TAB 10MG 4,447 47 4,524 38 1.73%
VENLAFAXINE  CAP 150MG ER 4,485 46 4,516 39 0.69%
PANTOPRAZOLE TAB 40MG 4,424 49 4,504 40 1.81%
CITALOPRAM   TAB 20MG 4,554 44 4,478 41 -1.67%
SERTRALINE   TAB 50MG 4,595 42 4,465 42 -2.83%
HYDROCO/APAP TAB 7.5-325 4,372 51 4,449 43 1.76%
Sennosides-Docusate Sodium Tab 8.6-50 
MG
4,428 48 4,424 44 -0.09%
POLYETH GLYC POW 3350 NF 4,996 36 4,423 45 -11.47%
ALPRAZOLAM   TAB 1MG 4,340 52 4,416 46 1.75%
LANTUS       INJ 100/ML 4,316 53 4,382 47 1.53%
AMOXICILLIN  CAP 500MG 5,516 33 4,367 48 -20.83%
SMZ/TMP DS   TAB 800-160 4,270 54 4,297 49 0.63%
HYDROCO/APAP TAB 10-325MG 3,962 65 4,276 50 7.93%
NAPROXEN     TAB 500MG 4,244 55 4,271 51 0.64%
ATORVASTATIN TAB 40MG 3,918 66 4,192 52 6.99%
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MONTELUKAST  CHW 5MG 4,391 50 4,164 53 -5.17%
METHYLPHENID TAB 36MG ER 5,359 34 4,074 54 -23.98%
Aspirin Chew Tab 81 MG 4,186 56 4,072 55 -2.72%
CLONAZEPAM   TAB 0.5MG 4,120 58 4,036 56 -2.04%
ALPRAZOLAM   TAB 0.5MG 3,997 62 4,014 57 0.43%
CITALOPRAM   TAB 40MG 4,019 61 4,006 58 -0.32%
ZOLPIDEM     TAB 10MG 3,980 63 3,892 59 -2.21%
AMLODIPINE   TAB 5MG 3,760 68 3,851 60 2.42%
Cetirizine HCl Oral Soln 1 MG/ML (5 
MG/5ML)
3,763 67 3,849 61 2.29%
PROAIR HFA   AER 3,673 69 3,795 62 3.32%
FOLIC ACID   TAB 1MG 3,665 70 3,747 63 2.24%
METOPROL TAR TAB 25MG 3,508 72 3,602 64 2.68%
DULOXETINE   CAP 60MG 2,327 107 3,520 65 51.27%
HYDROXYZ PAM CAP 25MG 3,524 71 3,460 66 -1.82%
AZITHROMYCIN SUS 200/5ML 6,588 23 3,444 67 -47.72%
BUPROPN HCL  TAB 300MG XL 3,419 74 3,390 68 -0.85%
LORAZEPAM    TAB 1MG 3,302 76 3,345 69 1.30%
ATORVASTATIN TAB 20MG 3,190 78 3,334 70 4.51%
SPIRIVA      CAP HANDIHLR 3,060 81 3,331 71 8.86%
Acetaminophen Tab 500 MG 3,508 73 3,289 72 -6.24%
SIMVASTATIN  TAB 20MG 3,280 77 3,203 73 -2.35%
AMOX/K CLAV  TAB 875MG 4,061 60 3,171 74 -21.92%
METHYLPHENID TAB 54MG ER 4,070 59 3,100 75 -23.83%
BUPROPN HCL  TAB 150MG XL 3,149 79 3,094 76 -1.75%
LISINOPRIL   TAB 40MG 2,930 84 3,038 77 3.69%
LEVOTHYROXIN TAB 50MCG 2,925 85 3,001 78 2.60%
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VENLAFAXINE  CAP 75MG ER 2,961 83 2,998 79 1.25%
ONDANSETRON  TAB 4MG ODT 4,573 43 2,982 80 -34.79%
FUROSEMIDE   TAB 40MG 2,906 86 2,942 81 1.24%
LORAZEPAM    TAB 0.5MG 3,066 80 2,934 82 -4.31%
FLUCONAZOLE  TAB 150MG 2,866 88 2,781 83 -2.97%
SIMVASTATIN  TAB 40MG 2,850 89 2,771 84 -2.77%
AMOXICILLIN  SUS 250/5ML 4,134 57 2,731 85 -33.94%
HUMALOG      INJ 100/ML 1,921 142 2,729 86 42.06%
RISPERIDONE  TAB 1MG 2,890 87 2,708 87 -6.30%
VYVANSE      CAP 30MG 3,375 75 2,695 88 -20.15%
PREDNISONE   TAB 10MG 2,756 91 2,652 89 -3.77%
LISINOPRIL   TAB 5MG 2,666 93 2,652 90 -0.53%
METRONIDAZOL TAB 500MG 2,707 92 2,651 91 -2.07%
MONTELUKAST  CHW 4MG 2,770 90 2,645 92 -4.51%
QUETIAPINE   TAB 100MG 2,637 94 2,592 93 -1.71%
VYVANSE      CAP 40MG 3,005 82 2,551 94 -15.11%
FUROSEMIDE   TAB 20MG 2,466 99 2,531 95 2.64%
CLOPIDOGREL  TAB 75MG 2,541 97 2,527 96 -0.55%
TRIAMCINOLON CRE 0.1% 2,424 101 2,525 97 4.17%
PREDNISOLONE SOL 15MG/5ML 5,565 31 2,512 98 -54.86%
METOPROL TAR TAB 50MG 2,400 104 2,424 99 1.00%
APAP/CODEINE TAB 300-30MG 2,490 98 2,416 100 -2.97%
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Iowa Medicaid Drug Utilization Review Commission 
Meeting Minutes August 6, 2014 
Attendees: 
Commission Members 
Mark Graber, M.D., FACEP; Laurie Pestel, Pharm.D.; Gregory Barclay, M.D.; Kellen 
Ludvigson, Pharm.D.; Larry Ambroson, R.Ph.; Brett Faine, Pharm.D.; Brian Couse, 
M.D.; and Susan Parker, Pharm.D. 
 
Staff 
Pam Smith, R.Ph.  
 
Guests 
Jason Kessler, M.D., IME; Erin Halverson, R.Ph., IME; Megan Smith, Pharm.D., 
IME; and Melissa Biddle, IME. 
 
 
Welcome & Introductions 
Mark Graber, M.D. called the meeting to order at 9:32 a.m. at the Learning Resource 
Center in West Des Moines. The minutes from the June 4, 2014 meeting were 
reviewed.  Gregory Barclay, M.D. motioned to accept them, and Brian Couse, M.D. 
and Brett Faine, Pharm.D. seconded simultaneously.  All members were in favor.  
Annual conflict of interest disclosures were collected in closed session.  Brett Faine, 
Pharm.D. nominated Mark Graber, M.D. to remain Chairperson.  Laurie Pestel, 
Pharm.D. seconded, and all members were in favor.  Kellen Ludvigson, Pharm.D. 
then nominated Laurie Pestel, Pharm.D. to remain Vice-Chairperson, which was 
seconded by Larry Ambroson, R.Ph. and agreed upon by all members.  The 
recommendation letter sent to DHS after the June 2014 meeting, in addition to an 
article about the variation among states in the prescribing of opioids and 
benzodiazepines, were also reviewed. 
 
IME Updates 
Medicaid Director Jennifer Vermeer will be leaving Iowa Medicaid for a position at 
the University of Iowa effective August 21, 2014.  Julie Lovelady will be interim 
director while a national search is conducted.  Over 100,000 members are now 
enrolled in the Iowa Health and Wellness Plan (IHAWP). A new DHS website was 
launched in June, along with a new website featuring the latest information on 
IHAWP: http://www.iahealthlink.gov.  A recent informational letter notified providers 
of a change to the dispensing fee effective August 1, 2014, increasing it to $11.73 
once CMS approves the State Plan Amendment.  Claims will be adjusted 
retroactively once approval is obtained. 
 
Prevalence Report Summary 
Statistics from May though June 2014 were discussed, including: cost per user 
($287.06), number of total prescriptions dispensed (an increase of 1.2% compared 
to the previous reporting period), average cost per prescription ($59.02), and generic 
2 
 
utilization (83.8%).  The total paid amount increased by 1.6% from the previous 
reporting period.  There were 180,950 unique users, which is 1.5% less than the 
total for March and April.  Lists of the top 20 therapeutic classes were provided.  
SSRIs had the highest prescription count, and Anticonvulsants came in second.  The 
top 100 drugs were also reviewed.  The ten most expensive medications were: 
Abilify, Vyvanse, methylphenidate hcl er, Advate, Lantus, Focalin XR, Cymbalta, 
Adderall, Advair Diskus, and Strattera. 
 
Case Studies 
Pam Smith, R.Ph. presented 4 case studies.  Recommendations by Commissioners 
from these four examples resulted in annualized total savings of $3,191.10 pre-
rebate (state and federal).   
 
Public Comment 
 
Name Representing Drug/Topic 
Nancy Bell Pfizer Chronic Pain Syndromes PA Criteria and Lyrica 
Amy Shertzer Kaleo Evzio 
Neetha Molakala Primary Health Care Prior Authorization Issues (Inhalers and Insulin Pens) 
Lorraine Dansie Vanda Pharma Hetlioz 
Teresa Wakefield Vanda Pharma (Ambassador) Hetlioz 
 
Focus Studies 
 
Emergency Contraception: This was a follow-up discussion.  One-hundred thirty-
two (132) of the 227 members identified changed therapy, for an annualized cost 
savings of $461.58 (state and federal, pre-rebate) as a result of the 587 surveys sent 
out to prescribers and pharmacies.  Responses were received for 239 (40.72%) of 
those surveys. 
 
Albuterol MDI Over-Utilization: This was a follow-up discussion.  Two-hundred 
(200) of the 522 members identified changed therapy, for an annualized cost 
savings of $52,346.55 (state and federal, pre-rebate) as a result of the 1,980 
surveys sent out to prescribers and pharmacies.  Responses were received for 734 
(37.07%) of those surveys. 
 
Albuterol MDI Over-Utilization without Inhaled Corticosteroid: This was a follow-
up discussion.  Twenty-five (25) of the 257 members identified changed therapy, 
increasing annual costs by $6,566.32 (state and federal, pre-rebate) as a result of 
the 783 surveys sent out to prescribers and pharmacies.  Responses were received 
for 297 (37.93%) of those surveys. 
 
Long Term Use of Short-Acting Opioids: The Commission wants to lower the 
existing quantity limits to a quantity of 120 per 30 days, or 4 per day.  Kellen 
Ludvigson, Pharm.D. suggested using morphine equivalents to allow for titration 
without additional prior authorization.  Erin Halverson will get more information about 
programming an accumulator in POS for the category, and if a “max 4 per day” 
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reject message could be added to rejected claims for the convenience of the 
pharmacies.  Susan Parker, Pharm.D. suggested doing this in stages, with soft POS 
edits notifying providers of the changes prior to implementation of the quantity limits.   
Providers could be forewarned via letter before the limits are put into place.  This will 
be brought back to the next meeting.   
 
Prasugrel Contraindications: Letters will be sent to the prescribers of the six 
members identified as having a contraindication for use of prasugrel, and this topic 
will be revisited in 6 months to see if the numbers increase. 
 
Duplicate Antipsychotics: Pam Smith, R.Ph. will rerun the numbers to include 
Typical Antipsychotics as well.  This will be brought back to the next meeting. 
 
Eszopiclone Dose: Letters will be sent to the providers of the members identified as 
taking eszopiclone 3mg to inquire if a dose reduction could be attempted based on 
the new FDA warning, and if not, if the patient has been warned of the risk of next-
day impairment and was instructed not to drive or engage in other activities that 
require complete mental alertness the day after use. 
 
Public Comment 
 
Name Representing Drug/Topic 
John Strezewski Bristol-Myers Squibb Eliquis 
Lisa Willshaw MedImmune Synagis 
Rachel Anhorn Boehringer-Ingelheim Pradaxa 
Christina Reimers Merck Zontivity 
Paul James Genentech Xolair 
 
Prior Authorization 
 
Chronic Pain Syndromes: The Commission reviewed the prior authorization 
criteria as follows: 
A prior authorization is required for duloxetine (Cymbalta
®
), pregabalin (Lyrica
®
), 
and milnacipran (Savella
™
).  For patients with a chronic pain diagnosis who are 
currently taking opioids, as seen in pharmacy claims, a plan to decrease and/or 
discontinue the opioid(s) must be provided with the initial request.  Initial 
authorization will be given for three (3) months.  There must be a significant decrease 
in opioid use or discontinuation of opioid(s) after the initial three (3) month 
authorization for further consideration.  Additional prior authorizations will be 
considered with documentation of a continued decrease in opioid utilization.  
Payment will be considered under the following conditions: 
1. A diagnosis of fibromyalgia (Cymbalta®, Lyrica®, and Savella™)  
a. A trial and therapy failure at a therapeutic dose with gabapentin  plus one of 
the following: tricyclic antidepressant,  SSRI, or SNRI, WITH 
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b. Documented non-pharmacologic therapies (cognitive behavior therapies, 
exercise, etc.), AND  
c. Documentation of a previous trial and therapy failure at a therapeutic dose 
with Savella
™ 
when Cymbalta
®
 and Lyrica
®
 are requested.  
2. A diagnosis of post-herpetic neuralgia (Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of the 
following: tricyclic antidepressant, topical lidocaine, valproate, or 
carbamazepine. 
3. A diagnosis of diabetic peripheral neuropathy (Cymbalta® and Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of the 
following: tricyclic antidepressant or topical lidocaine. 
4. A diagnosis of partial onset seizures, as adjunct therapy (Lyrica®) 
5. A diagnosis of major depressive disorder or generalized anxiety disorder   
(Cymbalta
®
) 
6. A diagnosis of chronic musculoskeletal pain (Cymbalta®) 
A trial and therapy failure at a therapeutic dose with at least three drugs from 
three distinct therapeutic classes from the following: NSAIDs, opioids, tramadol, 
or tricyclic antidepressants.  
Requests for concomitant use of these agents for an indicated chronic pain diagnosis may 
only be considered once each agent has been tried at maximum tolerated dose separately. 
Duplicate use of drugs from the same therapeutic category will not be considered.   
Requests for doses above the manufacturer recommended dose will not be considered. 
 
Brett Faine, Pharm.D. motioned to accept the criteria, and Brian Couse, M.D. 
seconded.  All members were in favor.  The criteria will be sent out for public 
comment and brought back to the next meeting for further discussion. 
 
Naloxone (Evzio): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for naloxone auto-injector (Evzio).  Payment will be 
considered for patients when the following criteria are met: 
1. Patient is currently being treated with a long-acting opioid for a chronic pain 
condition; and 
2. Evidence of use of a long-acting opioid is found in the patients current pharmacy 
claims history (must be billed to and paid for by Iowa Medicaid); and 
3. Documentation patient has a caregiver that will be able to administer Evzio 
should the patient be found unresponsive and an opioid overdose is suspected; 
and 
4. Patient has a contraindication to use of intranasal naloxone; and 
5. The prescriber must review the patient’s use of controlled substances on the Iowa 
Prescription Monitoring Program website at  
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https://pmp.iowa.gov/IAPMPWebCenter/Login.aspx?ReturnUrl=%2fIAPMPWeb
Center%2fdefault.aspx prior to requesting prior authorization. 
6. Lost, stolen, or destroyed medication replacement requests will not be authorized. 
7. The 72-hour emergency supply rule does not apply to naloxone auto-injector 
products. 
 
The commission determined the delivery system used for administration of naloxone 
was a convenience for the patient or patient’s caregiver.  Additionally, the 
commission determined that the use of intranasal naloxone would be the least costly 
service which would reasonably meet the medical need of the patient.  Since the 
DUR determined Evzio is a convenience item and there are other cost-effective 
alternatives to Evzio, the DUR recommends not covering this product.  Kellen 
Ludvigson, Pharm.D. made the motion to refer this recommendation to the P&T 
Committee, and Brian Couse, M.D. seconded.  All members were in favor.  The P&T 
Committee will discuss this at their November meeting. 
 
Oral Immunotherapy: The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for sublingual allergen immunotherapy.  Payment will 
be considered under the following conditions: 
1. Medication is prescribed by an allergist; and 
2. Patient is diagnosed with pollen-induced allergic rhinitis with or without 
conjunctivitis; and 
3. Patient has documented trials and therapy failures with allergen avoidance and 
pharmacotherapy (intranasal corticosteroids and antihistamines); and 
4. Patient has a documented intolerance to immunotherapy injections; and 
5. The first dose has been administered under the supervision of a health care 
provider to observe for allergic reactions (date of administration and response 
required prior to consideration). 
6. If patient receives other immunotherapy by subcutaneous allergen 
immunotherapy (SCIT), treatment of allergic rhinitis with sublingual allergen 
immunotherapy (SLIT) will not be approved. 
 
Short Ragweed Pollen (Ragwitek
®
) In addition to the above criteria being met: 
 Patient is 18 through 65 years of age; and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE 
antibodies) to short ragweed pollen. 
 If criteria for coverage are met, authorization will be considered at least 12 
weeks before the expected onset of ragweed pollen season and continued 
throughout the season. 
 
Grass Pollen (Grastek
®
 and Oralair
®
) In addition to the above criteria being met: 
Grastek
®
 
 Patient is 10 through 65 years of age (Oralair®); and 
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 Patient has a positive skin test or in vitro testing (pollen-specific IgE 
antibodies) to sweet vernal, orchard/cocksfoot, perennial rye, timothy, and 
Kentucky blue/June grass. 
 If criteria for coverage are met, authorization will be considered at least 4 
months prior to the expected onset of each grass pollen season and continued 
throughout the grass pollen season; or 
Oralair
®
  
 Patient is 5 through 65 year of age (Grastek®); and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE 
antibodies) to timothy grass (or cross reactive grasses such as sweet vernal, 
orchard/cocksfoot, perennial rye, Kentucky blue/June, meadow fescue, and 
redtop). 
 If criteria for coverage are met, authorization will be considered at least 12 
weeks before the expected onset of each grass pollen season. 
 
Brian Couse, M.D. motioned to accept the criteria as amended, and Larry 
Ambroson, R.Ph. seconded.  All members were in favor.  The criteria will be sent out 
for public comment and brought back to the next meeting for further discussion. 
 
Methotrexate Injection: The Commission reviewed the prior authorization criteria 
as follows: 
Prior authorization is required for non-preferred methotrexate injection.  Payment 
will be considered under the following conditions: 
1. Diagnosis of severe, active rheumatoid arthritis (RA) or polyarticular juvenile 
idiopathic arthritis (pJIA) and ALL of the following: 
a. Prescribed by a rheumatologist; and 
b. Patient has a documented trial and intolerance with oral methotrexate; and 
c. Patient has a documented trial and therapy failure or intolerance with at least 
one other non-biologic DMARD (hydroxychloroquine, leflunomide, 
minocycline or sulfasalazine); and 
d. Patient’s visual or motor skills are impaired to such that they cannot 
accurately draw up their own preferred generic methotrexate injection and 
there is no caregiver available to provide assistance; and 
e. Patient does not reside in a long-term care facility. 
2. Diagnosis of severe, recalcitrant, disabling psoriasis and ALL of the following: 
a. Patient is 18 years of age or older; and 
b. Prescribed by a dermatologist; and 
c. Patient has documentation of an inadequate response to all other standard 
therapies (oral methotrexate, topical corticosteroids, vitamin D analogues, 
cyclosporine, systemic retinoids, tazarotene, and phototherapy). 
d. Patient’s visual or motor skills are impaired to such that they cannot 
accurately draw up their own preferred generic methotrexate injection and 
there is no caregiver available to provide assistance; and 
e. Patient does not reside in a long-term care facility. 
The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
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Kellen Ludvigson, Pharm.D. motioned to accept the criteria, and Brett Faine, 
Pharm.D. seconded.  All members were in favor. The criteria will be sent out for 
public comment and brought back to the next meeting for further discussion. 
 
Tasimelteon (Helitoz): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for tasimelteon (Hetlioz) Requests for doses above the 
manufacturer recommended dose will not be considered.  Payment will be considered 
under the following conditions: 
1. Patient has a diagnosis of Non-24-Hour Sleep-Wake Disorder (Non-24) as 
confirmed by a sleep specialist; and 
2. Patient is 18 years of age or older; and 
3. Documentation the patient is totally blind with no perception of light is provided; 
and 
4. Patient has a documented trial and therapy failure with at least one preferred 
sedative/hypnotic – non-benzodiazepine agent; and 
5. Patient has a documented trial and therapy failure with ramelteon (Rozerem). 
If criteria for coverage are met, initial requests will be given for 3 months.  
Requests for continuation of therapy will be considered when the patient has 
received 3 months of continuous therapy and patient has achieved adequate 
results with tasimelteon (Hetlioz), such as entrainment, significant increases in 
nighttime sleep, and/or significant decreases in daytime sleep. 
 
Brett Faine, Pharm.D. motioned to accept the criteria as amended, and Larry 
Ambroson, R.Ph. seconded.  All members were in favor. The criteria will be sent out 
for public comment and brought back to the next meeting for further discussion. 
 
Apremilast (Otezla): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for apremilast (Otezla
®
).  Payment will be considered 
under the following conditions: 
1. Patient is 18 years of age or older; and 
2. Patient has a diagnosis of active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 
tender joints); and 
3. Prescribed by a rheumatologist or a dermatologist; and 
4. Patient does not have severe renal impairment (CrCl < 30 mL/min); and 
5. Patient has documentation of a trial and inadequate response to therapy with the 
preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may be used 
if methotrexate is contraindicated); and 
6. Patient has documentation of trials and therapy failures with two preferred 
biological agents used for psoriatic arthritis. 
 
The required trials may be overridden when documented evidence is provided that the 
use of these agents would be medically contraindicated. 
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Larry Ambroson, R.Ph. motioned to accept the criteria, and Gregory Barclay, M.D. 
seconded.  All members were in favor. The criteria will be sent out for public 
comment and brought back to the next meeting for further discussion. 
 
Palivizumab (Synagis): The Commission reviewed the prior authorization criteria 
as follows: 
Prior authorization is required for therapy with palivizumab. Prior authorizations 
will be approved for administration during the RSV season for a maximum of five 
doses per patient. No allowances will be made for a sixth dose. Patients, who 
experience a breakthrough RSV hospitalization, should have their monthly 
prophylaxis discontinued, as there is an extremely low likelihood of a second RSV 
hospitalization in the same season. Payment for palivizumab will be considered for 
patients who meet one of the following criteria: 
Chronic Lung Disease (CLD) of Prematurity 
 Patient is less than 12 months of age at start of therapy and develops CLD 
of prematurity (defined as gestational age less than 32 weeks and required 
greater than 21% oxygen for at least the first 28 days after birth.  
 Requests for patients during their second year of life (12 months to < 24 
months) will be considered for patients meeting the CLD of prematurity 
definition above and continue to require medical support (chronic 
corticosteroid therapy, diuretic therapy, or supplemental oxygen) during 
the 6-month period before the start of the second RSV season. 
Hemodynamically Significant Congenital Heart Disease (CHD) 
 Patient is less than 12 months of age at start of therapy and has 
hemodynamically significant CHD further defined by any of the following: 
o Patient with acyanotic heart disease who is receiving medication 
to control congestive heart failure and will require cardiac 
surgical procedures or 
o Patient with moderate to severe pulmonary hypertension.  
o Requests for patients with cyanotic heart defects will be considered 
with documentation of consultation with a pediatric cardiologist 
that recommends patient receive palivizumab prophylaxis. 
Premature Infants (without CLD of Prematurity or CHD)  
 Patient is less than 12 months of age at start of therapy with a gestational 
age of less than 29 weeks. 
Children with Anatomic Pulmonary Abnormalities or Neuromuscular Disorder  
 Patient is 12 months of age or younger at the start of therapy and has 
either severe neuromuscular disease or congenital anomaly that impairs 
the ability to clear secretions from the upper airway due to an ineffective 
cough. 
Immunocompromised Children  
 Patient is less than 24 months of age at start of therapy and is profoundly 
immunocopromised during the RSV season (e.g., severe combined 
immunodeficiency, advanced acquired immunodeficiency syndrome, 
receiving chemotherapy). 
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Larry Ambroson, R.Ph. motioned to accept the criteria as amended, and Brian 
Couse, M.D. seconded.  All members were in favor. The criteria will be sent out for 
public comment and brought back to the next meeting for further discussion. 
 
Vorapaxar (Zontivity): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for vorapaxar (Zontivity™).  Payment will be 
considered under the following conditions: 
1. Patient has a history of myocardial infarction (MI) or peripheral artery disease; 
and 
2. Patient does not have a history of stroke, transient ischemic attack (TIA), 
intracranial bleeding, or active peptic ulcer; and 
3. Patient has documentation of an adequate trial and therapy failure with 
clopidogrel; and 
4. Patient will use concurrently with aspirin and/or clopidogrel. 
 
The required trial may be overridden when documented evidence is provided that the 
use of this agent would be medically contraindicated. 
 
The Commission wondered if a trial and therapy failure on aspirin should be added.  
This will be revised and brought back to the next meeting. 
 
Omalizumab (Xolair): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for Xolair
®
.  Payment for Xolair
®
 will be authorized when 
the following criteria are met: 
 
Moderate to Severe Persistent Asthma 
1. Patient has a diagnosis of moderate to severe persistent asthma for at least one year; 
and 
2. Patient is 12 years of age or older; and 
3. Pretreatment IgE level is between 30 IU/mL and 700 IU/mL; and 
4. Patient’s weight is between 30 kg and 150 kg; and 
5. History of positive skin or RAST test to a perennial aeroallergen; and 
6. Prescriber is an allergist, immunologist, or pulmonologist; and 
7. Patient is currently using a high dose inhaled corticosteroid AND long-acting beta-
agonist, is compliant with therapy and asthma symptoms are not adequately 
controlled after at least three (3) months of therapy. 
8. Patient must have access to an EpiPen to treat allergic reactions that may occur after 
administration of Xolair
®
. 
 
If the criteria for coverage are met, the initial authorization will be given for 16 weeks to 
assess the need for continued therapy. Requests for continuation of therapy will not be 
granted for patients who have not shown adequate response to Xolair
®
 therapy and for 
patients who do not continue concurrent use with a high dose corticosteroid and long-
acting beta-agonist. 
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Chronic Idiopathic Urticaria 
1. Patient has a diagnosis of moderate to severe chronic idiopathic urticaria; and 
2. Patient is 12 years of age or older; and 
3. Patient has documentation of a trial and therapy failure with at least one second-
generation antihistamine, one of which must be cetirizine at a dose up to 20 mg per 
day; and 
4. Patient has documentation of a trial and therapy failure with at least one first-
generation antihistamine; and  
5. Patient has documentation of a trial and therapy failure with at least one potent H1 
receptor antagonist (hydroxyzine and/or doxepin); and  
6. Patient has documentation of a trial and therapy failure with a preferred leukotriene 
receptor antagonist in combination with a first or second-generation antihistamine. 
 
If criteria for coverage are met, the initial authorization will be given for 12 weeks to 
assess the need for continued therapy.   
 
The required trials may be overridden when documented evidence is provided that use of 
these agents would be medically contraindicated. 
 
As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be forwarded to the Department for consideration. 
 
Apixaban (Eliquis): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for apixaban (Eliquis®). Payment will be considered 
under the following conditions:  
1. Patient does not have a mechanical prosthetic heart valve; and  
2. Patient does not have active pathological bleeding; and 
3. Patient has a diagnosis of non-valvular atrial fibrillation; with  
4. Documentation of a previous trial and therapy failure with warfarin (TIA, stroke, 
or inability to maintain a therapeutic INR with a minimum 6 month trial); and  
5. Presence of at least one additional risk factor for stroke, with a CHADS2 score ≥ 
1; OR 
6. For patients requiring deep vein thrombosis (DVT) prophylaxis undergoing hip or 
knee replacement.  Requests will be considered when the patient has 
contraindications to use of the preferred agent(s).  If patient meets criteria for 
coverage, requests will be approved for the following doses: 
 Hip replacement:  2.5 mg twice daily for up to 35 days following hip 
replacement; or 
 Knee replacement:  2.5 mg twice daily for up to 12 days following knee 
replacement. 
 
The required trials may be overridden when documented evidence is provided that the 
use of these agents would be medically contraindicated. 
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As this was the second review of these criteria, no motion was necessary. The 
recommendation will be forwarded to the Department for consideration. 
 
Dabigatran (Pradaxa): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for dabigatran (Pradaxa
®
). Payment will be 
considered for patients under the following conditions: 
1. Patient does not have a mechanical prosthetic heart valve; and 
2. Patient does not have active pathological bleeding; and 
3. Patient has documentation of a previous trial and therapy failure with 
warfarin (TIA, stroke, recurrence of DVT/PE, or inability to maintain a 
therapeutic INR with a minimum 6 month trial). 
 
Non-valvular atrial fibrillation (in addition to the above) 
 Patient has the presence of at least one additional risk factor for stroke, with 
a CHADS2 score ≥ 1; and 
 Patient does not have severe renal impairment (CrCl < 15mL/min) or is not 
on dialysis. 
 
Treatment and prevention of DVT or PE (in addition to the above) 
 Patient does not have a CrCl < 30mL/min or is not on dialysis. 
 For patients with current DVT/PE, patient must have documentation of 5 to 
10 days of parenteral anticoagulation prior to initiation of dabigatran. 
 
The required trials may be overridden when documented evidence is provided that 
use of these agents would be medically contraindicated.   
 
As this was the second review of these criteria, no motion was necessary. The 
recommendation will be forwarded to the Department for consideration. 
 
Neuraminidase Inhibitor Utilization 
The Commission is interested in developing prior authorization criteria, as studies 
have shown these only reduce symptoms by half a day.  Additionally, to be effective, 
these have to be used within a very limited time frame that would be further reduced 
by a prior authorization process.  Brett Faine, Pharm.D. and Mark Graber, M.D. 
offered to create some criteria.  Pam Smith, R.Ph. will work with them and bring this 
to the next meeting.  Erin Halverson, R.Ph. also suggested the three day emergency 
override option be removed for this drug class.  Susan Parker, Pharm.D. said that 
was a possibility, as DHS has the right to determine what constitutes an emergency.  
 
Miscellaneous 
 
DUR Digest: The Commission members reviewed the draft for DUR Digest Volume 
27, Number 1.  Mark Graber, M.D. requested the wording for the first bullet on page 
1 be updated.  This was the first review and will be brought back to the next meeting 
for a second and final review. 
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MedWatch: The Commission members received FDA announcements concerning 
new Black Box Warnings. 
A unanimous roll call vote was made at 12:38 to adjourn the meeting and move to 
closed session (motion by Larry Ambroson, R.Ph., second by Brian Couse, M.D. and 
Kellen Ludvigson, Pharm.D.). 
The next meeting will be held at 9:30 a.m. on Wednesday, October 1, 2014, at 
the Learning Resource Center in West Des Moines. 
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Iowa Medicaid Drug Utilization Review Commission 
Meeting Minutes October 1, 2014 
Attendees: 
Commission Members 
Mark Graber, M.D., FACEP; Laurie Pestel, Pharm.D.; Gregory Barclay, M.D.; Kellen 
Ludvigson, Pharm.D.; Larry Ambroson, R.Ph.; Brett Faine, Pharm.D.; Brian Couse, 
M.D.; Jason Wilbur, M.D.; and Susan Parker, Pharm.D. 
 
Staff 
Pam Smith, R.Ph.  
 
Guests 
Jason Kessler, M.D., IME; Erin Halverson, R.Ph., IME; Megan Smith, Pharm.D., 
IME; and Melissa Biddle, IME. 
 
 
Welcome & Introductions 
Mark Graber called the meeting to order at 9:33 a.m. at the Learning Resource 
Center in West Des Moines. The minutes from the August 6, 2014 meeting were 
reviewed.  Gregory Barclay motioned to accept them, and Kellen Ludvigson 
seconded simultaneously.  All members were in favor.  The recommendation letter 
sent to DHS after the last meeting, in addition to a letter sent to the DUR 
Commission from the P&T Committee requesting development of PA criteria for 
Hetlioz, Otezla, and Zykadia, were also reviewed. 
 
IME Updates 
Medicaid Director Jennifer Vermeer left Iowa Medicaid for a position at the University 
of Iowa on August 21, 2014.  Julie Lovelady is the interim director while a national 
search is conducted.  Over 115,000 members are now enrolled in the Iowa Health 
and Wellness Plan (IHAWP).  A new DHS website was launched in June, along with 
a new website featuring the latest information on IHAWP: 
http://www.iahealthlink.gov.  Magellan and the IME are working together on the 
health homes for chronic conditions project.  CMS approved the State Plan 
Amendment to increase the dispensing fee to $11.73 on September 24, 2014.  
Claims will be adjusted retroactively back to August 1, 2014.   Providers will be 
notified of this change via informational letter.  Pam Smith will bring results from the 
annual Federal and State DUR reports to the next meeting.  
 
Prevalence Report Summary 
Statistics from July though August 2014 were discussed, including: cost per user 
($299.24), number of total prescriptions dispensed (an increase of 4% compared to 
the previous reporting period), average cost per prescription ($60.48), and generic 
utilization (83.6%).  The total paid amount increased by 6.6% from the previous 
reporting period.  There were 183,702 unique users, which is 2% more than the total 
for May and June.  Lists of the top 20 therapeutic classes were provided.  SSRIs had 
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the highest prescription count, and Anticonvulsants came in second.  The top 100 
drugs were also reviewed.  The ten most expensive medications were: Abilify, 
Vyvanse, methylphenidate hcl er, Lantus, Advate, Cymbalta, Focalin XR, Adderall, 
Advair Diskus, and Strattera. 
 
Case Studies 
Pam Smith presented 4 case studies.  Recommendations by commissioners from 
these four examples resulted in annualized total savings of $2,054.31 pre-rebate 
(state and federal).   
 
Public Comment 
There were none, as both speakers chose to defer to the second public comment 
section. 
 
ProDUR Edit 
 
Antipsychotics – Age Edit and Duplicate Therapy Edit: The DUR Commission 
reviewed recommendations they initially made in April 2012 to implement ProDUR 
edits on antipsychotics in members less than 18 years of age.  Specifically, the 
recommendation was to: 1) implement an age edit on risperidone for members less 
than five (5) years of age and an age edit on all other antipsychotics for members 
less than six (6) years of age; and 2) apply a duplicate therapy edit to all 
antipsychotics.  After discussion, the Commission continues to support 
implementation of the aforementioned ProDUR edits, tentatively scheduled for 
implementation in the summer of 2015.  Prior to initiation of these edits, an 
informational letter will be sent to all providers, to encourage changes to drug 
regimen or submission of a PA prior to implementation of the edits and prior to 
discharge.  Soft edits will also be programmed into the Point of Sale (POS) system 
indicating the claim(s) will deny for a PA at the specific date indicated, which should 
prompt the pharmacy to notify the prescriber.   
 
Focus Studies 
 
Valproate Use for Migraine in Females: This was a follow-up discussion.  Ninteen 
(19) of the 39 members identified changed therapy, for an annualized cost savings 
of $2,998.62 (state and federal, pre-rebate) as a result of the 93 surveys sent out to 
prescribers and pharmacies.  Forty-two (42), or 45%, of those surveys were 
returned. 
 
Ketoconazole Utilization: This was a follow-up discussion.  Fifty-four (54) of the 66 
members identified changed therapy, for an annualized cost savings of $3,764.10 
(state and federal, pre-rebate) as a result of the 132 surveys sent out to prescribers 
and pharmacies.  Sixty-six (66), or 50%, of those surveys were returned. 
 
Overutilization of Opioids: This was a follow-up discussion.  One-hundred twenty 
(120) of the 244 members identified changed therapy, for an annualized cost 
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savings of $66,768.90 (state and federal, pre-rebate) as a result of the 941 surveys 
sent out to prescribers and pharmacies.  Three-hundred eighty-one (381), or 40% of 
those surveys were returned. 
 
Opioid Utilization Potential Drug Seeking Behavior: This was a follow-up 
discussion.  Twenty-two (22) of the 38 members identified changed therapy, for an 
annualized cost savings of $5,445.06 (state and federal, pre-rebate) as a result of 
the 375 surveys sent out to prescribers and pharmacies.  One-hundred thirty (130), 
or 35%, of those surveys were returned.  The Commission was curious as to the 
algorithm used by the lock-in department to identify potential members, and Pam 
Smith will look into that. 
 
Valproate Use in Women of Childbearing Age without Seizure or Bipolar 
Diagnosis: This was a follow-up discussion.  Twenty-six (26) of the 70 members 
identified changed therapy, for an annualized cost savings of $4,856.64 (state and 
federal, pre-rebate) as a result of the 154 surveys sent out to prescribers and 
pharmacies.  Sixty-four (64), or 42%, of those surveys were returned. 
 
Valproate Use in Women of Childbearing Age with Seizure or Bipolar 
Diagnosis: This was a follow-up discussion.  Seventy-five (75) of the 270 members 
identified changed therapy, for an annualized cost savings of $14,919.44 (state and 
federal, pre-rebate) as a result of the 592 surveys sent out to prescribers and 
pharmacies.  Two-hundred fifty-six (256), or 43% of those surveys were returned. 
 
Long Term Use of Short-Acting Opioids: The Commission wants to lower the 
existing quantity limits to a quantity of 120 per 30 days, or 4 per day, across the 
entire drug class.  Jason Wilbur motioned to implement this quantity limit, and Brett 
Faine seconded.  All members were in favor.  Soft POS edits will be put into place to 
notify providers of the changes prior to implementation of the quantity limits, and an 
information letter will also be sent out to prescribers and pharmacies.      
 
Duplicate Antipsychotics: Letters will be sent to those who will be affected by the 
ProDUR edits that were agreed upon at previous meetings for members 17 years of 
age and younger, as documented above.  The Commission also wants to send 
letters to the prescribers of adults on 2 or more second generation antipsychotics 
concurrently for greater than 90 days to ask: 1) if the patient would be a candidate to 
taper to one agent, 2) if the patient is a candidate for clozapine therapy, and 3) if the 
patient has had three failed trials of monotherapy prior to using two or more 
antipsychotics. 
 
Duplicate Benzodiazepines: The Commission wants to review the quantity limits 
on all benzodiazepines, and also look at the numbers on combination therapy.  This 
information will be brought to the December meeting.  Additionally, letters will be 
sent to the prescribers of the members identified to ask if the patient could be 
adequately controlled on one agent. 
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Niacin Utilization: Letters will be sent to the prescribers of the members taking 
niacin with a statin to suggest dose optimization of the statin and discontinuation of 
niacin.  Additionally, the DUR Commission made a recommendation that the P&T 
Committee make niacin non-preferred on the PDL, requiring use of a statin prior to 
use. 
 
Public Comment 
 
Name Representing Drug/Topic 
Lisa Willshaw MedImmune Synagis 
Christina Reimers Merck Zontivity, Grastek, and Ragwitek 
 
Prior Authorization 
 
Annual Review of the PA Criteria: Changes were suggested for the following 
categories, to be discussed at upcoming meetings:  
PA Category Recommend Changes 
Alpha2 Agonists, 
Extended-Release  
Define length of trial. 
Amylino Mimetic 
(Symlin®)  
Add requirement of 0.5% improvement in A1C 
Anti-Acne  Waiting for American Academy of Dermatology to update 
guidelines, anticipated in November, 2014. 
Apixaban (Eliquis) Update criteria based on new FDA approved indications 
Benzodiazepines Require SSRI failure for GAD. 
Biologic 
Immunomodulators 
Add TB screening across all biologic immumomodulator PA 
forms. 
Erythropoiesis Stimulating 
Agents 
Require response to treatment. 
Hepatitis C Antiviral 
Agents 
Possibly allow other tests in addition to biopsy, as there have 
already been 33 appeals. Remove Incivek criteria. 
Pulmonary Arterial 
Hypertension Agents 
Limit access to responsive types, not smokers. 
Testosterone Products Update diagnosis for coverage based on recent FDA review. 
Thrombopoietin Receptor 
Agonists 
Update Promacta criteria for new indications. 
Antiemetics Look at increasing the number of ondansetron units allowed 
with out PA. 
Topical corticosteroids 
(new) 
Require multiple trials with preferred agents prior to a non-
preferred agent. 
Antineoplastics (new) Universal PA form for oral agents - Check for diagnosis and 
dosing. 
Immunoglobulin serums 
(new) 
Look at utilization and determine if PA criteria is required. 
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Vorapaxar (Zontivity): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for vorapaxar (Zontivity™).  Payment will be 
considered under the following conditions: 
1. Patient has a history of myocardial infarction (MI) or peripheral artery disease; 
and 
2. Patient does not have a history of stroke, transient ischemic attack (TIA), 
intracranial bleeding, or active peptic ulcer; and 
3. Patient has documentation of an adequate trial and therapy failure with aspirin 
plus clopidogrel; and 
4. Patient will use vorapaxar concurrently with aspirin and/or clopidogrel. 
 
The required trials may be overridden when documented evidence is provided that the 
use of this agent would be medically contraindicated. 
 
Mark Graber commented that there is no active coagulation for stints, and suggested 
requiring a second trial with Brillinta.  An age limit was also suggested as this is not 
effective over age 75.  This will be brought back to the next meeting. 
 
Ceritinib (Zykadia): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for ceritinib (Zykadia™). Payment will be considered 
under the following conditions: 
1. Patient has a diagnosis of metastatic non-small cell lung cancer (NSCLC) that is 
anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test 
(attach copy of results); and 
2. Patient is 18 years of age or older; and 
3. Prescribed by a oncologist; and 
4. Patient has documentation of treatment with crizotinib and the disease has   
progressed while on treatment or is intolerant to treatment. 
5. Liver function tests (ALT, AST, and total bilirubin) will be monitored at least 
monthly while on ceritinib. 
 
If criteria for coverage are met, initial requests will be given for 3 months.  Requests 
for continuation of therapy will be considered with documentation patient has not 
experienced disease progression or unacceptable toxicity. 
 
Brett Faine motioned to accept the criteria, and Jason Wilbur seconded.  All 
members were in favor. 
 
Chronic Pain Syndromes: The Commission reviewed the prior authorization 
criteria as follows: 
A prior authorization is required for duloxetine (Cymbalta
®
), pregabalin (Lyrica
®
), 
and milnacipran (Savella
™
).  For patients with a chronic pain diagnosis who are 
currently taking opioids, as seen in pharmacy claims, a plan to decrease and/or 
discontinue the opioid(s) must be provided with the initial request.  Initial 
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authorization will be given for three (3) months.  There must be a significant decrease 
in opioid use or discontinuation of opioid(s) after the initial three (3) month 
authorization for further consideration.  Additional prior authorizations will be 
considered with documentation of a continued decrease in opioid utilization.  
Payment will be considered under the following conditions: 
1. A diagnosis of fibromyalgia (Cymbalta®, Lyrica®, and Savella™)  
a. A trial and therapy failure at a therapeutic dose with gabapentin  plus one of 
the following: tricyclic antidepressant,  SSRI, or SNRI, WITH 
b. Documented non-pharmacologic therapies (cognitive behavior therapies, 
exercise, etc.), AND  
c. Documentation of a previous trial and therapy failure at a therapeutic dose 
with Savella
™ 
when Cymbalta
®
 and Lyrica
®
 are requested.  
2. A diagnosis of post-herpetic neuralgia (Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of the 
following: tricyclic antidepressant, topical lidocaine, valproate, or 
carbamazepine. 
3. A diagnosis of diabetic peripheral neuropathy (Cymbalta® and Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of the 
following: tricyclic antidepressant or topical lidocaine. 
4. A diagnosis of partial onset seizures, as adjunct therapy (Lyrica®) 
5. A diagnosis of major depressive disorder or generalized anxiety disorder   
(Cymbalta
®
) 
6. A diagnosis of chronic musculoskeletal pain (Cymbalta®) 
A trial and therapy failure at a therapeutic dose with at least two drugs from two 
distinct therapeutic classes from the following: NSAIDs, opioids, tramadol, or 
tricyclic antidepressants.  
Requests for concomitant use of these agents for an indicated chronic pain diagnosis may 
only be considered once each agent has been tried at maximum tolerated dose separately. 
Duplicate use of drugs from the same therapeutic category will not be considered.   
Requests for doses above the manufacturer recommended dose will not be considered. 
 
Kellen Ludvigson motioned to accept the criteria as amended (chronic 
musculoskeletal pain), and Brian Couse seconded.  All members were in favor.  The 
recommendation will be sent to the Department for consideration. 
 
Oral Immunotherapy: The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for sublingual allergen immunotherapy.  Payment will 
be considered under the following conditions: 
1. Medication is prescribed in consultation with an allergist; and 
7 
 
2. Patient is diagnosed with pollen-induced allergic rhinitis with or without 
conjunctivitis; and 
3. Patient has documented trials and therapy failures with allergen avoidance and 
pharmacotherapy (intranasal corticosteroids and antihistamines); and 
4. Patient has a documented intolerance to immunotherapy injections; and 
5. The first dose has been administered under the supervision of a health care 
provider to observe for allergic reactions (date of administration and response 
required prior to consideration). 
6. If patient receives other immunotherapy by subcutaneous allergen 
immunotherapy (SCIT), treatment of allergic rhinitis with sublingual allergen 
immunotherapy (SLIT) will not be approved. 
 
Short Ragweed Pollen (Ragwitek
®
) In addition to the above criteria being met: 
 Patient is 18 through 65 years of age; and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE 
antibodies) to short ragweed pollen. 
 If criteria for coverage are met, authorization will be considered at least 12 
weeks before the expected onset of ragweed pollen season and continued 
throughout the season. 
 
Grass Pollen (Grastek
®
 and Oralair
®
) In addition to the above criteria being met: 
Grastek
®
 
 Patient is 10 through 65 years of age (Oralair®); and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE 
antibodies) to sweet vernal, orchard/cocksfoot, perennial rye, timothy, and 
Kentucky blue/June grass. 
 If criteria for coverage are met, authorization will be considered at least 4 
months prior to the expected onset of each grass pollen season and continued 
throughout the grass pollen season; or 
Oralair
®
  
 Patient is 5 through 65 year of age (Grastek®); and 
 Patient has a positive skin test or in vitro testing (pollen-specific IgE 
antibodies) to timothy grass (or cross reactive grasses such as sweet vernal, 
orchard/cocksfoot, perennial rye, Kentucky blue/June, meadow fescue, and 
redtop). 
 If criteria for coverage are met, authorization will be considered at least 12 
weeks before the expected onset of each grass pollen season. 
 
Jason Wilbur motioned to accept the criteria as amended, and Larry Ambroson and 
Brian Couse seconded simultaneously.  All members were in favor.  The 
recommendation will be sent to the Department for consideration. 
 
Methotrexate Injection: The Commission reviewed the prior authorization criteria 
as follows: 
Prior authorization is required for non-preferred methotrexate injection.  Payment 
will be considered under the following conditions: 
8 
 
1. Diagnosis of severe, active rheumatoid arthritis (RA) or polyarticular juvenile 
idiopathic arthritis (pJIA) and ALL of the following: 
a. Prescribed by a rheumatologist; and 
b. Patient has a documented trial and intolerance with oral methotrexate; and 
c. Patient has a documented trial and therapy failure or intolerance with at least 
one other non-biologic DMARD (hydroxychloroquine, leflunomide, 
minocycline or sulfasalazine); and 
d. Patient’s visual or motor skills are impaired to such that they cannot 
accurately draw up their own preferred generic methotrexate injection and 
there is no caregiver available to provide assistance; and 
e. Patient does not reside in a long-term care facility. 
2. Diagnosis of severe, recalcitrant, disabling psoriasis and ALL of the following: 
a. Patient is 18 years of age or older; and 
b. Prescribed by a dermatologist; and 
c. Patient has documentation of an inadequate response to all other standard 
therapies (oral methotrexate, topical corticosteroids, vitamin D analogues, 
cyclosporine, systemic retinoids, tazarotene, and phototherapy). 
d. Patient’s visual or motor skills are impaired to such that they cannot 
accurately draw up their own preferred generic methotrexate injection and 
there is no caregiver available to provide assistance; and 
e. Patient does not reside in a long-term care facility. 
The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
 
As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be sent to the Department for consideration. 
 
Tasimelteon (Helitoz): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for tasimelteon (Hetlioz) Requests for doses above the 
manufacturer recommended dose will not be considered.  Payment will be considered 
under the following conditions: 
1. Patient has a diagnosis of Non-24-Hour Sleep-Wake Disorder (Non-24) as 
confirmed by a sleep specialist; and 
2. Patient is 18 years of age or older; and 
3. Documentation the patient is totally blind with no perception of light is provided; 
and 
4. Patient has a documented trial and therapy failure with at least one preferred 
sedative/hypnotic – non-benzodiazepine agent; and 
5. Patient has a documented trial and therapy failure with ramelteon (Rozerem). 
If criteria for coverage are met, initial requests will be given for 3 months.  
Requests for continuation of therapy will be considered when the patient has 
received 3 months of continuous therapy and patient has achieved adequate 
results with tasimelteon (Hetlioz), such as entrainment, significant increases in 
nighttime sleep, and/or significant decreases in daytime sleep. 
 
9 
 
As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be sent to the Department for consideration. 
 
Apremilast (Otezla): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for apremilast (Otezla
®
).  Payment will be considered 
under the following conditions: 
1. Patient is 18 years of age or older; and 
2. Patient has a diagnosis of active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 
tender joints); and 
3. Prescribed by a rheumatologist or a dermatologist; and 
4. Patient does not have severe renal impairment (CrCl < 30 mL/min); and 
5. Patient has documentation of a trial and inadequate response to therapy with the 
preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may be used 
if methotrexate is contraindicated); and 
6. Patient has documentation of trials and therapy failures with two preferred 
biological agents used for psoriatic arthritis. 
 
The required trials may be overridden when documented evidence is provided that the 
use of these agents would be medically contraindicated. 
 
As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be sent to the Department for consideration. 
 
Palivizumab (Synagis): The Commission reviewed the prior authorization criteria 
as follows: 
Prior authorization is required for therapy with palivizumab. Prior authorizations 
will be approved for administration during the RSV season for a maximum of five 
doses per patient. No allowances will be made for a sixth dose. Patients, who 
experience a breakthrough RSV hospitalization, should have their monthly 
prophylaxis discontinued, as there is an extremely low likelihood of a second RSV 
hospitalization in the same season. Payment for palivizumab will be considered for 
patients who meet one of the following criteria: 
Chronic Lung Disease (CLD) of Prematurity 
 Patient is less than 12 months of age at start of therapy and develops CLD 
of prematurity (defined as gestational age less than 32 weeks and required 
greater than 21% oxygen for at least the first 28 days after birth.  
 Requests for patients during their second year of life (12 months to < 24 
months) will be considered for patients meeting the CLD of prematurity 
definition above and continue to require medical support (chronic 
corticosteroid therapy, diuretic therapy, or supplemental oxygen) during 
the 6-month period before the start of the second RSV season. 
Hemodynamically Significant Congenital Heart Disease (CHD) 
 Patient is less than 12 months of age at start of therapy and has 
hemodynamically significant CHD further defined by any of the following: 
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o Patient with acyanotic heart disease who is receiving medication 
to control congestive heart failure and will require cardiac 
surgical procedures or 
o Patient with moderate to severe pulmonary hypertension.  
o Requests for patients with cyanotic heart defects will be considered 
with documentation of consultation with a pediatric cardiologist 
that recommends patient receive palivizumab prophylaxis. 
Premature Infants (without CLD of Prematurity or CHD)  
 Patient is less than 12 months of age at start of therapy with a gestational 
age of less than 29 weeks. 
Children with Anatomic Pulmonary Abnormalities or Neuromuscular Disorder  
 Patient is 12 months of age or younger at the start of therapy and has 
either severe neuromuscular disease or congenital anomaly that impairs 
the ability to clear secretions from the upper airway due to an ineffective 
cough. 
Immunocompromised Children  
 Patient is less than 24 months of age at start of therapy and is profoundly 
immunocopromised during the RSV season (e.g., severe combined 
immunodeficiency, advanced acquired immunodeficiency syndrome, 
receiving chemotherapy). 
 
Pam Smith consulted other states on their criteria for the upcoming RSV season; 
only a few who accepted the supplemental rebate offer, contingent upon not 
updating their criteria, would not be adopting the new AAP guidelines.  Wellmark will 
also be adopting the new guidelines, and the Iowa AAP is also supports the new 
AAP guidelines.  As this was the second review of these criteria, no motion was 
necessary.  The recommendation will be sent to the Department for consideration. 
 
Miscellaneous 
 
DUR Digest: The Commission members reviewed the draft for DUR Digest Volume 
27, Number 1.   
 
MedWatch: The Commission members received FDA announcements concerning 
new Black Box Warnings. 
Off-label Pharmaceutical Marketing: The Commission members received copies 
of the information provided by CMS on this topic. 
 
A unanimous roll call vote was made at 11:50 to adjourn the meeting and move to 
closed session (motion by Brian Couse, second by Jason Wilbur). 
The next meeting will be held at 9:30 a.m. on Wednesday, December 3, 2014, at 
the Learning Resource Center in West Des Moines. 
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Iowa Medicaid Drug Utilization Review Commission 
Meeting Minutes December 3, 2014 
Attendees: 
Commission Members 
Mark Graber, M.D., FACEP, MSHCE; Laurie Pestel, Pharm.D.; Gregory Barclay, 
M.D.; Kellen Ludvigson, Pharm.D.; Larry Ambroson, R.Ph.; Brett Faine, Pharm.D.; 
Brian Couse, M.D.; Jason Wilbur, M.D.; and Susan Parker, Pharm.D. 
 
Staff 
Pam Smith, R.Ph.  
 
Guests 
Erin Halverson, R.Ph., IME; Megan Smith, Pharm.D., IME; and Melissa Biddle, IME. 
 
 
Welcome & Introductions 
Mark Graber called the meeting to order at 9:32 a.m. at the Learning Resource 
Center in West Des Moines. The minutes from the October 1, 2014 meeting were 
reviewed.  Brian Couse motioned to accept them, and Kellen Ludvigson and 
Gregory Barclay seconded simultaneously.  All members were in favor.  The 
recommendation letter sent to DHS after the last meeting, the letter sent to the P&T 
Committee by the DUR Commission recommending niacin products be made non-
preferred on the PDL, and the annual Federal and State DUR reports were also 
reviewed. 
 
IME Updates 
As of December 1, 2014, Iowa Medicaid is now covering an additional 9,700 
members previously enrolled in CoOportunity under the Iowa Health and Wellness 
Plan (IHAWP), as CoOportunity has withdrawn participation in the Marketplace.  The 
State is currently working with CMS to establish ongoing options for these 
individuals that had been enrolled in the Marketplace Choice Plan, but these 
members will remain in the Wellness Plan until options are explored with CMS.  
Prescribers and members have received notification.  DHS is working on budget 
issues, and the legislative session starts in mid-January.  As requested at the last 
meeting, Pam Smith provided more information as to how the IME Lock-in 
department identifies members for their program.  Parameters include: the number 
of controlled substances, different prescribers of controlled substances, multiple 
pharmacies, number and days supply of the controlled substances, exclusivity of 
short-acting opioids, multiple ER visits, along with other things such as diagnosis of 
poisoning by a prescribed controlled substance or if the member is seeing multiple 
providers for the same diagnosis.  Diagnoses and eligibility are also incorporated 
into the score algorithm, and members are locked in for 24 months once they have 
been identified.  Members with a malignancy or tumor are excluded.  There are 
currently about 1800 members in the lock-in program. 
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Prevalence Report Summary 
Statistics from September though October 2014 were discussed, including: cost per 
user ($298.51), number of total prescriptions dispensed (an increase of 9.4% 
compared to the previous reporting period), average cost per prescription ($60.27), 
and generic utilization (83.7%).  The total paid amount increased by 8.4% from the 
previous reporting period.  There were 198,167 unique users, which is 8.4% more 
than the total for July and August.  Lists of the top 20 therapeutic classes were 
provided.  SSRIs had the highest prescription count, and Anticonvulsants came in 
second.  The top 100 drugs were also reviewed.  The ten most expensive 
medications were: Abilify, Vyvanse, methylphenidate hcl er, Lantus, Focalin XR, 
Cymbalta, Advate, Ventolin HFA, Advair Diskus, and Strattera. 
 
Case Studies 
Pam Smith presented 4 case studies.  Recommendations by Commissioners from 
these four examples resulted in annualized total savings of $11,496.61 pre-rebate 
(state and federal).   
 
Public Comment 
Name Representing Drug/Topic 
Paul Miner Gilead Sovaldi and Harvoni 
Kendig Bergstresser Celgene Otezla 
Michael Voight Patient Representative Hepatitis C PA Criteria 
Antonio Sanchez University of Iowa Liver Transplant Center Harvoni 
Donald Hilldebrand UnityPoint (Gilead and Abbvie Speaker Bureaus) Harvoni 
Jennifer Stoffel Janssen Olysio 
Tyler Whisman Novartis Zykadia and Exjade 
 
Focus Studies 
Three or More Antiepileptics with a Seizure Diagnosis: This was a follow-up 
discussion.  Fifty-three (53) of the 291 members identified changed therapy, for an 
annualized cost savings of $255,021.08 (state and federal, pre-rebate) as a result of 
the 751 surveys sent out to prescribers and pharmacies.  A total of 312 (41.54%) 
surveys were returned. 
 
Three or More Antiepileptics without a Seizure Diagnosis: This was a follow-up 
discussion.  Ten (10) of the 25 members identified changed therapy, increasing the 
annual cost by $3,832.96 (state and federal, pre-rebate) due to pre-rebate costs 
being reported, as a result of the 73 surveys sent out to prescribers and pharmacies.  
A total of 29 (39.73%) surveys were returned. 
 
Memantine Utilization without a Valid Diagnosis: This was a follow-up 
discussion.  Nineteen (19) of the 51 members identified changed therapy, for an 
annualized cost savings of $42,567.64 (state and federal, pre-rebate) as a result of 
the 108 surveys sent out to prescribers and pharmacies.  A total of 48 (44.44%) 
surveys were returned. 
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Duloxetine Dose Greater than 120mg per Day: This was a follow-up discussion.  
Both of the members identified lost Medicaid eligibility since October 1, 2013.  Four 
surveys had been sent out to prescribers and pharmacies, but only 1 (25%) of the 
surveys was returned.   
 
High Dose Stimulants in Children: The providers of members exceeding 40mg per 
day of immediate-release amphetamine salt combo tablets will be contacted to ask if 
the dose could be decreased to a maximum of 40mg per day.  Additionally, the 
providers of members exceeding 60mg per day of immediate-release 
methylphenidate tablets will be contacted to ask if the dose could be decreased to a 
maximum of 60mg per day.  The Commission suggested looking into all stimulants, 
including long-acting, or those on combinations of long and short acting.  Pam Smith 
agreed that the quantity limits on the long-acting stimulants needed to be adjusted, 
and will bring recommendations back to the next meeting. 
 
Benzodiazepine Dosing: Letters will be sent to the prescribers of members 
combining two or more benzodiazepines concomitantly, and also those prescribing 
benzodiazepines without an SSRI or SNRI in patients that have an anxiety 
diagnosis.  Pam Smith will break down the claims data to help determine appropriate 
quantity limits.  She will also look at alprazolam usage to determine the impact of 
these limits.  Erin Halverson suggested lowering the quantity limits slowly prior to 
adding a duplicate edit to control access to multiple strengths. 
 
Public Comment 
There were no additional public speakers. 
 
Prior Authorization 
Hepatitis C Agents: The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for direct-acting oral antiviral agents against the 
hepatitis C virus.   Requests for non-preferred agents may be considered when 
documented evidence is provided that the use of the preferred agents would be 
medically contraindicated.  Payment will be considered under the following 
conditions: 
1. Patient is 18 years of age or older; and 
2. Patient’s prior treatment history is provided (treatment naïve, prior null 
responder, partial responder, or relapser); and 
3. Documentation of viral load taken within 6 months before beginning therapy; and 
4. Viral load will be submitted by prescriber 12 weeks after completion of therapy; 
and 
5. If patient has a history of failed treatment due to non-compliance, documentation 
that steps have been taken to correct or address the causes of non-compliance are 
provided; and  
6. For patients on a regimen containing ribavirin, the following must be documented 
on the PA form: 
a) Patient is not a pregnant female or a male with a pregnant female partner; 
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and 
b) Women of childbearing potential and their male partners must use two forms 
of effective contraception (non-hormonal contraception for patients taking 
Sovaldi
™
) during treatment and for at least 6 months after treatment has 
concluded; and 
c) Documentation that routine monthly pregnancy tests are performed during 
this time; and 
7. Patient has abstained from the use of illicit drugs and alcohol for a minimum of 
three (3) months as evidenced by a negative urine confirmation test; and 
8. Prescriber is an infectious disease specialist, gastroenterologist, hepatologist or 
other hepatitis specialist. 
9. Where applicable, requests for peg-interferon alfa free regimens will be 
considered on a case-by-case basis for patients with hepatitis C genotype 1 or 4 
where peg-interferon alfa is contraindicated.  Contraindications include:  
documented life-threatening side effects; decompensated hepatic disease; 
autoimmune hepatitis and other autoimmune disorders; a baseline neutrophil 
count below 1500/µL, a baseline platelet count below 90,000/ µL, or a baseline 
hemoglobin below 10g/dL; or a history of preexisting unstable cardiac disease. 
10. Non-FDA approved or non-compendia indicated combination therapy regimens 
will not be approved. 
11. If patient is recently eligible for Iowa Medicaid, and has been started and 
stabilized on therapy while covered under a different plan, documentation of how 
long the patient has been on medication will be required.  Patient will be eligible 
for the remainder of therapy needed, based on established length of therapy for 
the particular treatment (defined below). 
12. Lost or stolen medication replacement requests will not be authorized. 
13. The 72-hour emergency supply rule does not apply to oral hepatitis C antiviral 
agents. 
 
Victrelis  
 Patient has a documented diagnosis of hepatitis C genotype 1; and  
 Administered in combination with peg-interferon alfa and ribavirin; and 
 Patient does not have HIV co-infection; and 
 Patient does not have decompensated cirrhosis; and  
 Patient has not previously tried or failed therapy with a hepatitis C protease 
inhibitor; and 
 HCV-RNA results are required at treatment week 8, 12, and 24 (including lead in 
period) for boceprevir (Victrelis
™
).  
 Additional prior authorizations will be considered with documentation of 
response to treatment, measured by HCV-RNA levels.  
 Prior authorizations will be approved for a maximum of 24, 32, or 44 weeks of 
therapy with boceprevir (Victrelis
™
) based on response. 
 
 
Olysio 
 Patient has a documented diagnosis of hepatitis C genotype 1; and  
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 Administered in combination with peg-interferon alfa and ribavirin; and 
 Patient does not have HIV co-infection; and 
 Patient does not have the NS3 Q80K polymorphism with hepatitis C genotype 1a; 
and 
 The patient is not receiving dialysis or does not have a CrCl < 30 mL/min; and 
 Patient has not previously tried or failed therapy with a hepatitis C protease 
inhibitor; and 
 HCV-RNA results are required at treatment week 4 for simeprevir (Olysio™). 
 Additional prior authorizations will be considered with documentation of 
response to treatment, measured by HCV-RNA levels. 
 A maximum 12 weeks of therapy will be allowed.  
 
Sovaldi 
 The patient is not receiving dialysis or does not have a CrCl < 30 mL/min; and  
 Patient does not have decompensated cirrhosis; and 
 Documentation the patient has advanced liver disease stage 3 or greater fibrosis 
as confirmed by one of the following indicators related to staging of liver fibrosis 
(attach test results/documentation):  
o Liver biopsy confirming a Metavir score ≥ F3; or   
o Transient elastography (FibroScan) score ≥ 9.5kPa; or  
o FibroSURE (FibroTest) score ≥ 0.58; or 
o APRI score > 1.5; or 
o Radiological imaging consistent with cirrhosis (i.e. evidence of portal 
hypertension); and 
o Physical findings or clinical evidence consistent with cirrhosis. 
 Dosing and length of therapy will be based on the following: 
o Genotype 1:  Patient has a documented diagnosis of hepatitis C genotype 1 
(mono-infected or HCV/HIV co-infected) and used in combination with peg-
interferon alfa and ribavirin.  A maximum 12 weeks therapy will be allowed.   
o Genotype 2:  Patient has a documented diagnosis of hepatitis C genotype 2 
(mono-infected or HCV/HIV co-infected) and used in combination with 
ribavirin.  A maximum 12 weeks of therapy will be allowed. 
o Genotype 3:  Patient has a documented diagnosis of hepatitis C genotype 3 
(mono-infected or HCV/HIV co-infected) and used in combination with 
ribavirin. A maximum 24 weeks of therapy will be allowed. 
o Genotype 4:  Patient has a documented diagnosis of hepatitis C genotype 4 
(mono-infected or HCV/HIV co-infected) and used in combination with peg-
interferon alfa and ribavirin. A maximum 12 weeks of therapy will be allowed. 
 Hepatocellular carcinoma:  Patient has a documented diagnosis of hepatitis C 
genotype 1, 2, 3, 4 with a diagnosis of hepatocellular carcinoma meeting Milan 
criteria (awaiting liver transplantation) and in combination with ribavirin for up 
to 48 weeks or until liver transplantation, whichever comes first.  Milan criteria 
are defined as: 
o One lesion smaller than  5 cm in diameter for subjects with a  single lesion; 
o Up to 3 lesions smaller than 3 cm in diameter in subjects with multiple 
lesions; 
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o No extrahepatic manifestations; 
o No vascular invasion. 
 
Harvoni 
 Patient has documentation of hepatitis C genotype 1a or 1b; and 
 The patient is not receiving dialysis or does not have a CrCl < 30 mL/min; and  
 Patient is not co-infected with hepatitis B or HIV; and 
 Patient does not have decompensated liver disease; and 
 Patient has a contraindication to a preferred peg-interferon alfa plus ribavirin 
based regimen (e.g. sofosbuvir + peg-interferon + ribavirin); and 
 Documentation the patient has advanced liver disease as confirmed by one of the 
following indicators related to staging of liver fibrosis (attach test 
results/documentation):  
o Liver biopsy confirming a Metavir score ≥ F3; or   
o Transient elastography (FibroScan) score ≥ 9.5kPa; or  
o FibroSURE (FibroTest) score ≥ 0.58; or 
o APRI score > 1.5; or 
o Radiological imaging consistent with cirrhosis (i.e. evidence of portal 
hypertension); and 
o Physical findings or clinical evidence consistent with cirrhosis. 
 Dosing and length of therapy will be based on the following: 
o Patient is treatment-naïve without cirrhosis and has a documented pre-
treatment baseline HCV RNA less than 6 million IU/mL.  A maximum 8 weeks 
of therapy will be allowed; or 
o Patient is treatment-naïve with or without cirrhosis and has a documented 
pre-treatment baseline HCV RNA greater than 6 million IU/mL.  A maximum 
12 weeks of therapy will be allowed; or 
o Patient is treatment-experienced without cirrhosis and experienced failure 
with a previous treatment regimen that included either peg-interferon alfa + 
ribavirin or an HCV protease inhibitor + peg-interferon alfa + ribavirin.  A 
maximum 12 weeks of therapy will be allowed; or 
o Patient is treatment-experienced with cirrhosis and experienced failure with a 
previous treatment regimen that included either peg-interferon alfa + 
ribavirin or an HCV protease inhibitor + peg-interferon alfa + ribavirin.  A 
maximum 24 weeks of therapy will be allowed. 
Jason Wilbur motioned to accept the criteria as modified, and Brian Couse 
seconded.  All members were in favor.  Criteria will be sent to the medical and 
pharmacy associations for comment. 
 
Deferasirox (Exjade): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for deferasirox.  Payment will be considered under 
the following conditions: 
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1. Patient does not have a serum creatinine greater than 2 times the age-appropriate 
upper limit of normal or creatinine clearance <40mL/min; and 
2. Patient does not have a poor performance status; and 
3. Patient does not have a high-risk myelodysplastic syndrome; and  
4. Patient does not have advanced malignancies; and 
5. Patient does not have a platelet count <50 x 109/L. 
 
Transfusional Iron Overload 
Initiation of Therapy 
1. Patient is 2 years of age or older; and 
2. Patient has documentation of iron overload related to anemia (attach 
documentation); and 
3. Patient has documentation of a recent history of frequent blood transfusions that has 
resulted in chronic iron overload; and 
4. Serum ferritin is consistently >1000 mcg/L (attach lab results dated within the past 
month); and 
5. Starting dose does not exceed 20mg/kg/day.  Calculate dose to the nearest whole 
tablet. 
6. Initial requests will be considered for up to 3 months. 
Continuation of Therapy 
1. Serum ferritin has been measured within 30 days of continuation of therapy request 
(attach lab results); and 
2. Ferritin levels are >500mcg/L; and 
3. Dose does not exceed 40mg/kg/day. 
 
Non-Transfusional Iron Overload 
Initiation of Therapy 
1. Patient is 10 years of age or older; and 
2. Patient has documentation of iron overload related to anemia (attach 
documentation); and 
3. Serum ferritin and liver iron concentration (LIC) has been measured within 30 days 
of initiation (attach lab results); and 
4. Serum ferritin levels are >300mcg/L. 
5. Liver iron concentration (LIC) are >3mg Fe/g dw; and 
6. Dose does not exceed 10mg/kg/day (if LIC is <15mg Fe/g dw), or 20mg/kg/day (if 
LIC is >15mg Fe/g dw). 
7. Initial authorization will be considered for up to 6 months. 
Continuation of Therapy 
1. Serum ferritin and LIC have been measured within 30 days of continuation of therapy 
request; and 
2. Serum ferritin levels are >300mcg/L; and 
3. Liver iron concentration (LIC) is >3mg Fe/g dw; and 
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4. Dose does not exceed 10mg/kg/day (if LIC is 3 to 7mg Fe/g dw) or 20mg/kg/day (if 
LIC is >7mg Fe/g dw). 
 
Kellen Ludvigson motioned to accept the criteria as modified, and Brian Couse 
seconded.  All members were in favor. Criteria will be sent to the medical and 
pharmacy associations for comment. 
 
Vorapaxar (Zontivity): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for vorapaxar (Zontivity™).  Payment will be 
considered under the following conditions: 
1. Patient has a history of myocardial infarction (MI) or peripheral artery disease; 
and 
2. Patient does not have a history of stroke, transient ischemic attack (TIA), 
intracranial bleeding, or active peptic ulcer; and 
3. Patient has documentation of an adequate trial and therapy failure with aspirin 
plus clopidogrel; and 
4. Patient will use vorapaxar concurrently with aspirin and/or clopidogrel. 
 
The required trials may be overridden when documented evidence is provided that the 
use of this agent would be medically contraindicated. 
 
Brett Faine and Kellen Ludvigson simultaneously motioned to accept the criteria as 
modified, and Brian Couse seconded.  All members were in favor. Criteria will be 
sent to the medical and pharmacy associations for comment. 
 
Ceritinib (Zykadia): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for ceritinib (Zykadia™). Payment will be considered 
under the following conditions: 
1. Patient has a diagnosis of metastatic non-small cell lung cancer (NSCLC) that is 
anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test 
(attach copy of results); and 
2. Patient is 18 years of age or older; and 
3. Prescribed by a oncologist; and 
4. Patient has documentation of treatment with crizotinib and the disease has   
progressed while on treatment or is intolerant to treatment. 
5. Liver function tests (ALT, AST, and total bilirubin) will be monitored at least 
monthly while on ceritinib. 
 
If criteria for coverage are met, initial requests will be given for 3 months.  Requests 
for continuation of therapy will be considered with documentation patient has not 
experienced disease progression or unacceptable toxicity. 
 
As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be sent to the Department for consideration. 
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ProDUR Edit  
Antipsychotics – Age Edit and Duplicate Therapy Edit: The DUR Commission 
also discussed the Mental Health Advisory Group’s (MHAG) comments on the 
recommendations the DUR Commission initially made in April 2012 to implement 
ProDUR edits on antipsychotics in members less than 18 years of age.  Specifically, 
the recommendation was to: 1) implement an age edit on risperidone for members 
less than five (5) years of age and an age edit on all other antipsychotics for 
members less than six (6) years of age; and 2) apply a duplicate therapy edit to all 
antipsychotics.  The MHAG wondered if the age edits on haloperidol and 
chlorpromazine should be lowered to 3 years of age and six months of age 
respectively, to match the FDA standards.  After discussion, the Commission 
continues to support implementation of the aforementioned ProDUR edits, 
tentatively scheduled for implementation in the summer of 2015.  The members feel 
the age edits should not be lowered for haloperidol and chlorpromazine, and that 
requiring prior authorization for cases in which the prescribers want to use these 
medications for young children would be a good idea to confirm appropriate use.  
Prior to initiation of these edits, an informational letter will be sent to all providers, to 
encourage changes to drug regimen or submission of a PA prior to implementation 
of the edits and prior to discharge.  Soft edits will also be programmed into the Point 
of Sale (POS) system indicating the claim(s) will deny for a PA at the specific date 
indicated, which should prompt the pharmacy to notify the prescriber.  A draft of a 
FAQ document, which will likely be attached to the upcoming informational letter, 
was also provided.  It covered topics such as how the ProDUR edits work in the 
POS system, the prior authorization process, and which antipsychotic medications 
would require prior authorization due to the new ProDUR edits.  Chronic concurrent 
use will be considered on a case by case basis, but should be avoided if possible.  A 
POS edit for a 30 day grace period to allow for tapering is being explored to 
decrease the need for PA when transitioning from one agent to another.   
 
Miscellaneous 
DUR Digest: The Commission members reviewed the draft for DUR Digest Volume 
27, Number 2.  No changes were recommended.  It will be brought back to the next 
meeting for final review. 
 
MedWatch: The Commission members received FDA announcements regarding:  
methylphenidate hcl er tablets made by Mallinckrodt and Kudco; FDA approval of 
extended-release, single-entity hydrocodone product with abuse-deterrent 
properties; warning of case of rare brain infection PML with Tecfidera; and FDA 
approval of first combination pill to treat hepatitis C. 
New York Times Article – Cystic Fibrosis Foundation: The Commission 
members received copies of this recent article detailing the Cystic Fibrosis 
Foundation deal that allows for the foundation to receive 3.3 billion from selling the 
rights to royalties of drugs developed for the lung disease. 
http://www.nytimes.com/2014/11/19/business/for-cystic-fibrosis-foundation-venture-
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yields-windfall-in-hope-and-cash.html 
 
A unanimous roll call vote was made at 11:50 to adjourn the meeting and move to 
closed session (motion by Brian Couse, second by Jason Wilbur). 
The next meeting will be held at 9:30 a.m. on Wednesday, February 4, 2015, at 
the Learning Resource Center in West Des Moines. 
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Iowa Medicaid Drug Utilization Review Commission 
Meeting Minutes February 4, 2015 
Attendees: 
Commission Members 
Brian Couse, M.D.; Kellen Ludvigson, Pharm.D.; Mark Graber, M.D., FACEP (via 
phone); Laurie Pestel, Pharm.D. (via phone); Larry Ambroson, R.Ph. (via phone); 
Brett Faine, Pharm.D. (via phone); Jason Wilbur, M.D. (via phone); and Susan 
Parker, Pharm.D. 
 
Staff 
Pam Smith, R.Ph.  
 
Guests 
Chuck Wadle, D.O., Magellan; Jason Kessler, M.D., IME; Erin Halverson, R.Ph., 
IME; and Melissa Biddle, IME. 
 
 
Welcome & Introductions 
Pam Smith called the meeting to order at 9:32 a.m. at the Learning Resource Center 
in West Des Moines, as both the chairperson and vice-chairperson were attending 
via phone. In total, five Commission members attended via phone, because 
attending in person was impractical due to inclement weather.  The minutes from the 
December 3, 2014 meeting were reviewed.  Mark Graber motioned to accept them, 
and Brian Couse seconded.  All members were in favor.  The recommendation letter 
sent to DHS after the last meeting was also reviewed. 
 
IME Updates 
More than 115,000 members are now enrolled in the Iowa Health and Wellness Plan 
(IHAWP).  As of December 1, 2014, Iowa Medicaid is now covering an additional 
9,700 members previously enrolled in CoOportunity under IHAWP, as CoOportunity 
has withdrawn participation in the marketplace.  Governor Brandstad has announced 
plans to modernize Medicaid and bring some budget predictability to the program.  
More details will be provided in the coming weeks. Public meetings will be scheduled 
once information is available.  The Complex Pharmaceutical Oversight Program 
(CPOP), which provides oversight of clinically complex and high-cost drugs, went 
into effect on January 1, 2015.  The pharmacist who provides oversight for this 
program will hopefully be able to provide an overview at the next meeting.  During 
closed session profile reviews at the last meeting, it was suggested a maximum 
dose on Vimpat be implemented, as well as a duplicate therapy edit on beta-
blockers, splitting out the propanolol.  The Commission would like to address these 
issues at a future meeting. 
 
Prevalence Report Summary 
Statistics from November though December 2014 were discussed, including: cost 
per user ($307.69), number of total prescriptions dispensed (a decrease of 1.4% 
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compared to the previous reporting period), average cost per prescription ($64.27), 
and generic utilization (83.7%).  The total paid amount increased by 4.7% from the 
previous reporting period.  There were 199,594 unique users, which is 1.9% more 
than the total for September and October.  Lists of the top 20 therapeutic classes 
were provided.  SSRIs had the highest prescription count, and Anticonvulsants came 
in second.  The top 100 drugs were also reviewed.  The ten most expensive 
medications were: Abilify, Vyvanse, methylphenidate hcl er, Advate, Lantus, Focalin 
XR, Cymbalta, Synagis, Strattera, and Tamiflu. 
 
Case Studies 
Pam Smith presented 4 case studies.  Recommendations by Commissioners from 
these four examples resulted in annualized total savings of $2,494.32 pre-rebate 
(state and federal).   
 
Public Comment 
Name Representing Drug/Topic 
Alan Koslow Heartland Vascular apixiban 
Nancy Bell Pfizer apixiban 
Diane Hannah Celgene Otezla 
 
ProDUR Edits 
ADD/ADHD/Narcolepsy Agents: The DUR Commission discussed implementing 
quantity limits on multiple stimulant medications.  The members requested data to 
be brought back to the next meeting to determine the impact to prescribers and prior 
authorization department of implementing these quantity limits and to seek input 
from the medical and pharmacy associations regarding the proposed quantity limits.  
Blocking multiple strengths was also suggested, and IME staff will look into this 
possibility.  Current recommendations (applies to both brand and generic agents) 
are as follows: 
 
Drug Proposed Quantity Limit 
Per 30 Days 
Current Quantity Limit 
Per 30 Days 
Adderall 12.5mg tablet 90 120 
Adderall 20mg tablet 90 120 
Concerta 18mg tablet 30 60 
Concerta 27mg tablet 30 60 
Concerta 54mg tablet 30 60 
Focalin IR tablet (all 
strengths) 
60 None 
Focalin XR 5mg 30 60 
Focalin XR 10mg 30 60 
Focalin XR 15mg 30 90 
Focalin XR 20mg 30 60 
Focalin XR 25mg 30 60 
Focalin XR 30mg 30 60 
Ritalin IR (all strengths) 90 None 
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Focus Studies 
Sublingual/Translingual Nitroglycerin Utilization: This was a follow-up 
discussion.  Twelve of the 16 members identified changed therapy, for an 
annualized cost savings of $1,769.12 (state and federal, pre-rebate) as a result of 
the 43 surveys sent out to prescribers and pharmacies.  There were 19 (44.19%)  
surveys returned. 
 
Chronic Transdermal Scopolamine Utilization: This was a follow-up discussion.  
Thirteen of the 34 members identified changed therapy, for an annualized cost 
savings of $21,112.16 (state and federal, pre-rebate) as a result of the 71 surveys 
sent out to prescribers and pharmacies.  There were 29 (40.85%) surveys returned. 
 
Benzodiazepine Dosing: At the October 2014 meeting, the Commission expressed 
and interest in reviewing the quantity limits on all benzodiazepines, and also looking 
at the numbers on combination therapy.  Letters were sent to the prescribers of the 
members identified as using duplicate benzodiazepines to ask if the patient could be 
adequately controlled on one agent.  The Commission had also requested to update 
the data on number of units by dosage form and that maximum dose data be 
refined, to exclude those patients that may have received two fills of the 
benzodiazepine in the same month.  After reviewing the updated data, the DUR 
Commission discussed lowering the quantity limits on select benzodiazepines 
(alprazolam, clonazepam, lorazepam) to 120 units per 30 days.  Duplicate therapy 
edits may be discussed at a later date.  Letters will be sent to prescribers of 
members exceeding the proposed limits.  Current recommendations are as follows: 
 
Drug Proposed Quantity Limit 
Per 30 Days 
Current Quantity Limit 
Per 30 Days 
Alprazolam IR tablet (all 
strengths) 
120 150 
Clonazepam tablet (all 
strengths) 
120 150 
Lorazepam tablet (all 
strengths) 
120 150 
 
Long-Acting Plus Short-Acting Stimulants in Children: The Commission would 
like to begin by implementing the new quantity limits mentioned above, then revisit 
this topic again in at least six months to see if there has been improvement.  
 
Medication Adherence for Antidiabetics, Antihypertensives, and Statins: IME 
Member Services will be contacted to see if they already do member outreach and 
discuss the possibility of sending letters if not.  Laurie Pestel mentioned that Hy-Vee 
now has a compliance report in their system.  The Commission also wondered if a 
message could be added to the POS system, potentially even blocking the claim 
from payment.  Erin will look into this, and evaluate its impact to IME staff and 
pharmacies. 
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Public Comment 
There were no additional public speakers. 
 
Prior Authorization 
Apixaban (Eliquis): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for apixaban (Eliquis®). Payment will be 
considered under the following conditions:  
1. Patient does not have a mechanical prosthetic heart valve; and  
2. Patient does not have active pathological bleeding. 
 
Atrial Fibrillation 
 Patient has a diagnosis of non-valvular atrial fibrillation; with 
 Documentation of a previous trial and therapy failure with warfarin 
(TIA, stroke, or inability to maintain a therapeutic INR with a minimum 
6 month trial); and  
 Presence of at least one additional risk factor for stroke, with a 
CHADS2 score ≥ 1.  
 Requests will be considered for the following dosing: 
o 5mg twice daily; or 
o 2.5mg twice daily in patients with any two (2) of the following: 
 Age ≥80 years 
 Body weight ≤60 kg 
 Serum creatinine ≥1.5 mg/dL. 
 
Treatment and Prevention of DVT or PE  
 Patient has documentation of a previous trial and therapy failure with 
warfarin (TIA, stroke, or inability to maintain a therapeutic INR with a 
minimum 6 month trial). 
 Requests will be considered for the following dosing: 
o Initial Treatment of DVT or PE:  10mg twice daily for 7 days, 
followed by 5mg twice daily up to 12 months of treatment. 
o Prevention of DVT or PE following initial therapy with standard 
anticoagulation therapy for 6 to 12 months of treatment for DVT or 
PE: 2.5mg twice daily 
 
Prophylaxis of DVT following hip or knee replacement surgery 
 Requests will be considered when the patient has contraindications to 
use of the preferred agent(s).  
 Requests will be considered for the following dosing: 
o Hip replacement: 2.5mg twice daily for up to 35 days following hip 
replacement; or 
o Knee replacement: 2.5mg twice daily for up to 12 days after knee 
replacement. 
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The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
 
Jason Wilbur motioned to accept the criteria, and Brett Faine seconded.  All 
members were in favor.  The recommended PA criteria will be sent to the 
medical/pharmacy associations for comment and brought back to the next DUR 
meeting. The DUR Commission also made a recommendation that the P&T 
Committee conduct an overall cost comparison of the Novel Oral Anticoagulants 
(NOACs) versus warfarin to determine if one or more of these agents could be 
available to members without requiring a warfarin trial.  When looking at costs for 
warfarin, the DUR Commission would like the following factors to be taken into 
account: the costs for INR monitoring, frequent office visits to stabilize INR, and 
bridging therapy while patient is being stabilized on warfarin. 
 
Thrombopoietin Receptor Agonists: The Commission reviewed the prior 
authorization criteria as follows: 
Payment for a preferred thrombopoietin receptor agonist will only be 
considered for cases in which there is a diagnosis of chronic immune 
thrombocytopenic purpura (ITP) including documentation of an insufficient 
response to a corticosteroid, an immunoglobulin, or the patient has 
undergone a splenectomy. 
 
Payment for eltrombopag (Promacta®) for the treatment of chronic hepatitis C 
associated thrombocytopenia will only be considered to allow for initiation 
and/or maintenance of interferon-based therapy with ribavirin when the 
patient has a baseline platelet count less then 75 x 109/L. Requests will not 
be considered under the following conditions: 
1. Patients taking direct acting antiviral agents for the treatment of chronic 
hepatitis C infection in addition to interferon based therapy with 
ribavirin. 
2. Patients taking direct acting antiviral agents used without interferon for 
treatment of chronic hepatitis C infection. 
3. Patients with decompensated liver disease with a Child-Pugh score > 6 
(Class B & C). 
4. Patients with a history of ascites. 
5. Patients with hepatic encephalopathy. 
 
Payment for eltrombopag (Promacta®) for the treatment of severe aplastic 
anemia will only be considered under the following conditions: 
1. Patient has documentation of an insufficient response or intolerance to 
at least one prior immunosuppressive therapy; and 
2. Patient has a platelet count less than or equal 30 X 109/L. 
3. If criteria for coverage are met, initial authorization will be given for 16 
weeks.  Documentation of hematologic response after 16 weeks of 
therapy will be required for further consideration. 
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Payment for a non-preferred thrombopoietin receptor agonist will be 
considered following documentation of a recent trial and therapy failure with a 
preferred thrombopoietin receptor agonist unless such a trial would be 
medically contraindicated. 
 
Brian Couse motioned to accept the criteria, and Larry Ambroson seconded.  All 
members were in favor. The recommended PA criteria will be sent to the 
medical/pharmacy associations for comment and brought back to the next DUR 
meeting. 
 
Testosterone Products: The Commission reviewed the prior authorization criteria 
as follows: 
Prior authorization is required for testosterone products.  Payment will be 
considered with documentation of a specific testicular or 
hypothalamic/pituitary disease (primary hypogonadism or hypogonadotropic 
hypogonadism) that results in classic hypogonadism. Requests for FDA 
approved indications other than hypogonadism will not be subject to prior 
authorization criteria with adequate documentation of diagnosis. Payment for 
non-preferred testosterone products will be authorized only for cases in which 
there is documentation of previous trials and therapy failures with two 
preferred agents. Requests for erectile dysfunction, infertility, and age-related 
hypogonadism will not be considered.  Payment will be considered under the 
following conditions: 
1. Patient is male and 18 years of age or older (or 12 years of age and older 
for testosterone cypionate); and 
2. Patient has two (2) morning pre-treatment testosterone levels below the 
lower limit of the normal testosterone reference range of the individual 
laboratory used (Please attach lab results); and 
3. Patient has primary hypogonadism or hypogonadotropic hypogonadism 
(further defined below): 
 Primary hypogonadism (congenital or acquired) caused by testicular 
failure due to one of the following: 
o Cryptorchidism 
o Bilateral torsion 
o Orchitis 
o Vanishing testes syndrome, 
o Orchiectomy 
o Klinefelter’s syndrome, 
o Chemotherapy 
o Toxic damage from alcohol or heavy metals 
 Hypogonadotropic hypogonadism  
o Idiopathic gonadotropin or lutenizing hormone-releasing (LHRH) 
deficiency 
o Pituitary-hypothalamic injury from tumors, trauma, or radiation 
4. Patient does not have: 
 Breast or prostate cancer 
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 Palpable prostate nodule or prostate-specific antigen (PSA) > 4ng/mL 
 Hematocrit > 50% 
 Untreated severe obstructive sleep apnea 
 Severe lower urinary tract symptoms 
 Uncontrolled or poorly controlled heart failure 
 
Requests for continuation of therapy will require the following: 
1. An updated testosterone level (Please attach lab result); and 
2. Documentation the patient has not experienced a hematocrit > 54% or an 
increase in PSA > 1.4ng/mL in the past 12 months. 
 
The required trials may be overridden when documented evidence is provided 
that use of these agents would be medically contraindicated. 
 
Brian Couse motioned to accept the criteria, and Mark Graber seconded.  All 
members were in favor. The recommended PA criteria will be sent to the 
medical/pharmacy associations for comment and brought back to the next DUR 
meeting. 
 
Apremilast (Otezla): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for apremilast (Otezla®). Payment will be 
considered under the following conditions: 
1. Patient is 18 years of age or older; and  
2. Patient has a diagnosis of active psoriatic arthritis (≥ 3 swollen joints and ≥ 
3 tender joints) or  
3. Patient has a diagnosis of moderate to severe plaque psoriasis; and  
4. Prescribed by a rheumatologist or a dermatologist; and  
5. Patient does not have severe renal impairment (CrCl < 30mL/min). 
 
Psoriatic Arthritis 
 Patient has documentation of a trial and inadequate response to therapy 
with the preferred oral DMARD, methotrexate (leflunomide or 
sulfasalazine may be used if methotrexate is contraindicated); and 
 Patient has documentation of trials and therapy failures with two preferred 
biological agents used for psoriatic arthritis.  
 
Plaque Psoriasis 
 Patient has documentation of a trial and inadequate response to 
phototherapy, systemic retinoids, methotrexate, or cyclosporine; and 
 Patient has documentation of trials and therapy failures with two preferred 
biological agents. 
The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
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Mark Graber motioned to accept the criteria, and Jason Wilbur seconded.  All 
members were in favor. The recommended PA criteria will be sent to the 
medical/pharmacy associations for comment and brought back to the next DUR 
meeting. 
 
Hepatitis C Agents: The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for direct-acting oral antiviral agents against the 
hepatitis C virus.   Requests for non-preferred agents may be considered 
when documented evidence is provided that the use of the preferred agents 
would be medically contraindicated.  Payment will be considered under the 
following conditions: 
1. Patient is 18 years of age or older; and 
2. Patient’s prior treatment history is provided (treatment naïve, prior null 
responder, partial responder, or relapser); and 
3. Documentation of viral load taken within 6 months before beginning 
therapy; and 
4. Viral load will be submitted by prescriber 12 weeks after completion of 
therapy; and 
5. If patient has a history of failed treatment due to non-compliance, 
documentation that steps have been taken to correct or address the 
causes of non-compliance are provided; and  
6. For patients on a regimen containing ribavirin, the following must be 
documented on the PA form: 
a) Patient is not a pregnant female or a male with a pregnant female 
partner; and 
b) Women of childbearing potential and their male partners must use two 
forms of effective contraception (non-hormonal contraception for 
patients taking Sovaldi™) during treatment and for at least 6 months 
after treatment has concluded; and 
c) Documentation that routine monthly pregnancy tests are performed 
during this time; and 
7. Patient has abstained from the use of illicit drugs and alcohol for a 
minimum of three (3) months as evidenced by a negative urine 
confirmation test; and 
8. Prescriber is an infectious disease specialist, gastroenterologist, 
hepatologist or other hepatitis specialist. 
9. Where applicable, requests for peg-interferon alfa free regimens will be 
considered on a case-by-case basis for patients with hepatitis C genotype 
1 or 4 where peg-interferon alfa is contraindicated.  Contraindications 
include:  documented life-threatening side effects; decompensated hepatic 
disease; autoimmune hepatitis and other autoimmune disorders; a 
baseline neutrophil count below 1500/µL, a baseline platelet count below 
90,000/ µL, or a baseline hemoglobin below 10g/dL; or a history of 
preexisting unstable cardiac disease. 
10. Non-FDA approved or non-compendia indicated combination therapy 
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regimens will not be approved. 
11. If patient is recently eligible for Iowa Medicaid, and has been started and 
stabilized on therapy while covered under a different plan, documentation 
of how long the patient has been on medication will be required.  Patient 
will be eligible for the remainder of therapy needed, based on established 
length of therapy for the particular treatment (defined below). 
12. Lost or stolen medication replacement requests will not be authorized. 
13. The 72-hour emergency supply rule does not apply to oral hepatitis C 
antiviral agents. 
 
Victrelis  
 Patient has a documented diagnosis of hepatitis C genotype 1; and  
 Administered in combination with peg-interferon alfa and ribavirin; and 
 Patient does not have HIV co-infection; and 
 Patient does not have decompensated cirrhosis; and  
 Patient has not previously tried or failed therapy with a hepatitis C 
protease inhibitor; and 
 HCV-RNA results are required at treatment week 8, 12, and 24 (including 
lead in period) for boceprevir (Victrelis™).  
 Additional prior authorizations will be considered with documentation of 
response to treatment, measured by HCV-RNA levels.  
 Prior authorizations will be approved for a maximum of 24, 32, or 44 
weeks of therapy with boceprevir (Victrelis™) based on response. 
 
Olysio 
 Patient has a documented diagnosis of hepatitis C genotype 1; and  
 Administered in combination with peg-interferon alfa and ribavirin; and 
 Patient does not have HIV co-infection; and 
 Patient does not have the NS3 Q80K polymorphism with hepatitis C 
genotype 1a; and 
 The patient is not receiving dialysis or does not have a CrCl < 30 mL/min; 
and 
 Patient has not previously tried or failed therapy with a hepatitis C 
protease inhibitor; and 
 HCV-RNA results are required at treatment week 4 for simeprevir 
(Olysio™). 
 Additional prior authorizations will be considered with documentation of 
response to treatment, measured by HCV-RNA levels. 
 A maximum 12 weeks of therapy will be allowed.  
 
Sovaldi 
 The patient is not receiving dialysis or does not have a CrCl < 30 mL/min; 
and  
 Patient does not have decompensated cirrhosis; and 
 Documentation the patient has advanced liver disease corresponding to a 
10 
 
Metavir score of 3 or greater fibrosis as confirmed by one of the following 
indicators related to staging of liver fibrosis (attach test 
results/documentation):  
o Liver biopsy confirming a Metavir score ≥ F3; or   
o Transient elastography (FibroScan) score ≥ 9.5kPa; or  
o FibroSURE (FibroTest) score ≥ 0.58; or 
o APRI score > 1.5; or 
o Radiological imaging consistent with cirrhosis (i.e. evidence of portal 
hypertension); and 
o Physical findings or clinical evidence consistent with cirrhosis. 
 Dosing and length of therapy will be based on the following: 
o Genotype 1:  Patient has a documented diagnosis of hepatitis C 
genotype 1 (mono-infected or HCV/HIV co-infected) and used in 
combination with peg-interferon alfa and ribavirin.  A maximum 12 
weeks therapy will be allowed.   
o Genotype 2:  Patient has a documented diagnosis of hepatitis C 
genotype 2 (mono-infected or HCV/HIV co-infected) and used in 
combination with ribavirin.  A maximum 12 weeks of therapy will be 
allowed. 
o Genotype 3:  Patient has a documented diagnosis of hepatitis C 
genotype 3 (mono-infected or HCV/HIV co-infected) and used in 
combination with ribavirin. A maximum 24 weeks of therapy will be 
allowed. 
o Genotype 4:  Patient has a documented diagnosis of hepatitis C 
genotype 4 (mono-infected or HCV/HIV co-infected) and used in 
combination with peg-interferon alfa and ribavirin. A maximum 12 
weeks of therapy will be allowed. 
 Hepatocellular carcinoma:  Patient has a documented diagnosis of 
hepatitis C genotype 1, 2, 3, 4 with a diagnosis of hepatocellular 
carcinoma meeting Milan criteria (awaiting liver transplantation) and in 
combination with ribavirin for up to 48 weeks or until liver transplantation, 
whichever comes first.  Milan criteria are defined as: 
o One lesion smaller than  5 cm in diameter for subjects with a  single 
lesion; 
o Up to 3 lesions smaller than 3 cm in diameter in subjects with multiple 
lesions; 
o No extrahepatic manifestations; 
o No vascular invasion. 
 
Harvoni 
 Patient has documentation of hepatitis C genotype 1a or 1b; and 
 The patient is not receiving dialysis or does not have a CrCl < 30 mL/min; 
and  
 Patient is not co-infected with hepatitis B or HIV; and 
 Patient does not have decompensated liver disease; and 
 Patient has a contraindication to a preferred peg-interferon alfa plus 
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ribavirin based regimen (e.g. sofosbuvir + peg-interferon + ribavirin); and 
 Documentation the patient has advanced liver disease as confirmed by 
one of the following indicators related to staging of liver fibrosis (attach 
test results/documentation):  
o Liver biopsy confirming a Metavir score ≥ F3; or   
o Transient elastography (FibroScan) score ≥ 9.5kPa; or  
o FibroSURE (FibroTest) score ≥ 0.58; or 
o APRI score > 1.5; or 
o Radiological imaging consistent with cirrhosis (i.e. evidence of portal 
hypertension); and 
o Physical findings or clinical evidence consistent with cirrhosis. 
 Dosing and length of therapy will be based on the following: 
o Patient is treatment-naïve without cirrhosis and has a documented pre-
treatment baseline HCV RNA less than 6 million IU/mL.  A maximum 8 
weeks of therapy will be allowed; or 
o Patient is treatment-naïve with or without cirrhosis and has a 
documented pre-treatment baseline HCV RNA greater than 6 million 
IU/mL.  A maximum 12 weeks of therapy will be allowed; or 
o Patient is treatment-experienced without cirrhosis and experienced 
failure with a previous treatment regimen that included either peg-
interferon alfa + ribavirin or an HCV protease inhibitor + peg-interferon 
alfa + ribavirin.  A maximum 12 weeks of therapy will be allowed; or 
o Patient is treatment-experienced with cirrhosis and experienced failure 
with a previous treatment regimen that included either peg-interferon 
alfa + ribavirin or an HCV protease inhibitor + peg-interferon alfa + 
ribavirin.  A maximum 24 weeks of therapy will be allowed. 
As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be sent to the Department for consideration. 
 
Deferasirox (Exjade): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for deferasirox.  Payment will be considered 
under the following conditions: 
1. Patient does not have a serum creatinine greater than 2 times the age-
appropriate upper limit of normal or creatinine clearance <40mL/min; and 
2. Patient does not have a poor performance status; and 
3. Patient does not have a high-risk myelodysplastic syndrome; and  
4. Patient does not have advanced malignancies; and 
5. Patient does not have a platelet count <50 x 109/L. 
 
Transfusional Iron Overload 
Initiation of Therapy 
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1. Patient is 2 years of age or older; and 
2. Patient has documentation of iron overload related to anemia (attach 
documentation); and 
3. Patient has documentation of a recent history of frequent blood transfusions 
that has resulted in chronic iron overload; and 
4. Serum ferritin is consistently >1000 mcg/L (attach lab results dated within the 
past month); and 
5. Starting dose does not exceed 20mg/kg/day.  Calculate dose to the nearest 
whole tablet. 
6. Initial requests will be considered for up to 3 months. 
Continuation of Therapy 
1. Serum ferritin has been measured within 30 days of continuation of therapy 
request (attach lab results); and 
2. Ferritin levels are >500mcg/L; and 
3. Dose does not exceed 40mg/kg/day. 
 
Non-Transfusional Iron Overload 
Initiation of Therapy 
1. Patient is 10 years of age or older; and 
2. Patient has documentation of iron overload related to anemia (attach 
documentation); and 
3. Serum ferritin and liver iron concentration (LIC) has been measured within 30 
days of initiation (attach lab results); and 
4. Serum ferritin levels are >300mcg/L. 
5. Liver iron concentration (LIC) are >3mg Fe/g dw; and 
6. Dose does not exceed 10mg/kg/day (if LIC is <15mg Fe/g dw), or 
20mg/kg/day (if LIC is >15mg Fe/g dw). 
7. Initial authorization will be considered for up to 6 months. 
Continuation of Therapy 
1. Serum ferritin and LIC have been measured within 30 days of continuation of 
therapy request; and 
2. Serum ferritin levels are >300mcg/L; and 
3. Liver iron concentration (LIC) is >3mg Fe/g dw; and 
4. Dose does not exceed 10mg/kg/day (if LIC is 3 to 7mg Fe/g dw) or 
20mg/kg/day (if LIC is >7mg Fe/g dw). 
 
As this was the second review of these criteria, no motion was necessary. The 
recommendation will be sent to the Department for consideration. 
 
Vorapaxar (Zontivity): The Commission reviewed the prior authorization criteria as 
follows: 
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Prior authorization is required for vorapaxar (Zontivity™).  Payment will be 
considered under the following conditions: 
1. Patient has a history of myocardial infarction (MI) or peripheral artery 
disease; and 
2. Patient does not have a history of stroke, transient ischemic attack (TIA), 
intracranial bleeding, or active peptic ulcer; and 
3. Patient has documentation of an adequate trial and therapy failure with 
aspirin plus clopidogrel; and 
4. Patient will use vorapaxar concurrently with aspirin and/or clopidogrel. 
The required trials may be overridden when documented evidence is provided 
that the use of this agent would be medically contraindicated. 
 
As this was the second review of these criteria, no motion was necessary. The 
recommendation will be sent to the Department for consideration. 
 
Miscellaneous 
DUR Digest: The Commission members reviewed the draft for DUR Digest Volume 
27, Number 2.  As this was the second review and no changes were recommended, 
the DUR Digest will be posted to the website. 
 
MedWatch: The Commission members received FDA announcements concerning 
new Black Box Warnings. 
A unanimous roll call vote was made at 11:47 a.m. to adjourn the meeting and move 
to closed session (motion by Kellen Ludvigson, second by Brian Couse and Mark 
Graber simultaneously). 
The next meeting will be held at 9:30 a.m. on Wednesday, April 1, 2015, at the 
Fred Maytag II Scout Center in Des Moines. 
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Iowa Medicaid Drug Utilization Review Commission 
Meeting Minutes April 1, 2015 
Attendees: 
Commission Members 
Mark Graber, M.D., FACEP; Laurie Pestel, Pharm.D.; Gregory Barclay, M.D.; 
Kellen Ludvigson, Pharm.D.; Larry Ambroson, R.Ph.; Brett Faine, Pharm.D.; 
Brian Couse, M.D.; and Susan Parker, Pharm.D. 
 
Staff 
Pam Smith, R.Ph.  
 
Guests 
Chuck Wadle, D.O., Magellan; Jason Kessler, M.D., IME; Erin Halverson, R.Ph., 
IME; Megan Smith, Pharm.D., IME; Tina Valentino, Pharm.D., IME; Andria Seip, 
IME; Elizabeth Matney, IME: and Melissa Biddle, IME. 
 
 
Welcome & Introductions 
Mark Graber called the meeting to order at 9:37 a.m. at the Fred Maytag II Scout 
Center in Des Moines.  The minutes from the February 4, 2015 meeting were 
reviewed.  Kellen Ludvigson motioned to accept them, and Brian Couse 
seconded.  All members were in favor.  Andria Seip and Elizabeth Matney gave a 
presentation regarding Medicaid Modernization and its projected impact to 
providers and members.  This initiative aims to improve the coordination and 
quality of care while providing predictability and sustainability for taxpayers in 
Medicaid spending.  There will still be a preferred drug list (PDL) that all of the 
chosen managed care organizations will have to follow.  Questions and 
comments may be emailed to MedicaidModernization@dhs.state.ia.us, and a 
new site has been created focusing on Iowa Medicaid’s change to managed care 
organizations effective January 1, 2016: 
https://dhs.iowa.gov/ime/about/initiatives/MedicaidModernization.  The full 
presentation can be accessed at the following link: 
https://dhs.iowa.gov/sites/default/files/IME_ModernizationPresentation_031815.p
df.  Tina Valentino spoke about the new Complex Pharmaceutical Oversight 
Program (CPOP) started in January 2015, which focuses on complex high-cost 
medications, and reaches out to patients and prescribers to review medical 
records and maintain outcomes, as well as finding problem patterns for certain 
medications.  The goal of the program is to reduce waste and improve clinical 
outcomes.  There have been 270 members processed through CPOP since 
January.  The resulting cost avoidance savings will be reported in quarterly 
reports.  The DUR recommendation letter sent to DHS after the last meeting was 
also reviewed. 
 
IME Updates 
There was nothing additional to those listed above. 
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Prevalence Report Summary 
Statistics from January though February 2015 were discussed, including: cost 
per user ($310.79), number of total prescriptions dispensed (an increase of 2.2% 
compared to the previous reporting period), average cost per prescription 
($65.61), and generic utilization (84.4%).  The total paid amount increased by 
4.5% from the previous reporting period.  There were 204,409 unique users, 
which is 3.0% more than the total for November and December.  Lists of the top 
20 therapeutic classes were provided.  SSRIs had the highest prescription count, 
and Anticonvulsants came in second.  The top 100 drugs were also reviewed.  
The ten most expensive medications were: Abilify, Vyvanse, methylphenidate hcl 
er, Lantus, Focalin XR, Advate, Synagis, Strattera, Cymbalta, and Tamiflu. 
 
Case Studies 
Pam Smith presented 4 case studies.  Recommendations by commissioners 
from these four examples resulted in annualized total savings of $1,552.85 pre-
rebate (state and federal).   
 
Public Comment 
 
Name Representing Drug/Topic 
Alan Koslow Heartland Vascular apixiban 
Elizabeth Potente Avanir Nuedexta 
Nancy Bell Pfizer Apixiban and Lyrica 
Karen Loihl Iowa Psychiatric Society ProDUR edit on stimulants 
Andrew Ko Shire Vyvanse 
Tami Sova UCB Vimpat 
Deepak Patel Novo Nordisk Victoza 
Diane Hanna Celgene Otezla 
Randy Maigaard Broadlawns Hepatitis C PA criteria 
Doug Hanson Broadlawns Hepatitis C PA criteria 
Gary Riley Abbvie Viekira Pak 
 
ProDUR Edits 
Impact of Select CNS Stimulant Quantity Limits: The DUR Commission 
discussed implementing quantity limits on multiple stimulant medications at the 
February meeting.  The members had requested data be brought back to the 
next meeting to determine the impact to prescribers and the prior authorization 
department of implementing these quantity limits and to seek input from the 
medical and pharmacy associations regarding the proposed quantity limits.  
Blocking multiple strengths was also suggested, and IME staff will look into this 
possibility.  After further discussion and feedback from the Iowa Psychiatric 
Society, the Commission decided to refer this to the Mental Health Advisory 
Group (MHAG) again prior to implementation.  Current recommendations are as 
follows: 
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Drug Proposed Quantity Limit 
Per 30 Days 
Current Quantity Limit 
Per 30 Days 
Adderall 12.5mg tablet 90 120 
Adderall 20mg tablet 90 120 
Concerta 18mg tablet 30 60 
Concerta 27mg tablet 30 60 
Concerta 54mg tablet 30 60 
Focalin IR tablet (all 
strengths) 
60 None 
Focalin XR 5mg 30 60 
Focalin XR 10mg 30 60 
Focalin XR 15mg 30 90 
Focalin XR 20mg 30 60 
Focalin XR 25mg 30 60 
Focalin XR 30mg 30 60 
Ritalin IR (all strengths) 90 None 
 
Focus Studies 
 
Naltrexone Utilization in the Pediatric Population: This was a follow-up 
discussion.  Five (5) of the 12 members identified changed therapy, for an 
annualized cost savings of $2,161.96 (state and federal, pre-rebate) as a result 
of the 26 surveys sent out to prescribers and pharmacies.  Fourteen (53.85%) of 
those surveys were returned. 
 
Adalimumab Use without Methotrexate: This was a follow-up discussion.  Two 
of the 10 members identified changed therapy, increasing annual costs by 
$934.40 (state and federal, pre-rebate) as a result of the 20 surveys sent out to 
prescribers and pharmacies with 11 (55.00%) of those surveys returned. 
 
Duplicate Beta-Blockers: Letters will be sent to the providers of the members 
identified as using more than one beta-blocker concurrently in January 2015 to 
ask if the patient could be adequately controlled with one beta-blocker. 
 
Vimpat Dosing: Letters will be sent to the providers of the members exceeding 
400mg per day of Vimpat to ask if the dose could be slowly decreased to 400mg 
per day.  Depending on the responses received, a ProDUR edit limiting the 
maximum dose to 400mg daily across all strengths and dosage forms might also 
be implemented in the future. 
 
Public Comment 
 
Name Representing Drug/Topic 
Kevin Nelson Merck Belsomra 
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Prior Authorization 
 
Hepatitis C Agents: The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for hepatitis C treatments.   Requests for non-
preferred agents may be considered when documented evidence is provided that 
the use of the preferred agents would be medically contraindicated.  Payment will 
be considered under the following conditions: 
1. Patient is 18 years of age or older and has a diagnosis of chronic hepatitis C; 
and 
2. Patient has had testing for hepatitis C virus (HCV) genotype; and 
3. Patient has an active HCV infection verified by a detectable viral load within 
12 months of starting treatment; and 
4. Viral load will be submitted by prescriber 12 weeks after completion of 
therapy; and 
5. Patient has advanced liver disease corresponding to a Metavir score of 3 or 
greater fibrosis as confirmed by one of the following: 
o Liver biopsy confirming a Metavir score ≥ F3; or   
o Transient elastography (FibroScan) score ≥ 9.5kPa; or  
o FibroSURE (FibroTest) score ≥ 0.58; or 
o APRI score > 1.5; or 
o Radiological imaging consistent with cirrhosis (i.e. evidence of portal 
hypertension); or 
o Physical findings or clinical evidence consistent with cirrhosis; or 
o Patients at highest risk for severe complications: organ transplant, 
type 2 or 3 essential mixed cryoglobulinemia with end-organ 
manifestations (e.g. vasculitis), proteinuria, nephrotic syndrome, or 
membranoproliferative glomerulonephritis. 
6. Patient’s prior treatment history is provided (treatment naïve or treatment 
experienced); and 
7. If patient has a history of non-compliance, documentation that steps have 
been taken to correct or address the causes of non-compliance are provided; 
and  
8. Patient has abstained from the use of illicit drugs and alcohol for a minimum 
of three (3) months as evidenced by a negative urine confirmation test; and 
9. Patient does not have severe renal impairment (creatinine clearance 
<30ml/min) or end stage renal disease requiring hemodialysis; and  
10. HCV treatment is prescribed by a digestive disease, liver disease, or 
infectious disease provider practice; and 
11. For patients on a regimen containing ribavirin, the following must be 
documented on the PA form: 
a) Patient is not a pregnant female or a male with a pregnant female 
partner; and 
b) Women of childbearing potential and their male partners must use two 
forms of effective contraception during treatment and for at least 6 
months after treatment has concluded; and 
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c) Monthly pregnancy tests will be performed during treatment; and 
12. Prescriber has reviewed the patient’s current medication list and 
acknowledged that there are no significant drug interactions with the HCV 
medication. 
13. Documentation is provided for patients who are ineligible to receive 
interferon or ribavirin. 
14. Non-FDA approved or non-compendia indicated combination therapy 
regimens will not be approved. 
15. If patient is recently eligible for Iowa Medicaid, and has been started and 
stabilized on therapy while covered under a different plan, documentation of 
how long the patient has been on medication will be required.  Patient will be 
eligible for the remainder of therapy needed, based on established length of 
therapy for the particular treatment (defined below). 
16. Lost or stolen medication replacement requests will not be authorized. 
17. The 72-hour emergency supply rule does not apply to oral hepatitis C 
antiviral agents. 
 
Brett Faine motioned to accept the criteria as amended, and Larry Ambroson 
seconded.  All members were in favor.  The recommended PA criteria will be 
sent to the medical/pharmacy associations for comment and brought back to the 
next DUR meeting. 
 
CNS Stimulants and Atomoxetine: The Commission reviewed the prior 
authorization criteria as follows: 
Prior authorization (PA) is required for CNS stimulants and Atomoxetine for 
patients 21 years of age or older.  Prior to requesting prior authorization for any 
covered diagnosis, the prescriber must review the patient’s use of controlled 
substances on the Iowa Prescription Monitoring Program website at  
https://pmp.iowa.gov/IAPMPWebCenter/.   Payment for CNS stimulants and 
Atomoxetine will be considered under the following conditions: 
1. Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity 
Disorder (ADHD) meeting the DSM-5 criteria and confirmed by a 
standardized rating scale (such as Conners, Vanderbilt, Brown, SNAP-
IV). Symptoms must have been present before twelve (12) years of age and 
there must be clear evidence of clinically significant impairment in two or 
more current environments (social, academic, or occupational).  
Documentation of a recent clinical visit that confirms the patient continues 
to require medication to treat the symptoms of ADD/ADHD will be 
required for renewals or patients newly eligible that are established on 
medication to treat ADD/ADHD. 
2. Narcolepsy with diagnosis confirmed with a recent sleep study (ESS, 
MSLT, PSG). 
3. Excessive sleepiness from obstructive sleep apnea/hypopnea syndrome 
(OSAHS) with documentation of non-pharmacological therapies tried 
(weight loss, position therapy, CPAP at maximum titration, BiPAP at 
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maximum titration or surgery) and results from a recent sleep study (ESS, 
MSLT, PSG) with the diagnosis confirmed by a sleep specialist. 
4. Binge Eating Disorder (Vyvanse only)  
 Patient is 18 to 55 years of age; and 
 Patient meets the DSM-5 criteria for Binge Eating Disorder; and  
 Patient has documentation of moderate to severe BED, as defined by 
the number of binge eating episodes per week (number of episodes 
must be reported); and 
 Patient has documentation of non-pharmacologic therapies tried, such 
as cognitive-behavioral therapy or interpersonal therapy, for a recent 
3 month period, that did not significantly reduce the number of binge 
eating episodes; and  
 Patient has documentation of an adequate trial and therapy failure at 
a therapeutic dose with topiramate and fluvoxamine 
 Prescription is written by a psychiatrist or psychiatric nurse 
practitioner; and 
 Patient has a BMI of 25 to 45; and 
 Patient does not have personal or family history of cardiovascular 
disease; and 
 Patient has no history of substance abuse; and 
 Is not being prescribed for the treatment of obesity or weight loss; and 
 Doses above 70mg per day will not be considered. 
 Initial requests will be approved for 12 weeks. 
 Requests for renewal must include documentation of a change from 
baseline at week 12 in the number of binge days per week. 
 
DSM-5 Criteria 
i. Recurrent episodes of binge eating, including eating an 
abnormally large amount of food in a discrete period of time and 
has a feeling of lack of control over eating; and 
ii. The binge eating episodes are marked by at least three of the 
following: 
1. Eating more rapidly than normal 
2. Eating until feeling uncomfortably full 
3. Eating large amounts of food when not feeling physically 
hungry 
4. Eating alone because of embarrassment by the amount of 
food consumed 
5. Feeling disgusted with oneself, depressed, or guilty after 
overeating; and 
iii. Episodes occur at least 1 day a week for at least 3 months; and 
iv. No regular use of inappropriate compensatory behaviors (e.g. 
purging, fasting, or excessive exercise) as are seen in bulimia 
nervosa; and  
v. Does not occur solely during the course of bulimia nervosa or 
anorexia nervosa. 
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Moderate to Severe BED 
Based on the number of binge eating episodes per week:   
Moderate - 4 to 7  
Severe – 8 to 13 
Extreme – 14 or more 
 
Payment for a non-preferred agent will be authorized only for cases in which 
there is documentation of a previous trial and therapy failure with a preferred 
agent. *If a non-preferred long-acting medication is requested, a trial with the 
preferred immediate release and extended release product of the same chemical 
entity (methylphenidate class) or chemically related agent (amphetamine class) is 
required. 
 
The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
 
Larry Ambroson motioned to accept the criteria, and Brian Couse seconded.  All 
members were in favor.  The recommended PA criteria will be sent to the 
medical/pharmacy associations for comment and brought back to the next DUR 
meeting. 
 
Dextromethorphan/Quinidine (Nuedexta): The Commission reviewed the prior 
authorization criteria as follows: 
Prior authorization is required for Nuedexta
®
. Payment will be considered under 
the following conditions: 
1. Patients must have a diagnosis of pseudobulbar affect (PBA) secondary to a 
neurological condition. 
2. A trial and therapy failure at a therapeutic dose with amitriptyline or an 
SSRI; and 
3. Patient has documentation of a current EKG (within the past 3 months) 
without QT prolongation. 
4. Initial authorizations will be approved for 12 weeks with a baseline Center for 
Neurologic Studies Lability Scale (CNS-LS) questionnaire.  
5. Subsequent prior authorizations will be considered at 6 month intervals with 
documented efficacy as seen in an improvement in the CNS-LS questionnaire. 
 
The required trials may be overridden when documented evidence is provided 
that use of these agents would be medically contraindicated. 
 
Brett Faine motioned to accept the criteria, and Kellen Ludvigson seconded.  All 
members were in favor. The recommended PA criteria will be sent to the 
medical/pharmacy associations for comment and brought back to the next DUR 
meeting. 
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Chronic Pain Syndromes: The Commission reviewed the prior authorization 
criteria as follows: 
A prior authorization is required for pregabalin (Lyrica
®
) and milnacipran 
(Savella
™
).  These drugs will be considered for their FDA indication(s) and other 
conditions as listed in the compendia.  Requests for doses above the manufacturer 
recommended dose will not be considered.  For patients with a chronic pain 
diagnosis who are currently taking opioids, as seen in pharmacy claims, a plan to 
decrease and/or discontinue the opioid(s) must be provided with the initial 
request.  Initial authorization will be given for three (3) months.  There must be a 
significant decrease in opioid use or discontinuation of opioid(s) after the initial 
three (3) month authorization for further approval consideration.  Additional 
prior authorizations will be considered with documentation of a continued 
decrease in opioid utilization.  Payment will be considered under the following 
conditions: 
1. A diagnosis of fibromyalgia (Lyrica® and Savella™)  
a. A trial and therapy failure at a therapeutic dose with gabapentin plus one 
of the following preferred generic agents: tricyclic antidepressant, SSRI, 
or  SNRI, WITH 
b. Documented non-pharmacologic therapies (cognitive behavior therapies, 
exercise, etc.).  
2. A diagnosis of postherpetic neuralgia (Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of 
the following: tricyclic antidepressant, topical lidocaine, or valproate. 
3.  A diagnosis of diabetic peripheral neuropathy (Lyrica
®
) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of 
the following: tricyclic antidepressant, duloxetine or topical lidocaine. 
4.  A diagnosis of partial onset seizures, as adjunct therapy (Lyrica
®
) 
 
Kellen Ludvigson motioned to accept the criteria, and Brett Faine seconded.  All 
members were in favor. The recommended PA criteria will be sent to the 
medical/pharmacy associations for comment and brought back to the next DUR 
meeting. 
 
Sedative/Hypnotics – Non-Benzodiazepines: The Commission reviewed the 
prior authorization criteria as follows: 
Preferred agents are available without prior authorization (PA). Requests for 
doses above the manufacturer recommended dose will not be considered.  Prior 
authorization is required for all non-preferred non-benzodiazepine 
sedative/hypnotics. Payment for non-preferred non-benzodiazepine 
sedative/hypnotics will be authorized only for cases in which there is 
documentation of previous trials and therapy failures with, at a minimum, three 
(3) preferred agents. Payment for non-preferred non-benzodiazepine 
sedative/hypnotics will be considered when the following criteria are met: 
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1. A diagnosis of insomnia; and 
2. Medications with a side effect of insomnia (i.e. stimulants) are decreased 
in dose, changed to a short acting product, and/or discontinued; and 
3. Enforcement of good sleep hygiene is documented; and 
4. All medical, neurological, and psychiatric disease states causing chronic 
insomnia are being adequately treated with appropriate medication at 
therapeutic doses. 
5. In addition to the above criteria, requests for suvorexant (Belsomra) will 
require documentation of a trial and therapy failure with at least one non-
preferred agent, other than suvorexant, prior to consideration of 
coverage. 
6. Non-preferred alternative delivery systems will only be considered for 
cases in which the use of the alternative delivery system is medically 
necessary and there is a previous trial and therapy failure with a 
preferred alternative delivery system if available. 
 
The required trials may be overridden when documented evidence is provided 
that use of these agents would be medically contraindicated. 
 
Brett Faine motioned to accept the criteria, and Larry Ambroson seconded.  All 
members were in favor. The recommended PA criteria will be sent to the 
medical/pharmacy associations for comment and brought back to the next DUR 
meeting. 
 
Apixaban (Eliquis): The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for apixaban (Eliquis®). Payment will be 
considered under the following conditions:  
1. Patient does not have a mechanical prosthetic heart valve; and  
2. Patient does not have active pathological bleeding. 
 
Atrial Fibrillation 
 Patient has a diagnosis of non-valvular atrial fibrillation; with 
 Documentation of a previous trial and therapy failure with warfarin (TIA, 
stroke, or inability to maintain a therapeutic INR with a minimum 6 month 
trial); and  
 Presence of at least one additional risk factor for stroke, with a CHADS2 
score ≥ 1.  
 Requests will be considered for the following dosing: 
o 5mg twice daily; or 
o 2.5mg twice daily in patients with any two (2) of the following: 
 Age ≥80 years 
 Body weight ≤60 kg 
 Serum creatinine ≥1.5 mg/dL. 
 
Treatment and Prevention of DVT or PE  
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 Patient has documentation of a previous trial and therapy failure with 
warfarin (TIA, stroke, or inability to maintain a therapeutic INR with a 
minimum 6 month trial). 
 Requests will be considered for the following dosing: 
o Initial Treatment of DVT or PE:  10mg twice daily for 7 days, followed 
by 5mg twice daily up to 12 months of treatment. 
o Prevention of DVT or PE following initial therapy with standard 
anticoagulation therapy for 6 to 12 months of treatment for DVT or 
PE: 2.5mg twice daily 
 
Prophylaxis of DVT following hip or knee replacement surgery 
 Requests will be considered when the patient has contraindications to use 
of the preferred agent(s).  
 Requests will be considered for the following dosing: 
o Hip replacement: 2.5mg twice daily for up to 35 days following hip 
replacement; or 
o Knee replacement: 2.5mg twice daily for up to 12 days after knee 
replacement. 
 
The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
 
As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be sent to the Department for consideration. 
 
In February, the DUR Commission also made a recommendation that the P&T 
Committee conduct an overall cost comparison of the Novel Oral Anticoagulants 
(NOACs) versus warfarin to determine if one or more of these agents could be 
available to members without requiring a warfarin trial.  When looking at costs for 
warfarin, the DUR Commission would like the following factors to be taken into 
account: the costs for INR monitoring, frequent office visits to stabilize INR, and 
bridging therapy while the patient is being stabilized on warfarin.  Erin Halverson 
said the P&T Committee will review this issue at their August meeting. 
 
Thrombopoietin Receptor Agonists: The Commission reviewed the prior 
authorization criteria as follows: 
Payment for a preferred thrombopoietin receptor agonist will only be considered 
for cases in which there is a diagnosis of chronic immune thrombocytopenic 
purpura (ITP) including documentation of an insufficient response to a 
corticosteroid, an immunoglobulin, or the patient has undergone a splenectomy. 
 
Payment for eltrombopag (Promacta®) for the treatment of chronic hepatitis C 
associated thrombocytopenia will only be considered to allow for initiation 
and/or maintenance of interferon-based therapy with ribavirin when the patient 
has a baseline platelet count less then 75 x 10
9
/L. Requests will not be considered 
under the following conditions: 
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1. Patients taking direct acting antiviral agents for the treatment of chronic 
hepatitis C infection in addition to interferon based therapy with ribavirin. 
2. Patients taking direct acting antiviral agents used without interferon for 
treatment of chronic hepatitis C infection. 
3. Patients with decompensated liver disease with a Child-Pugh score > 6 
(Class B & C). 
4. Patients with a history of ascites. 
5. Patients with hepatic encephalopathy. 
 
Payment for eltrombopag (Promacta
®
) for the treatment of severe aplastic 
anemia will only be considered under the following conditions: 
1. Patient has documentation of an insufficient response or intolerance to at 
least one prior immunosuppressive therapy; and 
2. Patient has a platelet count less than or equal 30 X 109/L. 
3. If criteria for coverage are met, initial authorization will be given for 16 
weeks.  Documentation of hematologic response after 16 weeks of therapy 
will be required for further consideration. 
 
Payment for a non-preferred thrombopoietin receptor agonist will be considered 
following documentation of a recent trial and therapy failure with a preferred 
thrombopoietin receptor agonist unless such a trial would be medically 
contraindicated. 
 
As this was the second review of these criteria, no motion was necessary. The 
recommendation will be sent to the Department for consideration. 
 
Testosterone Products: The Commission reviewed the prior authorization 
criteria as follows: 
Prior authorization is required for testosterone products.  Payment will be 
considered with documentation of a specific testicular or hypothalamic/pituitary 
disease (primary hypogonadism or hypogonadotropic hypogonadism) that results 
in classic hypogonadism. Requests for FDA approved indications other than 
hypogonadism will not be subject to prior authorization criteria with adequate 
documentation of diagnosis. Payment for non-preferred testosterone products will 
be authorized only for cases in which there is documentation of previous trials 
and therapy failures with two preferred agents. Requests for erectile dysfunction, 
infertility, and age-related hypogonadism will not be considered.  Payment will be 
considered under the following conditions: 
1. Patient is male and 18 years of age or older (or 12 years of age and older for 
testosterone cypionate); and 
2. Patient has two (2) morning pre-treatment testosterone levels below the lower 
limit of the normal testosterone reference range of the individual laboratory 
used (Please attach lab results); and 
3. Patient has primary hypogonadism or hypogonadotropic hypogonadism 
(further defined below): 
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 Primary hypogonadism (congenital or acquired) caused by testicular 
failure due to one of the following: 
o Cryptorchidism 
o Bilateral torsion 
o Orchitis 
o Vanishing testes syndrome, 
o Orchiectomy 
o Klinefelter’s syndrome, 
o Chemotherapy 
o Toxic damage from alcohol or heavy metals 
 Hypogonadotropic hypogonadism  
o Idiopathic gonadotropin or lutenizing hormone-releasing (LHRH) 
deficiency 
o Pituitary-hypothalamic injury from tumors, trauma, or radiation 
4. Patient does not have: 
 Breast or prostate cancer 
 Palpable prostate nodule or prostate-specific antigen (PSA) > 4ng/mL 
 Hematocrit > 50% 
 Untreated severe obstructive sleep apnea 
 Severe lower urinary tract symptoms 
 Uncontrolled or poorly controlled heart failure 
 
Requests for continuation of therapy will require the following: 
1. An updated testosterone level (Please attach lab result); and 
2. Documentation the patient has not experienced a hematocrit > 54% or an 
increase in PSA > 1.4ng/mL in the past 12 months. 
 
The required trials may be overridden when documented evidence is provided 
that use of these agents would be medically contraindicated. 
 
As this was the second review of these criteria, no motion was necessary. The 
recommendation will be sent to the Department for consideration. 
 
Apremilast (Otezla): The Commission reviewed the prior authorization criteria 
as follows: 
Prior authorization is required for apremilast (Otezla®). Payment will be 
considered under the following conditions: 
1. Patient is 18 years of age or older; and  
2. Patient has a diagnosis of active psoriatic arthritis (≥ 3 swollen joints and ≥ 3 
tender joints) or  
3. Patient has a diagnosis of moderate to severe plaque psoriasis; and  
4. Prescribed by a rheumatologist or a dermatologist; and  
5. Patient does not have severe renal impairment (CrCl < 30mL/min). 
 
Psoriatic Arthritis 
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 Patient has documentation of a trial and inadequate response to therapy with 
the preferred oral DMARD, methotrexate (leflunomide or sulfasalazine may 
be used if methotrexate is contraindicated); and 
 Patient has documentation of trials and therapy failures with two preferred 
biological agents used for psoriatic arthritis.  
 
Plaque Psoriasis 
 Patient has documentation of a trial and inadequate response to 
phototherapy, systemic retinoids, methotrexate, or cyclosporine; and 
 Patient has documentation of trials and therapy failures with two preferred 
biological agents. 
The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
 
As this was the second review of these criteria, no motion was necessary. The 
recommendation will be sent to the Department for consideration. 
 
Miscellaneous 
 
DUR Digest: The Commission members reviewed the draft for DUR Digest 
Volume 27, Number 3.   
 
MedWatch: The Commission members received FDA announcements 
concerning new Black Box Warnings. 
A unanimous roll call vote was made at 12:46 to adjourn the meeting and move 
to closed session (motion by Kellen Ludvigson, second by Brian Couse and Larry 
Ambroson simultaneously). 
The next meeting will be held at 9:30 a.m. on Wednesday, June 3, 2015, at 
the Learning Resource Center in West Des Moines. 
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Iowa Medicaid Drug Utilization Review Commission 
Meeting Minutes June 3, 2015 
Attendees: 
Commission Members 
Mark Graber, M.D., FACEP; Laurie Pestel, Pharm.D.; Gregory Barclay, M.D.; 
Jason Wilbur, M.D.: Kellen Ludvigson, Pharm.D.; Brett Faine, Pharm.D.; Brian 
Couse, M.D.; and Susan Parker, Pharm.D. 
 
Staff 
Pam Smith, R.Ph.  
 
Guests 
Jason Kessler, M.D., IME; Erin Halverson, R.Ph., IME; Megan Smith, Pharm.D., 
IME; Tina Valentino, Pharm.D., IME; and Melissa Biddle, IME. 
 
 
Welcome & Introductions 
Mark Graber called the meeting to order at 9:34 a.m. at the Learning Resource 
Center in West Des Moines.  The minutes from the April 1, 2015 meeting were 
reviewed.  Jason Wilbur motioned to accept them, and Gregory Barclay 
seconded.  All members were in favor.  The recommendation letter sent to DHS 
after the last meeting was also reviewed, along with a recommendation from the 
P&T Committee requesting that the DUR Commission develop prior authorization 
criteria for Esbriet, Ofev, Lynparza, and Savaysa.  The results of an OIG study 
conducted for second-generation antipsychotic use among Medicaid-enrolled 
children were also provided, available at http://oig.hhs.gov/oei/reports/oei-07-12-
00320.asp. 
 
IME Updates 
There have been some changes to the wellness exam portion of the Iowa Health 
and Wellness Plan (IHAWP).  Eleven (11) bids were submitted in response to the 
Medicaid Modernization managed care Request for Proposal (RFP).  Awards are 
expected to be announced on or around August 7, 2015, with implementation still 
slated for January 1, 2016.  Mikki Stier, formerly the Vice President of 
Government and External Relations at Broadlawns Medical Center, is the new 
Iowa Medicaid Director.  CMS just released a 201-page document with proposed 
changes for managed care guidelines as relating to Medicaid; comments can be 
submitted online and must be received no later than July 27, 2015.  Megan Smith 
has resigned her position as Clinical Pharmacy Manager, and this will be her last 
meeting.  Tina Valentino provided a quarterly report on the new Complex 
Pharmaceutical Oversight Program (CPOP), which brought $287,747 in direct 
cost avoidance savings (State and Federal dollars extrapolated to the end of the 
state fiscal year) from 12 interventions in its first quarter of operation.  There 
have already been an additional 30 interventions in the second quarter.  
Members on Hepatitis C treatments are being closely monitored by CPOP, and 
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there are currently 55 of them, with 14 having completed therapy since January.  
Pam Smith presented Dr. Barclay with a letter and certificate signed by the 
Medicaid Director in thanks for his four years service, and this will be his last 
meeting.  
 
Prevalence Report Summary 
Statistics from March through April 2015 were discussed, including: cost per user 
($331.81), number of total prescriptions dispensed (an increase of 10.0% 
compared to the previous reporting period), average cost per prescription 
($66.90), and generic utilization (84.8%).  The total paid amount increased by 
13.3% from the previous reporting period.  There were 211,678 unique users, 
which is 4.4% more than the total for January and February.  Lists of the top 20 
therapeutic classes were provided.  SSRIs had the highest prescription count, 
and Anticonvulsants came in second.  The Hepatitis C category is quickly rising 
up the top therapeutic classes by paid amount report, currently in eleventh place 
with $1,781,823 in expenditures, an increase of 108.7% from the previous 
reporting period.  The top 100 drugs were also reviewed.  The ten most 
expensive medications were: Abilify, methylphenidate hcl er, Vyvanse, Lantus, 
Focalin XR, Advate, Strattera, Harvoni, Advair Diskus, and Spiriva Handihaler.  
Kellen Ludvigson asked about the top drugs for a non-Medicaid population, and 
Pam Smith will look for information prior to the next meeting. 
 
Case Studies 
Pam Smith presented four case studies.  Recommendations by Commissioners 
from these four examples resulted in annualized total savings of $4,925.40 pre-
rebate (state and federal).   
 
Public Comment 
 
Name Representing Drug/Topic 
Elizabeth Potente Avanir Nuedexta 
Paul McCray University of Iowa Pediatrics, Pulmonary Division ivacaftor 
 
Mental Health Advisory Group Update 
 
ProDUR Edits on Antipsychotics in Children: At their May 8, 2015 meeting, 
the MHAG re-reviewed the recommendations originally made in 2012 and 
recently approved for implementation by DHS.  Pam Smith shared the concerns 
of the MHAG, which included: 1.)Dr. Augspurger wanted his objection noted 
again that chlorpromazine is FDA approved to be dosed down to six months of 
age and haloperidol is FDA approved to be dosed down to three years of age, 
which are outside of the proposed ProDUR age edits. The DUR Commission was 
made aware of his objection, but decided to proceed with the edits as initially 
recommended as they felt it is important to track members that young on 
antipsychotics.  2.) The MHAG is concerned the ProDUR edits will delay 
discharge of admitted patients due to PA requirements.  Everyone was reminded 
there is a 24 hour turnaround time for PA once received and pharmacies have 
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the option to process a three day emergency supply.  The DUR recommended 
proceeding with the original recommendations.  An age edit will be applied on 
risperidone for members less than five years of age and an age edit on all other 
antipsychotics for members less than six years of age.  Additionally, edits will be 
put into place to prevent duplicate therapy for members less than 18 years of age 
initially, with the same edit to be applied to members 18 and older in the second 
phase of implementation, at a time to be determined at a later date.   
 
Proposed ProDUR Edits on CNS Stimulants: After discussion and feedback 
from the Iowa Psychiatric Society at the April DUR meeting, the DUR 
Commission decided to refer this topic to the Mental Health Advisory Group 
(MHAG) again prior to implementation.  The MHAG met in May and felt that the 
quantity limit for Concerta 54mg should remain at 60 for 30 days as literature 
exists to support dosing at 108mg per day, and there are children weighing 80-90 
kilograms that require a higher dose.  The DUR Commission agreed 
unanimously with this change (motion by Kellen Ludvigson, second by Brian 
Couse.)  Current recommendations are as follows: 
 
Drug Proposed Quantity Limit 
Per 30 Days 
Current Quantity Limit 
Per 30 Days 
Adderall 12.5mg tablet 90 120 
Adderall 20mg tablet 90 120 
Concerta 18mg tablet 30 60 
Concerta 27mg tablet 30 60 
Concerta 54mg tablet 60 60 
Focalin IR tablet (all 
strengths) 
60 None 
Focalin XR 5mg 30 60 
Focalin XR 10mg 30 60 
Focalin XR 15mg 30 90 
Focalin XR 20mg 30 60 
Focalin XR 25mg 30 60 
Focalin XR 30mg 30 60 
Ritalin IR (all strengths) 90 None 
 
Focus Studies 
 
Prasugrel Contraindications: This was a follow-up discussion.  Two of the six 
members identified changed therapy, for an annualized cost savings of 
$1,194.92 (state and federal, pre-rebate) as a result of the 14 surveys sent out to 
prescribers and pharmacies.  Six (42.86%) of those surveys were returned. 
 
Eszopiclone Dose: This was a follow-up discussion.  Thirty-one of the 52 
members identified changed therapy, for an annualized cost savings of 
$48,667.64 (state and federal, pre-rebate) as a result of the 105 surveys sent out 
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to prescribers and pharmacies.  Thirty-seven (35.24%) of those surveys were 
returned. 
Second Generation Antipsychotics with Anticholinergics: One letter will be 
sent, asking if the member has experienced EPS, pointing out being on more 
than one Second Generation Antipsychotic (SGA) increases the risk of EPS.  
Providers will be asked the following: if the SGA could be discontinued (if multiple 
SGAs) or the dose decreased; and/or if the anticholinergic could be discontinued 
if patient has not experience EPS in the past.  Dr. Graber asked that members on 
multiple anticholinergics also be evaluated in the future. 
 
Metoclopramide Utilization Greater than 12 Weeks: Gastroparesis and 
chemotherapy regimens will be removed from the results.  Data will be rerun and 
brought back to the Commission at the next meeting prior to further action. 
 
Public Comment 
 
Name Representing Drug/Topic 
Nancy Bell Pfizer Chronic Pain PA Criteria 
Ketul Patel Vertex Kalydeco 
 
 
Prior Authorization 
 
Topical Antifungals for Onychomycosis: The Commission reviewed the prior 
authorization criteria as follows: 
Jublia (efinaconazole) and Kerydin (tavaborole) will be considered for up to 48-
weeks treatment in patients when the following criteria are met: 
1. Patient has a diagnosis of onychomycosis of the toenail(s) confirmed by a 
positive potassium hydroxide (KOH) preparation, fungal culture, or nail 
biopsy (attach results) without dermatophytomas or lunula (matrix) 
involvement; and 
2. Patient is 18 years of age or older; and  
3. Patient has documentation of a trial and therapy failure or intolerance to oral 
terbinafine; and 
4. Patient has documentation of a trial and therapy failure or intolerance to 
ciclopirox 8% topical solution. 
 
The required trials may be overridden when documented evidence is provided 
that use of these agents would be medically contraindicated. 
 
The Commission would like to add language clarifying that this must be used for 
medical purposes, such as pain, diabetes, or other certain comorbidities, rather 
than aesthetics, and only allow 1 course of treatment with recurrence not 
covered.  Pam Smith will revise the wording and bring it back to the next 
meeting. 
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Topical Corticosteroids: The Commission reviewed the prior authorization 
criteria as follows: 
Prior authorization is required for non-preferred topical corticosteroids.  
Payment will be considered for patients when there is documentation of adequate 
trials and therapy failures with at least two preferred, chemically distinct, topical 
corticosteroid agents within the same potency class or a higher potency class in 
the past 12 months.  The required trials may be overridden when documented 
evidence is provided that the use of these agents would be medically 
contraindicated. 
 
Agents will be separated by potency on the PDL as requested.  Jason Wilbur 
motioned to accept the criteria, and Brett Faine seconded.  All members were in 
favor.  The recommended PA criteria will be sent to the medical/pharmacy 
associations for comment and brought back to the next DUR meeting. 
 
Ivacaftor (Kalydeco): The Commission reviewed the prior authorization criteria 
as follows: 
Prior authorization is required for Kalydeco™ (ivacaftor). Payment will be 
considered for patients when the following criteria are met:  
1. Patient is 2 years of age or older; and  
2. Has a diagnosis of cystic fibrosis with one of the following mutations in the 
CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, 
S549N, S549R, and R117H  as detected by a FDA-cleared CF mutation test; 
and  
3. Prescriber is a CF specialist or pulmonologist; and  
4. Baseline  liver function tests (AST/ALT) and FEV1, if age appropriate, are 
provided; and  
5. Patient does not have one of the following infections: Burkholderia 
cenocepacia, Burkholderia dolosa, or Mycobacterium abcessus.  
 
If the criteria for coverage are met, an initial authorization will be given for 3 
months.  Additional approvals will be granted for 6 months at a time if the 
following criteria are met: 
1. Adherence to ivacaftor therapy is confirmed; and 
2. Response to therapy is documented by prescriber (e.g., improved FEV1 from 
baseline, weight increased from baseline, decreased exacerbations and/or 
improved quality of life or rationale for continued care); and 
3. Liver function tests (AST/ALT) are assessed every 3 months during the first 
year of treatment an annually thereafter. 
 
Jason Wilbur motioned to accept the criteria as modified, and Brett Faine 
seconded.  All members were in favor. The recommended PA criteria will be sent 
to the medical/pharmacy associations for comment and brought back to the next 
DUR meeting. 
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Olaparib (Lynparza): This topic was put aside as it will be included on the 
Oncology Agents PA form that is currently in progress. 
 
Idiopathic Pulmonary Fibrosis: The Commission reviewed the prior 
authorization criteria as follows: 
Prior authorization is required for pirfenidone (Esbriet
®
) and nintedanib (Ofev
®
). 
Dosing outside of the FDA approved dosing will not be considered.  Concomitant 
use of pirfenidone and nintedanib will not be considered.  Payment will be 
considered for patients when the following criteria are met:  
1. Patient is 40 years of age or older; and  
2. Is prescribed by a pulmonologist; and 
3. Patient has a diagnosis of idiopathic pulmonary fibrosis as confirmed by 
one of the following (attach documentation): 
a) Findings on high-resolution computed tomography (HRCT) indicating 
usual interstitial pneumonia (UIP); or 
b) A surgical lung biopsy demonstrating usual interstitial pneumonia 
(UIP); and 
4. Prescriber has excluded other known causes of interstitial lung disease 
(ILD) such as domestic and occupational environmental exposures, 
connective tissue disease, and drug toxicity; and  
5. Patient has documentation of pulmonary function tests within the prior 60 
days with a forced vital capacity (FVC) ≥50% predicted; and 
6. Patient has a carbon monoxide diffusion capacity (%DLco) of ≥30% 
predicted; and 
7. Patient does not have hepatic impairment as defined below: 
a) Nintedanib - Patient does not have moderate or severe hepatic 
impairment (Child Pugh B or C)  or  
b) Pifenidone - Patient does not have severe hepatic impairment (Child 
Pugh C); and 
8. Patient does not have renal impairment as defined below: 
a) Nintedanib - Patient does not have severe renal impairment (CrCl 
<30ml/min) or end-stage renal disease or  
b) Pirfenidone – Patient does not have end-stage renal disease requiring 
dialysis; and 
9. Patient is a nonsmoker or has been abstinent from smoking for at least six 
weeks. 
 
If the criteria for coverage are met, initial requests will be given for 6 months.  
Additional authorizations will be considered at 6 month intervals when the 
following criteria are met: 
a) Adherence to pirfenidone (Esbriet®) and nintedanib (Ofev®) is confirmed; 
and 
b) Patient is tolerating treatment defined as improvement or maintenance of 
disease (<10% decline in percent predicted FVC or < 200 mL decrease in 
FVC); and 
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c) Documentation is provided that the patient has remained tobacco-free; 
and 
d) Patient is tolerating treatment; and ALT, AST, and bilirubin are assessed 
periodically during therapy. 
 
Brett Faine motioned to accept the criteria as modified, and Kellen Ludvigson 
seconded.  All members were in favor. The recommended PA criteria will be sent 
to the medical/pharmacy associations for comment and brought back to the next 
DUR meeting. 
 
Edoxaban (Savaysa): The Commission reviewed the prior authorization criteria 
as follows: 
Prior authorization is required for edoxaban (Savaysa
®
).  Payment will be 
considered for patients when the following criteria are met:  
 
1. Patient does not have a mechanical heart valve; and 
2. Patient does not have moderate to severe mitral stenosis; and 
3. Patient does not have active pathological bleeding; and  
4. A recent creatinine clearance (CrCl) is provided and is within specified range 
listed below; and 
5. Patient does not have moderate or severe hepatic impairment (Child-Pugh B 
or C). 
6. Patient has documentation of a previous trial and therapy failure with 
apixaban or rivaroxaban, where applicable. 
 
Atrial Fibrillation 
1. Patient has documentation of a diagnosis of non-valvular atrial fibrillation; 
with 
2. Documentation of a previous trial and therapy failure with warfarin (TIA, 
stroke, or inability to maintain a therapeutic INR with a minimum 6 month 
trial); and 
3. Presence of at least one additional risk factor for stroke, with a CHADS2 
score ≥1; and 
4. Patient does not have a creatinine clearance (CrCl) > 95 mL/min. 
5. Requests will be considered for the following dosing: 
a) 60mg once daily in patients with a CrCl of > 50 mL/min to ≤ 95 
mL/min; or 
b) 30mg once daily in patients with a CrCl of 15 to 50 mL/min 
 
Treatment of Deep Vein Thrombosis or Pulmonary Embolism 
1. Patient has documentation of a current deep vein thrombosis or pulmonary 
embolism; with 
2. Documentation of a previous trial and therapy failure with warfarin (TIA, 
stroke, or inability to maintain a therapeutic INR with a minimum 6 month 
trial); with  
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3. Documentation patient has had 5 to 10 days of initial therapy with a 
parenteral anticoagulant (low molecular weight heparin or unfractionated 
heparin). 
4. Requests will be considered for the following dosing: 
a. 60mg once daily; or 
b. 30mg once daily in patients with any of the following: 
i. CrCl 15 mL/min to 50 mL/min 
ii. Body weight ≤60 kg 
 
The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
 
Brett Faine motioned to accept the criteria as modified, and Jason Wilbur 
seconded.  All members were in favor.  The recommended PA criteria will be 
sent to the medical/pharmacy associations for comment and brought back to the 
next DUR meeting.  The P&T Committee will also be reviewing the NOACs at a 
future meeting, so there may be additional recommended changes in the up 
coming months. 
 
Oral Oncology Agents: The Commission reviewed the prior authorization 
criteria as follows: 
Prior authorization is required for oral oncology agents.  FDA approved labeling 
will be followed.  The following must be submitted with the prior authorization 
request:  copies of medical records (i.e. diagnostic evaluations and recent chart 
notes), the original prescription, and the most recent copies of related laboratory 
results.  If criteria for coverage are met, authorizations will be given at three (3) 
month intervals.  Updates on disease progression must be provided with each 
renewal request.  If disease progression is noted, therapy will not be continued. 
 
Brian Couse motioned to accept the criteria, and Brett Faine seconded.  All 
members were in favor. The recommended PA criteria will be sent to the 
medical/pharmacy associations for comment and brought back to the next DUR 
meeting. 
 
Hepatitis C Agents: The Commission reviewed the prior authorization criteria as 
follows: 
Prior authorization is required for hepatitis C treatments.   Requests for non-
preferred agents may be considered when documented evidence is provided that 
the use of the preferred agents would be medically contraindicated.  Payment will 
be considered under the following conditions: 
1. Patient is 18 years of age or older and has a diagnosis of chronic hepatitis C; 
and 
2. Patient has had testing for hepatitis C virus (HCV) genotype; and 
3. Patient has an active HCV infection verified by a detectable viral load within 
12 months of starting treatment; and 
4. Viral load will be submitted by prescriber 12 weeks after completion of 
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therapy; and 
5. Patient has advanced liver disease corresponding to a Metavir score of 3 or 
greater fibrosis as confirmed by one of the following: 
o Liver biopsy confirming a Metavir score ≥ F3; or   
o Transient elastography (FibroScan) score ≥ 9.5kPa; or  
o FibroSURE (FibroTest) score ≥ 0.58; or 
o APRI score > 1.5; or 
o Radiological imaging consistent with cirrhosis (i.e. evidence of portal 
hypertension); or 
o Physical findings or clinical evidence consistent with cirrhosis; or 
o Patients at highest risk for severe complications: organ transplant, 
type 2 or 3 essential mixed cryoglobulinemia with end-organ 
manifestations (e.g. vasculitis), proteinuria, nephrotic syndrome, or 
membranoproliferative glomerulonephritis. 
6. Patient’s prior treatment history is provided (treatment naïve or treatment 
experienced); and 
7. If patient has a history of non-compliance, documentation that steps have 
been taken to correct or address the causes of non-compliance are provided; 
and  
8. Patient has abstained from the use of illicit drugs and alcohol for a minimum 
of three (3) months as evidenced by a negative urine confirmation test; and 
9. Patient does not have severe renal impairment (creatinine clearance 
<30ml/min) or end stage renal disease requiring hemodialysis; and  
10. HCV treatment is prescribed by a digestive disease, liver disease, or 
infectious disease provider practice; and 
11. For patients on a regimen containing ribavirin, the following must be 
documented on the PA form: 
a) Patient is not a pregnant female or a male with a pregnant female 
partner; and 
b) Women of childbearing potential and their male partners must use two 
forms of effective contraception during treatment and for at least 6 
months after treatment has concluded; and 
c) Monthly pregnancy tests will be performed during treatment; and 
12. Prescriber has reviewed the patient’s current medication list and 
acknowledged that there are no significant drug interactions with the HCV 
medication. 
13. Documentation is provided for patients who are ineligible to receive 
interferon or ribavirin. 
14. Non-FDA approved or non-compendia indicated combination therapy 
regimens will not be approved. 
15. If patient is recently eligible for Iowa Medicaid, and has been started and 
stabilized on therapy while covered under a different plan, documentation of 
how long the patient has been on medication will be required.  Patient will be 
eligible for the remainder of therapy needed, based on established length of 
therapy for the particular treatment (defined below). 
16. Lost or stolen medication replacement requests will not be authorized. 
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17. The 72-hour emergency supply rule does not apply to oral hepatitis C 
antiviral agents. 
 
As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be sent to the Department for consideration. 
 
CNS Stimulants and Atomoxetine: The Commission reviewed the prior 
authorization criteria as follows: 
Prior authorization (PA) is required for CNS stimulants and Atomoxetine for 
patients 21 years of age or older.  Prior to requesting prior authorization for any 
covered diagnosis, the prescriber must review the patient’s use of controlled 
substances on the Iowa Prescription Monitoring Program website at 
https://pmp.iowa.gov/IAPMPWebCenter/.   Payment for CNS stimulants and 
Atomoxetine will be considered under the following conditions: 
1. Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity 
Disorder (ADHD) meeting the DSM-5 criteria and confirmed by a 
standardized rating scale (such as Conners, Vanderbilt, Brown, SNAP-
IV).  Symptoms must have been present before twelve (12) years of age 
and there must be clear evidence of clinically significant impairment in 
two or more current environments (social, academic, or occupational).  
Documentation of a recent clinical visit that confirms the patient continues 
to require medication to treat the symptoms of ADD/ADHD will be 
required for renewals or patients newly eligible that are established on 
medication to treat ADD/ADHD. 
2. Narcolepsy with diagnosis confirmed with a recent sleep study (ESS, 
MSLT, PSG). 
3. Excessive sleepiness from obstructive sleep apnea/hypopnea syndrome 
(OSAHS) with documentation of non-pharmacological therapies tried 
(weight loss, position therapy, CPAP at maximum titration, BiPAP at 
maximum titration or surgery) and results from a recent sleep study (ESS, 
MSLT, PSG) with the diagnosis confirmed by a sleep specialist. 
4. Binge Eating Disorder (Vyvanse only)  
 Patient is 18 to 55 years of age; and 
 Patient meets the DSM-5 criteria for Binge Eating Disorder; and  
 Patient has documentation of moderate to severe BED, as defined by 
the number of binge eating episodes per week (number of episodes 
must be reported); and 
 Patient has documentation of non-pharmacologic therapies tried, such 
as cognitive-behavioral therapy or interpersonal therapy, for a recent 
3 month period, that did not significantly reduce the number of binge 
eating episodes; and  
 Patient has documentation of an adequate trial and therapy failure at 
a therapeutic dose with topiramate and fluvoxamine 
 Prescription is written by a psychiatrist or psychiatric nurse 
practitioner; and 
 Patient has a BMI of 25 to 45; and 
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 Patient does not have a personal history of cardiovascular disease; 
and 
 Patient has no history of substance abuse; and 
 Is not being prescribed for the treatment of obesity or weight loss; and 
 Doses above 70mg per day will not be considered. 
 Initial requests will be approved for 12 weeks. 
 Requests for renewal must include documentation of a change from 
baseline at week 12 in the number of binge days per week. 
 
DSM-5 Criteria 
i. Recurrent episodes of binge eating, including eating an 
abnormally large amount of food in a discrete period of time and 
has a feeling of lack of control over eating; and 
ii. The binge eating episodes are marked by at least three of the 
following: 
1. Eating more rapidly than normal 
2. Eating until feeling uncomfortably full 
3. Eating large amounts of food when not feeling physically 
hungry 
4. Eating alone because of embarrassment by the amount of 
food consumed 
5. Feeling disgusted with oneself, depressed, or guilty after 
overeating; and 
iii. Episodes occur at least 1 day a week for at least 3 months; and 
iv. No regular use of inappropriate compensatory behaviors (e.g. 
purging, fasting, or excessive exercise) as are seen in bulimia 
nervosa; and  
v. Does not occur solely during the course of bulimia nervosa or 
anorexia nervosa. 
 
Moderate to Severe BED 
Based on the number of binge eating episodes per week:   
Moderate - 4 to 7  
Severe – 8 to 13 
Extreme – 14 or more 
 
Payment for a non-preferred agent will be authorized only for cases in which 
there is documentation of a previous trial and therapy failure with a preferred 
agent. *If a non-preferred long-acting medication is requested, a trial with the 
preferred immediate release and extended release product of the same chemical 
entity (methylphenidate class) or chemically related agent (amphetamine class) is 
required. 
 
The required trials may be overridden when documented evidence is provided 
that the use of these agents would be medically contraindicated. 
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As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be sent to the Department for consideration. 
 
Dextromethorphan/Quinidine (Nuedexta): The Commission reviewed the prior 
authorization criteria as follows: 
Prior authorization is required for Nuedexta
®
. Payment will be considered under 
the following conditions: 
1. Patients must have a diagnosis of pseudobulbar affect (PBA) secondary to a 
neurological condition. 
2. A trial and therapy failure at a therapeutic dose with amitriptyline or an 
SSRI; and 
3. Patient has documentation of a current EKG (within the past 3 months) 
without QT prolongation. 
4. Initial authorizations will be approved for 12 weeks with a baseline Center for 
Neurologic Studies Lability Scale (CNS-LS) questionnaire.  
5. Subsequent prior authorizations will be considered at 6 month intervals with 
documented efficacy as seen in an improvement in the CNS-LS questionnaire. 
 
The required trials may be overridden when documented evidence is provided 
that use of these agents would be medically contraindicated. 
 
As this was the second review of these criteria, no motion was necessary.  The 
recommendation will be sent to the Department for consideration. 
 
Chronic Pain Syndromes: The Commission reviewed the prior authorization 
criteria as follows: 
A prior authorization is required for pregabalin (Lyrica
®
) and milnacipran 
(Savella
™
).  These drugs will be considered for their FDA indication(s) and other 
conditions as listed in the compendia.  For patients with a chronic pain diagnosis 
who are currently taking opioids, as seen in pharmacy claims, a plan to decrease 
and/or discontinue the opioid(s) must be provided with the initial request.  Initial 
authorization will be given for three (3) months.  There must be a significant 
decrease in opioid use or discontinuation of opioid(s) after the initial three (3) 
month authorization for further approval consideration.  Additional prior 
authorizations will be considered with documentation of a continued decrease in 
opioid utilization.  Payment will be considered under the following conditions: 
1. A diagnosis of fibromyalgia (Lyrica® and Savella™)  
a. A trial and therapy failure at a therapeutic dose with gabapentin plus one 
of the following preferred generic agents: tricyclic antidepressant or  
SNRI, WITH 
b. Documented non-pharmacologic therapies (cognitive behavior therapies, 
exercise, etc.).  
2. A diagnosis of postherpetic neuralgia (Lyrica®) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of 
the following: tricyclic antidepressant, topical lidocaine, or valproate. 
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3.  A diagnosis of diabetic peripheral neuropathy (Lyrica
®
) 
A trial and therapy failure at a therapeutic dose with gabapentin plus one of 
the following: tricyclic antidepressant, duloxetine or topical lidocaine. 
4.  A diagnosis of partial onset seizures, as adjunct therapy (Lyrica
®
) 
Requests for doses above the manufacturer recommended dose will not be 
considered.   
As this was the second review of these criteria, no motion was necessary.  
However, the Commission wanted to remove the SSRI trial for a fibromyalgia 
diagnosis.  Brett Faine motioned to accept this modification, and Brian Couse 
seconded.  All members were in favor. The recommendation will be sent to the 
Department for consideration. 
 
Sedative/Hypnotics – Non-Benzodiazepines: The Commission reviewed the 
prior authorization criteria as follows: 
Preferred agents are available without prior authorization (PA). Requests for 
doses above the manufacturer recommended dose will not be considered.  Prior 
authorization is required for all non-preferred non-benzodiazepine 
sedative/hypnotics. Payment for non-preferred non-benzodiazepine 
sedative/hypnotics will be authorized only for cases in which there is 
documentation of previous trials and therapy failures with, at a minimum, three 
(3) preferred agents. Payment for non-preferred non-benzodiazepine 
sedative/hypnotics will be considered when the following criteria are met: 
1. A diagnosis of insomnia; and 
2. Medications with a side effect of insomnia (i.e. stimulants) are decreased 
in dose, changed to a short acting product, and/or discontinued; and 
3. Enforcement of good sleep hygiene is documented; and 
4. All medical, neurological, and psychiatric disease states causing chronic 
insomnia are being adequately treated with appropriate medication at 
therapeutic doses. 
5. In addition to the above criteria, requests for suvorexant (Belsomra) will 
require documentation of a trial and therapy failure with at least one non-
preferred agent, other than suvorexant, prior to consideration of 
coverage. 
6. Non-preferred alternative delivery systems will only be considered for 
cases in which the use of the alternative delivery system is medically 
necessary and there is a previous trial and therapy failure with a 
preferred alternative delivery system if available. 
 
The required trials may be overridden when documented evidence is provided 
that use of these agents would be medically contraindicated. 
 
As this was the second review of these criteria, no motion was necessary. The 
recommendation will be sent to the Department for consideration. 
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Miscellaneous 
 
DUR Digest: The Commission members reviewed the draft for DUR Digest 
Volume 27, Number 3.  This was the second review of the DUR Digest and will 
be posted to the website. 
 
MedWatch: The Commission members received FDA announcements 
concerning new Black Box Warnings. 
A unanimous roll call vote was made at 11:42 to adjourn the meeting and move 
to closed session (motion by Jason Wilbur). 
The next meeting will be held at 9:30 a.m. on Wednesday, August 5, 2015, 
at the Learning Resource Center in West Des Moines. 
Appendix M 
Mental Health Advisory Group 
Mental Health Advisory Group 
 
The Iowa Medicaid Drug Utilization Review Mental Health Advisory Group 
(MHAG), formerly know as the Mental Health Work Group, was established in 
SFY08.  It is currently comprised of two members of the Drug Utilization Review 
Commission (psychiatrist and pharmacist), several pediatric and adolescent 
psychiatrists, an adult psychiatrist, a psychiatric pharmacist, a pediatrician and a 
psychiatrist from Magellan Health Services. 
 
The Mental Health Advisory Group is a separate entity from the Iowa Medicaid 
Drug Utilization Review (DUR) Commission.  All recommendations from the 
MHAG must be approved by the DUR Commission before they can be 
implemented. 
 
The original goal of the MHWG was to address issues that developed specific to 
the pediatric and adolescent psychiatrists within the State of Iowa when mental 
health drug consolidation edits were implemented in October, 2007.  Since then, 
the DUR Commission has made the decision to refer other mental health issues 
that impact the entire mental health population of Iowa Medicaid, regardless of 
the members’ age. 
 
The MHAG met twice in SFY15.  The minutes from the October 2014 and May 
2015 meetings have been included. 
Iowa Medicaid DUR Mental Health Advisory Group 
 Meeting Minutes October 10, 2014 
Attendees: 
Commission Members 
Terry Augspurger, M.D.; Charles Wadle, D.O.; Samuel Kuperman, M.D.; Kellen 
Ludvigson, Pharm.D.; and Gregory Barclay, M.D. 
 
Staff 
Pam Smith, R.Ph.  
 
Guests 
Susan Parker, Pharm.D., DHS; Erin Halverson, R.Ph., IME, and Melissa Biddle, IME. 
 
 
Welcome & Introductions 
Pam Smith called the meeting to order at 8:05 a.m. at the Iowa Medicaid Enterprise. All 
members joined via telephone, except for Dr. Wadle, who attended the meeting in 
person. 
The minutes from the October 18, 2013 meeting were approved.  (Motion by Dr. Wadle, 
second by Dr. Barclay, unanimous approval by voice vote.)   
ProDUR Edits on Antipsychotics 
 
Background, Edits, Implementation: The DUR Commission, in consultation with the 
Medicaid Mental Health Advisory Group (MHAG), recommended the Department 
implement edits on antipsychotic medications in April 2012.  They recommended an age 
edit be applied on risperidone for members less than five years of age and an age edit 
on all other antipsychotics for members less than six years of age.  Additionally, edits 
would be put into place to prevent duplicate therapy for members less than 18 years of 
age initially, with the same edit to be applied to members 18 and older in the second 
phase of implementation, four to six months after the first.  If a claim denies for these 
edits, a prior authorization (PA) request would need to be submitted and approved in 
order for the claim to pay.  Prior to initiation of these edits, an informational letter will be 
sent to all providers, including discharge planners, to encourage changes to current 
drug regimen or submission of a PA prior to implementation of the edits and prior to 
discharge.  Soft edits will also be programmed into the Point of Sale (POS) system 
indicating the claim(s) will deny for a PA at the specific date indicated, which should 
prompt the pharmacy to notify the prescriber.  Additionally, the Iowa Medicaid 
Enterprise (IME) will produce a report of members impacted and notify those 
prescribers that their patients will be impacted by the change, along with specifics about 
the change and the proposed effective date.  Dr. Kuperman commented that 
chlorpromazine is FDA approved to be dosed down to 6 months of age and haloperidol 
is FDA approved to be dosed down to 3 years of age, which are outside of the proposed 
ProDUR age edits.   He also noted that it could take 3 to 6 months to taper a dose.  Dr. 
Kuperman also asked if requests would be excluded based on diagnosis.  When a claim 
denies for one of the ProDUR edits, a PA would be required, which will be subject to 
review of diagnosis.    
 
A suggestion was made to allow a one time 30 day grace period for tapering as there 
was concern prescribers may not submit a PA for cross tapering of medications due to 
time constraints.  The IME will research options for providing this allowance to 
providers. There was concern that IME PA pharmacists might not have psychotropic 
expertise; however, they do have resources to contact if necessary, and thorough 
documentation will help lessen the need for resubmissions.  Ultimately, staff are 
required to observe the Iowa rules.  Information regarding provider portal enrollment will 
be included in the informational letter, as prior authorizations can be submitted 
electronically through the provider portal now, and may help ease the burden of 
additional paperwork in submitting prior authorizations.  The MHAG members requested 
a copy of the informational letter regarding portal enrollment be emailed to them.  Dr. 
Kuperman said he hadn’t received any mail from the DUR Commission, and wondered 
if those items were getting lost along the way or how he should be receiving them.  Pam 
Smith will consult with Provider Services.  Dr. Wadle asked the committee members if 
they knew of any available information that would be helpful for PA staff to have when 
reviewing prior authorization requests.  A readable synopsis in a textbook called Green 
was suggested; Pam Smith will look into this after Dr. Kuperman sends her more 
specifics about it, and potentially get a copy for the IME to use as a reference.  Dr. 
Kuperman mentioned that Iowa ranks 48th among the States, based on percentage of 
population, in regards to the number of child psychiatric practitioners. Dr. Ludvigson 
noted this is exactly why edits like this need to be implemented. Due to the low number 
of specialty providers, family practitioners bare the responsibility of prescribing 
psychotropics and may lack the necessary training to do so. The MHAG members 
wondered how many family practice doctors, nurse practitioners, and physician 
assistants were writing prescriptions for antipsychotics, and if some educational 
outreach should be done.  They also thought it would be a good idea to ask an ARNP to 
sit on the Mental Health Advisory Group; they will send suggestions to Pam Smith. 
Magellan, as well as the University of Iowa offer hotlines for practitioners prescribing 
psychotropic medications. Dr. Wadle and Dr. Kuperman indicated it is not a widely used 
tool at this point in time. 
 
Frequently Asked Questions Document: A draft of a FAQ document, which will be 
attached to the upcoming informational letter, was provided.  It covered topics such as 
how the ProDUR edits work in the POS system, the prior authorization process, and 
which antipsychotic medications would require prior authorization due to the new 
ProDUR edits.  Chronic, concurrent use will be considered on a case by case basis, but 
should be avoided if possible.   
 
The meeting adjourned at 8:57 a.m. by unanimous decision.  The next meeting is 
tentatively scheduled for May 8, 2015 at the Iowa Medicaid Enterprise in Des 
Moines, IA, with another one tentatively scheduled for October 9, 2015.  
Iowa Medicaid DUR Mental Health Advisory Group 
 Meeting Minutes May 8, 2015 
Attendees: 
Commission Members 
Terry Augspurger, M.D.; Charles Wadle, D.O.; Samuel Kuperman, M.D.; Tami Argo, 
Pharm.D.; and Gregory Barclay. 
 
Staff 
Pam Smith, R.Ph.  
 
Guests 
Susan Parker, Pharm.D., DHS; Jeffrey Barkin, M.D., IME; Erin Halverson, R.Ph., IME, 
and Melissa Biddle, IME. 
 
 
Welcome & Introductions 
Pam Smith called the meeting to order at 8:05 a.m. at the Iowa Medicaid Enterprise.  
The minutes from the October 10, 2014 meeting were approved.  (Motion by Gregory 
Barclay, second by Charles Wadle, unanimous approval by voice vote.)   
ProDUR Edits on Antipsychotics 
 
Background, Edits, Implementation: At the October 10, 2014 Mental Health Advisory 
Group (MHAG) Meeting, the committee members re-reviewed the edits that the DUR 
Commission, in consultation with MHAG, had recommended be implemented on 
antipsychotic medications back in April 2012.  They recommended an age edit be 
applied on risperidone for members less than five years of age and an age edit on all 
other antipsychotics for members less than six years of age.  Additionally, edits would 
be put into place to prevent duplicate therapy for members less than 18 years of age 
initially, with the same edit to be applied to members 18 and older in the second phase 
of implementation.  If a claim denies for these edits, a prior authorization (PA) request 
would need to be submitted and approved in order for the claim to pay.  At the October 
MHAG Meeting, Dr. Augspurger had commented that chlorpromazine is FDA approved 
to be dosed down to 6 months of age and haloperidol is FDA approved to be dosed 
down to 3 years of age, which are outside of the proposed ProDUR age edits.   The 
DUR Commission was made aware of these concerns, but decided to proceed with the 
edits as initially recommended.  A one-time 30 day grace period for tapering will be 
provided through POS programming when these edits are implemented.  Prior to 
initiation of these edits, an informational letter will be sent to all providers, including 
discharge planners, to encourage changes to current drug regimens or submission of a 
PA prior to implementation of the edits and prior to discharge if needed.  IME is 
currently in the process of identifying providers that may be affected, with no set 
implementation date as of yet.  Dr. Kuperman was worried that the prior authorization 
process would delay discharge of admitted patients.  Dr. Augspurger asked that his 
objection to not allowing claims for chlorpromazine and haloperidol for their FDA 
approved age to pay without PA be put on record again (see above).  In response, Dr. 
Wadle commented that it appeared only 20 cases over 4 years would have been 
affected by the new edits.  Pam Smith mentioned that other states had also 
implemented edits for antipsychotic use in children, with many states being more 
restrictive that what has been recommended by the DUR.   
 
ProDUR Edits on Select CNS Stimulants 
The DUR Commission reviewed quantity limits for stimulants used in the treatment of 
Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy at the February 2015 
meeting, and they made recommendations to change or add quantity limits on select 
CNS stimulants.  Additionally, the DUR requested claims exceeding the proposed 
quantity limits be identified to determine the impact to members, providers, and the prior 
authorization department, which was reviewed at the April 2015 DUR meeting (see 
chart below reflecting claims from January 2015).  The DUR made the recommendation 
to refer the proposed quantity limits to the MHAG for their comment.  Several MHAG 
members felt that the limit of 30 tablets for 30 days on Concerta 54mg was too low as 
there are children weighing 80-90 kilograms that require a higher dose, and literature 
exists to support dosing at 108mg per day.  Dr. Kuperman shared a recent experience 
in obtaining a quantity limit override for amphetamine salt combo tablets.  It was 
stressed that providing ample information for the reviewing pharmacist is important 
when submitting quantity limit override requests. These concerns will be taken back to 
the DUR Commission for consideration. 
 
Drug (applies to 
brand and generic) 
Proposed 
QL 
N of Claims 
(age 0-20 
years 
N of Claims 
(age 21+ 
years)  
Current 
QL 
Adderall IR 12.5mg  90 2 0 120 
Adderall IR 20mg  90 10 22 120 
Concerta 18mg  30 21 0 60 
Concerta 27mg  30 12 0 60 
Concerta 54mg  30 115 7 60 
Focalin IR 2.5mg 60 6 1 None 
Focalin IR 5mg 60 50 1 None 
Focalin IR 10mg 60 75 2 None 
Focalin XR 5mg 30 16 0 60 
Focalin XR 10mg 30 35 0 60 
Focalin XR 15mg 30 34 0 90 
Focalin XR 20mg 30 63 0 60 
Focalin XR 25mg 30 30 0 60 
Focalin XR 30mg 30 79 0 60 
Ritalin IR 5mg 90 44 0 None 
Ritalin IR 10mg 90 62 20 None 
Ritalin IR 20mg 90 24 19 None 
 
CNS Stimulants and Atomoxetine Prior Authorization Criteria 
In January 2015, Vyvanse received FDA approval for the treatment of moderate to 
severe Binge Eating Disorder (BED), so the prior authorization criteria are being 
updated.  Changes include a requirement that the prescriber check the Iowa 
Prescription Monitoring website (PMP) for the patient’s use of controlled substances 
prior to requesting a prior authorization for any CNS stimulant or atomoxetine, which Dr. 
Kuperman felt might require significant time on the part of the prescriber for the more 
troubled patients.  He says PMP does send out email alerts that he’s already receiving.  
Dr. Barkin also suggested requiring a consult with someone who specializes in eating 
disorders, but there was concern that there aren’t enough inpatient programs in Iowa, 
and that all members would be referred to the University of Iowa and have to sit on a 
waitlist for a long period of time.  These concerns will also be relayed back to the DUR 
Commission. 
 
The meeting adjourned at 8:53 a.m. by unanimous decision.  The next meeting is 
tentatively scheduled for October 9, 2015 at the Iowa Medicaid Enterprise in Des 
Moines, IA.  
Appendix N 
Recommendations to the P&T 
 
P & T Recommendations 
SFY15 
 
The DUR Commission makes recommendations to the Iowa Medicaid 
Pharmaceutical & Therapeutics (P&T) Committee regarding the status of a 
medication on the Preferred Drug List (PDL) as issues arise.  During the time 
period for this report there were two recommendations made to the P&T 
Committee.     
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IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 
 100 Army Post Road – (515) 974-3131 -866-626-0216 
 
Brett Faine, Pharm.D. 
Larry Ambroson, R.Ph.  
Brian Couse, M.D.  
Mark Graber, M.D., FACEP   
Kellen Ludvigson, Pharm.D. 
Susan Parker, R.Ph., Pharm.D. 
Laurie Pestel, R.Ph., Pharm.D. 
Gregory Barclay, M.D. 
Jason Wilbur, M. D. 
 
Professional Staff:                               Pam Smith, R.Ph.     
        DUR Project Coordinator 
 
 
October 2, 2014 
 
 
Susan L. Parker, R.Ph., Pharm.D.  
Pharmacy Director 
Iowa Medicaid Enterprise  
100 Army Post Road  
Des Moines, Iowa 50315 
 
 
Dear Susan: 
 
At the request of the DUR Commission members, I am forwarding the following referral to the 
Pharmaceutical and Therapeutics (P&T) Committee members for further consideration. 
 
The DUR Commission reviewed clinical information regarding niacin at their October 1, 2014 
meeting.   
 
In 2011, the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low 
HDL/High Triglycerides: Impact on Global Health Outcomes) trial found niacin, added to a 
statin, failed to improve outcomes in patients with cardiovascular disease.  Recently, the 
results from another niacin trial, HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to 
Reduce the Incidence of Vascular Events), were released.  This study involved roughly 26,000 
patients with known vascular disease whose mean LDL and HDL cholesterol levels were 
64mg/dL and 44mg/dL, respectively, while taking simvastatin (40mg daily; some participates 
were also taking ezetimibe).  Patients received either 2g of extended-release niacin daily or 
placebo.  It should be noted, niacin was combined with laropiprant, a drug that reduces the 
incidence of niacin-related flushing.  Laropiprant does not have a cholesterol lowering effect.  
The results of this study found that niacin had lowered LDL cholesterol levels by a mean of 
10mg/dL and raised HDL cholesterol levels by a mean of 6mg/dL as compared to placebo.  
Yet, there was no difference between groups in incidence of major adverse cardiovascular 
events (13.2% vs. 13.7% respectively).  Niacin was associated with a slight increase in overall 
mortality (6.2% vs. 5.7%) and a greater risk for serious adverse events typically associated 
with this drug (e.g., gastrointestinal, musculoskeletal, and diabetes-related), as well as for 
infection and bleeding. 
 
According to the prescribing information for Niaspan, the following limitations of use are listed: 
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 No incremental benefit of Niaspan coadministered with simvastatin or lovastatin on 
cardiovascular morbidity and mortality over and above that demonstrated for niacin, 
simvastatin and lovastatin monotherapy, has been established. 
 Niaspan, at doses of 1,500-2,000 mg/day, in combination with simvastatin, did not 
reduce the incidence of cardiovascular events more than simvastatin in a randomized 
controlled trial of patients with cardiovascular disease and mean baseline LDL-C levels 
of 74mg/dL. 
 
Based on the findings from the aforementioned studies and limitations to use listed in the 
Niaspan label, the DUR Commission requests the P&T Committee consider making niacin 
products non-preferred on the Preferred Drug List (PDL), requiring documentation of an 
intolerance to, or failure with, a preferred statin at an optimized dose.   
 
Thank you in advance for consideration of moving niacin products to non-preferred status on 
the PDL. 
 
 
Sincerely,  
 
 
Pamela Smith, R.Ph.  
Drug Utilization Review Project Coordinator 
Iowa Medicaid Enterprise 
 
Cc:  Erin Halverson, R.Ph., IME 
 Megan Smith, R.Ph., Pharm.D., IME 
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February 16, 2015 
 
 
Susan L. Parker, R.Ph., Pharm.D.  
Pharmacy Director 
Iowa Medicaid Enterprise  
100 Army Post Road  
Des Moines, Iowa 50315 
 
 
Dear Susan: 
 
At the request of the DUR Commission members, I am forwarding the following referral to the 
Pharmaceutical and Therapeutics (P&T) Committee members for further consideration. 
 
The DUR Commission reviewed proposed Prior Authorization (PA) criteria for apixiban 
(Eliquis) at their February 4, 2015 meeting.  Currently, for the diagnosis of non-valvular atrial 
fibrillation or treatment and prevention of deep vein thrombosis (DVT) and pulmonary 
embolism (PE), criteria for apixiban and other Novel Oral Anticoagulants (NOACs) require 
documentation of a previous trial and therapy failure with warfarin (failure is defined as a 
previous TIA, stroke, or inability to maintain a therapeutic INR with a minimum 6 month trial).  
Several written comments from prescribers have been reviewed by the DUR Commission 
members, requesting the NOACs be available without requiring a failure on warfarin for 
treatment of non-valvular atrial fibrillation or treatment and prevention of DVT and PE.   
 
The DUR Commission respectfully requests the P&T Committee conduct an overall cost 
comparison of the NOACs versus warfarin to determine if one or more of these agents could 
be available to members without requiring a warfarin trial.  When looking at costs for warfarin, 
the DUR Commission would like the following factors to be taken into account: the costs for 
INR monitoring, frequent office visits to stabilize INR, and bridging therapy while patient is 
being stabilized on warfarin.     
 
Thank you in advance for conducting this cost comparison between warfarin and the NOACs 
to determine if one or more of these agents could be available to members without requiring a 
warfarin trial. 
 
 
 
 2 
Sincerely,  
 
 
Pamela Smith, R.Ph.  
Drug Utilization Review Project Coordinator 
Iowa Medicaid Enterprise 
 
Cc:  Erin Halverson, R.Ph., IME 
 Megan Smith, R.Ph., Pharm.D., IME 
